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The mucosal tissues such as gastrointestinal, urogenital and respiratory tracts are 
highly vulnerable to external environmental factors. These tracts are all covered 
with  protective  mucosal  layer,  which  form  together  an  area  of  approximately 
400m
2 in an adult human (Brandtzaeg et al., 1999). Normally, the intestinal tract is 
in  a  state  of  peaceful  co-existence  with  the  complex  milieu  of  microbes.  Its 
epithelial barrier function is further enhanced by a pre-epithelial layer and a well-
developed  mucosal  immune  network.  It  responds  to  a  range  of  microbial 
environmental  conditions  including  colonization,  commensalisms,  symbiosis, 
persistent infections, and pathogen-induced diseases. 
In general the mucosal immune system employs two different paths. One originates 
from innate cells and the other from adaptive immune cells. Innate immune cells 
rapidly  sense  pathogens,  followed  by  the  generation  of  effector  functions  like 
activation  of  cellular  transcription  and  pro-inflammatory  protein  synthesis.  For 
example, essential pathogen-associated motif sensing receptors on these cells are 
the Toll Like Receptors (TLR) recognize a wide range of antigens (Jiang et al., 
2004) and prompt the cells to activate many signal transduction proteins. Though 
the  action  of  these  proteins,  the  innate  immune  cells  can  promptly  respond  to 
pathogen/commensal challenges and eliminate the microbes. After elimination the 
affected tissue returns back to its normal functional state with minimal pathology. 
The adaptive immune system mainly consists of two types of lymphocytes: B cells 
and T-cells. The former provides antigen specific humoral immune responses and 
the latter provides cell-mediated immune responses, respectively. In the present 
thesis we investigate and discuss the role of B cell responses in mucosal immunity.  
The B cells in the mucosal immune systems produce high amounts of antibodies. 
Already as early as 1870, Alexandre Besredka, a Russian pathologist discovered 
the presence of antibodies in external secretion, specifically in gastrointestinal tract 
secretions.  A  lot  of  attention  was  given  to  this  antibody  whose  presence  was 
reported in most of the external secretions like intestinal fluid, milk and stool. 
Heremans  and  his  co-workers  demonstrated  that  the  carbohydrate-rich, 
serologically  peculiar  b-globulin  constituted  a  type  of  antibody,  which  was 
designated as Immunoglobulin A (IgA) in 1964 (Rockey et al., 1964) . Since then 
it has been shown that IgA is an important component in the mucosal defence 
mechanism. An a constant region in the immunoglobulin defines the IgA antibody. 
In human two IgA subclasses are present they are IgA1 and IgA2, were in the later, 
13  amino  acid  is  deleted  at  the  hinge  region  (Flanagan  et  al.,  1984).  The 
distribution and physiological function of these subclasses is not clear. Literature Framework 
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This  thesis  is  focused  on  IgA  and  in  the  current  chapter  we  shall  discuss  its 
biogenesis. IgA function and their production is described in the part-1 and the 
possible clinical application of IgA dependent therapy is depicted in part-2  
1.1   PART-1 IgA Production and Physiological function 
IgA  production  in  the  gut  is  a  highly  sophisticated  process,  the  processes 
underlying this production are now reasonably well-defined in molecular terms. It 
starts with the recruitment of B cells to the various regions of the gut and following 
stimulation by antigen (e.g. normal gut flora, food constitutents or pathogens) these 
cells can undergo a differentiation process yielding IgA as an end product. In this 
section, all the steps involved in the production of IgA are summarised.  
1.1.1   Induction of IgA production 
1.1.1.1   Recruitment of B cells. 
Intestinal  IgA
+  B  cells  are  produced  from  IgM
+  B  cells  in  two  distinct  gut 
microenvironments: organized follicular structures and lamina propria (LP). Upon 
gut environment experience, B cells express integrin a4b7 at high levels and this 
expression mediates migration of these B cells to the intestine. The origin, however 
of IgM
+ B cells in the gut LP is as yet unidentified. Aly/aly mice are defective in 
all their organized follicular structures because of an NF-kB-inducing kinase (NIK) 
mutation.  In  addition,  in  vivo  and  in  vitro  experiments  reported  that
  aly/aly 
peritoneal  cavity  (PEC)  cells  have  a  defect  that  affects  their  homing  capacity,
 
especially to the GALT system (Fagarasan et al., 2000). The in vivo migration 
defect
 of aly/aly PEC cells correlates well with the in vitro impaired
 chemotactic 
response toward secondary lymphoid
 tissue chemokine (SLC) and B lymphocyte 
chemoattractant (BLC). It was found that SLC stimulation
 did not activate NF-kB 
in aly/aly PEC cells, whereas the same
 stimulation increases the nuclear NF-kB in 
aly/
+  PEC  cells,  thus
  demonstrating  that  NIK  is  located  downstream  of  the 
signalling
 pathway through the receptors for SLC, and that aly-type NIK
 affects 
this pathway (Fagarasan et al., 2000). NIK is known to participate in the signalling
 
cascade responsible for NF-kB activation through receptors of
 the TNF and IL-
1R/toll-like  receptor  families  (Figure-1)  (Siebenlist  et  al.,  2005;Malinin  et  al., 
1997;Medzhitov et al., 1997). Transfer experiments to reconstitute IgM
+ B cells 
and IgA plasma cells in LP of aly/aly mice revealed that naive B cells can directly 
migrate to the LP. This migration requires NIK-dependent activation of gut stromal 
cells. By contrast, the entry of gut-primed IgM
+ B cells to the LP is independent of 
stromal cells with functional NIK. These data indicate that naive B cells directly 
migrate to the LP by a distinct pathway from gut-primed B cells (Suzuki et al.,  
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2005). Apart from its role in migration the NF-kB dependent pathway is also an 
important factor in IgA class switching (Stavnezer, 1996). 
 
Fig. 1 Nuclear factor-kB (NF-kB) is activated by signalling through many receptors. These receptors 
can be grouped into two classes: first, receptors that only, or mainly, activate the classical pathway of 
NF-kB activation; and second, receptors that activate both the classical and the non-classical pathway 
of NF-kB activation. The first class includes tumour-necrosis-factor receptor (TNFR), interleukin-1 
receptor (IL-1R) and members of the Toll-like receptor (TLR) family. These receptors signal through 
various  kinases  and  adaptors,  including  members  of  the  TNFR-associated  factor  (TRAF)  family, 
which are recruited to these receptors and relay signals to various downstream targets. The B-cell 
receptor (BCR) and T-cell receptor (TCR) activate NF-kB through a phosphorylation cascade that 
includes (but is not limited to) BLK (B-lymphoid kinase), FYN, LYN, SYK (spleen tyrosine kinase), 
BTK (Bruton's tyrosine kinase), LCK and ZAP70 (z-chain-associated protein kinase of 70 kDa), 
which leads to activation of protein kinase C-b (PKC-b) following ligation of the BCR and PKC-q 
following  ligation  of  the  TCR  (PKC-b and PKC-q  are  essential  for  signalling  through  NF-kB  in 
mature lymphocytes but not in immature lymphocytes or thymocytes). After activation of PKC, the 
IkB kinase (IKK) complex is activated through CARMA1 (CARD (caspase-recruitment domain)–
MAGUK (membrane-associated guanylate  kinase) protein 1), BCL-10 (B-cell lymphoma 10) and 
MALT1 (mucosa-associated lymphoid-tissue lymphoma translocation gene 1). The second class of 
receptors,  which  activate  both  the  classical  and  the  non-classical  pathway  of  NF-kB  activation, 
includes the lymphotoxin-b receptor (LT-bR), receptor activator of NF-kB (RANK), CD40 and the Literature Framework 
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B-cell-activating-factor  receptor  (BAFFR),  although  BAFFR  only  weakly  activates  the  classical 
pathway.  In  the  classical  pathway,  upstream  signals  induce  phosphorylation  of  IkBa  bound  to 
cytosolic NF-kB. Phosphorylation is carried out by the IKK complex, which is composed of IKK-g 
and  two  catalytic  subunits,  IKK-a and  IKK-b.  Phosphorylation  tags  IkBa for  ubiquitylation  and, 
ultimately,  for  proteasomal  degradation,  liberating  NF-kB  for  translocation  to  the  nucleus  and 
activation of target genes. (Modifications of NF-kB proteins occur in the cytoplasm or nucleus to 
regulate  activation  of  transcription  and  other  functions.)  The  non-classical  pathway  is  controlled 
through TRAFs, NF-kB-inducing kinase (NIK) and IKK-a; this regulation occurs independently of 
the classical IKK complex and leads to processing of the p100 form of NF-kB2, generating p52–
REL-B heterodimers (and other NF-kB dimers), which migrate to the nucleus. 
1.1.1.2   The role of B cells in positive and negative immune regulation 
Naïve,  long  lived  memory  and/or  gut  experienced  B  cells  internalize  specific 
antigen efficiently in the M-cell
1 pockets. They provide efficient stimulation of 
adjacent CD4
+ CD40L
+ T cell by antigen presentation and B7-CD28 ligation. This 
interaction likely leads to a diversified T-cell response that can further diversify the 
B cell response (Ha et al., 2001). 
In comparison to ordinary antigen-presenting cells(APC), naïve B cells have low or 
absent levels of co-stimulatory molecules, thus internalization of antigen, either 
specifically or non-specifically and its presentation to T cells produces tolerance. 
Moreover,  interaction  of  B  and  T-cells  via  B7-CTLA-4  might  also  result  in 
tolerance.  
1.1.1.3   Germinal Center(GC) formation. 
Follicular dendritic cells (FDC) also present native antigens to B and T-cells to 
induce an immune response. Primary lymphoid follicles contain recirculating naïve 
B  lymphocytes  (sIgD
+IgM
+).  They  pass  into  the  network  formed  by  antigen-
capturing FDC which are turned into secondary follicles by the GC reaction. The 
GC is of crucial importance for T cell-dependent generation of memory B cells, 
affinity maturation of the B cell receptor, and Ig class switching. It has been shown 
that naïve B cells are first stimulated at the edge of the primary follicle by cognate 
interaction  with  activated  CD4
+T  cells.  These  T-cells  have  previously  been 
exposed  to  processed  antigen  in  MHC  class  II  expressing  interdigitating  DCs 
(Garside et al., 1998;Manser, 2004). The naïve B cells now designated as founder 
B cells re-enter the follicle to become a proliferating GC. The GC founder cells 
                                                       
1  The  M  cell  is  a  extraordinary  cell  type  found  in  the  epithelium  that  covers  mucosa-associated 
lymphoid tissue in the digestive tract and the airways. M cells internalize macromolecules and micro-
organisms efficiently and deliver them to the underlying lymphoid tissue. In the gut, M cells, unlike 
the neighbouring absorptive enterocytes, lack a highly organized apical brush border and glycocalyx, 
and are poorly equipped with digestive enzymes.  
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activated in the extrafollicular compartment then migrate to the dark zone, where 
they proliferate and differentiate.  
The  stimulated  B  cells  in  the  GC  produce  low  affinity  IgM  that  can  bind  to 
circulating  antigen.  Later  the  soluble  immune  complexes  subsequently  become 
deposited  on  the  FDCs  where  antigen  is  maintained  for  prolonged  periods  to 
maintain  B  cell  responses  (Ahmed  and  Gray,  1996;MacLennan  et  al., 
1997;Lindhout et al., 1997). Such a role for IgM in the induction of secondary 
immune responses with antibody affinity maturation has been strongly supported 
by  observations  in  knockout  mice  lacking  natural  background  IgM  antibodies 
(Ehrenstein et al., 1998). In the GC, B cells of different subsets undergo somatic 
hypermutation (SHM) and class switching recombination (CSR) to increase the 
diversity  of  the  antibody  responses.  Let  us  now  review  these  two  important 
processes: 
1.1.1.4   Somatic Hypermutation (SHM). 
SHM is a process which introduces non-templated point mutations in the variable 
region of rearranged immunoglobulin heavy and light chain genes. SHM leads to 
affinity maturation, which results in the selected outgrowth of B cells expressing an 
immunoglobulin that has high affinity for its cognate antigen. Activation-induced 
cytidine deaminase (AID) is essentially required for SHM and its expression is 
restricted to GC B cells. Initially AID was thought to be a RNA-editing enzyme 
that targets mRNA (Muramatsu et al., 2000), but no experimental evidence was 
acquired to prove this. In contrast, accumulating evidence supported that AID acts 
directly on DNA. AID begins SHM by the deamination of cytidine (C) nucleotides 
on  single-stranded  DNA  of  the  immunoglobulin  gene.  As  first  proposed  by 
Neuberger (Neuberger et al., 2003) and colleagues, the mismatch of C results in 
uridine (U) and guanosine (G) that can be repaired by one of following the three 
pathways. (1) For a mutation to be fixed at the site of deamination, error-free DNA 
repair  must  be  perturbed  to  become  error-prone.  If  the  mismatch  is  carried 
unrepaired to replication, DNA polymerase will insert an adenosine (A) opposite 
the U nucleotide, ultimately creating C to T and G to A transition mutations. (2) In 
base-excision repair (BER), replication over an abasic site created by uracil-DNA 
glycosylase (UNG) will give rise to both transition and transversion mutations. (3) 
Mismatch repair (MMR) machinery might create mutations on A to T base pairs. Literature Framework 
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1.1.1.5   Class Switching Recombination. 
Immunoglobulin is made of two heavy chains and two light chains. Each heavy (H) 
and light (L) chain contains a variable
2 (V) region which binds to the antigen and a 
constant
3 (C) region which is responsible for the effector function. Upon activation 
by  antigen  and  accessory  signals,  naive  IgM
+IgD
+  B  cells  undergo  Ig  CSR, 
resulting in expression
 of a different CH gene, while maintaining expression of the
 
same V region gene. CSR allows optimization of the
 antibodies for elimination of 
different  pathogens.  It  is
  mediated  by  DNA  recombination  between  switch  (S) 
region sequences
 located 5' to each CH gene, except Cm. This results in a new Ig 
isotype producing IgA
+ B cells as well as the switch circles (Figure-2). The isotype 
to  which  the
  B  cells  will  switch  is  regulated  by  Th  cells,  the  particular  APC
 
involved, and the anatomical site of antigen presentation. 
CSR occurs only in the presence of cytokines (for example TGF-b, IL-4, IL-5, IL-
6, etc) and AID. AID is an essential enzyme to regulate CSR also other proteins are 
important. The histone methyltransferase Suv39h1 increases CSR specifically to 
IgA (Bradley et al., 2006). A crucial role for Smad2 is to mediate signals for the 
TGF-b-directed class switch to IgA. It also influences induction of IgA responses 
in vivo (Klein et al., 2006). It has been proposed by Qiao et al (Qiao et al., 2006) 
that  negative  factor  (Nef)  protein,  is  an  immunosuppressive  HIV1  protein 
expressed and released by infected cells, penetrates B cells both in vivo and in 
vitro. Nef suppresses immunoglobulin CSR by inducing IkBa and SOCS proteins. 
These induced proteins block CD154 and cytokine signaling via NF-kB and STAT 
transcription factors. 
RUNX proteins like RUNX3 are important mediators of TGF-b which induce B 
cell CSR to IgA. RUNX3 is induced by TGF-b1 in the mouse IgM B cell lines 
1.29m, CH12.lX  (which  can  switch  to  IgA  antibody  expression),  and  activated 
spleen B cells. This is not observed in mouse IgG2a B cell line A20.3 (which is 
unable to switch to IgA antibody expression), suggesting a role for RUNX3 in 
regulating antibody class switching to IgA. Over expression of RUNX3 or Smad3 
and Smad4 was found to increase the amount of IgA secreted from normal spleen 
cells and IgM C12.LX.4927 mouse B cells treated with TGF-b. Consistent with the 
synergistic activation of Ig Ca promoter constructs by RUNX3, and Smad3 and 
Smad4, their co-transfection further increased the surface expression and secretion 
of  IgA  in  LPS-activated  spleen  B  cells  following  TGF-b  treatment  (Figure-3) 
(Blyth  et  al.,  2005;Whiteman  and  Farrell,  2006).  Together,  these  observations 
highlight the importance of TGF-b signalling for IgA responses.  
                                                       
2 Contains 7 families of variables in heavy chain 
3 Contains g, d, e, a, m constant regions in heavy chain  
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Fig. 2 Top line shows Ig heavy chain genes in a B cell that expresses IgM and IgD (by 
alternative  RNA  processing).  CSR  occurs  after  AID  deaminates  dC  residues  within  S 
regions  that  are  transcriptionally  active.Transcripts  from  the  unrearranged  heavy  chain 
genes  are  called  germline  transcripts.  Middle  line  illustrates  the  intrachromosomal 
deletional recombination between two switch (S) regions during CSR from IgM to IgE. The 
DNA  in  between  Smand  Seis  excised  from  the  chromosome  as  a  circle.  Bottom  line 
illustrates  the  chromosome  after  CSR  showing  that  the  identical  VH  region  originally 
expressed with the Cmgene is now expressed with Cegene in cells expressing IgE  
 
1.1.1.6   Repertoire development. 
Recent studies show that the peripheral circulating B cell repertoire, which reflects 
a complex group of cells expressing IgV genes, might have been influenced by a 
variety of immunological stimuli. The IgV genes of B cells infiltrating the different 
tissues may provide a more skewed population owing to the local selection and/or 
(antigen-dependent) proliferation. Clonal B cell expansions in the target tissues of 
many different autoimmune diseases are well established (Steiman-Shimony et al., 
2006). Molecular analyses of Ig heavy chain rearrangements from peripheral blood 
and tonsils have shown a polyclonal pattern of IgV gene usage. IgA heavy chain 
repertoire has a restricted pattern in intestine and salivary gland (Dunn-Walters et 
al., 2000). In other mucosal tissues the IgA repertoire is unknown.  Literature Framework 
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1.1.1.7   Inductive site for the switch to IgA producing B cells. 
The evidence for the inductive site comes from the presence of AID expression and 
switch circles (Figure-2). Lamina Propia (LP) stromal cells can recruit naïve B cell 
to the gut through an independent pathway that involves the activation of NF-kB 
by NIK (Suzuki et al., 2005). Later the recirculating IgM
+ B cells undergoes CSR 
to generate IgA
+ antibody secreting Cells (ASC) or IgA
+ memory cells in the GC of 
Peyer’s patches (PP) and mesenteric lymph nodes. Butcher et al demonstrated this 
phenomenon  for  the  first  time  in  mice  (Butcher  et  al.,  1982).  In  mice 
approximately half of these IgA ASCs in the gut wall are derived from a particular 
(B-1) lineage of B cell precursors (Kroese et al., 1989). Fagarasan et al. showed 
that  both  the  organized  Gut-Associated  Lymphoid  Tissue  (GALT)  and  the 
intestinal  lamina  propria  (i-LP)  were  sites  of  generation  and  diversification  of 
plasma cell precursors, which were largely B-1 cells in mice (Fagarasan et al., 
2001). In humans no data support that i-LP is the inductive site for IgA. If this 
occurs, it is a rare and possibly transient phenomenon.  
Bronchus Associated Lymphoid Tissues (BALT) is not constitutive feature of the 
normal human lungs. The human airway epithelium constitutively produces IL-2, 
TGF-b, IL-5, and IL-10, factors essential for IgA isotype switch and differentiation 
into  IgA-producing  plasma  cells. The close  proximity  of  B  cells  to  the  airway 
epithelium  probably  guarantees  a  constant  supply  of  growth  and  differentiation 
factors needed for mucosal IgA production (Salvi and Holgate, 1999). 
 
 
Fig.  3  This  diagram  illustrates  the  central  role  of  RUNX–CBF  complexes  in  the 
orchestration  of  cell  fate  in  response  to  exogenous  factors  (yellow  circles)  and 
environmental  signals  (green  circles).  A  subset  of  the  known  RUNX  target  genes  is 
depicted (grey boxes), and these targets have been selected for their potential relevance to 
cancer. This model might be helpful in understanding the effects of loss of function or  
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dominant-negative  inhibitors  that  require  collaborating  events  to  drive  tumour-cell 
proliferation (indicated by the red box). By contrast, ectopic expression of RUNX factors 
leads to activation of both growth-promoting and -suppressive signals (indicated by both 
the  red  and  purple  boxes,  respectively).  In  the  absence  of  collaborating  mutations  that 
prevent  growth-suppressive  effects  (purple  box),  cell  growth  is  restricted.  The  role  of 
individual target genes in these phenomena remain to be established and it is conceivable 
that the consequences of RUNX-gene deregulation involve multiple downstream effectors. 
BMP, bone  morphogenetic protein; C/EBPd, CCAAT/enhancer binding protein-d;  FGF, 
fibroblast  growth  factor;  GM-CSF,  granulocyte–macrophage  colony-stimulating  factor; 
IgA1, immunoglobulin A1; IL-3, interleukin-3; M-CSFR, macrophage colony-stimulating 
factor receptor; MPO, myeloperoxidase; PI3K, phosphatidylinositol 3-kinase; PKC, protein 
kinase C; TCRa, T-cell receptor-a; TGF-b, transforming growth factor-b; TGFbR1, TGFb 
type I receptor; VEGF, vascular endothelial growth factor. 
1.1.1.8   High and low affinity IgA antibody. 
SHM can provide certain advantages like generation of high-avidity antibodies. 
Autoantibodies  encoded  by  germline  genes  could  lose  self-reactivity  following 
mutation. In order to maintain B cell memory, higher-avidity BCRs might provide 
a survival advantage, particularly when nominal antigen availability is a limiting 
factor. SHM may generate B cells with high-avidity Ig receptors, that could also 
become  efficient  activators  of  T  cells  who  are  specific  for  peptide  fragments 
(Longo and Lipsky, 2006). 
Diversity  might  be  more  important  than  avidity  in  response  to  SHM-inducing 
pathogens. It is important to note that in the context of efficient B cell responses 
apart from the obvious advantages, SHM has disadvantages as well: (1) The BCR 
might no longer recognize the stimulating antigen, which can result in the lack of 
selection and death or, if selected, the B cell responds to a different antigen. (2) It 
may alter the tertiary structure, resulting in B cell death. (3) The mutated BCR 
recognizes self antigens instead of foreign antigens. This is usually not a problem 
because  autoreactive  peripheral  B  cells  fail  to  receive  cognate  T-cell  help,  as 
autoreactive T cells are usually deleted or tolerized in the thymus, preventing their 
functional presence in the periphery. 
In vitro experiments have suggested that stochastic or non-selective mechanisms 
are of primary importance in the regulation of plasma cell differentiation (Hasbold 
et  al.,  2004).  On  the  other  hand,  indirect  evidence  suggests  that  plasma  cell 
differentiation of GC B cells may be more selective, with only those cells that 
exceed a threshold antigen affinity contribute to the antibody response (Smith et 
al., 1997;Smith et al., 2000). Affinity maturation is therefore driven by a tightly Literature Framework 
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controlled  mechanism  that  ensures  only  antibodies with  the  highest  potency  of 
neutralizing foreign antigens (Phan et al., 2006). 
Low affinity B cells that are fully able to generate antibody-forming cells have a 
physiologic significance. Transgenic models demonstrate that low-avidity antigen–
antibody interactions are sufficient for deletion, receptor editing, and induction of 
an immune response against antigens like gut flora (Macpherson et al., 2000). 
1.1.2   Migration of IgA producing B cells to the effector site. 
1.1.2.1   Chemotaxis of antibody producing cells or memory IgA cells. 
Several  molecules  like  chemokines  and  adhesion  molecules  are  involved  in 
lymphocytes trafficking into mucosal tissues. Selective expression of MAdCAM-1 
on the mucosal high endothelial venules (HEV) indicates a role for this molecule in 
homing of lymphoid cells to mucosal tissues (Hamann et al., 1994). MAdCAM-1 
expression on HEV is increased by cytokines, such as TNF-a and IL-1, suggesting 
that recruitment of lymphocytes to the mucosa can be modulated. There are two 
major adhesion molecules, L-selectin and a4b7 integrin on lymphocytes that bind 
to  MAdCAM-1.  Another  integrin,  aEb7  is  suggested  to  be  involved  in  the 
migration of lymphocytes into the intestinal epithelium.  
Intestinally  induced  IgA  ASCs  can  populate  the  bone  marrow  and  produce 
antibodies, which are present in the circulation (Forster et al., 1994;Hargreaves et 
al., 2001;Youngman et al., 2002). CXC4 is probably the chemokine mediator in 
trafficking  of  IgA-secreting  plasma  cells  to  the  bone  marrow(Kunkel  et  al., 
2003;Lazarus  et  al.,  2003),  where  its  ligand  CXCL12  is  highly  expressed  by 
stromal cells. It also plays a crucial role for the development and retention of B cell 
progenitors  (Ma  et  al.,  1998;Egawa  et  al.,  2001).  The  chemokines  CCR9  and 
CCR10 are mainly involved in the trafficking of IgA ASCs in the mucosal tissues. 
1.1.3   The Function of IgA in the immune response 
1.1.3.1   In serum. 
In addition to barrier protection, IgA performs other vital functions as well, which 
are discussed below. Using cellular Fc receptors, IgA is efficient way of delivering 
antigens to the immune system. IgA is in this manner important for recruitment of 
effector leukocytes and is a trigger for the initiation of potent protective pathways 
or pathological and inflammatory reactions. IgA can interact with various cell types 
like  neutrophils,  eosinophils,  monocytes  and  macrophages  which  express 
FcaRI(CD89). Serum IgAs in immune complexes are very effective at initiating a 
wide range of inflammatory responses such as: phagocytosis, antibody dependent  
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cellular cytotoxicity, oxidative burst, and cytokine release (Monteiro and Van De 
Winkel, 2003). In humans, serum IgA, is the second most abundant serum antibody 
class. It plays pro- and anti-inflammatory roles and interfaces with the mucosal and 
systemic immunity. Serum IgA is predominantly of the IgA1 subclass, and this 
antibody  subclass  also  predominates  in  mucosal  effector  sites  such  as  the 
mammary glands, salivary glands, nasal mucosa, bronchial mucosa and the upper 
digestive tract. Parental immunisation with protein antigens tends to elicit serum 
IgA1.  The  IgA2  subclass  is  more  abundant  in  the  colon  and  is  induced  by 
polysaccharide antigens. These antibody subclasses are highly homologous except 
for a short mucin-like hinge region which is unique to primate IgA1. This region is 
responsible for some of the unique receptor and lectin-binding properties (Wines 
and Hogarth, 2006).  
1.1.3.2   In mucosal tissues. 
Mucosal antibodies effectively reduce absorption of soluble or particulate antigens 
on  mucosal  surfaces.  However,  the  antibody  isotype  essentially  influences  the 
quantity of absorbed antigen. In the mucosal tissue IgA exists as secretory IgA 
(SIgA).  Two  monomeric  IgA  molecules  are  held  together  by  a  J  chain  that  is 
produced  by  the  plasma  cells.  This  entire  IgA  complex  binds  to  the  poly 
immunoglobulin receptor (pIgR) present on epithelial cells of the mucosa and gets 
subsequently transported to the lumen of the gut. Then extracellular part of the 
pIgR is also released along with the dimeric IgA into the lumen as SIgA (Johansen 
and  Brandtzaeg,  2004).  Its  anti-inflammatory  properties  and  multiple  antigen-
binding sites make SIgA an effective inhibitor of immune responses. At mucosal 
surfaces antigen-specific SIgA bound to commensal as well as pathogenic micro-
organisms effectively inhibit their adherence to epithelial cells. These cells display 
corresponding receptors to bacterial antigens on their surfaces (van der Waaij et al., 
2004). SIgA confers microbes with a negatively charged and hydrophilic 'coat' that 
repels their attachment to mucosal surfaces. Interactions of SIgA  with antigens 
such as enzymes, toxins, and viruses may neutralize the biological activities by 
binding to their critical epitopes. SIgA antibodies during pIgR-mediated transport 
might  be  able  to  neutralize  intracellular  viruses  as  demonstrated  in  vitro  with 
Sendai,  influenza,  and  human  immunodeficiency  viruses  (Fujioka  et  al., 
1998;Bomsel et al., 1998).  
The indirect function of IgA is to give a protective effect by interacting with mucin 
and several other humoral factors of innate immunity present in external secretions 
(Russell et al., 2005). SIgA is incapable to fix complement efficiently or to act as Literature Framework 
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an opsonin. This is an advantage in secretions, where initiation of an inflammatory 
reaction would affect the integrity of the mucosal surface.  
In contrast, antigen-specific IgG antibodies may cause complement activation and 
subsequently inflammation, influx of polymorphs, and altered mucosal integrity 
with increased absorption of bystander antigens (Russell et al., 1997;Brandtzaeg 
and Tolo, 1977). 
1.1.4   Receptors for IgA 
The receptors for Ig are specific for their Fc fragment. Fc receptors are defined by 
their specificity for the Fc fragment of immunoglobulin isotypes. Five different 
IgA receptors are recognized so far. They are polymeric Ig receptor (pIgR), Fc￿RI 
(or CD89), Fc￿/￿R, asialoglycoprotein(ASGP-R) and transferrin(TfR). 
pIgR is expressed on the basolateral surface of mucosal epithelial cells, and is 
specific  for  polymeric  IgA  and  IgM.  It  is  responsible  for  the  transcytosis  of 
polymeric IgA and IgM across the mucosal epithelium to form Secretory IgA or 
IgM. pIgR has no inflammatory role and functions primarily in transcytosis.  
Fc￿RI (CD89) is the major activating IgA receptor on myeloid cells and is capable 
of eliciting respiratory burst, phagocytosis, degranulation and cytokine production. 
Neutrophils, macrophages, Kuppfer cells and eosinophils are the cell types that 
express FcaRI. On myeloid DCs, it is involved in the capture of IgA complexes for 
subsequent  antigen  presentation.  This  receptor  is  absent  on  lymphocytes,  mast 
cells, basophils, and platelets (Wines and Hogarth, 2006). 
Fca/mR binds both IgM and IgA (Shibuya et al., 2000). This receptor is widely 
expressed in non-hematopoietic tissue with mRNA found mainly in kidney and 
intestine and at low levels in the lung, liver and heart. The in vivo function of this 
receptor is not clear, although, Fca/mR mediates similar responses to IgA and IgM 
immune complexes. 
Eosinophils are key mucosal mediators in protective and pathological reactions in 
the  gut  and  lung.  Human  eosinophils  express  all  the  above-mentioned  IgA 
receptors.  A  unique  receptor  which  is  not  yet  characterized  for  secretory 
component  (SC)  is  expressed  on  eosinophils  (Lamkhioued  et  al.,  1995).  This 
receptor binds SC and SIgA, but not serum IgA. Further, it triggers degranulation 
and release of eosinophil cationic protein and peroxidase. 
A novel mouse IgA receptor was described on Peyer’s patch M cells. An epithelial 
cell located exclusively within the follicle-associated epithelium overlying MALT 
(Mantis et al., 2002). Its molecular and other functions are not well known yet.  
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The liver plays an important role in maintaining homeostasis through regulation of 
IgA  catabolism.  The  ASGP-R  expressed  on  hepatocytes  (Stockert  et  al., 
1982;Grossetete  et  al.,  1998)  recognizes  terminal  Gal  residues  on  serum 
glycoproteins,  including  IgA,  and  conveys  bound  ligand  for  intracellular 
degradation.  The  rapid  clearance  of  IgA2,  compared  to  IgA1  in  the  liver  may 
contribute to the higher serum levels of IgA1 (Sakamoto et al., 2001). Transferrin 
receptor 1, TfR (or CD71), selectively binds IgA1 (Moura et al., 2001). In contrast 
to FcaRI, this IgA receptor is not fully expressed on mature blood leukocytes, but 
it is well-expressed on cultured renal mesangial cells as well as on glomerular 
mesangial cells in patients with IgA nephropathy. 
1.1.5   IgA in (auto)immunity 
IgA  associated  diseases  are  characterized  by  increased  serum  IgA  levels,  often 
paralleled  by  IgA  tissue  deposition.  These  disorders  include  IgA  nephropathy 
(IgAN),  ankylosing  spondylitis,  Sjogren’s  syndrome,  alcoholic  liver  cirrhosis 
(ALC), HIV infection, and dermatitis herpetiformis.  
1.1.5.1   IgA in nephropathy 
IgA  nephropathy  (IgAN)  is  the  most  common  form  of  glomerulonephritis, 
characterized by deposition of IgA immune complexes, followed by the infiltration 
of inflammatory immune cells, mesangial cell proliferation and mesangial matrix 
expansion  (Monteiro  et  al.,  2002).  IgAN  patients  display  several  major 
abnormalities  in  the  IgA  system  like  increased  levels  of  serum  IgA  and  IgA-
immune  complexes  (Monteiro  et  al.,  2002),  increased  ratio  of  polymeric  to 
monomeric  (Valentijn  et  al.,  1984;Novak  et  al.,  2001)  and  the  generation  of 
abnormally glycolated IgA1 (Tomana et al., 1999). Studies in IgAN patients and 
patients  with  other  IgA-associated  disease  including  HIV  infection,  ALC  and 
sphodyloarthropathies  reveal  reduced  FcaRI  expression  levels  on  circulating 
monocytes and neutrophils. In some IgAN patients soluble FcaRI is present in 
serum. This results in the IgA/FcaRI complexes into the circulation which later 
deposit in  kidney.  TfR  is  over  expressed on  the  kidney  cells in  IgAN  patients 
(Barratt  et  al.,  2000).  TfR  specifically  binds  IgA1  but  not  IgA2  with  clear 
preference for polymeric IgA1. TfR may be responsible for trappring IgA1 in the 
mesangium, leading to the well-known mesangial IgA1 deposits that are hallmarks 
of IgAN.  Literature Framework 
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1.1.5.2   IgA in multiple sclerosis (MS) 
IgA1 and IgA2 are found in the cerebrospinal fluid of patients with MS (Budka et 
al.,  1985;Henriksson  et  al.,  1985).  Zhang  et  al  (Zhang  et  al.,  2005)  have 
demonstrated the clonal expansion of IgA-bearing plasma cells in MS lesions with 
somatic mutations and ongoing intra-clonal mutations occurred in their VH genes. 
Via immunohistochemical  studies, infiltration of  dimer  and  polymer  IgA1-  and 
IgA2 positive plasma cells in perivascular spaces, parenchyma of MS lesions, and 
adjacent  white  matter  was  demonstrated.  Double  immunofluorescence  staining 
showed binding of IgA antibody on axons and walls of micro vessels in the areas 
of chronic active and inactive demyelination. 
1.1.5.3   IgA in Sjögren’s syndrome(pSS) 
High  levels  of  serum  monomeric  IgA,  SIgA,  IgA-rheumatoid  factor  and  IgA 
containing circulating immune complexes have been reported in pSS (Atkinson et 
al., 1989). In pSS patients enhanced sialyltransferase activity in B lymphocytes 
was observed (Basset et al., 2000b). Also, increased N-linked glycosylation leading 
to oversialylation of monomeric IgA1 was found (Basset et al., 2000a). Evidence 
for  IgA  producing  plasma  cells  was  first  observed  in  the  parotid  glands  after 
rituximab treatment (Pijpe et al., 2005) but the repertoire of these cells is largely 
unknown.  
1.1.5.4   Asthma and allergy 
Various  studies have  shown  that  mucosal and systemic  production  of  allergen-
specific IgA occurs in patients with asthma and/or allergic rhinitis (Peebles, Jr. et 
al., 2001,Nahm et al., 1998,Terada et al., 1996). Reports have shown that IgA 
induces an inflammatory type of immune response (Seminario and Gleich, 1994), 
while few reports show that IgA can suppress inflammatory responses in asthma 
and allergy. 
1.1.5.5   Ankylosing spondylitis (AS) 
Elevated  level  of  monomeric  IgA1  in  serum  was  reported  in  Ankylosing 
spondylitis, which is a chronic inflammatory form of arthritis that affects the spinal 
joints. At the same time, IgA deficient patients were shown to exhibit severe AS 
(Pilette et al., 2004).  
1.1.5.6   Inflammatory bowel Disease (IBD). 
IBD  includes  Crohn’s  disease  (CD)  and  ulcerative  colitis  (UC).  In  IBD  an 
imperfection  occurs  in  bacterial  antigen  sampling  by  the  epithelium,  maybe 
mediated by TLRs and controlled by genetic factors. A variety of autoantibodies,  
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including  ANCA,  antierythrocyte  antibodies,  pancreatic  antibodies, 
lympocytotoxic antibodies and antibodies to epithelial cells component, have been 
described (Seibold et al., 1996). These autoantibodies are not primarily responsible 
for  disease  pathogenesis  but  they  mark  for  disease-related  autoantigens.  These 
autoantigens prone to cross-react with bacterial antigens from the normal intestinal 
flora. The importance of most of these antibodies in the pathogenesis of IBD is 
unclear. IgA autoreactivity was most severe in celiac disease patients. Furthermore, 
it was shown that IgA deficiency is associated with a tenfold increase risk of celiac 
disease. 
1.1.6   Syndromes related to IgA deficiency 
1.1.6.1   Selective IgA syndrome. 
IgA deficiency is the most common primary immune deficiency disease in humans, 
affecting as many as 1:400 individuals. Most IgA-deficient individuals are healthy, 
but have an increased level of secretory IgM in mucosal secretions that compensate 
for  SIgA  (Cunningham-Rundles,  2001).  Low  IgA  secreting  plasma  cells  were 
observed in IgA deficient patients. The reason for this may be due to blockade in 
post-IgA switch differentiation of B cells (Wang et al., 1999). IgA production was 
attenuated  in  IgA-deficient  patients  which  might  be  due  to  T-cell  defect 
(Cunningham-Rundles, 2001). TGF-b is a key cytokine in CSR which is less in 
IgA-deficient sera when compared to normal donors (Muller et al., 1995). 
1.1.7   Treatment of diseases that are correlated with an IgA 
imbalance 
1.1.7.1   IgA producing B cell depletion. 
B cell-targeted therapy has been used to treat B cell lymphoma and autoimmune 
diseases
4.  Rituximab  is  a  potent  B  cell  cytolytic  chimeric  IgG1  CD20-specific 
monoclonal  antibody.  The  success  of  treating  rheumatoid  arthritis  (Dass  et  al., 
2006) with rituximab opened a new avenue in addressing autoimmune diseases.  
                                                       
4 thrombocytopaenia, SLE, vasculitis, auto-antibody associated neuropathies, multiple sclerosis, 
myasthenia gravis, myositis, blistering skin disorders, mixed cryoglobulineamia, thrombotic 
thrombocytopaenic purpura, Sjogren’s syndrome and anti-factor VIII syndrome Literature Framework 
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Epratuzumab, that targets the B cell epitope CD22, is also used for the treatment of 
autoimmune diseases.￿Recent studies have confirmed the efficacy and safety of 
epratuzumab  in  several  autoimmune  diseases,  including  systemic  lupus 
erythematosus  and  primary  Sjogren's  syndrome  (Steinfeld  and  Youinou,  2006). 
Another way to deplete B cells is the neutralization of survival factors for B cells 
interfering  with  signalling  mechanisms  in  B  cells  that  are  required  for  cell 
maintenance or activation. Bruton’s tyrosine kinase or spleen tyrosine kinase are 
interesting potential targets (Edwards and Cambridge, 2006). In this way plasma 
cells which are not targeted by rituximab can be specifically targeted.  
1.1.7.2   Intravenous immunoglobulin (IGIV) therapy 
There has been a considerable increase in the use of IGIV therapy for the treatment 
of autoimmune disease, systemic inflammatory diseases and for supportive therapy 
of immunodeficient patients. IGIV is beneficial in several diseases, including acute 
and chronic/relapsing diseases, autoimmune diseases and inflammatory disorders. 
Therapeutic  efficacy  of  IGIV  has  also  been  established  in  a  number  of 
dermatologic  diseases.  The  mode  of  action  of  IGIV  is  complex,  involving 
modulation of expression and function of Fc receptors. It also interferes with the 
activation  of  complement  and  the  cytokine  network,  modulation  of  idiotype 
network,  regulation  of  cell  growth,  alteration  of  cellular  adhesion  process,  and 
effects on the activation differentiation and effector functions of T and B cells and 
antigen-presenting cells. The therapeutic effects of IGIV most likely reflect the 
functions  of  natural  antibodies  in  maintaining  immune  homeostasis  in  healthy 
people (Misra et al., 2005). 
1.1.8   IgA mediated therapy 
Antibody-based immunotherapy has become an effective treatment for a number of 
different cancers. Therapeutic monoclonal antibodies (mAb) can induce tumor cell 
death by a variety of mechanisms. Some act by simply cross-linking antigens on 
tumor  cells,  leading  to  apoptosis,  cell  cycle  arrest  or  the  inhibition  of  cell 
proliferation (Glennie and Johnson, 2000). 
A number of studies showed that therapeutic antibodies able to trigger immune 
responses via FcaRI show exciting potential. These antibodies can either be intact 
IgA or bispecific antibodies (BsAb) that recognize both the ectodomain for FcaRI 
and the tumor antigen of interest (Valerius et al., 1997). In a comparison of hapten-
directed  antibodies  of  different  human  isotypes,  IgA2  was  found  to  be  more 
effective that IgG isotypes at recruiting neutrophils and inducing tumor cell death 
(Valerius et al., 1997). Similarly, an IgA1 antibody against EpCAM proved more 
effective than IgG1 at recruiting neutrophils to kill EpCAM-positive, solid tumor 
cells (Huls et al., 1999).  
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FcaRI  has  the  unique  ability  to  mediate  either  activation  or  inhibitory 
inflammatory  responses  depending  on  the  nature  of  its  interactions  with  IgA 
(Pasquier  et  al.,  2005).  Monoclonal  Fabs  targeting  the  FcaRI  ectodomain  or 
engineered  IgA  constructs  could  therefore  play  a  valuable  therapeutic  role  in 
inhibiting inflammatory processes in autoimmune disorders or allergy and asthma. 
Leukocyte infiltration, a key characteristic of asthma, was markedly inhibited by 
treatment with anti-FcaRI mAb in a murine model of IgE-triggered asthma. 
1.1.8.1   IgA therapy to treat cancer and autoimmune disease 
Targeted therapies that are developed to selectively induce apoptosis in cancer cells 
are presently among the most promising anti-cancer strategies. Bremer et al and 
others  have  provided  proof  of  principle  for  target-cell-restricted  apoptosis 
induction using recombinant fusion proteins in which a tumour-selective antibody 
fragment is fused to either sTRAIL or sFASL (Bremer et al., 2004;Bremer et al., 
2005). Many scFv like anti-TNF-a ￿(Scallon et al., 1995), anti-BAFF, anti-CD25 
(Onizuka et al., 1999) and many anti-interleukins etc is in clinical trial to treat 
autoimmune diseases. 
1.2   Part II 
1.2.1   2.1. Delivery systems 
1.2.1.1   GMO 
Functional  human  proteins  are  constitutively  produced  in  genetically  modified 
bacteria that survive happily on human mucosal surfaces to benefit the host. The 
successful  phase  1  clinical  trial  with  IL-10  producing  Lactococcus  lactis  for 
Crohn’s disease has opened new avenues to use transgenic bacteria as delivery 
vehicle (Braat et al., 2006). The major advantage of this novel strategy is to avoid 
systemic  side  effects  associated  with  conventional  therapies.  This  methodology 
opens up an alternative method for local delivery of therapeutic proteins to various 
mucosa tissues. 
1.2.1.2   Lactococcus lactis as a delivery vehicle of therapeutic molecules. 
Due to technological advances the insight into the molecular basis of disease is 
rapidly  expanding  and  as  a  consequence,  a  multitude  of  possible  therapeutic Literature Framework 
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proteins, including cytokines and signalling molecules have been identified. The 
therapeutic use of these possible clinically relevant proteins is hampered, however 
by  functional  and  economical  considerations.  The  most  important  of  these 
considerations are delivery and production of these proteins. Very recently, it has 
emerged that by using genetically engineered bacteria important barriers in this 
respect can be circumvented. Conventionally, therapeutic proteins are purified as to 
become endotoxin free (which is very expensive) and subsequently systemically 
administered with a suitable carrier into the bloodstream. The obvious drawbacks 
of this conventional strategy are the unwanted side effects as a consequence of the 
systemic delivery as well as often prohibitively high production costs. Genetically 
Modified (GM) bacteria that are qualified with high experience to co-exist with 
humans to produce human therapeutic proteins are opening new ways for those 
who are suffering from disease conditions: the delivery of proteins in the tractus 
circumvents the need for endotoxin free preparations, by their very nature bacteria 
are cheap producers of recombinant proteins and for digestive tract related diseases 
delivery can be topical rather as systemic. 
Microbes  have  been  consumed  from  ages  in  a  variety  of  fermented  foods  and 
drinks that reside in the intestinal milieu to benefit the host, and these probiotic 
microbes  are  classified  as  GRAS  (Generally  Regarded  As  Safe)  organisms. 
Furthermore,  these  food  grade  organisms  have  been  genetically  engineered  to 
produce various foreign proteins for immune modulation. For example, antigens 
from  pathogens  as  a  prophylactic  immunization,  and  proteins  like  cytokines, 
interleukins, and interferons have been expressed. Local delivery of recombinant 
therapeutical  proteins  to  the  disturbed  intestine  in many  disease  conditions  has 
many advantages: Targeting to the mucosa for delivering therapeutic proteins can 
be easily achieved by administering GM bacteria that produce therapeutic proteins 
to prevent and combat infections. In the oral cavity GM Streptococcus mutans were 
used  to  prevent  dental  carries  by  a  novel  approach  postulated  as  replacement 
therapy (Hillman, 2002). A different approach was reported by Paton et al that uses 
engineered  E  coli  that  express  a  range  of  toxin  binding  receptor  expression 
(Focareta et al., 2006;Paton et al., 2006;Paton et al., 2005) to capture bacterial 
toxins to prevent enteric infections. Similarly, GM Streptococcus gordonii were 
used to producing single chain antibodies (ScFv) specific for Candida albicans 
(Oggioni et al., 2001) and recombinant IL-1Ra (Ricci et al., 2003). The ScFv S 
gordonii could eliminate experimental Candida albicans in rats after successful 
colonization in the vagina along with the anti-inflammatory effects of the IL-1Ra 
expressing S gordonii. In addition, oral immunization of Listeria monocytogenes 
expressing Gag protein of HIV results in Gag specific CD8
+ cells increase in mice 
(Peters et al., 2003). Non-pathogenic strains of Salmonella typhimurium are used to 
express virulence factors of L .monocytogenes. A second use of GM bacteria is to 
restore metabolic enzyme deficiencies or other human proteins. For instance, L. 
lactis expressing eukaryotic lipase was effective in treating pancreatic insufficiency 
in pig (Drouault et al., 2002). Thirdly, GM bacteria can be used to modulate the  
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immune system. Lactobacillus casei is used to deliver bovine beta-lactoglobulin 
during  neonatal  colonization  to  prevent  milk  allergic  reactions  in  mice 
(Hazebrouck  et  al.,  2006).  Likewise  Lactobacillus  is  extensively  use  in  active 
vaccination and other immune interventions that will be discussed below. Thus 
both by niche occupation as well as by the production of recombinant proteins, GM 
bacteria may be clinically interesting. 
Especially  interesting  in  this  context  is  that  next  to  pancreatic  insufficiency  L 
.lactis has been used to deliver different therapeutic proteins orally. Trefolin factors 
(TTFs)  involved  in  the  protection  and  repair  of  the  intestinal  epithelium  were 
expressed in L. lactis and delivered orally they had a striking protection against 
DSS-colitis in mice (Vandenbroucke et al., 2004). Streptococcus gordonii that was 
genetically modified to express IL-1Ra (pro-inflammatory) improved the condition 
of IL-2
-/-  mice that spontaneously develop ulcerative-colitis-like pathology. The 
delivery of IL-10 locally by L. lactis has proven many advantages over systemic 
administration in mice. This improved status in mice IBD was followed by the first 
clinical trial of human IL-10 producing L .lactis to IBD patients (see below) (Braat 
et al., 2006;Steidler et al., 2003).  
Likewise,  Lactobacillus  jensenii  that  were  modified  to  secrete  cyanovirin-N 
successfully  inhibited  HIV  when  delivered  vaginally.  Lactobacillus  zeae, 
engineered  to  produce  a  ScFv  against  S.mutans  antigen  I/II  adhesion  molecule 
markedly reduced S.mutans counts and caries scores in caries rat model (Kruger et 
al.,  2002).  Intranasal  application  of  live  bacteria  that  express  antigens  has 
beneficial  effect  to  increase  the  antigen  specific  antibodies  during  infection 
(Steidler et al., 1998), at the same time it also lower the allergic epitope antibodies 
(Daniel et al., 2006).  
Braat et al conducted the first successful human trial with a GM L. lactis in which 
the thymidylate synthase gene was replaced with a synthetic sequence encoding 
mature human IL-10 (Braat et al., 2006). This novel treatment was safe with minor 
adverse events present and a decrease in disease activity was observed. Fecally 
recovered  L.  lactis-thy12  were  dependent  on  thymidine  for  growth  and  IL-10 
production indicated that the containment strategy was efficient. Bacterial-based 
topical  delivery  of  biological  active  proteins  is  a  novel  and  highly  promising 
avenue for combating mucosal disease. 
One possible disadvantage of the usage of GM probiotica is that the delivery of 
powerful recombinant proteins is not further targeted within the intestinal tract. 
Potentially this could lead to unwanted side effects. Therefore a new generation of 
targeted GM Lactococci are now being designed. Literature Framework 
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The execution of a first clinical trail is obvious importance for further development 
of  this  field,  but  future  studies  are  likely  to  include  more  specifically  targeted 
recombinant  proteins,  for  instance  is  by  membrane  expression  instead  of 
continuous secretion of the recombinant protein by the GM organisms. In support 
of this view, membrane expression of ScFv instead of secretion turned out to be 
more efficient in removal of S. mutans from the oral cavity (Kruger et al., 2002). 
Nevertheless, already the current generation of clinically interesting GM organisms 
has already substantial better local delivery of heterologously expressed proteins as 
compared to conventional systemic strategies. In this context it is important to note 
that where GMO-delivered IL-10 seemed effective in the first placebo-uncontrolled 
trail,  systemic  IL-10  delivery  did  not  seem  clinically  interesting,  dramatically 
highlighting the power of local delivery. Further refinement of targeting strategies 
by this novel class of therapeutics will only further add to the promise of GMOs in 
clinical medicine. As an alternative to conventional therapy, they are particularly 
attractive, given the increasing problem of side effect and the high production cost. 
The  most  convincing  evidence  for  the  clinical  effectiveness  of  recombinant 
probiotica  certainly  comes  from  first  clinical  trail  using  recombinant  L.  lactis 
secretion IL-10 and other animal studies. One important point to remember is that 
the  various  transgenic  probiotica  are  different  and  each  may  have  a  different 
clinical effect in a specific disease. Apart from modulating the immune response, 
transgenic probiotica are used to deliver growth factors, silencer RNA, peptides 
that inhibit appetite. Significant safety issues will need to be addressed. There is a 
seemingly limitless area for future research on the use of transgenic probiotica and 
this  novel  technology  clearly  has  great  potential.  Broad  usage  of  such  golden 
bullets both as pharmaceutica as well as functional food might revolutionize the 
usage of probiotica in the near future. 
1.3   Scope of this thesis. 
This thesis is focused on two main themes: 1) IgA and its repertoire and 2) in vitro 
production of the scFv SIgA molecule on the surface of L. lactis.  
IgA is the most abundant mucosal immunoglobulin present in different mucosal 
tissues.  It  is  produced  by  the  experienced  B  cells  in  different  tissues  upon 
stimulation  under  different  situations.  Functions  of  IgA  are  prevention  of 
attachment and translocation of gut bacteria (immune exclusion) (Kroese and Bos, 
1999), neutralisation of pathogens both in the gut lumen and the inside of gut 
epithelial cells (Fernandez et al., 2003), export of immune complexes from the 
lamina  propria  into  the  lumen  (Lamm,  1997)  and  anti-inflammatory  responses 
against food antigens (Frossard et al., 2004). In IgA deficiency patients, IgA is not 
produced  while  in  autoimmune  disease  like  IgA  nephropathy  an  altered  IgA 
production is seen. In the former conditions, these patients can be compensated by 
giving IgA intravenously and in later situation, the abnormal B cell can be deleted  
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by antibodies against them, for example Rituximab. It is obvious with the use of 
advanced  molecular  techniques  these  types  of  proteins  delivery  of  IgA  using 
bacteria like L. lactis would constitute a superior strategy. On the other hand B cell 
depletion  can  control  the  disease  conditions  when  the  disease  is  caused  by 
autoantibodies.  
This  First  chapter  provided  an  overview  of  various  aspects  of  IgA  and  its 
repertoire in various disease conditions and also the current state of the art with 
regard to delivery of IgA and different proteins was reviewed. 
The intestine is exposed to gut microflora and food antigens. This influences the 
development of the mucosal immune system and tolerance respectively. When the 
B  cell  is  exposed  to  this  wide  range  of  antigens  then  it  is  obvious  to  expect 
antibodies against these antigens. Therefore in the second chapter, to investigate 
the  IgA  repertoire,  IgA  genes  from  normal  human  ileum  were  cloned  and 
sequenced. In this chapter we shall report that IgA producing cells in the intestinal 
tract are derived from a limited number of precursors that undergo local expansion. 
While almost sequences showed evidence for SHM, only a relatively minor group 
of  these  sequences  have  an  R/S  ratio  that  is  consistent  with  an  antigen-driven 
selection.  
Human and humanised antibodies are now poised to become a new leading class of 
protein-based  therapeutic  agents.  Following  the  development,  a  model  L.  lactis 
expressing scFv SIgA as a membrane protein was constructed in chapter three. In 
this  chapter  it  will  be  shown  that  the  Fab  regions  specifically  bound  to  the 
Epithelial glycoprotein-2 (EGP-2) which is highly expressed on colon cancer cells. 
We shall discuss the release from L. lactis of membrane bound scFv SIgA occurs 
as a free molecule. 
In Crohn’s disease, few regions of the intestine are inflamed while the rest remains 
healthy.  The  Fourth  chapter  specifically  addresses  the  differences  of  the  IgA 
repertoire and the gut flora populations in the inflamed and healthy regions of 
human or mouse intestines. In particular we shall report a difference in the VH gene 
usage between the inflamed and uninflamed intestinal regions in the gut of such 
patients. 
The Fifth chapter we shall describe the involvement of the gut microflora in the 
development  of  Inflammatory  Bowel  Disease  (IBD)  in  a  mouse  model  for 
experimental  colitis.  Moreover,  in  this  chapter  it  will  be  shown  that  an  anti-
inflammatory response differentially induces iNOS responses in epithelial cells by 
gut bacteria (different types of bacteria).  Literature Framework 
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Excessive IgA may lead to autoimmune diseases like IgA nephropathy or Sjögren’s 
syndrome. Treatment of these diseases by depleting the B cells is reported to be 
beneficial. However, the relapsing nature of these diseases remains an important 
clinical challenge. In chapter six the IgA repertoire after anti-CD20 treatment in 
Sjögren’s syndrome patients is studied. A high influx of the IgA1 subtype in the 
diseased  salivary  glands  is  found.  Moreover  it  will  be  shown  that  the  rapid 
appearance of IgA producing cells in the salivary glands after treatment is not 
caused by regeneration of the B cell compartment, but rather by local expansion of 
pre-existing B cells. 
Cancer in general can be elegantly targeted by introducing the mutated or missing 
proteins,  whose  absence  underlies  development  of  pathology.  In  case  of  colon 
cancer in particular, epithelial BMP-2 signalling is lost. In the Seventh chapter we 
shall show the production of recombinant human BMP-2 and its apoptotic effect on 
the  colon  cancers  cells  employing  in  vitro  co-culture  of  recombinant  bacteria 
producing BMP-2 with colon cancer cell lines.  
In the Eighth chapter of this thesis, the main results of the experiments will be 
summarized, and discussed, followed by a short exposure on future perspectives. 
In  conclusion,  this  thesis  shall  show  that  IgA  production  is  heterogeneously 
regulated in number of different conditions and understanding IgA repertoire in 
various disease state can provide insight about the pathogenesis of the diseases. 
Application of the advanced technologies provides the opportunity to use GMO as 
a production factory to produce different proteins like scFv IgA, which potentially 
should have important clinical applications. 
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Chapter 2 
Human ileal plasma cells are derived 
from a limited number of precursor 
cells.  
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Abstract 
Immunoglobulin A plays a crucial role in the establishment and maintenance of 
mucosal  homeostasis  between  host  cells  and  commensal  bacteria.  Sequence 
analysis  of  IgA  VH  genes  taken  from  biopsies  of  human  ileum  show  that  the 
repertoire of IgA VH genes is very limited, despite the presence of large numbers of 
IgA plasma cells. These IgA VH genes revealed the occurrence of clonally related 
sequences, that all contain mutations compared to germline sequences. Although 
most  of  the  mutations  present in these  clonally  related  sequences  were shared, 
usually they also contained additional unique mutations. These data indicate that 
the ileum is composed of large clones of IgA producing plasma cells and that a 
relatively low number of about 100-300 (isotype switched) B-cell precursors are 
involved in the generation of 75,000 IgA producing cells within each biopsy. The 
limited diversity of IgA producing cells from these biopsies was further confirmed 
by  H-CDR3  size  spectrotyping  and  by  preferential  usage  of  VH1  gene  family 
members. Our data show evidence for two waves of expansion for IgA producing 
cells in human ileum. The first wave occurs during initial stimulation in germinal 
centers, while a second wave of expansion of IgA-committed cells occurs within 
the lamina propria. Limited precursors for ileal IgA plasma cells 
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2.1   Introduction 
The mucosae of the digestive tracts form the spacious area (~400m
2) of the human 
body where interactions take place between intestinal bacteria and the immune 
system. One important component of the mucosal immune system is IgA, produced 
by numerous plasma cells, located in the lamina propria
1. Dimeric IgA, secreted by 
these plasma cells, binds to the poly immunoglobulin receptor (pIgR) present on 
epithelial cells of the mucosa and is subsequently transported to the lumen of the 
gut. Then the IgA is released into the gut lumen, together with the extracellular part 
of the pIgR, as secretory IgA (SIgA)
2. The immense antigenic load at the mucosal 
epithelial surface requires a surplus in the production of IgA. At least 80% of all 
plasma cells in human mucosal tissues secrete IgA, resulting in the production of 
40 mg IgA per kg body weight per day
3. The specificities of these IgA molecules 
are largely unknown. 
The major function of SIgA is prevention of gut bacteria from attaching to the 
epithelium and their subsequent translocation into the body (immune exclusion)
4,5. 
In addition, SIgA is also involved in neutralization of pathogens, either present in 
the gut lumen or even inside gut epithelial cells
6, export of immune complexes 
from  the  lamina  propria  into  the  lumen
7  and  induction  of  anti-inflammatory 
responses against food antigens
8. Since, in vivo, SIgA also binds to commensal 
bacteria present in the gut lumen
9 , this IgA is therefore thought to play some role 
in  maintaining  the  balance  between  the  microflora  and  the  immune  system
10. 
Selective IgA deficiency in humans is associated with increased susceptibility for 
infection and development of autoimmune diseases 
12. 
In humans, there is some evidence that generation of IgA plasma cells from isotype 
switched  IgM
+  B  cell  precursors  occurs  only  in  Peyer’s  patches  and  isolated 
lymphoid  follicles  of  gut  associated  lymphoid  tissue  (GALT)  but  not  in  the 
intestinal lamina propria itself
13. During humoral immune responses that take place 
in these lymphoid tissues, the antibody repertoire becomes also more fine-tuned 
(i.e. high affinity to certain antigens) by somatic hypermutation of the V region 
genes. Indeed, high number of mutations are observed in human intestinal IgA 
plasma cells
14. Both class switch recombination (CSR) and somatic hypermutation 
(SHM) are thought to take place predominantly in the germinal centers of Peyer’s 
patches  and  isolated  lymphoid  follicles
15.  Accumulating  data  suggest,  however, 
that at least some CSR and SHM occurs outside germinal centers
16. 
Studies by Holtmeier et. al.
17, revealed that the VH gene repertoire of IgA plasma 
cells in the colon is rather limited and that clonally related cells can be found. 
Although this may suggest that the number of plasma cell precursors might be low, 
the number of precursor cells giving rise to the IgA plasma cell pool in the gut is 
not  known.  In  this  study  we  aimed  at  establishing  this  number  of  plasma  cell  
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precursors for the ileum, since most IgA plasma cells of the gut are located here. 
To address this issue we have analyzed the VH gene usage, clonal relationships and 
mutation  frequencies  of  IgA-producing  cells  in  ileal  biopsies  from  normal 
individuals.  All  IgA  sequences  were  strongly  mutated,  and  only  part  of  these 
mutations showed signs of antigen selection. The VH1 gene family was the most 
prevalently used VH gene by the ileal IgA producing cells. IgA sequences from 
clonally related cells were found in all biopsies. Taken together, our data strongly 
suggest that there is a local expansion of a low number of B-cell precursors, which 
gave rise to the IgA plasma cell pool in each biopsy. 
2.2   Results 
2.2.1   Number of IgA plasmablasts in ileum biopsies. 
Quantitative data about the number of IgA plasma cells in human ileum is limited. 
To address this issue we performed immunoperoxidase staining on normal ileum 
biopsies to identify IgA plasmablasts and plasma cells in the lamina propria (Figure 
1). From each healthy volunteer (n=3) (Table-1), three biopsies were completely 
analyzed for an estimation of the total number of IgA plasma cells present. Each 
biopsy weighted around 7 mg which yielded around 250 sections of 5 mm thick. 
IgA plasma cells were counted from every tenth section from the biopsy P5, while 
5 to 17 randomly selected sections were counted from the other biopsies. Using 
these counting we estimated that there are, on average, approximately 75,000 IgA 
producing cells present per biopsy (Table-2). cDNA was synthesized from RNA 
isolated  from  four  other  biopsies  from  other  volunteers,  which  resulted  in 
appropriate b-actin and IgA signals upon RT-PCR. Because of the high number of 
IgA  plasma  cells  within  our  biopsies  we  assume  that  the  IgA  signals  that  we 
obtained from our biopsies were strongly dominated by the  mRNA from these 
plasma cells and not from isotype-switched B cells.  
2.2.2   Estimation of the number of B-cell precursors giving rise to 
IgA plasma cells 
The number of precursors that generated the above mentioned IgA plasma cells can 
be estimated from the diversity of the IgA repertoire in the ileum. To this end we 
sequenced the IgA VH genes of a biopsy according to established methodology
18. 
Because  of  the  presence  of  many  clonally  related  sequences,  we  were  able  to 
estimate how well we covered the complexity of this population of IgA-producing Limited precursors for ileal IgA plasma cells 
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cells by comparing the number of unique sequences with the number of clonally 
related sequences. The coverage within our sample could in principle range from 
0% when every newly obtained sequence is unique to 100% when every newly 
obtained sequence represents a member of a previously described B cell clone. 
Using Good’s formula
19 we calculated a minimal coverage in the samples for each 
biopsy considering all 100% identical sequences as derived from the same cell, and 
a maximal coverage when identical VH sequences were considered to be derived 
from different cells. 
Of each volunteer fifty different IgA VH sequences from ileum were analyzed. In 
volunteers P1, P2 and P3 we obtained 25 sequences from proximal and 25 from 
distal ileal biopsies, while from P4 we cloned 50 sequences from one biopsy. Of 
the 200 sequences 183 sequences were productively rearranged (on-line supporting 
material, Table S1 and S2). Twenty-one sequences were 100% identical to at least 
one other sequence resulting in 162 truly unique sequences. Identical sequences 
were  only  observed  among  sequences  derived  from  individual  biopsies.  Fully 
identical sequences were obtained in 7 biopsies whereas one biopsy did not contain 
any identical sequences. Sequences are considered as clonally related sequences if 
they  have  the  same  H-CDR3  region,  that  is  the  same  VDJ  joining  (on-line 
supporting material Table S3). B cells with few mutations in the H-CDR3 regions 
can still be considered to be clonally related
17. No sequences with identical H-
CDR3 regions were observed in samples taken from one person at distant and 
proximal ileal sites. 
The  minimal  coverage  ranged  from  8%  to  25%  while  the  maximum  coverage 
ranged from 17% to 67% (Table-3). From the coverage it is possible to calculate 
the number of B cell precursors that gave rise to all IgA producing cells in one 
biopsy (about 75,000 cells) by using the formula of Choe and Lee (Table-3)
20. 
Employing this formula, the minimal coverage estimate resulted in a number of B 
cell precursors for all IgA plasma cells in a biopsy, that ranged from 94 to 373, 
while the maximal coverage ranged from 23 to 143. These data show that the 
number of IgA plasma cell precursors of the healthy ileum is very limited. 
2.2.3   Spectrotype analysis reveals restricted patterns of H-CDR3 
length distribution. 
The overall IgA repertoire of ileal IgA producing cells is not well documented. H-
CDR3  lengths  were  analyzed  by  performing  spectrotype  analysis.  With  this 
method, Ig gene PCR products from polyclonal B cell populations from normal 
tonsils, bone marrow and peripheral blood give a typical fluorescence peak pattern 
resembling a Gaussian (normal) distribution curve of the lengths of the products
21-
24. Deviations from Gaussian distributions have been used to detect clonally 
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Volunteer no.  Number of biopsies  Age  Sex  Complaint  Sampling area 
P1  2  57  Male  follow up polyps  terminal ileum 
P2  2  36  Male  constipation  terminal ileum 
P3  2  35  Female  anemia  terminal ileum 
P4  1  37  Female  abdominal pain  terminal ileum 
P5  3  18  Female  abdominal pain  terminal ileum 
P6  3  48  Female  anemia  terminal ileum 
P7  3  38  Female  Diarrhea  terminal ileum 
Table-1: Patient and biopsy descriptions: 
 Biopsies were taken from 7 volunteers. Reasons for endoscopy are described. 
From P1, P2 and P3 two biopsies were taken, one just before and one 
approximately 20 cm above the Bauhin’s valve. From P4 one biopsy and from P5, 
P6 and P7 three biopsies were taken from the terminal ileum. 
clonally rearranged immunoglobulins in suspected lympho-proliferative diseases 
24. In our study, we have amplified IgA VH genes using a single PCR with the 
described set of FR3-specific primers for all VH gene families 24 in combination 
with a labeled Ca primer. Spectrotype patterns of IgA H-CDR3 lengths from ileal 
samples deviate significantly from a Gaussian distribution (P<0.05). This is true for 
multiple biopsies of all volunteers (Figure 2). Patterns from samples taken at the 
proximal  and  distal  ileum  from  the  same  volunteer  showed  different  patterns 
(Figure 2). The range of H-CDR3 lengths in these ileal biopsies was 39 to 83 
nucleotides, which is in accordance with the variation in lengths of the H-CDR3 
regions observed in the sequenced samples (see below). To explore whether the 
spectrotypes were not limited by the amount of cDNA, spectrotyping on serially 
diluted cDNA was done. The resulting patterns were similar within a range of 200 
ng to 25 ng cDNA, with only slightly lower signals in the diluted cDNA samples 
(data not shown). Overall, the spectrotype patterns are thus restricted, indicating a 
limited variation of different H-CDR3 lengths being used in biopsies, which is in 
line  with  the  limited  number  of  precursors  as  calculated  above.  Total  RNA 
extraction and RT-PCR. 
2.2.4   IgA plasma cells in normal ileum express predominantly 
VH1 family genes. 
In volunteers P1, P2 and P3 more than 40% of the unique IgA sequences utilize 
VH1 family genes, followed by VH4 and VH3 (Figure 3A). To show that the utilized 
VH primer set can efficiently amplify members from all different VH gene families Limited precursors for ileal IgA plasma cells 
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separate  PCR  reactions  with  individual  VH  gene  family  specific  primers  were 
performed on the samples from volunteer P4. In the 50 sequences from volunteer 
P4 usage of all the VH gene families can be found among the IgA transcripts (on-
line  supporting  material,  Table  S2).  These  data  suggest  that  the  observed  high 
usage of VH1 in the ileum of volunteers P1-3, is probably not caused by biased 
usage of the VH1 gene family specific primer. 
2.2.5   Large range of H-CDR3 lengths in IgA plasma cells. 
In all volunteers a similar distribution of DH usage was observed with frequent 
usage of DH1, DH2 and DH3 gene segments (Fig 3B). The most frequently used JH 
gene  segment  in  all  volunteers  was  JH4.  More  than  50%  of  intestinal  IgA 
transcripts utilized this gene segment followed by JH6, JH5 and JH3 (Fig. 3C). Loss 
or gain of nucleotides at the VH-DH-JH junctions directly relates to the H-CDR3 
length. All rearranged sequences contained nucleotide additions at either the VH-DH 
or at the DH-JH junctions, or at both. The number of N additions at the VH-DH 
junctions ranged from 0 to 25 nucleotides and from 0 to 28 nucleotides at the DH-JH 
junction.  Much  variation  was  observed  in  the  pattern  of  nucleotide  loss  at  the 
joinings from all sequences. Most nucleotide deletions were observed in the DH-
region at the VH-DH joining followed by deletions in the DH region at the DH-JH 
junction, then deletions in the JH regions and very few losses in the VH genes (on-
line supporting material- Table S3). The average H-CDR3 length of the intestinal 
IgA transcripts was around 15 amino acids (AA) and ranged between 7 to 25 AA 
(21-75 nucleotides). This is in accordance with the observed range of 39 to 83 
nucleotides for the H-CDR3 lengths observed in the spectrotype analysis. 
2.2.6   Fourty percent of the intestinal IgA sequences have somatic 
mutations with R/S ratio’s significantly different from random 
mutations. 
Presence and nature of somatic mutations in obtained IgA sequences were analyzed 
by comparison these sequences with known germline VH sequences. This analysis 
revealed that all IgA sequences contained mutations; no germline IgA sequences 
were  observed.  The  mutation  frequency  varied  between  2  and  24%  (4-55 
mutations). The ratio’s of replacement (R) to silent (S) mutations for the CDR 
regions in this study were calculated as described
25. 40% of the sequences showed 
a significantly higher R/S ratio in the CDR regions than was expected from random 
mutations (on-line supporting material Table S1 and S2). 60% of sequences did not  
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Figure 1. IgA plasma cells within ileal biopsies: Cryostat ileum sections, stained 
with peroxidase (PO)-labeled rabbit anti-human IgA to view IgA producing plasma 
cells and hematoxylin staining to view nuclei. i.  
 
Patient   biopsy  No. of sections counted  Estimated number of 
IgA Plasma cells 
95 % CI 
P5  1  24  170,443  [150,950 , 189,933] 
P5  2  5  133,293  [109,327 , 157,262] 
P5  3  5  99,711  [75,191   , 124,232] 
P6  1  13  48,868  [40,436   ,   57,297] 
P6  2  17  57,080  [49,512   ,   64,650] 
P6  3  14  72,252  [61,826   ,   82,679] 
P7  1  7  36,288  [21,875   ,   50,701] 
P7  2  7  32,609  [27,322   ,   37,896] 
P7  3  8  21,965  [16,362   ,   27,566] 
 
Table-2: Number of IgA plasma cells per biopsy: Number of IgA plasma cells 
were counted in cryostat sections form three separate biopsies from P5, P6 and P7. 
The area of tissue was determined by morphometric analysis.  5-24 sections were 
completely counted per biopsy and numbers represent the mean number of plasma 
cells per biopsy with the 95% confidence interval. 
 
Table 3 
A: Minimal coverge 
 
Sample  Sequenced  Productively  
rearranged 
sequences* 
Numbers of 
sets 
Unique 
sequences 
Mimimal 
Coverage 
Estimated 
number of 
B-cells 
Estimated 
sd 
95% CI 
P1 H  25  20  2 set (1x2, 
1x3) 
15  25%  94  67  [24 , 
382] 
P1 L  25  22  1 set (1x2)  20  10%  231  230  [33 , 
1620] 
P2H  25  16  1 set (1x3)  13  12.5%  135  138  [18 , 
1002] 
P2L  25  22  2 set (2x2)  18  19%  110  73  [31 , 
401] 
P3H  25  21  2 set (2x2)  17  8%  100  66  [28 , 
362] Limited precursors for ileal IgA plasma cells 
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P3L  25  24  2 set (2x2)  20  17%  132  88  [36 , 
486] 
P4  50  37  2 set (1x2, 
1x3) 
32  14%  373  269  [91 , 
1526] 
 
 
 
B: Maximum Coverage. 
Sample  Sequenced  Productively  
rearranged 
sequences 
Numbers of 
sets 
Unique 
sequences 
Maximum 
Coverage 
Estimated 
number of 
B-cells 
Estimated 
sd 
95% CI 
P1 H  25  21  2 set (1x2, 
1x4) 
15  29%  111  82  [27 ,  
467] 
P1 L  25  24  3 set (3x2)  18  25%  84  43  [32 ,  
228] 
P2H  25  24  6 sets (3x2, 
2x3, 1x4) 
8  67%  23  7  [13 ,    
43] 
P2L  25  24  4 sets (4x2)  16  34%  60  24  [28 ,  
134] 
P3H  25  25  3 sets (2x2, 
1x5) 
16  35%  102  62  [32 ,  
336] 
P3L  25  24  2 sets (2x2)  20  17%  132  88  [36 ,  
486] 
P4  50  41  3 sets (3x2, 
2x3) 
29  30%  143  64  [61 ,  
345] 
 
Table 3 Number of B cell precursors for ileum IgA plasma cells: 
Estimation of the number of B-cell precursors giving rise to IgA-producing cells  
was done by comparing the number of unique VH sequences with the VH sequences 
that  were  obtained  from  multiple  members  of  the  same  set  of  clonally  related 
sequences.  Minimal  coverage  (A)  was  calculated  in  which  100%  identical 
sequences are considered to be derived from the same B cell (*), while maximum 
coverage  (B)  was  calculated  by  considering  all  sequences  to  be  derived  from 
different  B cells.  The  number  of sets  are  indicated with the  numbers  of  sets x 
number  of  members  of  those  sets  between  brackets.  The  number  of  B  cell 
precursors  giving  rise  to  all  IgA  plasma  cells  within  a  biopsy  is  estimated  by 
dividing the number of observed unique sequences of different B-cell precursors by 
the sample coverage, with a correction for non-equal class sizes 
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Figure 2. Spectrotype analysis of IgA VH genes.  
All IgA VH family genes were amplified in one reaction. Two biopsies from 
different regions were analyzed from each volunteer. Those biopsies were taken 
from the terminal ileum just before the Bauhin’s valve (labeled as L) and 
approximately 20 cm above Bauhin’s valve (labeled as H). 
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Figure 3. VH, DH and JH usage among the IgA sequences. 
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Utilization of VH family genes (A),  DH usage (B) and JH usage (C) among the IgA 
sequences as a percent of the total sequences of P1, P2 and P3. VH gene family 
usage is compared to the expected usage on the basis of the numbers of VH genes 
per family. 
 
Figure 4: A 
               <---------------------------------IMGT-FR1----------------------------------->_____________IMGT-CDR1_____ 
IGHV1-18       CAGGTTCAGCTGGTGCAGTCTGGAGCT...GAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGT... 
P1C22                                                                                  ---------C--------G----AA-----... 
P1C19                                                                                  -----------------------AA--CA-... 
P1C20                                                                                  -----------------------AA--CA-... 
P1C21                                                                                  -----------------------AA--CA-... 
 
 
               _________<--------------------IMGT-FR2--------------------->__________IMGT-CDR2___________<-------------- 
IGHV1-18       .........ATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACAATGGTAACACA......AACTATGCACAGAAG 
P1C22          .........-------------------------------------------------------A-A-----------------......--------------- 
P1C19          .........----T----------------------------------------------C---A-A-----------------......-TT------------ 
P1C20          .........----T----------------------------------------------C---A-A-----------------......-TT------------ 
P1C21          .........----T----------------------------------------------C---A-A-----------------......-TT------------ 
 
 
               -------------------------------------IMGT-FR3--------------------------------------------------------> 
IGHV1-18       CTCCAG...GGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTACATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGT 
P1C22          T-----...--------------------------------------------------------------------------------------------- 
P1C19          T-T---...-----------------------------------------G----------------------C------------------C-----T--- 
P1C20          T-T---...-----------------------------------------G----------------------C------------------C-----T--- 
P1C21          T-T---...-----------------------------------------G----------------------C------------------C-----T--- 
 
19              TGTGCGAGAGAGGCCTCGATTTCATATTGTGTTGGTGGTACCTGCTACTCCGACTGGTACTTCGATCTCTGG 
20              ------------------------------------------------------------------------ 
21              ---------------------------------------------------------C-------------- 
2              ----------------TA-C----------A----------------------------------------- 
 
 
 
<---------------------------------IMGT-FR1----------------------------------->_____________IMGT-
CDR1_____ 
   
Vh1-2-2        CAGGTGCAGCTGGTGCAGTCTGGGGCT...GAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGATACACCTTCACCGGCTACTAT... 
VH1-18 
5 
????
? 
p=0.003 
P1C22 
p=0.001 
AREALTSYCIGGTCYSDWYFD
L 
11+1 
2+4 
P1C19 
P=0.008 
AREASISYCVGGTCYSDWYFD
L 
P1C21 
p=0.008 
AREASISYCVGGTCYSDWHFD
L 
P1C20 
11  
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P3C8                                                          ------------------------------------T----------A-------... 
P3C7                                                          ------------------------------------T----------A-------... 
P3C11                                                         ---------------------------------G--T-G--------A-------... 
P3C9                                                          ---------------------------------G--T-G--------A-------... 
P3C10                                                         ---------------------------------G--T-G--------A-------... 
 
               _________<--------------------IMGT-FR2--------------------->__________IMGT-CDR2___________<-------------- 
            
Vh1-2-2        .........ATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAACCCTAACAGTGGTGGCACA......AACTATGCACAGAAG 
P3C8           .........--C--------------------------------------CG---C--AC-----G---C---------A----......--------------- 
P3C7           .........--C--------------------------------------CG---C--AC-----G---C---------A----......--------------- 
P3C11          .........--C------A---------T---------G--C--------CG---C--AC-----G---C--------------......--------------- 
P3C9           .........--C------A---------T---------G--C--------CG---C--AC-----G---C--------------......--------------- 
P3C10          .........--C------A---------T---------G--C--------CG---C--AC-----G---C--------------......--------------- 
 
               -------------------------------------IMGT-FR3--------------------------------------------------------> 
            
Vh1-2-2        TTTCAG...GGCAGGGTCACCATGACCAGGGACACGTCCATCAGCACAGCCTACATGGAGCTGAGCAGGCTGAGATCTGACGACACGGCCGTGTATTACTGT 
P3C8           ------...------------G-------------------------------------A-------------AT----------------------T---- 
P3C7           ------...------------G-------------------------------------A-------------AT----------------------T---- 
P3C11          ----TT...------------G------T--------------CT--------------A--------C----AT--A-------------------TT--- 
P3C9           ----TT...------------G------T--------------CT--------------A--------C----AT--A-------------------TT--- 
P3C10          ----TT...------------G------T--------------CT--------------A--------C----AT--A-------------------TT--- 
 
7               TGTGCGAGAAGTCGCGCACCGAGAGCTGAGCCGGGAATAGACCTGTGGTTTGACTCCTGG 
8               ------------------------------------------------------------ 
9               -----------------G-----TA-----G--CA---GGAG------------------ 
10              -----------------G-----TA-----G--CA---GGAG------------------ 
11              -----------------G-----TA-----G--CA---GGAG------------------ 
 
C 
<---------------------------------IMGT-FR1----------------------------------->_____________IMGT-CDR1_____ 
 
vh5-51         GAGGTGCAGCTGGTGCAGTCTGGAGCA...GAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGCTACTGG... 
P4C32                                 ----...---------------------------------------C-----------G----TA------C--C----... 
P4C33                                 ----...---------------------------------------C-----------G----TA--T---C--C----... 
P4C34                                 ----...--------------G------------------------C----------------T--C-----A------... 
 
               _________<--------------------IMGT-FR2--------------------->__________IMGT-CDR2___________<-------------- 
 
vh5-51         .........ATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACC......AGATACAGCCCGTCC 
P4C32          .........-------------------------------------------------------G--T--A-----T-------......-----T--------- 
P4C33          .........-------------------------------------------------------G--T--A-----T-------......-----T--------- 
P4C34          .........----------------------------------------------CA------------------------G--......-A------------- 
 
               -------------------------------------IMGT-FR3--------------------------------------------------------> 
         
vh5-51         TTCCAA...GGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGT 
P4C32          ------...----------------TT-------------C------------------------------------------------------------- 
P4C33          ------...----------------TT-------------C------------------------------------------------------------- 
P4C34          ------...-----A-------------T-----C---T---GCT--------------------------------------------------------- 
 
P4C32          TGTGCGAGACTCCCGAGTATAGCAGCTCGTCCGTGGTTTGACTACTGG  
P4C33          ------------------G------------G----------------  
P4C34          ------------------------------------------------  
VH1-02 
15 
????
? 
NS 
P3C7 
NS 
ARSRAPRAEPGIDLWFDS 
P3C1
0 
NS 
ARSRAPSTEAQMELWFDS 
1 
13+10 
P3C8 
P3C9 
P3C1
1 Limited precursors for ileal IgA plasma cells 
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Vh5-51
P4C34
P4C32
??
CARLPSIAARPWFDYW 
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2
12
14
P4C33
1
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Figure 4. Alignment of sets of clonally related IgA VH sequences 
 Sets of clonally related IgA VH sequences are aligned and compared to germline 
VH gene sequences. Sequences of the germline gene are shown on top. Dashes 
indicate identical nucleotides, and gaps introduced for uniform comparison of VH 
genes  are  marked  by  dots.  Genealogical  trees  deduced  from  the  mutations 
observed in the VH genes of these sets are drawn. Hypothetical members of the sets 
that were not obtained but that can be predicted from building the most logical tree 
are indicated with questionmarks (?). Under each arrow the number of mutations 
between different steps are indicated. When additional mutations are present in the 
H-CDR3 it is indicated separately (for instance as 1+1) where the second figure 
represents the H-CDR3 mutations. Under depicted members the significance (p) is 
indicated if the R/S ratio of the H-CDR regions is different then expected from 
random mutations (NS = non significant, P> 0.05). Boxed are the amino acid 
sequence  of  the  involved  H-CDR3.  A-L  represent  12  different  sets  of  clonally 
related sequences.  
 
2.3   Discussion 
Here we show by sequence analysis of IgA VH genes taken from biopsies of human 
ileum, that the repertoire of IgA VH genes is very limited, despite the presence of 
large numbers of IgA producing plasma cells. Sequence analysis of these IgA VH 
genes revealed the occurrence of many clonally related sequences, that all contain 
mutations  compared  to  germline  sequences.  Although  many  of  the  mutations 
present in these clonally related sequences were shared, most of the sequences also 
contained additional mutations, that varied between the different members of the 
clone. Taken together, the data indicate that the human ileum is composed of large 
clones of IgA producing plasma cells and that a relatively low number of (isotype 
switched) precursor cells are involved in the generation of IgA plasma cells in the 
gut.   
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The number of IgA plasma cells in the biopies taken from healthy human ileum 
was  calculated  to  be  approximately  75,000  IgA  plasma  cells  per  biopsy. 
Previously, Paniangua et al.
26 estimated that there are approximately 86 IgA plasma 
cells in the human gut per so-called ‘mucosal tissue unit’. This unit was defined on 
the basis of 5 mm thick tissue sections through a 500 mm wide area of the mucosa 
at full height, from muscularis mucosa to the tip of the villi.  
The mean number of IgA plasma cells in our nine counted biopsies was 172 cells 
per squared millimeter in tissue with a thickness of five micrometer. The volume of 
this  tissue  is  about  1.67  times  the  volume  of  the  mucosal  tissue  unit,  used by 
Paniangua et.al. Thus, our mean counted number (172) exceeds their number (1.67 
times 86=144) just about 20 % when we correct for the difference in volume.  
We  estimated  the  number  of  different  B  cell  precursors  that  gave  rise  to  IgA 
plasma cells present in a single biopsy by calculating the minimal and maximal 
coverage. This calculation is based upon the assumption that all IgA sequences are 
derived from plasma cells and that each plasma cell has equal amounts of mRNA, 
encoding  for  this  IgA.  The  minimal  coverage  yielded  a  mean  number  of  93 
precursor cells that gave rise to all IgA producing cells within the biopsies, whereas 
the  maximal  coverage  resulted  in  168  precursor  cells.  This  implies  that  these 
precursor cells must have divided approximately 9-10 divisions to give rise to the 
75,000 IgA plasma cells present in the biopsies. This expansion must take place 
locally, because we think that it is extremely unlikely that such large numbers of 
clonally related cells migrate specifically to a small defined region in the gut after 
dividing elsewhere in the body.  
There is only limited data available about turnover rate of IgA producing cells in 
the gut. Tomasi et al. has shown in neonatal mice that half life of IgA plasma cells 
is 4.7 days
35. In humans there is no good estimate for the turn-over rate of mucosal 
IgA plasma cells. Furthermore there is still an ongoing debate about the life span 
and turnover rate of plasma cells within the bone marrow
36, 37 . 
All IgA sequences, including those of the clonally related sets of sequences, exhibit 
mutations,  implying  that  all  V  genes  have  undergone  somatic  hypermutation. 
Because the majority of mutations are shared between the various members of a 
clone, this may indicate that IgA precursor cells that seed the lamina propria are 
already mutated, before they enter the lamina propria and expand locally. Somatic 
hypermutations and isotype switching are thought to take place in germinal centers 
of lymphoid organs. It is therefore likely that the generation of precursor cells starts 
in  germinal  centers  of  gut  associated  lymphoid  tissue  (e.g.  Peyer’s  patches  or Limited precursors for ileal IgA plasma cells 
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isolated lymphoid  follicles). This  process is antigen-driven,  and  antigen is also 
important for the selection of high affinity variants. The mutation pattern of 40% of 
the sequences show signs of antigen selection based on a higher replacement over 
silent ratio’s of the mutations within the CDR regions. Currently, we do not know 
why only 40% of the sequences show signs of antigen selection. One possible 
explanation could be that the chronic exposure to high amounts of antigen within 
the  mucosal  tissues  results  in  less  selection  pressure  on  high  affinity  during 
germinal center reactions. 
We speculate that IgA isotype switched, somatically hypermutated precursor cells, 
leave  the  germinal  centers  and  enter  the  blood,  to  home  back  into  the  lamina 
propria of the gut, where they undergo a second, post-germinal center, proliferation 
phase. Among the sequences derived from clonally related cells, most members (in 
18/27  sequences)  show  a relatively  low  number  of additional  mutations.  When 
there are only few (2-3) mutations, this does not necessarily need to be the result of 
somatic hypermutation, but this can easily be explained by the normal mutation 
rate of 1 mutation per million base pairs per generation. However, in those cases 
where  more  than  10  additional  mutations  are  found,  we  cannot  exclude  the 
possibility of ongoing somatic hypermutation. We do not know what the driving 
forces are for the second wave of expansion. The signals that are required for this 
local  expansion  in  the  lamina  propria  may  differ  from  those  needed  for  their 
expansion in germinal centers. Possibly, these isotype-switched activated B cells 
can expand independently from T cell help as suggested by the T-cell independent 
IgA production observed in T cell knock-out mice
31 and by the recent observation 
of large number of IgA producing cells in the lamina propria of CD40
-/- mice
16. 
Activation signals might come from bacterial ligands through toll like receptors 
(TLR)  signaling  or other T cell independent  B  cell  stimulation factors  such as 
BAFF. TLR’s are indeed present on B cells
27. Some bacterial ligands can even 
mimic CD40L signaling
28-30. BAFF is being produced by different cells such as 
neutrophils, macrophages or dendritic cells.  
A  number  of  studies  show  that  clonally  related  IgA
+  B  cells  can  be  found  at 
multiple  distant  sites  in  different  mucosal  tissues
17,32,33,  giving  support  for  the 
notion of the existence of a common mucosal immune system. Most evidence for 
such a distribution, however, is derived from studies conducted on selective groups 
of  B  cells.  For  instance,  by  amplifying  a  very  small  selected  VH  gene  family 
(VH4)
33, by selecting a particular H-CDR3 lengths
17 or after vaccination looking for 
antigen-specific  IgA  production
34.  In  our  samples  we  did  not  observe  shared 
sequences  between  different  biopsies  from  the  same  individual.  This  could  be 
explained by our unbiased screening for all VH genes. It is very well possible that 
with a larger sample size we would have obtained such shared sequences among 
different biopsies from the same person.   
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Further support for a limited set of precursors comes from our observation that IgA 
spectrotype patterns are restricted. The immunoglobulin repertoire can be studied 
by spectrotype analysis of the H-CDR3 lengths, since every B cell undergoes an 
unique VDJ rearrangement. The large diversity of possible rearrangements will 
lead to a Gaussian distribution of H-CDR3 lengths in an polyclonal population. 
The  spectrotype  pattern  in  our  ileal  IgA  producing  cells  was  not  normally 
distributed in most biopsies, which may suggest the presence a limited set of IgA 
precursors. 
Holtmeier  et  al  have  shown  that  dominant  peaks  in  a  spectrotype  of  H-CDR3 
lengths  of  IgA  producing  cells  contains  multiple  repetitive  or  clonally  related 
transcripts which further supports our notion that there is a limited number of IgA 
plasma  cell  precursors
17.  In  contrast,  peripheral  IgM
+  B  cells  from  blood  and 
tonsils, exhibits a polyclonal pattern
17,24. In cases where a limited number of B cells 
precursors  are  transferred  such  as  in  bone  marrow  transplantation  a  gradual 
increase in the diversity of H-CDR3 lengths in IgM
+ producing cells in the blood is 
seen
23,  38.  Also  during  neonatal  development  a  restricted repertoire  of  H-CDR3 
lengths  of  B-cells  is  observed,  which  correlates  with  a  limited  set  of  B  cell 
precursors in the bone marrow at that time
39. Our H-CDR3 spectrotypes from ileal 
IgA producing cells show a similar restricted pattern, suggesting that only few 
precursors home in the mucosal tissues giving rise to the large number of IgA 
producing cells. 
These limited sets of precursors seem to utilize a specific VH gene repertoire as IgA 
producing cells in the normal ileum preferentially use VH1 gene family members. 
Out of 151 unique sequences more than 40% utilize VH1 family genes. VH1 family 
genes are frequently being used in mucosal immunoglobulins, for instance VH1-46 
is the dominant Ig heavy chain gene segment in rotavirus-specific memory B cells 
expressing  the  intestinal  homing  receptor  a4b7
40. VH1  family  genes  are  highly 
expressed by B-cells in IBD patients at the colonic and terminal ileum
41. Also in 
salivary  gland  B-cells  of  Sjögren  syndrome  patients  VH1  family  genes  are 
preferentially  expressed
42.  In  advanced  HIV-1  diseased  patients  there  is  a  high 
expression of VH1 family gene members in IgM mRNA
43. It also has been reported 
that 30% of IgM B-cells of 104 day old fetal liver utilizes VH1 genes
44. The 51p1 
gene of the VH1 gene family is expressed by high numbers of fetal B cells45. Many 
autoantibodies  in  different  systemic  autoimmune  diseases  such  as  Multiple 
Sclerosis, Rheumatoid arthritis, Systemic lupus erythromateus , Sjögren syndrome 
utilize VH1 genes
46,47 and chronic lymphatic lymphoma B cells often use VH1-69 
gene
48.  The  correlation  of  high  expression  of VH1  family  members  in  mucosal 
tissues  with  a  high  expression in fetal  B  cells  and autoantibodies,  suggest  that Limited precursors for ileal IgA plasma cells 
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autoreactive B-cells could have been derived from mucosal precursors that seed the 
mucosal tissues early in life. Selection of B cells could be different in mucosal 
tissues leading to expression of autoreactive specificities. 
In conclusion, human IgA producing cells in the ileum are derived from a limited 
set of precursor B cells that are generated in different phases. In the first phase the 
multiplication of the precursor takes place in the GC and in the later phase these 
precursors  settle  in  different  regions  of  the  mucosal  tissue  and  undergo  local 
expansion. 
2.4   Materials and Methods: 
2.4.1   Human intestinal tissues 
After given informed consent (protocol approved by the medical ethical committee 
of the UMCG) ileum biopsies were taken from healthy volunteers with different 
intestinal problems (Table 1). Initially, biopsies frozen in Tissuetek were used to 
confirm the presence of IgA
+ plasmablasts by immunohistochemistry. Three ileal 
biopsies were taken from the ileum of 3 patients each. Four other biopsies (P1 to 
P4) were used for RNA extraction. Two samples were collected from volunteers 
P1-P3. Those biopsies were taken from the terminal ileum just before the Bauhin’s 
valve (labeled as low, (l)) and approximately 20 cm above Bauhin’s valve (labeled 
as high (h)). From volunteer 4 only one biopsy was taken from before the Bauhin’s 
valve. All biopsies for RNA extraction were immediately snap-frozen in liquid 
nitrogen along with RNAase out (Invitrogen). 
2.4.2   Immunohistochemistry Staining and counting of IgA 
Plasma cells. 
The mass of the biopsy were weighted. Each biopsy yielded around 200 of 5mm 
sized  sections.  Every  10th  section  was  stained  to  count  the  IgA  plasmablasts/ 
plasma cells. To detect the IgA plasmablasts in ileum biopsies, cryostat sections 
were fixed with acetone on microscopic slides and stained with peroxidase (PO)-
labeled  rabbit  anti-human  IgA  and  hematoxylin  staining  to  view  nuclei.  The 
surface area of each section was measured using the program Analysis® where the 
lumen measurements were excluded from the analysis. Counting and measuring the 
area was performed on 9 biopsies taken from three patients (three biopsies from 
each patient) analyzing 5-24 sections per biopsy.  
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2.4.3   Total RNA extraction and RT-PCR. 
Total RNA was isolated from total ileum biopsies by the Trizol® method (Sigma 
Ltd)  according  to  manufacturer’s  instructions.  cDNA  was  produced  by  using 
Oligo-dT primers (Invitrogen) in a final volume of 30 ￿l and integrity of the cDNA 
was analyzed by b-actin PCR49. VH primers used for samples from P1, P2 and P3 
are as described by van Dongen et al
24. In brief, sets of VH primers were designed 
corresponding to the VH FR1 or FR3 region which consisted of 6-7 primers capable 
of annealing to their corresponding VH gene families (VH1-VH7). These VH primer 
set were used in combination with a 3’ ca primer
50. PCR was performed for 35 
cycles using a 60-second denaturizing step at 94
0C, 60-second annealing step at 
60
0C and a 60-second extension step at 72
0C. The product was loaded onto agarose 
gel and the ethidium bromide stained band was recorded. cDNA from P4 was used 
to confirm the presence of individual VH family IgA transcripts by performing a 
PCR for individual VH gene families separately using FR1 VH gene family specific 
primers
51. 
2.4.4   H-CDR3 spectrotyping. 
For the analysis of the distribution of Ig heavy chain CDR3 (H-CDR3) lengths in 
P1, P2 and P3 volunteers, PCR was performed by combining the 5’ VH primers 
into three sets, each set specific for one of the three FR regions, which were used 
together  with  a  3’  FAM  labeled  ca  primer  and  the  fluorochrome-labeled  PCR 
products were size separated in a capillary sequencing polymer and detected by 
automated  scanning  with  a  laser  in  a  Megabase  sequencer  (Amersham 
biosciences).  Spectrotypes  were  analyzed  with  the  Genetic  profiler  program 
(Amersham biosciences). 
2.4.5   Cloning and DNA sequencing. 
 
PCR products from P1, P2 and P3 were obtained by amplification of cDNA using 
the 5’ FR1 primer set in combination with a 3’ ca primer. PCR products were gel 
purified  using  a  gel  purification  kit  (Roche),  cloned  into  pCR4  TOPO  vector 
(Invitrogen) and sequenced using an automated sequencing device as described
50. 
From  volunteer  P4,  PCR  products  from  individual  VH  families  were  cloned 
separately. Limited precursors for ileal IgA plasma cells 
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2.4.6   VH gene analysis. 
Nucleotide  sequences  were  compared  with  the  IMGT  databases  of  germline 
sequences
52  and  VH-DH-JH  regions  were  analyzed  using  IMGT  Quest
53  and 
Joinsolver
54. The lengths of the H-CDR3 domains of translated IgA heavy-chain 
transcripts  were  calculated  as  described  previously
55.  Replacement  over  silent 
mutation  (R/S)  ratios  for  FR  and  CDR  were  determined
25.  Sequences  having 
identical VDJ rearrangements were defined as clonally related. 
2.4.7   Coverage and estimation of B-cell precursors. 
Coverage  of  the  complexity  of  the  VH  gene  repertoire  was  calculated  by 
considering the number of clonally related sequences compared to the number of 
unique  VH  gene  sequences.  The  probability  of  picking  up  unique,  new  VH 
sequences in each sample is related to the number of B cell precursors giving rise 
to the IgA repertoire. Coverage was calculated as (1-n/N)*100% in which n= the 
number  of  unique,  individual  VH  sequences  and  N  is  the  total  number  of  VH 
sequences
19. Identical VH sequences could either be derived from the same cDNA 
or from different B cells having identical VH genes. An minimal estimate was made 
by excluding identical VH sequences from the calculation (so consider them as 
derived from the same B cell), while a maximum estimate was made under the 
assumption that also identical VH sequences were derived from different B cells. 
The estimates of the number of B-cells precursors and their standard deviations 
were calculated using formulas of Chao and Lee
20. The number of B cells precursor 
is  estimated  by  dividing  the  number  of  observed  classes  of  different  B  cell 
precursors by the sample coverage, with a correction for non-equal class sizes. The 
95% Confidence Intervals (CI) were calculated by transforming the estimated B 
cells to the natural logarithm scale, calculated 95% CI’s on this scale and transform 
them back to the original scale. 
2.4.8   Statistical analysis. 
The  areas  under  the  individual  peaks  in  the  spectrotypes  were  calculated  and 
compared to a standard normal distribution with a Kolmogorov-Smirnov test for 
normality with the SPSS 12.0.2 program. Curves were considered to be different 
from a normally distributed Gaussian curve with p-values > 0.05. 
2.4.9   Online Supplemental Material 
Table  S1  and  S2  contains  the  VH  gene  and  somatic  mutation  analysis  of  the 
sequences of P1, P2 and P3 (S1) and P4 (S2). Table S3 describes the H-CDR3 
sequences of all analyzed sequences.  
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Abstract  
Gastrointestinal tract is a complex niche and is the main port of entry of many 
pathogens that trigger a wide range of disease like inflammatory bowel disease 
(IBD) and colon cancer. Antibodies are effective for treating such diseases, but a 
system capable of local delivery at site of the pathology, thus avoiding systemic 
side effects, is not yet available. Here we report a novel recombinant scFvSIgA1 
protein produced by Lactococcus lactis, anchored to bacterial membrane, which 
retains its full immuno-recognizing potential. The scFv fragment employed was a 
sequence  targeted  to  a  colon  cancer  epitope,  epithelial  glycoprotein  protein-2 
(EGP-2). Accordingly L. lactis expressing this chimeric protein was capable of 
binding cells expressing this epitope. Expression of specific antibodies on bacteria 
may  allow  local  delivery  of  anti-cancer  agents  produced  by  such  bacteria  in 
conjunction with the antibody and provides a new avenue in the quest for targeted 
drug delivery.  Recombinant scFv SIgA on Lactococcus Lactis 
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3.1   Introduction 
The  gastrointestinal tract is  the locus  for  many  different  pathologies, including 
cancer and inflammatory disease, whose treatment remains problematic. Although 
substantial insight has been gained in the pathogenesis of these diseases (Braat et 
al.,  2006a;Vogelstein  and  Kinzler,  2004),  translating  this  knowledge  to  novel 
therapy  remains  troublesome.  These  problems  derive  from  the  difficulty  of 
delivering  functional  protein  therapeutics  to  the  mucosa  of  the  digestive  tract, 
mainly as a consequence of the protein-structure hostile nature of the lumen of the 
tract  and  the  occurrence  of  unwanted  side  effects  when  such  proteins  are 
introduced  in  a  systemic  fashion.  Molecules  that  normally  reside  in  the  tract, 
however, should be able to withstand protein degradation. The principal antibody 
on  most  mucosal  surfaces  is  Secretory  Immunoglobulin  A  (SIgA).  It  is  a 
polypeptide  complex  consisting  of  dimeric  IgA,  the  linking  J  chain  and  the 
secretory component. Its molecular stability and its in general anti-inflammatory 
properties  make  SIgA  an  apparently  ideal  molecule  to  function  in  passive 
protective  immunity  strategies  involving  its  exogenous  application  to  mucosal 
surfaces. Obvious candidates for such a strategy are conditions in the levels of 
endogenously produced IgA are reduced, e.g. in selective IgA deficiency, and HIV 
patients  IgA  is  reduced  or  absent.  Similar  conditions  appear  when  patients  are 
treated with immunosuppressive drugs. Evidently, however, immunoneutralisation 
of specific disease-related proteins is also an exiting possibility (e.g. neutralization 
of mucosal TNF in Crohn’s disease; (Van den Brande et al., 2006)). The possible 
use of SIgA for the treatment of disease is further facilitated by the advent of DNA 
recombinant  technology  which  now  enable  the  generation  of  monoclonal 
Antibodies (mAb) incorporating selective antibody fragments (scFv). The problem 
however how to get such molecules at their intended site of action in the digestive 
tract remains. 
Poly immunoglobulin receptor (pIgR) is expressed on all the intestinal epithelial 
cells (Brandtzaeg et al., 1999). Dimeric IgA, secreted by these plasma cells, binds 
to  the  pIgR  present  on  epithelial  cells  of  the  mucosa  and  is  subsequently 
transported to the lumen of the gut. Then the IgA is released into the gut lumen 
together with the extracellular part of the pIgR as secretory IgA (SIgA) (Johansen 
and  Brandtzaeg,  2004).  pIgR  is  composed  of  six  domains  the  6th  domain 
containing  the  protease  cleavage  site.  This  cleavage  site  on  the  pIgR  can  be 
exploited for specific drug delivery because epithelial cells have protease activity 
capable of specifically hydrolyzing and cleaving this site in the complex. A part of 
the  pIgR  remains  bound  to  the  polymeric  immunoglobulin to  become  SIgA  or 
SIgM.   
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A specific receptor for the IgA Fc region (FcaRI) exists; it is a novel apoptotic unit 
active systemically but not in the mucosa. In addition to its anti-inflammatory and 
inhibitory  signaling  action,  it  seems  essential  for  controlling  tumor  growth 
(Kanamaru et al., 2006). A number of reports showed that therapeutic antibodies 
are able to trigger immune responses via FcaRI. These antibodies can either be 
intact IgA or bispecific antibodies (BsAb) that recognize both the ectodomain for 
FcaRI and the tumor antigen of interest (Valerius et al., 1997). In a comparison of 
hapten-directed antibodies of different human isotypes, IgA2 was found to be more 
effective.  Also,  IgG  isotypes  recruits  neutrophils  and  induces  tumor  cell  death 
(Valerius et al., 1997). Similarly, an IgA1 antibody against EpCAM proved more 
effective than IgG1 recruiting neutrophils to kill EpCAM-positive tumor cells in 
solid tumors (Huls et al., 1999). Ideally, such antibodies would only be delivered at 
the intended site of action, i.e. the tractus digestivus where the EpCAM-bearing 
colon cancer cell resides, but strategies for gut-specific delivery have been poorly 
researched hitherto.  
Despite  the  high  production  costs  and  the  occurrence  of  systemic  side  effects, 
antibody-based immunotherapy has become an effective treatment for a number of 
different cancers. Therapeutic monoclonal antibodies (mAb) can be used to induce 
tumor  cell  death  by  a  variety  of  mechanisms.  For  example,  by  cross-linking 
antigens on tumor cells leading to: apoptosis, cell cycle arrest or the inhibition of 
cell proliferation (Glennie and Johnson, 2000). Smaller recombinant engineered 
antibody  fragments  and  variants  are  now  emerging  as  credible  conventional 
antibody based immunotherapy. These fragments preserve the targeting specificity 
of  whole  mAbs  and  can  be  economical,  furthermore  possess  a  wide  range  of 
diagnostic and therapeutic efficacy. The first clinical trial using scFv in ovarian 
cancer patients was reported in 2000 by the group of Alvarez et al (Alvarez et al., 
2000).  This  successful  clinical  trial  opened  a  new  era  to  many  recombinant 
antibodies  fragment  variants  like  dibodies,  triabodies  etc.  These  fragments  are 
extensively studied in various human carcinomas such as colorectal, breast and 
small  cell  lung  cancer  (Balzar  et  al.,  1999;Moldenhauer  et  al.,  1987).  The 
possibility to engineer this treasure of immunoneutralizing DNA sequences into 
stable IgA molecules greatly adds to the appeal of SIgA exotherapy, despite the as 
yet unsolved production and delivery problems. 
A possible target for SIgA exotherapy is epithelial glycoprotein-2 (EGP2), a well-
established target antigen in colorectal cancer that is overexpressed on the cell 
surface  of  various  human  cancinomas  (Balzar  et  al.,  1999;Moldenhauer  et  al., 
1987). Whereas in normal epithelia, EGP-2 expression is limited to the baso-lateral 
membrane and thus inaccessible for SIgA molecules present in lumen of the tracts, Recombinant scFv SIgA on Lactococcus Lactis 
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colorectal  cancer  cells  lose  this  polarity  of  EGP2  expression  (Bremer  et  al., 
2004;Bremer  et  al.,  2005).  The  advantage  of  targeting  EGP-2  is  that  it  is  not 
present in the circulation and has been extensively studied in antibody-mediated 
imaging (Ragnhammar et al., 1993b;Ragnhammar et al., 1993a;Riethmuller et al., 
1998). MOC31 scFv recognizes human EGP2 with constant gamma 1 chain and is 
thus ideally suited for engineering into SIgA for colon cancer SIgA exotherapy. 
Such SIgA exotherapy still critically awaits a solution to the delivery problems. 
Importantly a new mucosal delivery strategy has emerged via the execution of a 
first  clinical  trail  using  transgenic  Lactococcus  lactis  producing  IL-10  to  treat 
crohn’s disease, which was published by Braat et al. If L. lactis can be coached to 
produce scFv, the window to clinically useful SIgA exotharapy for colon cancer 
therapy  and  for  other  treatment  diseases,  will  be  opened.  This  consideration 
prompted us to construct scFvMOC31 IgA for targeting colon cells employing L. 
lactis as a heterologous expression system. The fragment antigen binding (Fab) 
region  was  derived  from  mAb  MOC31  that  can  recognize  EGP-2  and  it  was 
extended with constant a gene. The sixth domain (Sc) contains the cleaving sites 
and  the  remaining  5  domains  of  pIgR  were  cloned  in  MOC31  vector  to  get 
MOC31SIgA1.  Finally  we  expressed  this  scFv  as  a  part  of  natural  membrane 
protein  of  L.  lactis  bacteria.  Membrane  expression  was  confirmed  by  western 
blotting. These many changes in the MOC31 protein could recognize the EGP-2 
which were transiently expressed on the Ramos cell. Thus in this paper, we report 
an  important  next  step  in  the  quest  for  anti-colon  cancer  SIgA  exotherapy. 
Furthermore, the ability of antibody-expressing bacteria to bind to specific motifs 
also enables specific targeting to cell expressing such motifs and should thus allow 
treatment of these cells with bacterially-produced products co-engineered into the 
bacteria with the antibody. 
3.2   Materials and methods. 
3.2.1   Construction of scFvMOC31IgA1/2. 
The  Ca1/2  genes  were  amplified  from  normal  ileum  of  human  cDNA  with 
EcoRI/HindIII  restriction  sequences  (Table-1)  using  PCR  method.  Cg1  region 
present in MOC31IgG plasmid (Helfrich et al., 1998) was replaced with Ca1 and 
Ca2 using above mentioned restriction enzymes to get MOC31-IgA1 and MOC31-
IgA2 constructs respectively (Figure.1B). 
3.2.2   Construction of scFvMOC31IgA1SC1. 
Sixth domain of human pIgR was amplified from SC-his6 plasmid (Schjerven et 
al.,  2001)  and  was  designated  as  SC1.  MOC31SC1IgA1  and  MOC31SC1IgA2  
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were  constructed  by  inserting  SC1  using  BglII/PfoI  restriction  enzymes  into 
MOC31-IgA1 and MOC31-IgA2 (Figure.1C). 
3.2.3   SC2 
The remaining 5 domains of pIgR (referred as SC2) were amplified from SC-his6 
plasmid. For subcloning, 5’HindIII and 3’ Van91I were introduced in SC2. The 
entire five domains were cloned into the MOC31SC1IgA1 and MOC31SC1IgA2 to 
get MOC31SIgA1/SIgA2 (Figure.1D and 2a). 
3.2.4   pNZmlePSIgA1 
pNZmleP produce a membrane protein that is a malate transporter protein in L. 
lactis.  The  pNZmleP  was  constructed  as  described  in  reference  ((Bandell  and 
Lolkema,  2000)).  To  ligate  the  entire  MOC31SIgA1  into  the  pNZmlep,  AflIII 
restriction site was used. Additional AflIII restriction site was added at the 3’end of 
the MOC31SIgA1 by PCR. MOC31SIgA1 was ligated at the C-terminal of the 
mlep gene at the AflIII restriction site (Table-1). The cells with right orientation 
plasmid can grow. Because the AflIII restriction enzymes digest ACRYGT and we 
used  different  nucleotide  at  the  end  of  the  MOC31SIgA1  sequence.  Ligation 
mixtures were transformed to L. lactis NZ9000 using an electroporation protocol 
described by Holo and Nes (Holo and Nes, 1989) (Figure 2b). 
3.2.5   COS-7 cells transfection. 
Two six wells plates of COS-7 cells were transiently transfected with supercoiled 
plasmid DNA using the GeneJammer transfection reagent (Stratagene) according 
to the manufacturer’s recommendations. Transfection efficiency was normally in 
the  range  5–10%.  As  a  result  all  cellular  preparations  contain  90–95% 
untransfected cells. After two days, one transfected plate was fixed with acetic acid 
and Ethanol. These cells were used for immunoflourescent staining. The second 
plate was incubated for three days and scFvSIgA1 protein conditioned medium was 
aspirated  and  stored  at  -20°C  until  analysis. The rest  of the  COS-7  cells  were 
washed twice  with  PBS, pelleted  and  stored  at  -20°C  until  analysis.  Later, the 
proteins from these cells were extracted and stored at -80
0C. Recombinant scFv SIgA on Lactococcus Lactis 
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3.2.6   Bacterial strains, growth condition and induction of 
proteins. 
In our experiments E. coli K-12 strain was grown on LB agar and broth. The cells 
were  induced  by  IPTG  to  produce  the  proteins.  L.  lactis  strain  NZ9000  was 
cultivated semi-anaerobically at 30°C in M17 broth at pH 6.5, supplemented with 
1.0%  (w/v)  glucose  and  5  µg/ml  chloramphenicol  when  carrying  pNZmlep  or 
derivatives. For isolation of membrane vesicles, cells were grown to an OD600 of 1, 
after which transcription from the nisA promoter was switched on by the addition 
of  0.2%  (v/v)  culture  supernatant  of  the  nisin  A  producing  strain  NZ9700  (de 
Ruyter et al., 1996). Cells were harvested 1 h after the induction of nisin. 
 
Serial 
no 
Primer name  Primer sequence  Restriction 
enzyme sites 
Gene of interest 
to amplify 
1  IgAEcoRI2F  CTAGAATTCCCGACCAGCCCC
AAGG 
EcoRI  C a region 
2  IgAHIndIII2B  CGAAAGCTTGTAGCAGGTGCC
GTCCA 
HindIII  C a region 
3  SC1bgl2kas1F  AGATCTTAGGCGCCGACGCT
GCTCCTGATG 
BglII & Kas1  SC1 6
th domain 
of PIgR  
4  SC1pfo1afl2B  TCCTGGACTTAAGCTGCCGGA
ATCCAC 
PfoI & AflII  SC1 6
th domain 
of PIgR 
5  SC2hind3cla1F  CAAGAAGCTTATCGATTTTGG
TCCCGAGGAGGTG 
HindIII & 
ClaI 
SC2 5 domains 
of PIgR 
6  SC2van91sal1B  AATCCATAGGTTGGTTAGTC
GACCGCTGCCTTCCTCTC 
Van91 SalI  SC2 5 domains 
of PIgR 
7  extraSC1Afl2age1cla1F  CTTAAGACCGGTTATCGATGC
TGCTC 
AflII, AgeI, 
ClaI 
Extra SC1 6
th 
domain of PIgR 
8  ExtraSC1Pfo1B  TCCTGGAGAATCCACAGATG  PfoI  Extra SC1 6
th 
domain of PIgR 
9  LL-AflIII-startsIgA-F  ACGCGTCCACCATGGAGACAG
A 
AflIII  Extra Afl III site 
10  LL-AflII-BssHI-sIgA-B  ACTTAAGGCGCGCCTGCCGGA
ATCCACA 
AflII, BssHI  Extra Afl III site 
11  Van91I-AflIII end-sIgA 
F 
CCAACCTATGGACGTGTATGA
ATGGGAGCAGTG 
Van91I  Extra Afl III site 
end SIgA 
12  MunI-end-sIgA B  CAATTGGTTCAGGGGGAGGT  MunI  Extra Afl III site 
end SIgA 
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Table-1: Primer list, which was used to amplify different gene to construct scFv 
SIgA. The restriction enzymes introduced into the vector are underlined and bold. 
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Fig.  1  Figure-1:  schematic  representation  of  scFvSIgA  development  from 
MOC31IgG  with  the  plasmid  size  and  proteins  prediction  with  their  important 
properties.  Recombinant scFv SIgA on Lactococcus Lactis 
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Figure-2: (A) Schematic representation of scFvSIgA expressed on Lactococcus 
Lactis membrane protein mlep, (B) Detail description of the entire scFv 
MOC31SIgA with their respective functions. 
3.2.7   Membrane vesicle preparation of MOC31pNZmlepSIgA1. 
Cell were washed with 100mM KPO4, pH 7.0 and then resuspended in 100mM 
KPO4, pH 7.0 with 20% glycerol. Cells were recaptured in a bead beater at force 
6.5 for 30 seconds for 3 times. Whole cells were removed by centrifugation at 
16000 x g for 15 min and membrane fractions were removed by centrifugations at 
267000 x g for 30 min. Vesicles were resuspended in 100mM KPO4, pH 7.0 with 
20% glycerol and stored in -80 until used.  
3.2.8   Immunofluorescent staining. 
Cover slips containing transfected cells were fixed with ethanol and acetic acid. 
The  cells  transfected  with  MOC31-IgA  variants  were  stained  with  Anti-human 
IgA-FITC (Dako). MOC31-IgG transfected cells were stained with Alexa fluor 488 
goat anti human IgG (H+L) (molecular probes). DAPI was used to counter stain the 
nuclei.  
3.2.9   ELISA. 
scFv  MOC  variant  levels  in  cultured  supernatant  and  in  protein  extract  were 
measured  with  an  IgA  and  IgG  specific  enzyme-linked  immunosorbent-assay 
(ELISA).  Duplicate  wells  of  serially  diluted  supernatants  were  analyzed  as 
described previously (Guikema et al., 1999).  
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3.2.10   Jurkat and Ramos cells FACS 
Human  cell  lines  Jurkat  and  Ramos  were  stably  transfected  with  EGP-2  as 
described  previously  (Bremer  et  al.,  2004)  and  cultured  in  RPMI  (invitrogen) 
media supplemented with 15% fetal calf serum. These cells were incubated for 30 
minutes with transfected COS-7 supernatant and protein extract of different MOC 
variants. After a brief wash the cells were incubated with goat anti human IgA-PE. 
The FACS analysis was performed on Coulter EpicTM Elite flow cytometer. Data 
were  analyzed  by  using  flowjo  software  version  5.4.5  according  to  the 
manufactures protocol (Tree Star Inc). 
3.2.11   Western blotting 
Expression  of  all  MOC31  scFv  was  confirmed  by  the  western  blotting.  The 
expected size of proteins and percentage of the gel are described in the Table-2 and 
stained  with  comassie  blue.  For  immunodetection,  samples  were  separated  by 
reduced  SDS-PAGE  and  electrotransferred  to  a  nitrocellulose  membrane.  The 
membrane was blocked with 5% non-fat milk in PBS-T buffer (PBS containing 
0.05%  Tween  20),  and  then  incubated  with  different  (Table-2)  antibodies 
separately for 2 hours. The membrane was washed three times with PBS-T buffer 
and  then  incubated  in  HRP  conjugated  secondary  antibody  for  1  hour.  The 
membrane was washed three times with PBS-T buffer and the expressed proteins 
were visualized using ECL plus western blotting detection system (Amersham). 
3.3   Results 
3.3.1   Construction of scFvMOC31:SIgA1 
DNA  encoding  the  Ca1  and  Ca2  of  IgA1/IgA2  was  generated  by  PCR.  The 
resulting 1081 and 1053 bp PCR product encoded amino acids 330 and 317 of Ca1 
and Ca2 respectively. These DNA fragments were inserted separately in the EcoRI 
and  HindIII  of  eukaryotic  expression  vector  pMOC31IgG1,  yielding  plasmid 
pMOC31IgA1/IgA2. Sequence analysis confirmed the correct and in-frame of the 
pMOC31IgA1/IgA2 (data not shown).  Recombinant scFv SIgA on Lactococcus Lactis 
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3.3.2   SC1 
SC1 is the sixth domain of the PIgR that contains the proteolytic cleavage site. SC1 
DNA fragment was amplified from the entire PIgR vector. BglII and PfoI that is 
present within the framework 1 region. By inserting the SC1 using these restriction 
sites, 58 nucleotides from the end of FR1 and beginning of CDR1 region were 
deleted. This resulted in a new plasmid pMOC31IgA1SC1. 
3.3.3   SC2 
SC2 contained the 2 domains of the PIgR was amplified with HindIII and Van91I 
site.  A  stop  was  inserted  at  the  beginning  of  the  second  domain,  because  the 
domain 3 and 4 are used by the Streptococcus pneumoniae to invade the epithelial 
cells(Elm et al., 2004). The resulting 700bp PCR product was successfully cloned 
into the MOC31IgA1SC1 plasmid to get MOC31SIgA1.  
3.3.4   pNZmlePSIgA1 
Entire MOC31SIgA1 was ligated to the plasmid pNZmlep at the AflIII. AflIII has a 
special feature since it recognize ACRYGT (where R stands for A or G and Y for 
C or T ). In plasmid pMOC31SIgA this recognizes site is ACRYGT at the 3’ end 
and  ACRYGT  at  the  5’  end.  This  was  very  much  equivalent  of  using  two 
restriction enzymes. 
3.3.5   COS-7 cells transfection. 
COS-7  cells  were transiently  transfected  with the  entire MOC31  variant.  Right 
orientation of the constructs was validated by this method as well as by sequencing. 
The transfection efficiency of prokaryotic expression vector MOC31SIgA1 10% as 
shown by immunopositive for anti-human  IgA-FITC antibodies (Figure-3). The 
presence  of  secreted  scFv  MOC31  variants  in  the  transfected  COS-7  cells 
supernatant were analysed by ELISA (Figure-4). The positive control MOC31IgG1 
was produced in higher quantity than the other scFv variants. 
3.3.6   Western blotting 
Western  blotting  was  performed  on  all  the  MOC  variants.  MOC31  transfected 
COS-7 supernatant and COS-7 cell lysate were used for western blotting. All the 
products gave a expected band with a correct size (Figure-5). Membrane vesicle 
was  prepared  from  MOC31pNZmlepSIgA1  followed  by  western  blotting  for 
pNZmlep and pNZmlepSIgA1. Total protein precipitation of L. lactis with TCA 
was performed and used for western blotting. From the above set of experiments 
we concluded that all the MOC variants were produced, but with a low yield. In  
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order to test the functional activity of these proteins before using in the in vivo 
experiments, following experiment where performed. 
 
Table-2: The scFvSIgA was developed from the backbone MOC31IgG. This table 
contains the number of amino acid of each MOC31 vector, their expected size of 
proteins. To confirm their expression the proteins was probed with different 
specific antibodies. 
 
 
MOC31SIgA1 MOC31IgA1 MOC31IgG MOC31SIgA1 MOC31IgA1 MOC31IgG
 
Figure-3: COS-7 cells were transfected with MOC31 vectors, followed by staining 
with anti-human IgA FITC and DAPI.  
3.3.7   Jurkat and Ramos cells FACS 
Flow  cytometric  analysis  of  the  retrovirally  transduced  cell  lines  Jurkat.EGP2, 
Ramos  cells  confirmed  the  cell  surface  expression  of  EGP2.  MOC31-IgA 
Number  Vector name  Number 
of 
amino 
acid 
Protein size  Percentage 
of SDS-
PAGE 
GEL 
Primary antibody 
used 
Secondary antibody 
used 
1  pMOC31IgG  498   54.47 kD  10%  1. Anti human IgG-
HRP, 
2. Mouse anti-HA 
1. - 
2. Anti mouse-IgG-
HRP 
2  pMOC31IgA1  603   64.54 kD  10%  1. Anti-human IgA-
HRP,  
2. Mouse Anti-HA 
1. – 
2. Anti mouse-IgG-
HRP 
3  pMOC31IgASC1  638  68.05 kD  10%  1. Anti-human IgA-
HRP,  
2. Mouse anti-HA 
1. – 
2. Anti mouse-IgG-
HRP 
4  pMOC31SIgA1  1188  128.53 kD  8%  1. Anti-human IgA-
HRP,  
2. Mouse Anti-HA. 
1. – 
2. Anti mouse-IgG-
HRP 
5  pNZmleP  446  47.79 kD  12.5%  1. Rabbit Anti-his  1. Anti rabbit-IgG- 
HRP 
6  pNZmlePSIgA(sc
Fv SIgA) 
1675  180.84 kD  6%  1. Anti-human IgA-
HRP,  
2. Rabbit Anti-his 
1. – 
2. Anti rabbit-IgG- 
HRP Recombinant scFv SIgA on Lactococcus Lactis 
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containing supernatant were able to bind to these EGP2 on these cell surfaces and 
gave  strong  increase  in  percentage  of  functionally  active  scFv.  The  binding  of 
MOC31-IgA containing supernatant to the EGP2 expressed Ramos cells proves 
that IgA is indeed functional (Figure-6). 
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Figure-4. MOC31 vector trasfected COS-7 cell’s supernatant was used to analysis 
their protein production by ELISA. 
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Figure-5: Analysis of recombinant scFv polypeptide, proteins expression and their 
identity confirmed by immunodetection using specific antibody. The 
polyacrylamide with different percentage of SDS-containing gels was prepared. 
The Mr of the scFv and Ab indicated was calculated from protein markers run in 
parallel. 
MOC31IgA1 MOC31IgG MOC31SIgA MOC31IgA1 MOC31IgG MOC31SIgA  
Figure-6: Ramos cells were transfected with EGP-2. Supernatants of COS-7 cells 
which were transfected with different MOC31 vector was incubated with  
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transfected Ramos cells. This was followed by FACS analysis, to show MOC 
variant retains its binding properties. 
3.4   Discussion 
The clinical trail employing IL-10 expressing L. lactis for the treatment of Crohn’s 
disease  has  demonstrated that  such  bacteria  constitute  a  viable  strategy  for  the 
mucosal delivery of therapeutically interesting proteins (Braat et al., 2006b). This 
consideration prompted us to explore the potential usefulness for such bacteria to 
deliver the gut-stable IgA molecules. This would be important because already 
large  variety  of  antibody  fragments  is  available,  immunoneutralizing  a  large 
spectrum of clinically interesting molecules and their local production in a gut-
stable fashion could be exceedingly useful. Here we report a novel recombinant 
scFvSIgA1 protein produced by L. lactis anchored to their membrane which retains 
its full immuno-recognizing potential. As a model of an example intestinal disease 
for which such SIgA exotherapy might be useful, we targeted our scFv to colon 
cancer. With the recent advances in molecular biology, it has become possible to 
translate  improved  characterization  of  tumor  antigens  to  tailored  design  of 
recombinant antibodies specific for these antigens. ScFv molecules on their own 
generally do not have any built-in effector capacity nor are they able to engage 
natural  effector  molecules.  We  generated  an  eukaryotic  expression  plasmid, 
scFvSIgA1,  that  specifically  could  recognize  their  antigen.  To  demonstrate  the 
usefulness of our vector system we analyzed it specificity by binding to EGP-2 
antigen, but it is obvious that the same strategy can be employed with any scFv 
fragment. 
Upon exposure to non-tolerated antigens, the human humoral immune response 
generated a remarkable range of antibodies. In this study we attempt to design 
tumor targeting human recombinant scFvSIgA1 with binding specificity for the 
antigen  EGP-2.  This  molecule  contains  an  antigen  binding  site  (Fab)  which 
specifically binds to the EGP-2 antigen, constant a gene as their Fc region and the 
secretory component(SC) domains. The sixth domain of PIgR that contains the 
cleavage site was designated as SC1 and was inserted at the beginning of the Fab 
region and other domains of pIgR were included after the Fc region (Figure2). 
EGP-2 is abundantly present in the cells of human carcinomas of different origins 
and more importantly such carcinoma cells express this protein at apical side of the 
cell (in contrast to untransformed cells) making this epitope accessible for SIgA 
from  the  lumen.  Various  mAbs  directed  against  EGP-2  have  been  extensively 
studied  in  diagnostic  and  therapeutic  approaches  in  cancer  (Bremer  et  al., 
2004;Bremer et al., 2005). As colon cancer which also express high amount of Recombinant scFv SIgA on Lactococcus Lactis 
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EGP-2, this disease is a candidate for experimental treatment with the scFvSIgA-
producing organism created in the present study. In this context it is especially 
interesting that the antibody can be used to target the bacterium to the cancer cell, 
whereas a secondary produced bacterial product can then be employed to kill the 
cancer cell. In this context it is important to mention that whereas the SC2 part 
makes the scFvSIgA more stable (Almogren et al., 2006) in the intestinal niche, the 
SC1 contains a peptidase cleavage site. This site can be cleaved by the protease 
enzymes produced by the epithelial cells. By fusing small molecules like cytokines 
or signaling molecules between the SC1 could be delivered locally to the affected 
cells. 
The IgA Fc region was used to construct scFvSIgA because IgA is a  mucosal 
immunoglobulin and contains intrinsic properties generally considered to confer 
protection  to  the  immunoglobulin  in  the  hostile  gut  environment.  Many 
monoclonal antibodies and scFv are specifically targeted against EGP2 in tumor 
related to systemic immunity (Withoff et al., 2001). These antibodies or the scFv 
contains the IgG Fc region. Upon binding to the Fc receptor on effector cells they 
elicit  effector  function  like  Antigen  Dependant  Cell-mediated  Cytotoxicity 
(ADCC),  Complement  Dependant  Cytotoxicity  (CDC)  response  and  apoptosis 
(Schaedel and Reiter, 2006). It is well document to show that FcaRI elicit immune 
responses efficient than IgG Fc receptors (Gomes and Herr, 2006). Overall it seems 
that the use of IgA Fc region may be superior both in terms of stability of the 
chimeric molecule and in terms of bioeffectivity, and thus offers advantages for the 
development of antibodies to treat intestinal carcinoma and other mucosal disease.  
Delivery  of  therapeutical  proteins  locally  have  many  advantages  over  the 
administrating  systemically  (Yuvaraj  et  al.,  2007).  This  recombinant  human 
scFvSIgA is successfully expressed on the surface of the bacteria like L. lactis 
which is generally regard as safe (GRAS). Hence, delivery via oral administration 
of  the  organism  for  treating  gastrointestinal  cancer  cells  should  be  possible. 
Interestingly, the specificity of the antibody can be altered by changing the Fab 
region. By selecting appropriate VH genes one can generate natural antibodies or 
pathogen specific antibodies, of obvious interest for treatment of IgA deficiency 
patients or other intestinal diseases. 
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Abstract 
Among  the  most  fundamental  poorly  understood  issues  in  CD  is  the  regional 
restriction of the disease. Areas not showing any obvious inflammation are lying 
next  to  areas  with  intense  ulceration.  To  elucidate  the  molecular  basis  of  this 
phenomenon  we  were  interested  to  see  whether  we  could  obtain  evidence  for 
spatial differences with respect to the nature of the immune system. To this end we 
analysed the IgA repertoire in different biopsies samples from granulomatously 
inflamed tissues, and compared results to biopsy samples from normal tissue of 
different segments of the intestine (ileum) obtained from the same CD patients. We 
demonstrate marked differences in the immune repertoire between inflamed and 
inflamed parts of the intestine. Thus the spatial restriction of the disease is reflected 
in  a  spatially  different  identity  of  mucosal  system.  Evidently,  such  spatial 
restriction may be an important factor into explaining why Crohn’s disease has a 
highly localised phenotype. Immunoglobulin repertoire in Crohn’s Disease 
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4.1   Introduction 
Inflammatory bowel disease (IBD) is a chronic disease of the digestive tract, and 
usually  refers  to  two  related  conditions,  namely  ulcerative  colitis  and  Crohn' s 
disease (CD). CD is characterized by a chronic-intermittent transmural, segmental, 
and typically granulomatous inflammation of different segments of the intestine 
mainly located in the small intestine (ileum) and or in the colon. Although the 
pathogenesis  of  IBD  remains  elusive,  it  appears  that  there  is  an  exaggerated 
chronic  activation  of  the  immune  and  inflammatory  cascade  in  genetically 
susceptible individuals. In this sense, it is well described that the mutation in the 
Nod2 gene of subgroup of CD patients patient leads to the activation of immune 
competent  cells  and  uncontrolled  chronic  mucosal  inflammation  (Braat  et  al., 
2005).  In  the  last  years,  there  is  increasing  experimental  evidence  that  this 
deregulated immune reactivity against luminal bacteria plays a major role in the 
induction and perpetuation of this pathology (Podolsky, 2002). 
Although insight into the pathogenesis of Crohn’s disease increases rapidly (e.g. 
(Comalada  and  Peppelenbosch,  2006)),  it  is  still  not  fully  understood  why  the 
mucosal immune response is over-reactive in patients with this intestinal condition. 
However, it has become more and more evident that alterations in innate immunity 
are crucial in the pathogenesis of CD and involve a deregulated Th1 lymphocyte 
response (Canto et al., 2006;Romics, Jr. et al., 2006). Although CD4
+ T cell subset 
functions have been studied in great detail, the contributions of other immune cells 
to  the  development  of  IBD  are  just  beginning  to  be  understood.  In  particular, 
irregularities  in  B  cell  development  and  antigen-specific  immunoglobulin 
production may be critical for understanding the pathogenesis of IBD. A abnormal 
immunoreactivity of serum or mucosal antibodies toward enteric bacterial flora has 
been  reported  in  both  animal  models  and  IBD  patients(Brandwein  et  al., 
1997;Macpherson et al., 1996;Olson et al., 2004;van der Waaij et al., 2004). In CD 
patients, it has been reported a large relatively increase in the number of IgG-
secreting cells (especially of the IgG1 subclass)(Dorn et al., 2002) associated with 
the lowest frequency of IgM memory B cells (Di Sabatino et al., 2004) and IgA
+ 
plasma  cells.  Moreover,  a  variety  of  autoantibodies,  including  ANCA,  anti-
erythrocyte  antibodies,  pancreatic  antibodies,  lymphocytotoxic  antibodies,  anti-
Saccharomyces  cerevisiae  antibody  (ASCA)  and  antibodies  to  epithelial  cell 
components also have been described (Seibold et al., 1996). The importance of 
these autoantibodies in the pathogenesis of CD is unclear. It has been suggested 
that antibodies with specificity for epithelial cell components mediating antibody-
dependent cellular cytotoxicity or antibodies involved in epithelial deposition of 
activated  complement  can  contribute  to  mucosal  injury  in  CD  (Seibold  et  al., 
1996).  
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The IgA isotype, which is considered as a mucosal immunoglobulin plays a critical 
role  in  preventing  the  intestinal  invasion  of  both  pathogenic  and  commensal 
bacteria (Macpherson et al., 2001). However, the chronicity of IBD lesions implies 
failure  of  antigen  removal  with  constant  activation  of  various  non-specific 
biological  amplification  mechanisms.  This  unfavourable  development  involves 
sustained inflammation and tissue damage, featured as severely altered homeostasis 
and defective mucosal barrier function (Brandtzaeg, 2006). In active colonic IBD 
lesions there is also a shift from the IgA2 to the less stable IgA1 subclass (Kett and 
Brandtzaeg, 1987); more than 50% of the increased mucosal IgA1
+ plasma cells 
subset  is  J-chain  deficient  therefore  producing  monomeric  IgA  that  cannot  be 
translocated externally by pIgR (Brandtzaeg and Korsrud, 1984) and (Kett et al., 
1988).  The  same  happens  with  expanded  IgA2-producing  plasma  cells  with  a 
substantial fraction (25–35%) (Kett et al., 1988). Thus, it seems evident that in IBD 
a  less restricted  leukocyte  extravasation  due  to  a  changed  endothelial  adhesion 
pattern allows B cells expressing characteristics of systemic immunity to enter the 
lamina  propria  together  with  ordinary  inflammatory  leukocytes  (Brandtzaeg, 
2006).In  this  context,  it  is  interesting  to  note  that  recent  work  of  our  group 
demonstrated that the pool of IgA production cells in the normal ileum are derived 
form a limited set of precursors and that only part of these cells shows signs of 
antigen  selection,  as  suggested  from  a  study  of  the  IgA  repertoire  in  healthy 
individuals (Yuvaraj et al, submitted). 
Among  the  most  fundamental  poorly  understood  issues  in  CD  is  the  regional 
restriction of the disease. Areas not showing any obvious inflammation are lying 
next  to  areas  with  intense  ulceration.  To  elucidate  the  molecular  basis  of  this 
phenomenon  we  were  interested  to  see  whether  we  could  obtain  evidence  for 
spatial differences with respect to the nature of the immune system. To this end we 
analysed the IgA repertoire in different biopsies samples from granulomatously 
inflamed tissues, and compared results to biopsy samples from normal tissue of 
different segments of the intestine (ileum) obtained from the same CD patients. We 
demonstrate marked differences in the immune repertoire between inflamed and 
inflamed parts of the intestine. Thus the spatial restriction of the disease is reflected 
in  a  spatially  different  identity  of  mucosal  system.  Evidently,  such  spatial 
restriction may be an important factor into explaining why Crohn’s disease has a 
highly localized phenotype.  Immunoglobulin repertoire in Crohn’s Disease 
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4.2   Material and methods 
4.2.1   Ileum biopsies. 
After given informed consent (protocol approved by the medical ethical committee 
of the University Medical Center Groningen) terminal ileum biopsies were excised 
from the inflamed and non inflamed regions in 5 patients (Table-1). From patient 
625 two biopsies were taken from periphery of the different ulcer and 2 biopsies 
from the center of the ulcer. PBS was added to all the biopsies and centrifuged at 
1200 for 10 minutes. Later the supernant was used for gut microflora analysis and 
the tissues was digested trizol® for RNA isolation.  
4.2.2   Total RNA extraction and RT-PCR 
Total RNA was isolated from total ileum biopsies by the Trizol® method (Sigma 
Ltd  Zwijndrecht,  Netherlands)  according  to  manufacturer’s  instructions.  cDNA 
was produced by using Oligo-dT primers (Invitrogen, Breda, Netherlands) in a 
final  volume  of  30  ￿l  and  integrity  of  the  cDNA  was  analyzed  by  b-actin 
PCR(Guikema et al., 2003). VH primers used for different samples are as described 
by van Dongen et al (van Dongen et al., 2003). A 3’ Ca common (IgA common) 
primer  was  designed  that  can  be  used  for  both  IgA1  and  IgA2 
(GAATTCGAGTGGCTCCTGGGGGAA GA). On the basis of the sequenced PCR 
products  both  subtypes  of  IgA  can  be  distinguished  PCR  was  performed  as 
described  previously  (S.yuvaraj  submitted).  PCR  was  performed  for  35  cycles 
using a 60-second denaturizing step at 94
0C, 60-second annealing step at 60
0C and 
a 60-second extension step at 72
0C. The product was loaded onto agarose gel and 
the ethidium bromide stained band was recorded. 
Number  Patient number  Biopsy condition 
477-1  Not inflamed 
477-2  Inflamed 
477-3  Inflamed 
1 
477-4  Inflamed 
509-1  Not inflamed  2 
509-1  Inflamed 
513-1  Not inflamed  3 
513-2  Inflamed 
4  516-1  Not inflamed 
625-B1  Inflamed (periphery) 
625-B2  Inflamed (periphery) 
625-C1  Inflamed (center) 
5 
625-C2  Inflamed (center) 
 
Table-1: Biopsy sample from 5 CD patients.  
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4.2.3   Cloning and Sequencing IgA and IgG transcripts 
PCR products from all the biopsies were obtained by amplification of cDNA using 
the 5’ FR1 primer set in combination with a 3’ IgA common primer. PCR products 
were  gel  purified  using  a  gel  purification  kit  (Invitek,Germany),  cloned  into 
InsTAclone  vector  (Fermentas).  25  positive  clones  were  sequenced  using  an 
automated sequencing device as described(Guikema et al., 1999).  
4.2.4   Analysis of rearranged V genes 
Nucleotide  sequences  were  compared  with  the  IMGT  databases  of  germline 
sequences  (Giudicelli  et  al.,  2006)  and  VH-DH-JH  regions  were  analyzed  using 
IMGT Quest (Giudicelli et al., 2004) and Joinsolver (Souto-Carneiro et al., 2004). 
The lengths of the CDR3 domains of translated IgA heavy-chain transcripts were 
calculated as described previously (Rock et al., 1994). Replacement over silent 
mutation (R/S) ratios for FR and CDR were determined (Dammers et al., 2000). 
Sequences having identical VDJ rearrangements were defined as clonally related.  
4.3   Results 
We have studied the diversity of intestinal IgA and IgG heavy-chain transcripts 
obtained from ileum biopsies specimen of CD patients. IgA and  IgG encoding 
RNA was amplified from the inflamed and non inflamed biopsy by PCR using 
specific primers. High signals of IgA and IgG RNA were observed from all the 
disease  biopsies.  The  material  allowed  us  to  analyze  the  VH  family  usage  and 
evaluation of the relative propensity of IgA or IgG subclass of immunoglobulin 
production.  
4.3.1   Estimation of the number of B-cell precursors giving rise to 
IgA and IgG producing cells. 
Using the data from sequenced VH genes we estimated the number of different B 
cell  precursors  that  gave  rise  to  the  analysed  IgA  VH  gene  sequences  (in  one 
biopsy).  This  is  based  on  the  number  of  sets  of  clonally  related  sequences 
compared to the total number of obtained sequences from a certain biopsy and how 
well we cover the diversity of the Ig VH gene repertoire. This coverage of different 
precursors in our sample can range from 0% when every newly obtained sequence 
is unique to 100% when every newly obtained sequence represents a member of a Immunoglobulin repertoire in Crohn’s Disease 
    91 
 
 
 
 
 
previously described B cell clone. Using Good’s formula we calculated a minimal 
coverage in the samples for each biopsy, excluding all 100% identical sequences, 
and a maximal coverage when also identical VH sequences were considered to be 
derived from different B cells (Appendix Table-2). The minimal coverage ranged 
from 0% to 100% while the maximum was from 0% to 95%. The number of B-cell 
precursors that gave rise to the IgA producing cells in one biopsy was estimated 
using  Choe  and  Lee  formula  (Table-3)  (Chao  and  Lee,  1992).  The  minimal 
coverage estimate resulted in 110 B-cell precursors, while the maximal coverage 
estimate yielded 231 B-cells giving rise to the IgA producing cells in each biopsy. 
Patient 477 had only 1 and 3 precursors respectively from two biopsies, which 
apparently developed into the the entire complement of IgA producing cells in 
these  biopsies.  Apparently,  the  number  of  B  cell  precursors  yielding  the  IgA 
producing compartment is very limited and gives rise to IgA and IgG plasma cells 
both in inflamed and non-inflamed tissues (Table-4). Inflammatory B cells do not 
derive from a larger precursor compartment as observed in non-inflamed biopsies. 
Strikingly, the IgA producing B cell compartment derived from a much larger base 
of precursors when compared the set of IgA producing B cells.  
4.3.2   Clonally expanded ileum IgA and IgG B cells are 
commonly circulated. 
From each biopsy, 25 IgA sequences were analyzed and in total 12 biopsies were 
used. Of the 300 sequences, 243 sequences were productively rearranged (Table-
3). 41 sequences had 100% identical sequences resulting in 202 unique sequences. 
Some 100% identical sequences were observed from different biopsies within a 
single patient and could be assigned to different B cells, others were derived from 
the same biopsy not allowing assessment as to whether these identical sequences 
were derived from different B cells or whether we cloned multiple mRNA copies 
from a single B cell. In general, sequences are considered as clonally related if they 
have  the  same  H-CDR3  region,  i.e.  the  same  VDJ  joining.  B  cells  with  some 
mutations in the H-CDR3 regions can still be considered to be clonally related 
(Holtmeier et al., 2000). Sequences with identical H-CDR3 regions are observed in 
biopsies taken from one person at inflamed and non-inflamed ileal sites, suggesting 
a common precursor for a fraction of the B cells seen in both the inflamed and non-
inflamed tissue of the ileum. Fourteen sets of clonally related sequences that have 
most  mutations  in  common,  sequences  shared  between  different  biopsies,  were 
obtained (see Figure-1). Thus global expansions of B cells in the mucosal tissue 
seems a common feature of antibody repertoire in CD patients.   
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4.3.3   More mutations are observed in non-inflamed tissue-
derived ileal IgA genes as compared to inflamed tissue. 
SHM mechanism increases the diversity of the immunoglobulin repertoire. In the 
IgA  sequences  obtained  from  CD  patient  biopsies,  occurrence  and  nature  of 
somatic mutations were analysed by evaluation of these sequences with the known 
human germline VH sequences. Almost all IgA and IgG sequences display clear 
evidence for a high level of SHM, although two germline sequences were detected; 
one from inflamed region of diseased mucosa of patient 1 (sequence # 477-3 which 
represents an IgA) and the other was observed in the inflamed mucosa of patient 5 
(sequence  #  21.625-B1,  representing  a  IgG  isotype  nucleotide  sequence).  Non 
inflamed  biopsies  show  a  significantly  higher  number  of  IgA  gene  mutations 
(average  20.5  mutations  /  60  IgA  sequences)  when  compared  to  non  inflamed 
region-derived IgA genes (average 18.7/ 185 IgA sequences; p<0.05).  
The ratio of replacement (R) to silent (S) mutations for CDR in this study were 
calculated as described elsewhere(Dammers et al., 2000). 38% of the sequences 
from non-inflamed biopsy showed a significantly higher (p<0.05) R/S ratio in the 
CDR regions whereas 54% of inflamed IgA sequences exhibited significant R/S 
ratio. This IgA response in the inflamed regions may be due to antigen selection 
pressure and may thus indicate in the tractus of CD patients local differences in 
immune system function exist.  
4.3.4   Codon insertion and deletion is frequently observed in CD 
immunoglobulins. 
In VH gene, germline codons are deleted from the coding region and/or extra non-
templated  codons  are  inserted.  In  CD  IgA  and  IgG  sequences,  insertions  and 
deletions were often observed (Table-3) as compared to the non-inflamed tissue of 
the same patients (P<0.05), providing further evidence that in CD patients the tract 
area of disease is immunologically different from non-inflamed areas. 
4.3.5   IgA1 is high in non inflamed tissue. 
The newly designed 3’ Ca primer successfully amplifies IgA1 and IgA2 subclasses 
and thus our experimental set up allows to discern between IgA1 and IgA2 usage in 
the inflamed and non-inflamed areas, respectively. In this study, IgA1 was vastly 
present in the non-inflamed tissue compared to the inflamed tissue. The utilization Immunoglobulin repertoire in Crohn’s Disease 
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of IgA1 between inflamed and non-inflamed biopsies was significantly different 
(p=0.01). On the other hand IgA2 was 20% more in inflamed tissues (Figure-2). 
Sample  Productively 
rearranged sequences 
Estimated number 
of classes 
95 % CI 
477-1  24  149.9  [33.4 , 681.7] 
477-2  22  1.0  --- 
477-3  19  181.1  [23.7 , 1400.9] 
477-4  18  3.1  [1.2 , 13.8] 
509-1  14  ---   
509-2  18  60.8  [ 14.9 , 255.4] 
513-1  22  231.0  [ 33.2 , 1619.9] 
513-2  21  ---   
516-1  21  ---   
625 B1 IgA  22  ---   
625 B2 IgA  23  ---   
625 C1 IgA  17  ---   
625 C2 IgA  22  69.7  [26.8 , 186.2] 
625 B1 IgG  24  60.0  [27.8 , 139.0] 
625 B2 IgG  24  154.1  [37.2 , 647.1] 
625 C1 IgG  21  ---   
625 C2 IgG  24  56.9  [22.0 , 152.5] 
    4a 
Sample  Productively 
rearranged sequences 
Estimated number 
of classes 
95 % CI 
477-1  20  93.9  [ 23.6, 382.0] 
477-2  1  ---   
477-3  15  ---   
477-4  2  ---   
625 C2 IgA  21  99.8  [28.0 , 361.9] 
625 B1 IgG  22  110.0  [30.7 , 401.4] 
625 B2 IgG  20  ---   
625 C2 IgG  18  ---   
4b 
Table-4: Estimation of B-cell precursors. 4a-Including 100% identical sequences 
4b- Table excluding the 100% identical sequences 
 
 
Figure-1: Alignment of clonally related IgA VHDHJH sequence derived VH genes 
from ileum and genealogical trees deduced from the mutations observed in the VH 
genes of these clones. Sequences of the germline gene are shown on top. Dashes 
indicate  identical  nucleotides,  and  gaps  resulting  from  IMGT  subdivision  are 
marked by dots. Replacement mutations are shown in bold/underscored characters.  
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Fig. 2 IgA1 and IgA2 subclasses usage among the IgA sequences.  
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Fig. 3 Evidence IgG sequential switching from IgG1 to IgG2 
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Fig. 4 VH usage among the IgA and IgG sequence of inflamed and non-inflamed 
ileum biopsies of Crohn’s diseased patients. 
4.3.6   VDJ usage is reduced in the inflamed tissue. 
VH1  is  highly  used  in  the  mucosal  tissues  especially  in  ileum(S.  Yuvaraj 
submitted).  Similarly,  in  the  non-inflamed  tissue,  IgA  sequences  utilize  around 
48% VH1 (see Figure-4) family members, followed by VH4 and VH3. In the case of 
inflamed  tissue, VH3  is relatively  more  prevalent  as  compared  to non-inflamed 
tissue,  but  also  in  this  tissue  VH1  usage  predominates.  All  the  IgA  sequences 
analyzed from patient 4, biopsy # 625-C1 and biopsy # 625-C2 (both biopsies 
taken from the center of the ulcer) use VH1 genes. In the IgG sequences, the use of 
VH1, VH3 and VH4 genes is roughly equal, but VH1 usage is more often observed. 
Not much difference is observed in the DH gene usage when inflamed and non-
inflamed tissue is compared. In a similar manner we observed the same amount of 
usage of DH3 genes in the normal ileum. JH usage remains the same through out the 
different tissues, with JH4 being the most commonly used member in the intestine 
of CD patients. 
4.3.7   Evidence IgG sequential switching from IgG1 to IgG2. 
In general, during class switching recombination (CSR) IgM
+ B-cells changes their 
constant region to other isotypes such as IgG, IgA or IgE (Stavnezer, 1996). In the 
present study, for the first time we observe in inflamed ileum tissue that IgG1 and 
IgG2 constant regions can be derived from the same precursor (see Figure-3). In 
one set of 100% identical sequences, one sequence uses the IgG1 constant region 
while the other sequence uses the IgG2 region. The underlying mechanism for this 
sequential switching of IgG region use is not known.  
4.4   Discussion: 
CD shows a discontinuous, transmural inflammation pattern and can appear in the 
whole alimentary tract, and preferably affects the ileum. The peculiarity in CD is 
the  presence  of  spatially  restricted  inflamed  and  non-inflamed  regions  in  the 
diseased organ; the reason for this pattern remains unclear but presents one of the 
most fundamental questions in contemporary CD research. In an effort to obtain 
more  insight  into  this  issue,  we  analyse  in  the  present  study  the  IgA  and  IgG 
repertoire from biopsies taken from inflamed and non-inflamed terminal ileum. 
60% of the IgA and IgG sequences were selected in the inflamed region when 
compared to the non-inflamed region. Although statistically not significant, there 
was a clear trend for more mutations in IgA and IgG sequences in non-inflamed 
tissue when compared to inflamed regions. The most straightforward explanation is  
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that CD is an ongoing immune response with more antigen selection during the 
biogenesis of IgA and IgG plasma cells.  
Immunoglobulin repertoire of the inflamed region was further investigated to get 
more insight whether local differences in the immune response could play a role in 
explaining the hallmark spatial restriction of CD. To end we analysed IgA and IgG 
sequences from both the rim and from the central part of the inflamed region. 
Importantly, clonally related sequences also shared between these two regions and 
also between different ulcers. 8 sets of the 100% identical sequences and 2 sets of 
clonally related sequences were observed in IgG sequences which was relatively 
low in the IgA sequences in patient-4. Thus B cells involved in the disease undergo 
substantial expansion before they enter the mucosa. There is clear bias for these 
clonally-related sequences to end up in inflamed tissue, our data provide strong 
evidence that immunological functioning is fundamentally different in inflamed 
versus non-inflamed regions of the gut in CD. Whether these differences actually 
also explain the spatial restriction of the disease or whether these differences are a 
consequence of the disease remains subject, however, for further experimentation.  
An estimation of the number of precursors can be made from the ratio of unique 
verses  non-unique  sequences.  First,  the  coverage  can  be  calculated  as  the 
percentage  of  clonally  related  sequences  among  the  total  number  of  sequences 
within a single biopsy(Good, 1953). Coverage percentages ranging from 0% to 
99% were obtained. From these coverage’s the actual number of B cell precursors 
that gave rise to the IgA producing cells in each biopsy was estimated. For these 
calculations we did not include the sets of clonally related cells that were shared 
between  different  biopsies,  but  we  considered  each  biopsy  as  an  individual 
experiment. A surprisingly high number of about 190 B cell precursors gave rise to 
all  IgA  producing  cells  in  non-inflamed  biopsy  and  low  number  of  around  73 
precursors from inflamed tissues. This indicates that there are few precursors that 
give  rise  to  the  entire  IgA  produced  within  the  inflamed  tissues.  This  is  best 
illustrated by the large number of identical 24/24 and 18/24 sequences we obtained 
from two inflamed biopsies. Such areas must be dominated by largely expanded B 
cell population. We did not observe shared CDR3 regions between IgG and IgA 
sequences. This indicates that the IgA and IgG plasma cells were not derived from 
the same precursors.  
In general SHM was observed in almost all sequences of IgA as well as in IgG 
obtained  from  the  human  mucosa  like  we  observed  previously  in  that  healthy 
volunteers. (Yuvaraj et al submitted) In addition to base-pair substitutions, there 
are  several  reports  of  antibodies  in  which  germline  V-gene  codons  have  been 
deleted/inserted from the coding region. Such insertions and deletions have been Immunoglobulin repertoire in Crohn’s Disease 
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shown to occur in several human B cell malignancies, in GC B cells, in human 
hybridomas, and in peripheral blood. Reason et al. (Reason and Zhou, 2006) have 
recently shown that insertion/ deletion of codons occurs as a normal part of the 
somatic maturation of the human antibody response.  
 
The  presence  of  microflora  in  the  inflamed  region  is  higher  and  there  is  a 
difference  in  the  bacterial  composition  between  inflamed  and  non-inflamed 
biopsies (Bibiloni et al., 2006). Importantly, a preliminary investigation into the 
bacterial  composition  of  the  same  biopsies  as  we  used  for  characterising 
immunoglobulin repertoire in the present study demonstrated profound differences 
in flora composition between inflamed and non-inflamed samples (M. Comalada 
and S. Yuvaraj, unpublished observations), the diseased areas also containing more 
bacteria.  This  observation  correlates  well  with  our  results  on  IgA  repertoire 
differences  between  inflamed  and  non-inflamed  biopsies  which  involve  clonal 
expansion  and  selection  of  IgA  producing  cells  in  the  inflamed  region.  It  was 
reported  that  microflora  play  an  important  role in the  development  of  mucosal 
immune system, especially to increase the IgA producing cells (Bos et al., 2005) 
and  the  present  study  seems  to  reflect  this  observation.  Again,  however,  it  is 
difficult to distinguish whether locally the flora is different because of altered local 
immunity  or  whether  altered  local  immunity  facilitates  the  establishment  of  an 
alternative flora. 
In normal ileum, less than half of the IgA plasma cells show signs of antigen 
selection as eidenced by significant R/S ratio’s (Yuvaraj et al, submitted), while the 
remaining IgA plasma cells do not show signs of antigen selection in spite of a 
high number of somatic mutations. Non-inflamed tissues of CD patients represent a 
IgA repertoire that has the same characteristics as that observed in the mucosa of 
healthy volunteers. In contrast, affected areas in CD patients show a higher number 
of sequences displaying evident selection, that as discussed above could probably 
be directed towards the locally different microflora constituents Nevertheless, both 
normal as well as inflamed mucosa has strong prevalence of VH1 usage, further 
supporting our previous finding that this VH gene family is preferentially used in 
mucosal  tissue.  Surprisingly,  within  ulcerated  areas  spatial  differences  in  the 
development of immunorepertoire are observed: all the IgA sequences from the 
center of the inflammation have utilized VH1 family, whereas this was not observed 
at  the  rim  of  the  ulceration.  We  interpret  this  finding  as  further  evidence  that 
important  regional  differences  in  the  intestine  of  CD  patients  with  respect  to 
immunoregulation exist.  
In conclusion, in the present study for the first time we present evidence that the 
immune  system  is  developing  differently  at  the  inflamed  lesions  in  CD  as 
compared to uninflamed tissue of the same patient (which seems indistinguishable 
from  that  of  healthy  volunteers  in  this  respect).  Further  research  should  now  
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provide insight as to whether this regionality in immunoregulation is causative for 
CD and actually explains the spatial restriction of the disease or whether this is a 
reflection of deeper pathological mechanism at ulcerative sites. 
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Chapter 5 
Early bacterial dependent induction of 
inducible nitric oxide synthase (iNOS) 
in epithelial cells upon transfer of 
CD45RB
high CD4
+ T cells in a model for 
experimental colitis.  
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Abstract  
Both  the  role  of  inducible  nitric oxide  synthase  (iNOS)  in  the  development  of 
inflammatory bowel disease (IBD) as well as the molecular details governing its 
mucosal induction remain unclear. In the present study we evaluated the role of the 
residing intestinal microflora in the induction of epithelial iNOS upon transfer of 
CD45RB
high CD4
+ T cells to SCID mice. To this end, CB-17 SCID mice were 
reared with conventional flora (CNV) or germfree CB-17 SCID mice were mono-
associated  with  Helicobacter.muridarum,  act  A  (-)  mutant  L.  monocytogenes, 
segmented filamentous bacteria (SFB), or O. anthropi. Within 2 weeks CNV SCID 
mice  injected  with  CD45RB
high  CD4
+  T  cells  showed  a  focal,  epithelial  iNOS 
expression on the apical site of villi that preceded the infiltration of CD4
+ cells and 
cytokine production followed by extension of this expression to the entire surface 
along the whole crypt axis as the colitis progressed. SCID mice monoassociated 
with H.muridarum developed a severe colitis and showed high epithelial iNOS 
expression. CNV-SCID mice without T cells and SCID mice mono-associated with 
SFB did not show any iNOS expression, whereas SCID mice mono-associated with 
act  A(-)  mutant  Listeria.  monocytogenes  and  Ochrobactrum.  anthropi  showed 
some scattered epithelial iNOS staining on the apical site of a few villi, but none of 
these mice developed colitis. These findings demonstrate that the expression of 
epithelial iNOS is highly  bacterium-specific and correlates with the severity of 
disease, suggesting an important role for this enzyme in the development of IBD. Epithelial iNOS expression in the CD45RB
high transfer model of colitis 
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5.1   Introduction 
The inflammatory bowel diseases (IBD), Crohn’s disease and ulcerative colitis, are 
chronic  inflammatory  conditions  of  the  human  gastrointestinal  tract.  Studies  in 
animal models suggest that IBD is due to an aberrant mucosal T cell response to 
gut  bacteria.  Several  animal  models  have  shown  that  both  T  helper  cells  and 
bacterial flora are needed to induce disease (Strober et al., 2002). The bacterial 
species and lymphoid interactions involved, however, remain subject to intensive 
discussion. In a mono-association study we showed that out of five non-pathogenic 
bacteria, only H muridarum was capable of provoking an accelerated colitis when 
compared to conventionally reared (CNV) mice after transfer of CD45RB
high CD4
+ 
T cells to combined immunodeficient (SCID) mice (Jiang et al., 2002). A striking 
feature of H muridarum in comparison to many other bacterial species is that its 
ecological niche is in close contact with the epithelial cells of the crypts (Phillips 
and  Lee,  1983). Therefore  we  hypothesized that  epithelial  cell  activation  by  H 
muridarum  might  be  an  important  trigger  in  the  development  of  colitis  in  H 
muridarum-associated mice.  
In patients with active IBD, there is a strong expression of inducible nitric oxide 
synthase (iNOS) at the apical side of epithelial cells (Dijkstra et al., 1998). The 
induction of iNOS is mediated by the nuclear factor kB (NF-kB) and it is known 
that some bacteria can directly activate NF-kB whereas other bacteria silence the 
epithelial NF-kB response to avoid epithelial cell activation (Naumann, 2000). It is 
at present neither known whether this induction is an important causative factor for 
the disease nor is it clear whether bacterial colonisation per se is associated with 
epithelial iNOS expression or whether the induction of iNOS is associated with 
specific bacterial types. 
These  considerations  prompted  us  to  compare  the  induction  of  iNOS  after 
colonisation  of  the  mouse  intestine  by  different  microflora.  To  this  end  we 
investigated whether epithelial iNOS expression and the development of colitis in 
CNV  reared  and  mono-associated  SCID  mice  after  CD45RB
high  CD4
+  T  cell 
transfer and generated a kinetic study relating epithelial iNOS expression to T cell 
infiltration  and  pro-inflammatory  cytokine  production  in  CNV  and  mono-
associated  SCID  mice.  We  demonstrate  an  early  focal  expression  of  iNOS  in 
epithelial  cells  preceding  the  T  cell  infiltration  and  pro-inflammatory  cytokine 
production in  CNV  SCID  mice  after  transfer  of  naïve  T  cells.  At  the  terminal 
stages of colitis both CNV SCID mice as well as H muridarum mono-associated 
SCID mice showed strong iNOS expression along the whole crypt axis. In contrast, 
there was no or very low expression of iNOS in epithelial cells in SCID mice 
mono-associated with bacteria that did not induce colitis upon transfer of naïve T 
cells. These results demonstrate that bacteria specific epithelial cell activation and  
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subsequent  iNOS  induction  and  NO  production  is  an  early  event  in  the 
development of colitis in the CD45RB
high CD4
+ T cell transfer model of IBD. 
5.2   Materials and Methods 
5.2.1   Animal model 
We used the CDRB45
high CD4
+ T cell transfer model in SCID mice as described 
earlier  (Jiang  et  al.,  2002).  Briefly,  C.B-17  SCID  mice  were  reared  under 
conventional  (CNV)  or  mono-associated  conditions.  Three  weeks  after  stable 
colonization  of  germfree  C.B17  SCID  mice  (>1010  bacteria/gm  feces)  with 
segmented filamentous bacterium, an avirulent actA (-)  mutant DP-L1942 of L 
monocytogenes or after colonization by O anthropi, 5-10x105 CDRB45
high CD4
+ T 
cells were injected intraperitoneally into the mono-associated SCID mice. For the 
kinetic study of epithelial iNOS expression in conventionally reared SCID mice 2 
mice  were  sacrificed  1,2,3,4,5,7,8  and  13  weeks  after  T  cell  transfer.  Mono-
associated mice were sacrificed 6 weeks (H. muridarum) or 11 weeks (SFB, L. 
monocytogenes  and  O.  anthropi)  after  T  cell  transfer.  Normal  BALB/c, 
conventionally and germfree reared SCID mice that did not receive T cells were 
used as controls. All experiment were approved by the animal welfare board. 
5.2.2   Histology 
Specimens of the large intestine were embedded in OCT compound (Miles Inc, 
Elkhart,  IN)  and  frozen  in  2-methyl-butane  with  dry  ice.  Longitudinal  sections 
(4mM) were fixed with 4% paraformaldehyde, rinsed in PBS, and stained with 
hematoxylin-eosin. 
5.2.3   Immunohistochemistry 
For immunohistochemistry, 7 mm cryostat sections were cut, dried and fixed in 
acetone for 10 min at room temperature. For iNOS detection a rabbit polyclonal 
antibody  developed  in  our  laboratory  was  used  (Vos  et  al.,  1997).  For  CD4 
detection  a  monoclonal  biotin  conjugated  antibody  clone  H129.19 
(Pharmingen,USA)  was  used.  Slides  were  incubated  with  the  polyclonal  iNOS 
antibody (1:300) or monoclonal CD4 antibody (1: 50) in PBS containing 1% BSA 
for 60 min at room temperature. Subsequently, endogenous peroxidase activity was 
blocked  by  incubating  for  30  min  in  PBS  containing  0.075%  H2O2.  For  iNOS Epithelial iNOS expression in the CD45RB
high transfer model of colitis 
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detection,  peroxidase  conjugated  goat  anti-rabbit  Ig  (1:50)  and  peroxidase 
conjugated rabbit anti-goat Ig (1:50) all from Dako (Glostrup, Denmark) were used 
as secondary and tertiary antibodies. For CD4 detection streptavidin-peroxidase 
(Southern Biotechnology Associates,USA) was used as secondary step. Color was 
developed using 3-amino-9-ethylcarbazole (10mg/2.5mL dimethylformamide in 50 
ml 0.05 mol/L acetate buffer pH 4,9) containing 0,03% H2O2 for 10 minutes at 
room  temperature.  Counterstaining  was  performed  with  haematoxylin,  and  the 
slides were covered with Kaiser’s glycerin-gelatin. 
5.2.4   RNA isolation and reverse-transcriptase polymerase chain 
reaction (RT-PCR) 
RNA  was  isolated  from  tissue  specimens  using  Trizol  reagent  (Sigma-Aldrich 
Zwijndrecht,  Netherlands)  according  to  manufacturer’s  instructions.  Reverse 
transcription  was  performed  on  5  mg  of  total  RNA  using  Oligo-dT  primers 
(Invitrogen,  Breda,  Netherlands)  in  a  final  volume  of  30  ml.  Polymerase  chain 
reaction (PCR) on cDNA was performed with Taq polymerase (Invitrogen, Breda, 
Netherlands ) on the Biometra PCR system. The PCR primers for mice iNOS, 
TNF-a, IL-1b, IFN-g, Gro, MMIP and b-actin were selected from multiple exons 
and are depicted in table 1. The cycling program was 94°C for 2 min, 58°C for 60 
seconds, 72°C for 60 seconds for the first cycle and 94°C for 30 sec, 58°C for 60 
seconds, 72°C for 60 seconds for 30 cycles. The level of mRNA expression is 
expressed relative to the b-actin level. 
  Sense  Anti-sense  Bp 
iNOS  5' -ggtatgctgtgtttggcctt-3'   5' -ggctggacttttcactctgc-3'   390 
TNF-a  5' -ctcttcaagggacaaggctg-3'   5' -cggactccgcaaagtctaag-3'   253 
IL-1b  5' -caggcaggcagtatcactca-3'   5' -aggccacaggtattttgtcg-3'   350 
IFN-g  5' -actggcaaaaggatggtgac-3'   5' -tgagctcattgaatgcttgg-3'   237 
Gro  5' -gctgggattcacctcaagaa-3'   5' -tggggacaccttttagcatc-3'   169 
MMIP  5' -agtgaactgcgctgtcaatg-3'   5' -ttcagggtcaaggcaaactt-3'   153 
b-actin  5' -cctaaggccaaccgtgaaaag-3'   5' -tcttcatggtgctaggagcca-3'   672 
5.2.5   Statistical Analysis 
Significant differences between mean values were determined by Student t test. 
P<0.05 was considered significant.   
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5.3   Results 
5.3.1   Kinetics  of  T  cell  infiltration,  cytokine  production  and 
epithelial  iNOS  induction  in  CNV-reared  SCID  mice  after 
CD45RB
high CD4
+ T cell transfer. 
T  cell  transfer  in  SCID  mice  is  generally  considered  a  rodent  model  for  IBD, 
mimicking important aspects of the disease. CNV BALB/c showed sporadic CD4
+ 
T cells, whereas none were observed in the lamina propria of CNV SCID. Upon T 
cell transfer, CNV SCID mice show small aggregates of CD4
+ T cells near the 
muscularis propria (Figure 1 right panel). After 4 weeks the cells are no longer 
present near the muscularis but now small aggregates are present in the lamina 
propria, sometimes close to epithelial cell compartment. At 8 weeks, substantially 
more and larger lamina propria conglomerates of CD4
+ T cells are observed. The 
end-stage  of  colitis  is characterised  by  a  lamina  propria  completely  filled  with 
conglomerates  of  CD4
+  T  cells.  Thus  the  histology  observed  in  this  model  is 
consistent with an IBD like inflammatory reaction in the colon. 
This  notion  is  supported  by  RT-PCR  experiments  for  the  pro-inflammatory 
cytokines IL-1b, TNF-a, IFN-g and chemotactic cytokines Gro and mMIP. In these 
experiments we observe equal levels of TNF-a and IFN-g in BALB/c and SCID 
mice that did not receive CD4
+ T cells (Figure 2). IL-1b and mMIP levels are 
reduced in untreated SCID mice compared to BALB/c mice. The mRNA of the 
pro-inflammatory cytokines IL-1b, TNF-a and INF-g begins to rise 3 weeks after T 
cell transfer and shows a biphasic response with high peaks around 6 and 10 weeks 
Figure 2). The chemotactic cytokine Gro shows the same pattern, whereas another 
chemokine, mMIP shows only an increase in the terminal phase of colitis (Figure 
2). Subsequently experiments were initiated to investigate the expression of iNOS 
during such inflammation. 
Despite a critical function of iNOS in mucosal immune responses, the relationship 
between its expression and the composition of the gut flora is poorly understood. 
CNV BALB/c and CNV SCID mice do not show any iNOS expression in their 
colon tissue (Figure 3, left panel). CNV SCID mice show focal epithelial iNOS 
already 2 weeks after T cell transfer (Figure 1, left panel). The iNOS expression is 
on the apical site of the enterocytes on the top of the villi and not in the crypt 
epithelial cells. In week 3 and 4 after T cell transfer larger areas of epithelial cells 
show iNOS expression but it is still confined to the top of the villi. From week 5 Epithelial iNOS expression in the CD45RB
high transfer model of colitis 
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also crypt epithelial cells show iNOS expression. At week 8 the intensity of the 
iNOS  expression  is  further  increased  and  involves  almost  the  whole  epithelial 
surface (figure 3, right panel). 
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Fig. 1 Immunohistochemistry of the colon for iNOS (left panel) and CD4 (right 
panel) 1, 2, 3, 4, 5, 7, 8, 13 weeks after transfer of CD45RB
highCD4
+T cells into 
Severe Combined Immunodeficiency mice (SCID) reared with conventional flora 
(CNV). The epithelial cells express iNOS 2 weeks after T cell transfer. In the first Epithelial iNOS expression in the CD45RB
high transfer model of colitis 
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weeks this expression is focal and confined to top of the crypts, in the weeks 
thereafter the iNOS expression is diffuse and also present in epithelial cells in the 
crypts. CD4
+ T cells are first present near the muscularis propria (right panel) and 
expand into the lamina propria after 4 weeks. After 8 weeks the lamina propria is 
filled with conglomerates of CD4
+ T cells. 
 
 
Fig. 2 RT-PCR for mRNA of IL-1b, TNF-a, IFN-g and the chemokines Gro and 
mMIP. Equal levels of TNF-a and IFN-g mRNA are observed in BALB/c and SCID 
mice that did not yet receive CD4
+ T cells. IL-1b and mMIP were reduced in SCID 
mice  compared  to  BALB/c  mice.  The  mRNA  levels  of  the  pro-inflammatory 
cytokines IL-1b, TNF-a and INF-g start to increase 3 weeks after T cell transfer 
and showed a biphasic response with high peaks around 6 and 10 weeks (figure 3). 
The chemokine Gro showed the same pattern, whereas another chemokine mMIP 
increased only in the terminal phase of colitis  
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Fig. 3 Immunohistochemistry of the colon for iNOS without (left panel ) and 8 
weeks after (right panel) transfer of CD45RB
highCD4
+T cells into Severe Combined 
Immunodeficiency mice (SCID) reared with conventional flora (CNV). 
 
Fig. 1 RT-PCR for iNOS (mRNA expression relative to expression of b-actin) of the 
colon from CNV reared SCID mice colon 1, 2, 3, 4, 5, 7, 8, 13 weeks after transfer 
of CD45RB
highCD4
+T cells. The iNOS mRNA is detectable as early as 3 weeks after 
T cell transfer.  
 
 Epithelial iNOS expression in the CD45RB
high transfer model of colitis 
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Fig. 2 Immunohistochemistry of the colon for iNOS 11 weeks and 6 weeks (for 
H.muridarum) after transfer of CD45RB
highCD4
+T cells into Severe Combined 
Immunodeficiency mice (SCID) monoassociated with SFB, L. monocytogenes Act A 
(-), O. anthropi or H. muridarum. SFB-monoassociated mice did not induce iNOS 
expression 11 weeks after T cell transfer. Mice mono-associated with Act A(-) L. 
monocytogenes and O. anthropi demonstrated a low level of very focal iNOS 
staining that was confined to the apical site of the enterocyte and was only present 
in enterocytes on the top of a few villi (arrows). However, mice mono-associated 
with H. muridarum showed at 6 weeks an intense and diffuse iNOS staining of 
enterocytes along the whole crypt axis.  
 
At the end-stage of colitis the whole epithelial surface shows a diffuse but intense 
iNOS expression along the whole crypt axis. Inflammatory cells show no iNOS 
expression.  RT-PCR  analysis  (Figure  4)  confirms  the  immunohistochemistry 
results  although  the  RT-PCR  for  iNOS  was  positive  shortly  after  the  focal 
epithelial staining was already seen at 2 weeks. The inflammatory reaction in colon 
following  T  cell  transfer  correlates  with  the  induction  of  epithelial  iNOS 
expression.  Thus  expression  iNOS  correlates  with  the  severity  of  the  mucosal 
inflammatory reaction.  
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5.3.2   Epithelial iNOS induction in mono-associated SCID mice 
after CD45RB
high CD4
+ T cell transfer 
Subsequently, we investigated different flora components for their effect on iNOS 
expression  in  IBD.  Mice  mono-associated  with  SFB  do  not  show  any  iNOS 
expression 11 weeks after T cell transfer (figure 5). Mice mono-associated with 
Act A(-) L. monocytogenes and O. anthropi show very focal iNOS staining 11 
weeks after T cell transfer. The iNOS staining is confined to the apical site of the 
enterocyte and is only present in enterocytes on the top of a few villi (figure 5). 
However, 6 weeks after T cell transfer, concomitant with clear clinical syptoms of 
IBD in mice mono-associated with H. muridarum, an intense and diffuse iNOS 
staining of enterocytes along the whole crypt axis is observed (figure 5). Hence 
specific flora components are markedly different with respect to inducing iNOS 
expression and the extent of the iNos expression correlates with the severity of the 
mucosal inflammation. 
5.4   Discussion 
In this study we show that epithelial cells of CNV reared SCID mice express iNOS 
early in the development of colitis after CD45RB
high CD4
+ T cell transfer. The 
absence  of  epithelial  iNOS  expression  in  CNV  reared  SCID  mice  that  did  not 
receive naïve T cells demonstrates that both the bacteria and T cells are needed for 
epithelial iNOS expression and the development of colitis. The mono-association 
studies  show  that  certain  bacteria  (e.g.  SFB)  do  not  induce  iNOS  and  colitis, 
whereas other bacteria (e.g. L. monocytogenes act A(-), O. anthropi) induce a very 
low level of iNOS expression without causing full-blown colitis, whereas yet other 
bacteria  (e.g.  H.  muridarum)  give  rise  to  strong  epithelial  iNOS  induction  and 
accelerated colitis as compared to CNV reared SCID mice. Thus iNOS expression 
in general correlates with the severity of mucosal inflammation. 
The induction of iNOS is mediated by the nuclear transcription factor kB (NF-kB) 
in epithelial cells (Xie et al., 1994) and in other cells involved in intestinal colitis 
(Comalada et al., 2005). Our current data support this notion, iNOS expression 
correlates  well  with  the  severity  of  the  colitis  and  the  production  of  NF-kB-
dependent cytokines. The observation that a combination of cytokines (IL-1b, IFN-
g, TNF-a) and endotoxin (LPS) is needed for the in vitro induction of iNOS in 
native  colon  cells  and  intestinal  tumor  cell  lines  may  be  interpreted  as  that 
epithelial  cells  of  the  colon  are  relatively  resistant  to  cytokine  induced  NF-kB Epithelial iNOS expression in the CD45RB
high transfer model of colitis 
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activation (Jobin et al., 1997). More specifically a decreased IkB kinase (IKK) 
activity and a consequent resistance to IkBa degradation has been postulated as a 
protective  response  of  intestinal  epithelial  cells,  enabling  the  cells  to  remain 
quiescent in the hostile strongly pro-inflammatory colon environment (Jobin et al., 
1997). However, this relatively unresponsive state still allows several particulary 
pathogenic  enteroinvasive  organisms  such  as  Salmonella,  Shigella,  Listeria  and 
Helicobacter species to directly activate NF-kB (Naumann, 2000) and induce iNOS 
and pro-inflammatory cytokines in intestinal epithelial cells (Witthoft et al., 1998). 
This  may  be  an  important  defence  response  as  the  bacterial  pathogenic  genus 
Yersinia has developed delivery of virulence Yop factors capable of blocking the 
NF-kB  mediated  production  of  pro-inflammatory  cytokines,  thus  preventing  an 
anti-bacterial epithelial cell response (Schesser et al., 1998). It will be of interest to 
investigate whether reduced iNOS expression as a consequence of impaired NF-kB 
activation  in  Yersinia-infected  cells  is  important  in  this  reduced  anti-bacterial 
epithelial cell response.  
Apart from pathogenic bacteria there is also evidence that non-pathogenic bacteria 
in the normal gut can prevent epithelial NF-kB induction and hence contribute to 
the  reduction  of  the  mucosal  immune  response  against  normal  gut  bacteria. 
Therefore, the capability of bacteria to interfere with the epithelial NF-kB response 
might reflect its potential to induce or suppress IBD. Studies aimed at inhibition of 
NF-kB activation in IBD are promising (Dijkstra et al., 2002;Neurath et al., 1996) 
and the correlation observed in the present study between iNOS expression and the 
severity of the colitis calls for studies in which the importance of iNOS expression 
for mucosal inflammatory reaction in IBD is assessed directly. However, as shown 
by a conditional epithelial NF-kB knockout animal model an adequate epithelial 
NF-kB  response  is  also  an  important  anti-apoptotic  response  necessary  for 
epithelial  healing  and  repair,  thus  strategies  directly  aimed  at  inhibiting  iNOS 
downstream  of  its  induction  by  NF-kB  may  be  more  promising  as  future 
therapeutic avenues for dealing with IBD (Chen et al., 2003).  
In this context it is important to keep in mind that although we observe a clear 
correlation between the epithelial iNOS response and the development of colitis, 
the exact role of iNOS and epithelial derived NO in the development of IBD is not 
known (Grisham et al., 2002). In relation to this, an increase in iNOS expression in 
colonic  samples  has  been  observed  in  some  animal  models  (Camuesco  et  al., 
2004).  However,  studies  using  inhibitors  of  NOS  in  experimental  colitis  are 
conflicting and show little improvement (Hogaboam et al., 1995;Rachmilewitz et 
al., 1995); no effects (Conner et al., 1995;Ribbons et al., 1997), or even worse 
effects  (Pfeiffer  and  Qiu,  1995)  on  colitis  probably  due  to  the  lack  of  iNOS 
specificity  (i.e.  also  inhibition  of  endothelial  NOS)  of  the  inhibitors  used.  In 
addition,  studies  of  experimental  colitis  in  iNOS  knockout  mice  also  showed 
conflicting results even when the same experimental model was used (Beck et al.,  
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2004;Hokari  et  al.,  2001;Krieglstein  et  al.,  2001;McCafferty  et  al., 
1997;McCafferty et al., 1999;vallance et al., 2004;Zingarelli et al., 1999). IL-10 
knockout mice develop colitis spontaneously. Colitis developed at the same rate 
and  intensity  in  IL-10  knockout  mice  and  IL-10/iNOS  double  knockout  mice 
(McCafferty et al., 2000). Considering the absence of macroscopic ulcerations in 
the presence of large amounts of NO in patients suffering from microscopic colitis 
a role of NO in diarrhoea and ulcer healing has been suggested (Lundberg et al., 
1997).  Indeed  topical  administration  of  the  NOS  inhibitor  Ng-monomethyl-L-
arginine (L-NMMA) reduced fluid secretion in patients with collagenous colitis 
(Perner et al., 2001) and a NO donating mesalazine derivative had an additional 
beneficial  effect  on  TNBS  induced  colitis  (Wallace  et  al.,  1999).  The  reduced 
gastro-intestinal  toxicity  of  NO-donating  non  steroidal  anti-inflammatory  drugs 
(NSAID) (Elliott et al., 1995) and aspirin (Fiorucci et al., 2003) are in agreement 
with a protective effect of NO on intestinal epithelial cells. Apart from the above-
mentioned beneficial effects of NO in mucosal injury, NO can also inhibit NF-kB 
activation (Matthews et al., 1996). Therefore, high amounts of NO may participate 
in  a  negative  feedback  loop  to  block  prolonged  activation  of  NF-kB,  thereby 
limiting chronic inflammation, in which case strategies aimed at inhibiting NO 
production may be self-defeating. In this context it must be kept in mind that NO 
itself is not be toxic to many bacteria as tcertain enteric bacteria contain nitrate 
reductase  and  produce  NO  by  their  own  (Brittain  et  al.,  1992).  Importantly, 
however,  as  observed  in  septic  patients,  epithelial  iNOS  induction  and  NO 
production  may  cause  increased  intestinal  permeability  (Johnston  et  al.,  1996). 
Indeed  selective  inhibition  of  iNOS  in  endotoxemic  rats  ameliorated  mucosal 
permeability for dextran (MW 4000) (Unno et al., 1997) and reduced bacterial 
translocation  (Sorrells  et  al.,  1996).  The  absence  of  bacterial  translocation  in 
endotoxemic iNOS knockout mice further supports a pathogenic role of epithelial 
derived  NO  in  sepsis.  As  long  as  there  are  no  truly  selective  iNOS  inhibitors 
available it will be hard to examine the exact role of epithelial iNOS induction and 
NO production in IBD. In this study however, we provide evidence that epithelial 
iNOS expression is an early and bacteria dependent event in the development of 
colitis in the CD45RB
high CD4
+ T cell transfer model of IBD and that bacteria that 
cause colitis also induce high epithelial iNOS expression.  
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Chapter 6 
IgA1-producing cells that arise early after 
anti-CD20 treatment in primary Sjögren’s 
Syndrome are clonally related to IgA-
producing cells present before treatment.  
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Abstract 
Transient B cell depletion with the monoclonal anti-CD20 antibody Rituximab has 
resulted  in  promising  clinical  responses  in  patients  with  primary  Sjögren’s 
syndrome (SS). IgA producing cells emerge shortly after rituximab treatment. The 
origin of these cells in the salivary gland tissues is not known. The aim of the study 
was to elucidate whether these cells are regenerated from newly formed B cells or 
derive from persisting IgA producing B cells that are not sensitive  to Rituximab. 
Two patients with SS were treated with rituximab and biopsies were taken from 
salivary glands of each patient, before and 12 weeks after treatment. IgA heavy 
chain genes from these samples were analysed for the presence of clonally related 
sequences and their mutational status. Sequences from biopsies before and after 
treatment  were  clonally  clearly  related.  These  data  unequivocally  show  that 
reappearing  IgA  plasma  cells  are  derived  from  a  population  of  persisting  IgA 
producing  rituximab  treatment-insensitive  cells.  Furthermore,  a  high  number  of 
mutations  were  observed  in  all  VH  genes  of  the  IgA  transcripts.  Thus,  these 
rituximab-resistant B cells belong to the pool of recirculating IgA producing B 
cells within the common mucosal immune system and are not derived from newly 
developed  B  cells  in  the  bone  marrow.  In  addition,  most  IgA  producing  cells 
exhibited mutation patterns characteristic for those seen along the intestinal tract. 
Most  transcripts  used  the  IgA1  isoform  in  both  pre-  and  post-treated  biopsies, 
whereas  equal  proportions  of  IgA1  and  IgA2  were  observed  in  biopsies  from 
control salivary glands. Hence IgA1 B cells seem to have either the capacity to 
survive rituximab treatment or have a selective advantage during repopulation of 
the IgA plasma cell compartment in salivary glands in SS. High IgA1- Producing cells in Rituximab treated primary Sjögren’s syndrome 
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6.1   Introduction: 
Sjögren’s  syndrome  (SS)  is  an  autoimmune  disease  characterized  by  chronic 
inflammation of the salivary and lachrymal glands. The main clinical features are 
progressive dryness of mouth (xerostomia) and eyes (xerophthalmia) resulting in 
keratoconjuctivitis sicca. The prevalence of SS is estimated 0,5-1%, making it the 
second  common  autoimmune  disease  after  rheumatoid  arthritis.  There  are  two 
types of SS, primary SS (pSS) and secondary SS (sSS) that is secondary to another 
connective  tissues  disease  such  as  rheumatoid  arthritis  or  systemic  lupus 
erythematosus.  Currently  pSS  is  considered  a  complex  autoimmune  disease  in 
which many factors, in particular environmental and genetic factors, are involved 
pathogenetically. 
The  role  of  B  cells  in  the  pathogenesis  of  autoimmunity  is  not  completely 
understood.  Besides  differentiating  into  antibody-secreting  cells,  B  cells  are 
involved  in  providing  signals  to  T  cells  through  antigen  presentation.  T  cells 
‘support’ the B cells through the delivery of cytokines and cell-surface ligands. 
Disturbances of this interaction by either one of these components might trigger 
autoimmune disease. B cell activation factor (BAFF) is a TNF superfamily member 
that regulates B-lymphocyte proliferation, maturation and survival (Szodoray and 
Jonsson, 2005). High expression of BAFF increases survival of both immature and 
mature B cells. In SS patients the level of circulating BAFF correlates with the 
level of autoantibodies (Mariette et al., 2003). Increased levels of BAFF have been 
demonstrated in rheumatic diseases like pSS, SLE and rheumatoid arthritis, which 
are associated with abnormal B cell function and autoantibody production (Hansen 
et al., 2005). Autoantibodies such as rheumatoid factor, anti-Ro (SS-A) and anti-La 
(SS-B) are commonly present in SS patients. The role of these autoantibodies in 
disease pathogenesis is not known. They may be produced in the ectopic germinal 
center like structures that are reported to be present in the salivary glands of pSS 
patients.  Evidence  for  ectopic  germinal  center  reactions  were  confirmed  when 
clonally related B cells were observed in these germinal centers (Stott et al., 1998). 
Local  expansion occurs  in  diseased salivary  glands(Stott et al.,  1998).  Somatic 
hypermutation and class switching has been shown to occur in glandular B cells 
that later become immunoglobulin producing plasma cells (Stott et al., 1998). The 
benificial effects of B cell depletion from the salivary glands suggest an important 
role for B cells in the pathogenesis of SS. 
IgA is the mucosal immunoglobulin which is highly present in mucosal tissues and 
secretions. Human IgA occurs in two isotypic forms, IgA1 and IgA2, with IgA2 
existing  as  two  allotypic  variants,  IgA2  2m(1)  and  IgA2  2m(2).  Bone  marrow 
plasma  cells  are  mainly  responsible  for  serum  IgA  production,  that  consists 
predominantly of monomeric IgA1, while in the external secretions most of the 
IgA produced is polymeric and belongs to both subclasses. IgA is thought to plays  
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a  role  in  the  pathogenesis  of  pSS  and  the  molecular  background  for  increased 
levels of serum IgA remains largely unknown(Bendaoud et al., 1991;Muller et al., 
1989;Varki, 1993). IgA-containing immune complexes and IgA rheumatoid factor 
are reported to circulate in patients with pSS (Bendaoud et al., 1991;Muller et al., 
1989;Varki, 1993). Glycosylation of IgA in serum of pSS patients was observed. 
Increased N-linked glycosylation leads to oversialylation of monomeric IgA1 from 
patients with SS (Basset et al., 2000a)  
Bcell targeting therapies have beneficial effects both in B cell lymphoma(Mackay 
and Rose, 2001) and in autoimmune disease like RA(Roll et al., 2006), SLE(van 
Vollenhoven  et  al.,  2004),  pSS(Pijpe  et  al.,  2005a),  MS(Monson  et  al.,  2005), 
myositis  (Levine,  2005)  and  others.  Rituximab  is  an  efficient  B  cell  cytolytic 
chimeric IgG1 monoclonal antibody specific for CD20. Three mechanisms have 
been proposed for elimination of B cells including complement mediated cellular 
cytotoxicity (CDC) (Reff et al., 1994), antibody-dependent cellular cytotoxicity 
(ADCC)  (Reff  et  al.,  1994)  and  stimulation  of  apoptotic  pathways  (Pescovitz, 
2006). Rituximab can deplete B cells from the pre-B cell stage to the pre-plasma-
cell  stage.  The  period  of  Bcell  depletion  lasts  for  7-8  months  in  RA  patients 
(Edwards  and  Cambridge,  2006).  Following  depletion,  B  cells  return  with  an 
immature phenotype that is observed similarly after bone marrow transplantation or 
in umbilical cord blood(Leandro et al., 2006). Roll et al recently provided evidence 
for a characteristic regeneration pattern of B cell subpopulation after selective anti-
CD20 mediated B cell depletion in RA patients(Roll et al., 2006). Rouziere et al 
showed that new clones of B cells prevail the repopulation influx(Rouziere et al., 
2005).  B  cell  depletion  resulted  in  a  regeneration  of  a  diverse  and  polyclonal 
immunoglobulin heavy-chain repertoire and very highly mutated recirculating B 
cells were observed. 
Many open studies and case reports of the use of rituximab in pSS have been 
published (Pijpe et al., 2005b;Pijpe et al., 2005a;Seror et al., 2006;Touma et al., 
2006). In pSS patients treated with Rituximab (Pijpe et al., 2005b) we reported a 
small reduction in total Ig levels in the serum. pSS biopsies are dominated by the 
appearance of IgG producing cells. Three months after rituximab treatment in pSS 
patients, a decrease in IgG
+B cells was observed and a relative increase of IgA 
positive  plasma  cells  suggesting  reappearance  of  these  latter  cells.  Roll  et 
al(Rouziere et al., 2005) also report that most of the plasma cells in circulation 
express the IgA isotype after treatment with rituximab in RA patients. 
The aim of the present study was to determine the origin and clonality of the IgA 
plasma cell repertoire within the parotid glands of pSS patients after temporary B 
cell depletion by Rituximab. As anti-CD20 resist cells may cause relapse of pSS. High IgA1- Producing cells in Rituximab treated primary Sjögren’s syndrome 
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Analysis of the origin of these IgA plasma cells either persisting in the salivary 
gland or reappearing from the bone marrow, is important. The origin and diversity 
of these IgA plasma cells was investigated by analyzing the IgA heavy chain gene 
repertoire  in  parotid  gland  biopsies  from  two  pSS  patients  before  and  after 
treatment with Rituximab. 
6.2   Methods: 
6.2.1   Salivary gland biopsies. 
Four pSS patients were included in this study, of which two patients were treated 
with rituximab. Two parotid salivary gland biopsies were taken from patients who 
were  treated  with  rituximab  (4  weekly  infusions  of  375  mg/m2),  one  before 
administration and one 12 weeks after treatment. Two other parotid gland biopsies 
were taken from patients with sicca complaints, however, after evaluation, they did 
not fulfil the classification criteria for SS and were classified as non-Sjögren. The 
parotid gland biopsies of these patients showed only inflammation. Two biopsies 
were taken from healthy controls(Table-1). The biopsies were embedded in Tissue-
Tek OCT embedding medium (Sakura Finetek, Zoeterwoude, Netherlands) and as 
well as in the paraffin. Parotid biopsies (before and 12 weeks after completion of 
treatment) were available from two pSS treated with rituximab (4 weekly infusions 
of 375 mg/m2), As controls parotid biopsies were used from two pSS patients. Two 
non-SS patients (i.e. patients with complaints resembling pSS, but not fulfilling the 
diagnostic criteria for pSS) and two healthy controls (a parotid tissue biopsy was 
obtained during head neck dissection for a oral squamous carcinoma). So, in total 
10 biopsies were evaluated from 8 different patients/healthy controls.  
6.2.2   Immunochemical staining of tissue sections 
To detect IgA plasmablasts in parotid salivary gland, paraffin sections of 7mm size 
were fixed on microscopic slides and stained with peroxidase (PO)-labeled rabbit 
anti-human  IgA  (Jackson  ImmunoResearch,  Suffolk,  Uk)  and  haematoxylin 
staining to view nuclei. 
6.2.3   Total RNA extraction and RT-PCR 
Total RNA was isolated from ten subsequent cryostat sections of 5mm thick by the 
Trizol®  method  (Sigma  Ltd,  Zwijndrecht,  Netherlands)  according  to 
manufacturer’s instructions. The Biomed FR1 set of forward primers were used for 
VH  family  amplification  (van  Dongen  et  al.,  2003).  A  3’  Ca  common  (IgA 
common)  primer  was  designed  that  can  be  used  for  both  IgA1  and  IgA2 
(GAATTCGAGTGGCTCCTGGGGGAAGA). On the basis of the sequenced PCR 
products both subtypes of IgA can be distinguished PCR was performed (S.Yuvaraj  
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submitted). PCR was performed for 35 cycles using a 60-second denaturizing step 
at 94
0C, 60-second annealing step at 60
0C and a 60-second extension step at 72
0C. 
The product was loaded onto agarose gel and the ethidium bromide stained band 
was recorded. 
Patient number  Disease  treated with 
Rituximab 
1*  pSS  No 
2*  pSS  Yes 
3  minimal infiltrate; no Sjögren’s  No 
4  small lymphocytic infiltrate no Sjögren’s  No 
5  Control parotid biopsy  No 
6  Control parotid biopsy  No 
7  lymphoplasmacellur infiltrate, Sjögren’s  No 
8  lymphocytic infiltrate, lymphoepithelial 
lesions Sjogren’s 
No 
9**  pSS  No 
10**  pSS  Yes 
 
Table-1 Details of Sjögren’s syndrome Patients included in this study * 1& 2 are same 
patient’s biopsies taken before and after treatment with Rituximab, ** 9&10 are same 
patient’s biopsies taken before and after 0treatment with Rituximab 
 
Sample  Sequenced  Productively 
rearranged sequences 
Numbers of sets  Unique 
sequences 
1SS 
2SS 
25 
25 
23 
25 
3 set (1x2, 1x3, 1x5)  38 
3SS  25  22  3 set (3x2)  16 
4SS  25  23  1 set (1x2)  21 
5SS  25  20  2 set (2x2)  16 
6SS  25  23  1 set (1x3)  20 
7SS  25  20  2 set(1x2, 1x5)  13 
8SS  25  23  4 set(2x2, 2x3)  10 
9SS  25  24  35 
10SS  25  25 
5 set(2x2, 2x3, 1x4) 
 
 
Table-4 Number of sequences and clonally related sets obtained from this study.  
6.2.4   Cloning and Sequencing IgA transcripts 
PPCR  products  from  all the  biopsies  were  obtained  by  amplification of cDNA 
using the 5’ FR1 primer set in combination with a 3’ IgA common primer. PCR 
products were gel purified using a gel purification kit (Invitek, Foster City, CA), 
cloned  into  InsTAclone  vector  (Fermentas,  St.Leon-Rot,  Germany).  25  positive 
clones were sequenced from each biopsy using an automated sequencing device as 
described (Guikema et al., 1999).  High IgA1- Producing cells in Rituximab treated primary Sjögren’s syndrome 
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6.2.5   Analysis of rearranged V genes 
Nucleotide  sequences  were  compared  with  the  IMGT  databases  of  germline 
sequences  (Giudicelli  et  al.,  2006)  and  VH-DH-JH  regions  were  analyzed  using 
IMGT Quest (Giudicelli et al., 2004) and Joinsolver (Souto-Carneiro et al., 2004). 
The lengths of the CDR3 domains of translated IgA heavy-chain transcripts were 
calculated as described previously (Rock et al., 1994). Replacement over silent 
mutation (R/S) ratios for FR and CDR were determined (Dammers et al., 2000). 
Sequences having identical VDJ rearrangements were defined as clonally related.  
6.3   Results: 
6.3.1   Clinical outcome of rituximab treatment. 
The two patients described here participated in al larger trial in which in total 15 
pSS patients were treated with rituximab (Pijpe et al., 2005a) These two patients 
both showed complete B cell depletion in peripheral blood following treatment. In 
one patient B cells had returned within 24 weeks after treatment and in the other 
patient  within  36  weeks  after  treatment.  In  both  patients  subjective  symptoms 
improved significantly after treatment. Stimulated submandibular/sublingual flow 
rate improved in both patients. Flow rate increased from 0.04 ml/min and 0.08 
ml/min at baseline to 0.19 ml/min and 0.18 ml/min respectively. 
6.3.2   Staining revealed those IgA plasma cells appears first after 
Rituximab in more number. 
Following rituximab treatment there was a decrease of the lymphoid infiltrate, now 
mainly consisting of T cells, with recovery of salivary gland tissue morphology. 
Immunohistological  analysis  of  the  infiltrate  in  the  second  biopsy  specimen 
showed  an  increase  in  the  relative  percentage  of  IgA  positive  plasma  cells  as 
compared with IgG positive plasma cells (Figure-1). 
6.3.3   Clonally related IgA-producing cells are observed before and 
after rituximab treatment with additional mutations. 
From each biopsy of the parotid salivary gland 25 different IgA VH sequences were 
analyzed  from  each  biopsies.  Out  of  the  250  sequences  229  sequences  were 
productive rearrangements (Table-2, Table-3). No 100% identical sequences were 
observed  in  biopsies  of  patients  taken  both  before  and  after  treatment  with 
rituximab (Table-4). Sequences are considered as clonally related sequences if they 
have the same H-CDR3 region. B cells with few mutations in the H-CDR3 regions 
can still be considered to be clonally related (Holtmeier et al., 2000). Clonally 
related IgA VH rearrangements were observed in salivary glands before and after  
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rituximab treatment. Eight sets of clonally related sequences were obtained from 4 
biopsies of 2 patients before and after treatment. As an example in Figure-2D, 
sequence 18-9SS (pre treatment) and sequence 22-10SS (post-treatment) have 8 
shared mutations, the former sequence acquired 9 mutations, while the latter had 22 
mutations. In other examples (Figure-2B & 2C) of these clonally related cells, the 
sequences from after rituximab treatment biopsies had fewer mutations than the 
untreated tissues. No 100% identical sequences were observed in these 4 biopsies.  
Two sets of clonally related sequences and 7 sets of completely 100% identical 
sequences were present in the control biopsies. Identical sequences were excluded 
from clonal tree analysis since we cannot discriminate whether they derived from 
the same B cell or from clonally related B cells. These clonally related sequences 
observed shared most of their mutations. Some of the clonally related sequences 
resulted in high R/S ratio’s in the CDR regions, suggesting affinity maturation 
during germinal center reactions (Figure-2I clonally related figures), while another 
set  of  sequences  had  no  significant  R/S  ratio’s  in  their  mutations  (Figure  2G 
clonally related figure). 
6.3.4   Half of the salivary gland IgA sequences have somatic mutations 
with R/S ratio’s significantly different from random mutations. 
Presence and nature of somatic mutations in obtained IgA sequences were analyzed 
by comparison with known germline VH sequences. This analysis revealed that all 
sequences  contain  mutations  in  the  diseased  tissues  and  only  one  germline 
sequence was observed in normal parotid glands. The mutation frequency varied 
between 2 and 24% (4-55 mutations). The ratios of replacement (R) to silent (S) 
mutations for FR and CDR in this study were calculated as described (Dammers et 
al.,  2000).  In  pSS  39%  of  sequences  had  significant  R/S  ratio,  which  is  an 
indication for selection, but the remaining 61% sequences did not show signs of 
antigen-selection. In contrast, the percentage of selected sequences increased to 
48% after rituximab treatment which is more similar to normal salivary glands. In 
normal  salivary  glands  53%  of  sequences  showed  signs  of  selection  while  the 
remaining 46% did not show any sign for antigen-selection (Table-2). High IgA1- Producing cells in Rituximab treated primary Sjögren’s syndrome 
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Fig. 1 1 (A) Immunohistochemical staining for IgA positive plasma cells in parotid gland 
biopsy specimen before treatment, showing a few IgA positive plasma cells (arrow) and a 
massive infiltrate with a few ducts (magnification x200). (B) Immunohistochemical staining 
for IgA positive plasma cells in parotid gland biopsy specimen after rituximab treatment, 
showing  less  infiltrate  and  more  salivary  gland  ducts,  with  a  relative  increase  of  IgA 
positive plasma cells (arrows) (magnification x200). 
 
 
Fig. 2a  
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Fig. 2b 
 
Fig. 2c 
 High IgA1- Producing cells in Rituximab treated primary Sjögren’s syndrome 
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Fig. 2d 
 
Fig. 2e 
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Fig. 2f 
 
Fig. 2g High IgA1- Producing cells in Rituximab treated primary Sjögren’s syndrome 
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Fig. 2h 
 
 
Fig. 2i 
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Fig. 2j Alignment of clonally related IgA VHDHJH sequence derived VH genes from ileum 
and genealogical trees deduced from the mutations observed in the VH genes of these 
clones. Sequences of the germline gene are shown on top. Dashes indicate identical 
nucleotides, and gaps resulting from IMGT subdivision are marked by dots. Replacement 
mutations are shown in bold/underscored characters. 
 
 
Fig. 3 IgA1 and IgA2 subclasses usage among the IgA sequences. High IgA1- Producing cells in Rituximab treated primary Sjögren’s syndrome 
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6.3.5   IgA1 is prefentially used  in Sjogren’s syndrome disease. 
The use of our newly designed 3’ Ca primer which could distinguish IgA1 and 
IgA2  isoforms  revealed  that  B  cells  from  Sjögren’s  syndrome  salivary  glands 
preferentially use IgA1. In control biopsies form healthy persons and from other 
inflammatory conditions both IgA subclasses were present in approximately the 
same proportion (Figure-3). This increased usage of IgA1 was observed in biopsies 
after treatment with rituximab in patient 1 and 8. 
6.3.6   Sequential isotype switching observed in normal salivary glands. 
During class switching recombination (CSR) IgM
+ B cells change their constant 
region to other isotypes such as IgG, IgA or IgE (Stavnezer, 1996). CSR is under 
the influence of cytokines and other co-stimulatory molecules (Stavnezer, 1996). 
We observed in our collection of VH genes for the first time that IgA1 and IgA2 
constant regions can be derived from the same precursor. In 2 sets of clonally 
related sequences some sequences within one set had used IgA1 constant region 
while  the  other  sequence  had  used  IgA2  (Figure-2I  and  2J).  This  pattern  was 
observed in 2 healthy salivary glands. 
6.3.7   VH gene family usage varies before and after rituximab 
treatment. 
VH1 gene family usage was highly prevalent in biopsies from pSS patients both 
before and after rituximab treatment but in control biopsies VH4 family members 
were preferentially used. After treatment with rituximab the VH gene usage was 
similar to normal salivary gland tissue. In the biopsies from pSS Patient 1 and 8 
treated with Rituximab a similar VH gene family usage was observed with a high 
usage of the VH3 gene family members. In all patients a similar distribution of DH 
usage was observed with frequent usage of DH1, DH2 and DH3 gene segments. The 
most frequently used JH gene segment in all patients was JH4. More than 50% of 
salivary gland IgA transcripts utilized JH4 gene segment followed by JH6, JH5 and 
JH3. 
6.4   Discussion: 
In phase II clinical trials it has been shown that rituximab is effective for at least 6-
9  months  in  pSS  patients  with  active  disease,  improving  both  subjective  and 
objective symptoms (Mariette et al., 2003;Pijpe et al., 2005a). In all patients who 
responded well to the treatment with rituximab a total depletion of B cells was seen 
in peripheral blood drawn 12 weeks after treatment.  
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Peripheral blood B cells are depleted after treating with Rituximab as was noted in 
the pSS patients as well no Ig producing cells observed in the salivary glands (Pijpe 
et  al.,  2005b).  Twelve  weeks  after  rituximab  treatment  high  number  of  IgA 
producing cells were first observed in the parotid glands. At this time point the 
number of B cells in the peripheral blood was still very low. In this study we show 
that these IgA-producing cells are most likely not derived from newly formed B 
cells because of the high number of somatic mutations observed. Furthermore, we 
could  show  clonal  relationships  between  IgA  producing  cells  before  and  after 
treatment. Evidence for IgA to play an important role in the pathogenesis of pSS 
was suggested by the presence of IgA immune complexes, IgA rheumatoid factor, 
and high serum level of IgA in pSS patients (Levy et al., 1994). Recently it has 
been reported that clonal expansion of IgA-positive plasma cells and axon-reactive 
antibodies are present in multiple sclerosis lesions (Zhang et al., 2005). In both 
humans and mice, oral immunization leads to the presence of antigen-specific IgA 
in salivary glands (Weisz-Carrington et al., 1979). The CCR10 ligand CCL28 is 
produced by epithelial cells in various mucosal tissues including salivary glands 
indicating  a  broad  role for  this  chemokine  in  salivary  glands  (Hieshima  et  al., 
2003).  The  recruitment  of  IgA  plasma  cells  back  to  parotid  glands  may  be 
suggested by the high expression of CCL28 on the salivary gland epithelium. IgA 
plays  a  role  in  the  first  line  of  defence  mechanism.  High  numbers  of  micro-
organisms reside in the mouth cavity and their translocation is prevented by SIgA. 
IgA produced by plasma cells that are present in the parotid glands is secreted 
along  with  saliva.  Increased  numbers  of  IgA  plasma  cells  after  treatment  with 
rituximab could indicate the regeneration of a newly  formed normal IgA repertoire 
after depleting of B cells. It could also be an influx of recirculating IgA producing 
cells compensating for the depletion of all B cells. Some IgA producing cells might 
leave the gut associated lymphoid tissue and seed into the salivary glands(Roll et 
al., 2006). 
Rituximab specifically binds to the transmembrane protein CD-20 that is expressed 
on different stages of B cell differentiation except on plasma blasts and plasma 
cells (Pescovitz, 2006). Use of this mAb has successfully improved the clinical 
condition of many autoimmune diseases (Edwards and Cambridge, 2006) and B 
cell derived cancers (Reff et al., 1994). IgA sequences from biopsies taken before 
and after treatment with rituximab provided evidence for the presence of clonally 
related IgA producing cells in these two biopsies. This might indicate that few IgA 
producing  cells  escape  from  this  Rituximab  treatment.  The  accumulation  of 
somatic  hypermutations  in  all  IgA  sequences  obtained  from  the  biopsies  post-
treatment further supports the concept that a sub-population of memory B cells/ or 
plasma  blasts  can  escape  Rituximab  treatment.  It  was  remarkable  that  some 
sequences obtained after treatment show less mutations then their clonally related High IgA1- Producing cells in Rituximab treated primary Sjögren’s syndrome 
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counterparts before treatment. Our limited sampling size could explain why we 
have missed members from this set of clonally related B cells with equal number of 
somatic  mutations.  The  resistance  to  Rituximab  could  depend  on  the  tissue 
microenvironment (Gong et al., 2005;Smith, 2003). For instance, Marginal zone B 
cells from the spleen were found to be resistant to rituximab killing (Gong et al., 
2005).  Plasma  cells  and  plasmablast  do  not  express  CD20  and  hence  are  not 
depleted by rituximab. Within this study we cannot determine the B cell phenotype 
further because the entire tissue was used to amplify IgA genes rather then for 
instance sorting of different population of B cells. 
The use of our new IgA constant region 3’primer that can discriminate between 
IgA1 and IgA2 provided evidence that the IgA1 subclass is highly used in pSS. In 
the  salivary  gland  from  normal  controls  and  from  samples  that  do  show 
inflammation but not diagnosed as pSS an equal proportion of IgA1 and IgA2 
subtypes was observed. The high usage of IgA1 in pSS biopsies remained after 
treatment  with  Rituximab.  It  has  been  reported  that  increased  N-linked 
glycosylation can lead to oversialylation of IgA1 from pSS patients (Basset et al., 
2000b;Basset  et  al.,  2000a).  Dendritic  cells  skew  isotype  switching  of  CD40-
activated, naive B cells towards IgA1 and IgA2. DC provide a critical signal for the 
expression  and  the  secretion  of  the  IgA2  proteins  (Fayette  et  al.,  1997). 
Plasmacytoid dendritic cells (pDC) are present in the salivary glands of patients 
with  pSS.  Activation  of  pDCs  through  TLR  receptors  links  innate  to  adaptive 
immunity, leading to increased secretion of type I IFN. IFN-g in combination with 
IL-6 secretion by pDCs results in plasma cell differentiation and antibody secretion 
(Gottenberg et al., 2006), whereas IFN- g and IFN- g induce BAFF expression by 
myeloid  cells  and  salivary  epithelial  cells.  Indeed,  BAFF  over  expression  in 
salivary glands of patients with pSS might result in local activation and survival of 
autoreactive B and T cells (Lavie et al., 2004). The above phenomena may lead to 
high  production  of  IgA1  in  pSS  salivary  glands.  Rituximab  treatment  do  not 
change the restricted usage of IgA1. 
We report for the first time that 2 sequences that use the same CDR3 region use 
different constant alpha regions. This type of sequential class switching may occur 
from IgA1 to IgA2 since Ca2 is at the 3’upstream from Ca1 on chromosome 14. 
Evidence for sequential Sm-Sg, Sg-Sa DNA recombination has been reported in the 
human B cells (Zan et al., 1998). Alternatively, switching can occur from IgM to 
IgA1 and later in time the remaining parental IgM or memory IgM
+ B cells switch 
to the IgA2 isotype. 
In conclusion, our data provides evidence for persistence and outgrowth of certain 
subpopulations of IgA producing B cells after rituximab treatment. The preferential 
usage of the IgA1 subtype in pSS salivary glands suggest selective outgrowth and 
may give a clue about the aetiology of pSS. The possibility of sequential class 
switching between the IgA subclasses was suggested. Which B cells are finally  
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responsible  for  the  recurrence  of  the  disease  after  treatment  is  still  unknown. 
Complete removal of all subsets of B cells starting from pre B cell upto plasma 
cells might further improve the disease condition of pSS. 
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E. coli Produced Human BMP-2 
Induces Apoptosis In Colon Cancer 
Cells  
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Abstract: 
Bone  morphogenetic  protein  2  (BMP-2)  plays  a  influential  role  during  bone 
renewal and repair as well as during various steps of embryonal development. A 
cDNA encoding mature human BMP-2 was efficiently expressed in E. coli. The 
recombinant BMP-2 was functionally active as demonstrated by the induction of 
apoptotic  activity in the DLD-1 cell line. In the future the same molecule can be 
expressed on the surface of Lactococcus lactis as a fusion protein to target colon 
epithelial cells. Human BMP-2 Production in E. coli 
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7.1   Introduction 
Bone morphogenic protein (BMP) is a member of large TGF-￿ family ligands. 
Originally BMP was identified as a putative morphogen for bone formation (Reddi, 
1994) and later this protein emerged as an important signaling mediator during 
embryonic nervous system patterning(Liu and Niswander, 2005). BMP forms a 
complex with extracellular matrix proteins; for this reason its biological activity is 
confined to local niche. Furthermore, BMP signaling is antagonized by endogenous 
extracellular  proteins  such  as  follistatin  and  noggin  which  block  the  BMP 
receptors(Varga and Wrana, 2005). BMP binds to Type-I (BMPR1A,BMPR1B) 
and  Type-II  (BMPRII)  serine-threonine  kinase  transmembrane  receptors  and 
triggers a signal transduction cascade initiated via Smad family proteins. Signaling 
through  smads  takes  place  via  three  smad  family  proteins:  Receptor-mediated 
smads  (smad1,  5  and  8),  co-smad/smad4  (common  mediator  of  smad)  and 
inhibitory smads (smad 6 & 7, negative regulators of smad) (figure-1) (Beck et al., 
2006). Finally the BMP-smad pathway activates direct or indirectly BMP target 
genes in the nucleus via co-transcriptional partners (Varga and Wrana, 2005). 
BMP-2 plays a crucial role during the embryonic development of digestive organs 
including stomach gland formation (Narita et al., 2000). BMP is highly expressed 
in the normal human stomach and colon(van den Brink et al., 2001), (Hardwick et 
al.,  2004).  However,  in  colorectal  cancer  cells  (CRC)  BMP-2  inhibits  cell 
proliferation and induces differentiation (Hardwick et al., 2004). Wen et al. have 
demonstrated that BMP-2 inhibited cell growth, and induced cell differentiation in 
normal and cancerous gastric cell lines(Wen et al., 2004). Furthermore, BMP-2 
expression  is  lost  at  an  early  stage  of  human  familial  adenomatous  polyposis 
lesions and is causative in juvenile polyposis (van den Brink et al., 2001). The loss 
of BMP-2 expression in the gastric and colorectal cancer cells suggested as a result 
of methylation of BMP-2 gene promoter(Wen et al., 2006). Overall these studies 
suggest BMP signaling may be an potential therapeutic target to treat cancer.  
Colon cancer is an epithelial cancer which is mainly confined to colon. It develops 
as  a  result  of  uncontrolled  cellular  proliferation  and  dysregulation  of  cellular 
apoptotic mechanisms. Inactivation of TGF-b signaling appears to play a key role 
in colon cancer (Carthers JM, 2003). Conventional treatment for colon cancer such 
as surgery, radiotherapy, chemotherapy   
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Fig. 1 BMP binds to Type-I (BMPR1A,BMPR1B) and Type-II (BMPRII) serine-
threonine  kinase  transmembrane  receptors  and  triggers  a  signal  transduction 
cascade initiated via Smad family proteins. Signaling cascade through smad take 
place via three smad family proteins: Receptor-mediated smads(Figure adopted 
from Sigma).. 
 
leads to a serious side effects. Recently the targeted therapies that are intended to 
induce  apoptosis  selectively  in  cancer  cells  are  presently  envisaged  as  most 
promising anti-cancer strategies for example, use of antibodies such as rituximab is 
a breakthrough in cancer treatment(Barbera-Guillem et al., 2000). 
Despite  the  high  production  costs  and  the  occurrence  of  systemic  side  effects, 
antibody-based  immunotherapy  has  turn  out  to  be  a  valuable  treatment  for  a 
number of diverse cancers. Therapeutic monoclonal antibodies (mAb) can be used 
to  induce  tumor  cell  death  by  a  variety  of  mechanisms.  On  the  other  small 
signaling molecule that have undergone mutation in their gene results improper 
product or absent of this particular product. For example, PTEN gene is mutated in 
prostate cancer that does not yield in PTEN protein that lead to develop resistance 
for apoptosis. The cell Gene therapy with PTEN is used in prostate cancer is a 
promising approach, which have side effect (Yan et al., 2006). Delivering these 
type  of  important  therapeutic  molecule  local  rather  than  gene  therapy  have 
advantage. BMP-2 has been produced from mammalian cell cultures and in plants Human BMP-2 Production in E. coli 
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as a active form (Gao et al., 2006). In this context, first clinical trial of Lactococcus 
lactis production IL-10 to treat crohn’s disease is highly interesting (Braat et al., 
2006). IL-10 was delivered locally to the affected tissue by L. lactis, preventing 
adverse side effects associated with systemic administration. Biologically active 
BMP-2 has been produced in Escherichia coli, thus prokaryotes can make active 
BMP-2 (Long et al., 2006). In the present study we aim to produce BMP-2 in L. 
Lactis  for  oral  therapy.  As  a  model  for  this  long  term  goal  we  successfully 
expressed BMP-2 in E. coli. BMP-2 expressing E. coli induced apoptosis when co-
cultured with DLD-1 which are colon epithelial cancer cells providing proof of 
principle for this strategy.  
7.2   Methods and Materials. 
7.2.1   DLD1 culture condition, 
DLD cells were cultured at 370C in humidified 5% CO2 atmosphere. Attaching 
cells DLD were cultured in RPMI supplemented with 10% fetal calf serum.  
7.2.2   Human BMP-2 
The  human  BMP-2  cDNA  sequence  was  amplified  by  PCR  using  the  primer 
5’ATTGCCGGCGACCCGCTGTCTTCTA’3  and  5’ATCGATGCGACAC 
CCACAAC’3  from  normal  human  ileum.  The  primers  contained  the  ClaI  and 
NgoMIV restriction sites for future cloning into L.lactis. The entire PCR product 
was cloned into the Topo pTris prokaryotic expression vector and transformed into 
E. coli K-12 strain. The new plasmid was named as pTrisBMP-2. Confirmation of 
cloning and transformation was done by PCR on E. Coli colonies using above 
mentioned primer to confirm the presence of human BMP-2 in the colonies. Next, 
restriction enzyme  analysis  was  performed,  using  BamHI  and  AgeI,  to  confirm 
correct  orientation  of  the  insert  (human  BMP-2)  into  the  pTrcHis  TOPO  TA 
Expression  vector  (Figure:2).  The  expected  size  of  a  correct  orientation  of  the 
insert  in  the  backbone  was  291bp,  and  with  a  reversed  orientation  1030bp.  
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Subsequently the positive colonies were sequenced and checked for correct reading 
frame.
BMP-2 BMP-2 BMP-2 BMP-2
 
Fig. 2 pTrcHis TOPO TA Expression vector (Invitrogen, Netherland) used to clone 
human BMP-2. 
7.2.3   Expression of BMP-2 in E.coli 
The E. coli strain K-12 transformed with pTrisBMP-2 was cultured in LB medium 
containing ampicillin (50mg/ml) at 370C, when the OD600 of culture reached 0.6, 
the expression of BMP-2 was induced by addition of IPTG to a final concentration 
of 1mM and cultivated for more 2 hours. 
7.2.4   Western blotting 
Expression  of  BMP-2  was  confirmed  by  the  western  blotting.  The  molecular 
weight of the protein was checked by SDS-PAGE,  which present 44 kDa. For 
immunodetection, samples were separated by SDS-PAGE and electrotransferred to 
a nitrocellulose membrane. The membrane was blocked with 5% non-fat milk in 
PBS-T buffer (PBS containing 0.05% Tween 20), and then incubated with mouse 
anti-human BMP-2 polyclonal antibody (1:2000) and Rabbit anti-histaq (1:5000) Human BMP-2 Production in E. coli 
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antibodies for 2 hours. The membrane was washed three times with PBS-T buffer 
and  then  incubated  in  anti-mouse  and  anti-rabbit  HRP  conjugated  secondary 
antibody at 1:2000 dilution in PBS-T buffer for 1 hour. The membrane was washed 
three times with PBS-T buffer and the expressed proteins were visualized using 
ECL plus western blotting detection system (Amersham). 
7.2.5   Co-culture of DLD cells and E. coli and Caspase activity 
assay 
Experiment  was  set  up  to  show  the  apoptosis  effect  of  BMP-2  produced  from 
prokaryotic expression vector. An overnight culture of BMP-2 containing E.coli 
was inoculated in LB-broth until the OD600 reached 0.6 and induced with 1mM 
IPTG. The induced bacteria was incubated with confluent DLD-1 cell culture in 6-
wells plates for 5 hours. The cells were lysed and the protein concentrations were 
estimated using BIO-Rad DC Protein Assay kit (Bio-Rad). Caspase-3 activity was 
assayed in cells using a fluorimetric kit (Promega) according to the manufacturer' s 
instructions. 20 ￿g of protein was used (Conde de la Rosa et al., 2006). 
7.3   Results: 
7.3.1   Construction of pTrisBMP-2. 
Human BMP-2 gene was amplified from the normal ileum cDNA by PCR. The 
1088 bp product was successfully cloned into pTris to get pTrisBMP-2. By PCR 
and  restriction  analysis  the  plasmid  which  contained  the  BMP-2  in  the  correct 
orientation was selected. Sequence analysis revealed that the obtained BMP-2 was 
in the right reading frame with three mutation where observed where one led to 
change in the amino acid.. This mutation may be due to the Taq error or acquired 
mutation in the volunteer BMP-2 gene. 
7.3.2   BMP-2 expression in E. coli 
Small-size cultures (10ml) of the positive clones of pTrisBMP-2 were subjected to 
IPTG induction to identify clones capable of expressing high level of recombinant 
protein. Ten clones showed expression of the unique predicted 44 kDa protein after 
IPTG induction. The BMP-2 production increases in parallel with the duration of 
induction. Without IPTG induction, two clones did not show the expression of this 
protein as confirmed by SDS-PAGE. The expression of the BMP-2 was further 
confirmed by Western blot using anti-BMP-2 and anti-histaq antibody (Figure-3).  
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7.3.3   Apoptosis Assay 
E. coli colonies were co-cultured with DLD-1 cells for different time frame and 
afterwards  caspase  3  activity  was  measured.  Cells  co-cultured  with  bacteria 
producing BMP-2  gene showed a significant higher caspase-3 activity than the 
control bacteria which expressed LacZ gene. BMP-2 increases caspase-3 activity 
after 5 hour of incubation (Figure-4).  
45 kDa
A B
1 2 1 2
45 kDa
45 kDa
A B
1 2 1 2
45 kDa
 
Fig.  3  Western  blot  of  BMP-2  expressing  colonies  with  (A)  anti-Polyhistaq 
antibodies  and  (B)  anti-BMP-2  antibodies.  1.  2  hour  induction  ,  2.  3  hour 
induction. 
 Human BMP-2 Production in E. coli 
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Fig. 4 BMP-2 expressing colonies were co-cultured with DLD-1 cells. Caspase 3 
activity was measured with fluorescentie. Colony 4 and 5 show a significant higher 
caspase 3 activity compared to the negative control as was revealed by a T-test. As 
negative control we used bacteria containing a LacZ gene.  
7.4   Discussion 
The clinical trail utilizing IL-10 expressing L. Lactis for the  treatment of Crohn’s 
disease  has  confirmed  that  such  bacteria  represent  a  viable  approach  for  the 
mucosal release of therapeutically exciting proteins(Braat et al., 2006). This have 
brought up a new avenues to explore and use transgenic bacteria as a vehicle to 
delivery these type of target molecules locally and consequently avoid unwanted 
side effects while administered systemically. The BMP-2 was expressed in large 
amounts by E. coli. Here we report a potential approach for inducing colon cancer 
cells death by apoptosis mediates by a recombinant BMP-2 protein produced by E. 
coli. In recent years, a better perceptive of pathogenic mechanisms has provided 
novel  targets  and  strategies  for  colon  cancer  therapy.  These  vary  from  novel 
chemotherapeutic agents, therapeutic antibodies to target small molecules involved 
in the signal transduction. The first successful clinical trails to treat patients with 
IBD using L. lactis producing IL-10 opens the window to deliver anti-cancer agent 
via oral therapy with recombinant bacteria. Thus transgenic bacteria may become a 
vehicle  to  deliver  associated  target  molecules  locally  and  consequently  avoid 
unwanted side effects with systemic administration.  
BMP-2 expressed in E.coli show clear pro-apoptotic effects when co-cultured with 
DLD-1 cells. Although E. coli does not have the same post translation modification 
system as in humans, the BMP-2 produced by this bacterium is clearly biologically 
active. Recently many signaling pathway mediators involved in cancer have been  
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identified which are promising targets for cancer therapy. These molecules should 
be delivered specifically to the cancer cells by targeting to tumor cells. Based on 
these  requirements  we  developed  a  recombinant  human  BMP-2  molecule.  The 
presence of phosphorylated SMAD4 in the cancer cells showed that BMP-2 bound 
to their receptors and activated the SMAD pathway(Hardwick et al., 2004) which 
in turn results in apoptosis. Adding of noggin which is agnostic to BMP-2 inhibited 
the apoptosis in these cells (Hardwick et al., 2004;Narita et al., 2000). Recently it 
was reported that BMP inhibits the tumorigenic potential of human brain tumor-
initiating cells(Piccirillo et al., 2006).  BMP-2 expressed in E.coli shows some 
apoptotic affect when co-cultured with DLD-1 cells. In spite of E. coli system do 
not have the same post translation modification as in human, the BMP-2 produced 
by this bacterial induces apoptotic in colon cancer cells.  
Induction of apoptosis to DLD-1 cells when incubated with E.coli producing BMP-
2 activates the same mechanism in vivo system when living recombinant bacteria 
producing BMP-2 is administrated. These promising results further encourages to 
continue by expressing this recombinant BMP-2 on the surface of L. lactis to treat 
colon cancer.  
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The work in this thesis describes the biology of IgA under different situations and 
the recombinant production of scFv SIgA in Lactococcus lactis. IgA is one of the 
most important components of the mucosal immune system, hence biogenesis of 
IgA must be organized in a sophisticated manner to ensure proper bioaction. For 
instance, production of IgA from a B cell starts with antigen sampling and 
presentation to B cells in a proper co-stimulatory context that allows maturation. 
The matured cell subsequently differentiates into an IgA plasma cells and start to 
produce antibody. The resulting IgA molecules binds via their variable regions 
specifically to the relevant antigens, either commensal gut microflora but also 
pathogens. The IgA complex may then be cleared via two different routes, 
depending on the location of the complex: (1) in circulation, the Fc region of the 
IgA antibody binds to the effector cells which destroy this complex, via 
phagocytosis (2) in the intestinal tract the IgA encounters the antigen in the lumen, 
thus preventing entry of antigen into the body. Monoclonal antibodies including 
IgA are used in the treatment of disease, diagnostics, and in routine laboratory 
experiment. Advanced recombinant techniques now provide a platform for tailored 
design of new mAb, single chain variable region fragment (scFv) and fusion 
proteins for multiple clinically purposes. Together these consideration have 
prompted me to explore the role of IgA in mucosal biology in two different 
directions:  (1) IgA repertoire analysis in health and diseased humans [to obtain 
clues as to role of IgA in disease and to use the repertoire as a surrogate marker for 
the development state of disease] and (2) production of recombinant scFv SIgA in 
L. Lactis exploiting the unique character of IgA molecules for designing superior 
clinical treatment of gastrointestinal disease. 
In  Chapter-2 we standardised the procedure to isolate cDNA from the human 
ileum. By immunohistochemistry staining with anti-human IgA antibodies it was 
quantitatively estimated that there are around 75,000 IgA plasma cells per biopsy. 
From the pool of cDNA we labelled the IgA transcripts with FAM by PCR 
technique, followed by spectrotype analysis of CDR3 lengths. Surprisingly, we 
found that the large number of IgA producing cells in the ileum were not 
polyclonal as expected. Further investigations confirmed this notion using a 
different approach involving spectrotyping, cloning and sequencing the IgA 
transcripts. Interestingly, sequence analysis of the IgA V H genes revealed the 
frequent occurrence of clonally related sequences, containing large numbers of 
Chapter 8 
Summarizing discussion  
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mutations compared to germline sequences. Even though many of the mutations 
present in these clonally related sequences were shared, most of the sequences also 
contained additional mutations, yielding variety within such clonally related 
sequences. Taken together, the data indicate that the human ileum is composed of 
large numbers of IgA producing B cell clones, but that a relatively low number of 
(isotype switched) precursor cells are involved in the generation of IgA plasma 
cells in the gut. Here we would like to propose to commence the functional 
expression of clonally related IgA sequences in order to reveal the importance of 
the ongoing mutations with respect to affinity maturation and antigen selection. 
These experiments should be exceedingly useful for determining the factors that 
govern the balance between affinity and diversity in the antigen repertoire in the 
gut. 
A V H gene recognising the epithelial glycoprotein-2 (EGP-2), which is highly 
expressed on the epithelial cancer cells, was used to develop scFv SIgA molecule 
in Chapter-3, providing a model molecule for studies employing engineered IgA 
antibodies for the treatment of disease. In this chapter, we aimed to target this 
molecule to colon cancer cells. One of the limiting factors for these type of 
molecules is the availability of a delivery system. An attractive possibility is to 
employ for the mucosal distribution purposes of such engineered IgA molecules 
genetically recombinant gut residing bacteria. In the present study, L. lactis was 
employed. The entire scFv SIgA molecule was engineered and expressed in 
eukaryotic cells and in L. lactis. The eukaryotic recombinant was shown to be bind 
to the right target and that it can induce apoptosis in a colon cancer line. From the 
L. lactis protein we could show that it expressed as a membrane bound protein that 
can be recognized by anti-IgA antibodies. A further step in this research should be 
the confirmation of its biological activity, assessing the potential of the 
recombinant IgA on this organism to recognize native EGP-2 protein and to assess 
its effect on the cellular physiology of the epithelial cancer cells for whose 
treatment this organism is intended. Another possibly important follow up on the 
current project is to produce natural scFv SIgA. This can be achieved by replacing 
the VH gene that recognizes EGP-2 with the VH genes that are commonly used by 
IgA B cells and might constitute  a treatment for congenital or induced 
(immunosuppressive medicines, HIV) IgA deficiency. Also interesting is the 
mechanism underlying the formation of hybrid IgA molecules. We cloned and 
sequenced human constant  a region from normal ileum, to our surprise, we 
obtained a hybrid clone which contains both C a1 and C a2. The mechanism 
underlying this hybridism awaits further study.  Summary 
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IgA plays an important role in autoimmune disease because of its post-translational 
modification. For example, in the case of IgA nephropathy and Sjögren’s syndrome 
IgA complexes are not properly eliminated and pathology follows. Similarly, we 
investigated the involvement of IgA in Crohn’s disease (CD) by analysis of the IgA 
repertoire in the inflamed and non-inflamed regions of diseased tissues in Chapter-
4. Simultaneously we also investigated the IgG repertoire in these tissues. We can 
conclude from our results that CD is a ongoing immune response, with high influx 
of B cells to the inflamed region. Tantalising, these results may entail that CD 
contains more aspects of a B cell driven autoimmune disease than usually assumed. 
If true, treatment with Rituximab could be beneficial procedure for patients 
suffering from this disease. Rituximab is an antibody directed against B cells which 
is successfully used in many cancers and in autoimmune diseases. In an open label 
study, 15 primary Sjögren’s syndrome patients were treated with rituximab. The 
origin of the relatively high number of IgA plasma cells in the salivary gland 
tissues which appeared after treatment was analyzed in  Chapter-6. Sequences 
from biopsies before and after treatment were found to be clonally related cells. A 
high number of mutations were observed in all the sequences of IgA transcripts. 
This suggest that these B cells belong to the pool of recirculating IgA producing B 
cells within the common mucosal immune system and are not derived from newly 
developed B cells in the bone marrow. Most transcripts used the IgA1 isoform in 
both pre- and post-treated biopsies. This could be an indication of a more selective 
outgrowth within the SS salivary glands already before treatment. Furthermore, we 
have some evidence that in the human salivary gland IgA repertoire, 2 clones have 
used the same V gene but different C alpha genes, which we have termed as 
sequentional switching. We are particularly interested in the molecular mechanisms 
that underlie sequential switching between 2 IgA's. The next intriguing aspect is to 
understand the physiological and functional differences between IgA1 and IgA2. 
For example, what are the signaling pathways that produces hybrids of IgA1/2 ? 
The observation in chapter 4 that inflammatory lesions exhibit different IgA 
repertoire as compared to uninflamed mucosa may explain the spatial restriction in 
CD (healthy and ulcerated areas lying next to each other). Alternatively, different 
groups of microflora in different region may influence the pathogenesis of the 
disease. The involvement of the gut microflora in the development of Inflammatory 
Bowel Disease in a mouse model for experimental colitis was studied in Chapter-
5. We show that an anti-inflammatory response differently induces inducible nitric 
oxide synthase responses in epithelial cells by different gut bacteria, especially 
those that were able to induce inflammatory bowel disease. The remainder of the 
thesis deals with harnessing the bacteria for therapy, by using them as 
biopharmaceutical factories. 
In analogy, as also discussed in Chapter-2, apart from being part of the problem in 
auto-immune disease, IgA can also be part of the solution. In future experiments 
we intend to target recombinant normal gut bacteria to certain location and employ  
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these organisms to produce beneficial substances, for instance BMP-2 as an anti-
cancer agent. The proof of principle that BMP-2 can induce apoptosis in colon 
cancer cells was shown in Chapter-7. This molecule was produced in the E. coli 
and was biologically active. This entire molecule can be cloned into scFv SIgA 
followed by the expression on the membrane of L. lactis. A first possibility to more 
specifically target recombinant proteins is by membrane expression instead of 
continuous secretion by the GM organisms. Membrane expression of ScFv instead 
of secretion turned out to be more efficient in removal of S. mutans from the oral 
cavity (Kruger C., 2002,Nature Biotechnology). Alternatively, local delivery of 
recombinant proteins can be obtained by usage of natural endopeptidases produced 
by mucosal epithelial cells. A good candidate is the endopeptidase that is used to 
split the Secretory Component (SC) from the poly-Ig receptor on the apical 
membrane of intestinal epithelial cells during epithelial transport of secretory IgA 
antibodies. The primary target sequence is known and is successfully introduced to 
free membrane bound ScFv IgA molecules  
 
Fig. 1 Hypothetical model of targeted delivery of recombinant proteins by 
Lactococcus lactis to colon cancer cells in the digestive tract. Expression of IgA-
ScFv on the surface of L. lactis that contains a IgA antibody specific for an marker Summary 
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highly present on colon cancer cells (Epcam) allows specific attachment of the 
GMO to the cancer cells. For this example, the IgA molecule is combined with a 
bioactive protein that induces apoptosis (BMP-2) in the malignant cells and SC 
endopeptidase proteolytic cleavage sites. Subsequently locally produced BMP-2 is 
released. 
 
from L. lactis. As a model to test this targeted delivery of recombinant proteins by 
L. lactis , we expressed a IgA-ScFv on the surface of L. lactis that contains a IgA 
antibody specific for a marker highly expressed on colon cancer cells (Epcam). In a 
model to target such colon carcinoma cells this recombinant protein was combined 
with a bioactive protein that induces apoptosis (BMP-2) in the malignant cells and 
the above mentioned SC proteolytic cleavage sites. L. lactis is first successfully 
targeted to Epcam on colonic epithelial cells and will locally produce BMP-2 that 
is released by the action of the natural epithelial endopeptidase activity (Figure-1). 
Similar targeted GM L. lactis are being used to produce “natural” IgA antibodies to 
maintain a balance with the commensal bacteria within the gut. The latter 
application is very promising for conditions where the immune system is 
genetically or experimentally hampered in maintaining a good balance with the gut 
bacteria. These diseases range from autoimmune diseases such as IBD, RA or type 
1 diabetes. Furthermore, patients that suffer from temporarily induced immune 
suppression might also benefit from such passive immunization strategies.  
In conclusion, I feel that the work presented in this thesis contributes to the insight 
that IgA is an important factor for maintaining health in the vast extent of our 
mucosal surfaces and that its unique biology may actually be  used to combat 
disease in these mucosal surfaces.      
 
      
Dit proefschrift beschrijft de biologie van IgA onder verschillende omstandigheden 
en de productie van recombinant scFv SIgA in Lactococcus lactis. IgA is een van 
de belangrijkste onderdelen van het mucosale immuunsysteem en daarom is de 
manier waarop de productie van IgA is georganiseerd nauwkeurig afgestemd op 
zijn biologische functie. Zo start de productie van IgA door een B cel met het 
presenteren van antigenen aan B cellen in de context van de juiste co-stimulatie die 
de  B  cel  aanzet  tot  verdere  differentiatie.  De  volwassen  B  cel  differentiëert 
vervolgens  tot  een  IgA  producerende  plasmacel  die  grote  hoeveelheden  IgA 
antistoffen maakt.De zo ontstane IgA antistoffen binden met hun variabele gedeelte 
specifiek aan hun relevante antigenen op bijvoorbeeld commensale of pathogene 
darmbacteriën.Het IgA immuuncomplex kan dan vervolgens opgeruimd worden 
via twee verschillende routes: (1) in de circulatie kan het Fc gedeelte van de IgA 
antistoffen binden aan effector cellen die het complex opruimen door phagocytose 
en (2) in het lumen van het maagdarmkanaal kan IgA het antigen tegenkomen en 
door binding voorkomen dat het antigen in het lichaam binnen komt.Monoklonale 
antistoffen, onder andere van het IgA isotype worden gebruikt in de behandeling 
van ziekten, in de diagnose en in routine laboratorium experimenten.Met behulp 
van moderne recombinant technologie is momenteel een platform ontstaan voor het 
op maat maken van nieuwe monoklonale antistoffen, fragmenten van enkele-keten 
variabele delen (scFv) en fusie-eiwitten voor verschillende klinische toepassingen. 
Deze overwegingen hebben mij gemotiveerd om de rol van IgA in de mucosale 
biologie te bestuderen in twee verschillende richtingen: (1) Analyse van het IgA 
repertoire in ziekte en gezonde mensen [ om beter te kunnen begrijpen wat de rol 
van IgA kan zijn in het ziekte proces en om het repertoire te kunnen gebruiken als 
een surrogaat marker voor de ziekte] en (2) de productie van recombinant scFv 
SIgA in L. lactis om gebruik te maken van de unieke eigenschappen van de IgA 
molekulen  in  het  ontwerpen  van  betere  behandeling  van  ziekten  van  het 
maagdarmkanaal. 
In Hoofdstuk 2 hebben wij een procedure ontwikkeld om cDNA te isoleren uit de 
menselijke dunne darm. Na immunohistochemische kleuringen met anti-humane 
IgA antistoffen hebben wij  uitgerekend dat er ongeveer 75000 IgA plasmacellen 
zitten in een biopsie. Uit de hoeveelheid cDNA hebben wij de IgA transcripten van 
een  FAM  (fluorescerend)  label  voorzien  met  behulp  van  PCR,  waarna  de 
verschillende lengtes van de CDR3 zijn geanalyseerd met behulp van spectrotype 
Chapter 9 
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analyse. Tot onze verrassing vonden wij dat het grote aantal IgA cellen in de dunne 
darm veel minder polyklonaal was dan verwacht.Verdere analyse bevestigde deze 
eerste observatie met een andere benadering waarbij de IgA transcripten werden 
gekloneerd en de nucleotide volgorden werden bepaald.Uit de analyse van de DNA 
volgorden  (sequenties)  van  de  IgA  VH  genen  bleken  er  veelvuldig  klonaal 
gerelateerde sequenties voor te komen die een groot aantal mutaties bevatten ten 
opzichte  van  de  oorspronkelijke  kiemlijn  genen.  Alhoewel  deze  klonaal 
gerelateerde  sequenties  veel  gemeenschappelijke  mutaties  hadden,  bevatten  de 
meeste  sequenties  ook  extra  mutaties  die  extra  variatie  tussen  de  verschillende 
klonaal gerelateerde sequenties opleverde.  Samengevat laten deze data zien dat de 
humane dunne darm een groot aantal IgA producerende B cel klonen bevat, maar 
dat een relatief laag aantal van (reeds van isotype veranderde) voorlopercellen is 
betrokken in de ontwikkeling van de IgA plasmacellen in de darm. Wij willen 
daarom voorstellen om te beginnen met de functionele expressie van deze klonaal 
gerelateerde IgA sequenties om het belang van de ontstane mutaties te testen voor 
affiniteitsmaturatie en selectie. Deze experimenten zijn van groot belang om te 
bepalen  welke  factoren  van  belang  zijn  voor  de  balans  tussen  diversiteit  en 
affiniteit in het antigenen repertoire in de darm. 
In  Hoofdstuk  3  is  een  VH  gen  gebruikt  dat  codeert  voor  een  antistof  die  het 
epitheliale  glycoprotein-2  (EGP-2)  herkent  dat  hoog  tot  expressie  komt  op 
epitheliale  kankercellen  om  een  scFv  SIgA  molekuul  te  ontwerpen.  Dit  werd 
gebruikt  als  een  model  molekuul  voor  studies  gericht  op  het  gebruik  van 
recombinant IgA voor de behandeling van ziekten. In dit hoofdstuk wilden wij dit 
molekuul richten op dikke darm kankercellen. Een van de beperkende factoren 
voor dit type molekulen is de beschikbaarheid op de juiste plek. Een aantrekkelijke 
mogelijkheid voor een mogelijke mucosale verspreiding is om gebruik te maken 
van  de  productie  van  deze  recombinante  IgA  molekulen  in  genetisch 
gemanipuleerde darmbacteriën.In deze studie is L. lactis gebruikt. Het complete 
scFv  IgA  molekuul  werd  ontwikkeld  en  tot  expressie  gebracht  in  zowel 
eukaryotische cellen als in L. lactis.Van de eukaryotische recombinant hebben wij 
laten zien dat het kan binden aan het juiste doeleiwit en dat het in staat was om 
apoptose te induceren in een dikke darm kankercellijn. Van het eiwit in L. lactis 
hebben  wij  kunnen  laten  zien  dat  het  tot  expressie  gebracht  wordt  als 
membraaneiwit dat herkend kan worden door anti-IgA antistoffen.Een volgende 
stap in  dit  onderzoek  zou  zijn  om  ook  hiervan  de biologische aktiviteit  aan te 
tonen, met name het vermogen om te hechten aan het EGP-2 eiwit en het effect 
hiervan te bepalen op de cellulaire fysiologie van de epitheliale kankercellen waar 
deze behandeling op gericht is. Een andere belangrijke vervolg van het huidige 
project zou zijn om natuurlijke scFv SIgA molekulen te maken. Dit kan bereikt Samenvatting 
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worden door het VH gen dat EGP-2 herkent te vervangen door VH genen die veel 
gebruikt  worden  door  normale  IgA  B  cellen.  Dit  zou  een  behandeling  kunnen 
opleveren  van  genetische  of  verworven  (door  immunosuppresiva,  HIV)  IgA 
deficiëntie.Daarnaast is het interessant om te kijken wat het mechanisme is achter 
de vorming van hybride IgA molekulen. We hebben een humaan gen gekloneerd 
en de nucleotide volgorde bepaald van een constante gedeelte van IgA die tot onze 
verrassing een hybride kloon bleek te zijn dat zowel een stuk van Ca1  als van Ca2 
bevatte. Hoe zo’n hybride kloon is ontstaan en wat de betekenis is hiervan moet 
verder onderzocht worden. 
IgA  speelt  een  belangrijke  rol  in  autoimmuunziekten  vanwege  zijn  post-
translationele  veranderingen.  Bijvoorbeeld  bij  IgA  nephropathie  en  Sjörgen’s 
syndroom worden IgA immuuncomplexen niet goed verwijderd wat bijdraagt aan 
de pathologie van deze ziekten.Zo hebben wij in Hoofdstuk 4 de betrokkenheid 
van  IgA  bij  de  ziekte  van  Crohn  (CD)  onderzocht  door  analyse  van  het  IgA 
repertoire in ontstoken en niet-ontstoken delen van de darm. Tegelijkertijd hebben 
wij gekeken naar het IgG repertoire in deze weefsels. Uit onze resultaten kunnen 
we concluderen dat bij CD er sprake is van een voortdurende immuunrespons met 
een  grote  toeloop  van  B  cellen  naar  de  ontstoken  delen  van  de  darm.  Deze 
resultaten  kunnen  inhouden  dat  CD  meer  aspecten  van  een  B  cel  gemedieerde 
autoimmuunziekte  heeft  dan  gedacht.  Mocht  dit  waar  blijken  te  zijn  dan  zou 
behandeling met Rituximab een mogelijke behandelingwijze zijn voor patiënten 
met deze ziekte. Rituximab is een antistof  gericht tegen B cellen dat met succes 
gebruikt is in verschillende oncologische aandoeningen en in autoimmuun-ziekten. 
In een open-label studie werden 15 patiënten met Sjörgen’s syndroom behandeld 
met rituximab. De oorsprong van de relatief grote aantallen IgA plasmacellen in de 
speekselklieren  die  gevonden  werden  na  deze  behandeling  is  onderzocht  in 
Hoofdstuk  6.  Sequenties  van  biopsies  van  voor  en  na  de  behandeling  bleken 
afkomstig  te  zijn  van  klonaal  gerelateerde  cellen.    Er  werden  veel  mutaties 
gevonden in deze sequenties van de IgA transcripten. Dit doet vermoeden dat deze 
B cellen behoren tot de poel van recirculerende IgA producerende B cellen in het 
zogenaamde “common mucosal immune system” en niet afkomstig zijn van nieuw-
gevormde B cellen uit het beenmerg. De meeste IgA transcripten bleken de IgA1 
isoform te bevatten zowel in de biopsies van voor als die van na de behandeling. 
Dit kan mogelijk een aanwijzing zijn voor een selectieve uitgroei in de Sjörgen’s 
syndroom speekselklieren reeds voor de behandeling.  
Bovendien  vonden  wij  aanwijzingen  dat  2  klonen  dezelfde  V  genen  hebben 
gebruikt, maar verschillende C-￿ genen. Dit zou verklaard kunnen worden door een 
opeenvolgende switching tussen de twee isoformen van humaan IgA. Wij zijn met 
name geïnteresseerd in de moleculaire mechanismen die ten grondslag liggen aan 
een opeenvolgende switch tussen deze isoformen. Daarnaast is het intrigerend om 
te weten wat het fysiologische en functionele verschillen zijn tussen IgA1 en IgA2.  
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Bijvoorbeeld via wat voor soort signaleringsroute ontstaan hybriden van IgA1 en 
IgA2? 
De  observatie  in  hoofdstuk  4  dat  ontstekingshaarden  een  ander  IgA  repertoire 
hebben dan de niet-ontstoken mucosa zou mogelijk kunnen verklaren waarom er 
zo’n ruimtelijke verdeling is  bij CD (gezonde en ontstoken stukken darm liggen 
vlak  naast  elkaar).  Alternatief  kan  mogelijk  de  aanwezigheid  van  verschillende 
groepen  darmbacteriën  in  die  verschillende  regio’s  ook  bijdragen  aan  de 
pathogenese  van  deze  ziekte.  De  betrokkenheid  van  de  darmbacteriën  in  de 
ontwikkeling van een diermodel voor IBD in een muizenmodel voor experimentele 
colitis  werd  bestudeerd  in  Hoofdstuk  5.  Hier  laten  wij  zien  dat  een 
ontstekingreactie die geïnduceerd wordt door verschillende type darmbacteriën op 
verschillende wijze de expressie van  “inducible nitric oxide” (i-NOS) aanzet, met 
name in de respons tegen die darmbacteriën die in staat waren om een IBD respons 
op te wekken.De rest van dit proefschrift gaat over het gebruik van darmbacteriën 
als biofarmaceutische fabrieken voor therapie. 
Analoog tot wat ook besproken is in Hoofdstuk 2 kan IgA naast oorzaak ook een 
oplossing zijn voor autoimmuunziekten. In toekomstige experimenten willen wij 
onze  recombinante  normale  darmbacteriën  gebruiken  om  ze  gericht  naar  een 
bepaalde lokatie te laten gaan en tegelijkertijd dezelfde organismen te gebruiken 
voor  de  productie  van  gunstige  producten  zoals  bijvoorbeeld  BMP-2  als  anti-
kanker stof.Het principe dat BMP-2 in staat is om apoptose te induceren in dikke 
darm  kanker  cellen  is  aangetoond  in  Hoofdstuk  7.  Dit  molekuul  werd 
geproduceerd in E. coli en was biologisch aktief. Dit complete molekuul kan nu 
gekloneerd worden in de scFV SIgA waarna het op de membraan van L. lactis tot 
expressie  gebracht  kan  worden.Een  eerste  mogelijkheid  om  de  recombinante 
eiwitten meer specifiek op de goede plek te krijgen is door membraanexpressie in 
plaats van continue uitscheiding door de genetische gemodificeerde organismen. 
Membraanexpressie van scFV in plaats van secretie bleek bijvoorbeeld efficiënter 
te zijn om S. mutans uit de mondholte te verwijderen dan continue secretie van 
deze  producten.  Bovendien  kan  lokale  bezorging  van  recombinante  eiwitten 
gebeuren  door  gebruik  te  maken  van  natuurlijke  endopeptidases  die  gemaakt 
worden  door  mucosale  epitheliale  cellen.  Een  goede  mogelijkheid  hiervoor  is 
gebruik te maken van het vermogen om Secretory Component  (SC) af te splitsen 
van de poly-Ig receptor van de apicale membraan zoals gebeurt bij de uitscheiding 
van  secretoire  IgA  antistoffen.  De  nucleotide  volgorde  van  deze  knipplaats  is 
precies bekend en is met succes ingebracht om de membraangebonden scFV IgA 
molekulen van L. lactis te kunnen vrijmaken van de membraan. Als een model 
voor deze gerichte afleveringsmethode van recombinante eiwitten door L. lactis 
hebben wij een IgA scFV tot expressie gebracht op het oppervlak van L. lactis dat Samenvatting 
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een IgA antistof bevat gericht tegen een eiwit dat hoog tot expressie komt op dikke 
darm  kankercellen  (EGP-2=epcam).  In  een  model  bedoeld  om  gericht  deze 
carcinoom cellen aan te vallen was dit recombinante eiwit gecombineerd met een 
bioaktief  eiwit  dat  apoptose  kan  induceren  in  de  kankercellen  samen  met  de 
bovenvermelde SC proteolytische knipplaatsen.L. lactis wordt in eerste instantie 
specifiek  gebonden  door  de  dikke  darm  kanker  cellen  en  zal  lokaal  BMP-2 
produceren  dat  vervolgens  vrijgemaakt  wordt  door  de  natuurlijk  epitheliale 
endopeptidase aktiviteit (figuur 1).Op dezelfde wijze kunnen GM L. lactis gebruikt 
worden om “natuurlijke” IgA antistoffen te maken die in staat zijn om de balans 
met  de  normale  darmbacteriën  te  herstellen.  De  laatstgenoemde  toepassing  is 
veelbelovend voor die omstandigheden waarbij het immuunsysteem of genetisch of 
experimenteel  niet  goed in  staat  is  de  balans  met de  normale  darmbacteriën  te 
handhaven. Deze ziekten strekken zich uit van autoimmuunziekten zoals IBD, RA 
of  type  1  diabetes.  Verder  kunnen  mogelijk  ook  patiënten  waarbij    het 
immuunsysteem  tijdelijk  is  onderdrukt  profiteren  van  een  dergelijke  passieve 
immunisatie behandeling. 
Concluderend  draagt,  naar  mijn  mening,  het  werk  dat  beschreven  wordt  in  dit 
proefschrift bij aan het inzicht dat IgA een belangrijke factor is voor het handhaven 
van de gezondheid op het enorme mucosale oppervlak en de unieke biologie van 
IgA kan gebruikt worden om ziekten te bestrijden op deze mucosale oppervlakken.  
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Figuur  1:  Hypothetisch  model  van  gerichte  aflevering  van  recombinante  eiwitten  door 
Lactococcus lactis naar dikke darm kankercellen in het maagdarm kanaal. Expressie van 
scFV-IgA op het oppervlakte van L. lactis dat een IgA antistof bevat specifiek voor een 
eiwit dat hoog tot expressie komt op dikke darm kanker cellen (Epcam) zorgt voor een 
specifieke binding van het genetisch gemodificeerde organisme aan de kankercellen. In dit 
voorbeeld is het IgA molekuul gecombineerd met een bioaktief eiwit (BMP-2) dat apoptose 
induceert in de kankercellen en met SC endopeptidase gevoelige stukken eiwit. Hierdoor 
wordt vervolgens het lokaal geproduceerde BMP-2 losgeknipt.      
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￿￿￿￿￿￿ 4￿￿ ￿2 ￿ "￿￿ ￿￿￿. ￿ ,￿￿-5 ￿￿￿￿ ￿￿ . ! ￿%￿ ￿ ￿￿￿ ￿￿￿ ￿￿$ ￿￿ ￿￿￿"￿$ ￿￿￿￿￿ ￿
# ￿￿￿￿￿ ￿! ￿￿6 ￿ ￿￿ ￿￿ "￿￿ ￿ ￿￿ ￿ ￿￿ %’ ￿ ￿! ￿￿￿ ￿￿￿￿￿ 2￿￿*￿￿￿ ,￿￿-"￿￿ ￿￿￿￿￿ ￿ ￿. ! ￿￿￿
￿￿￿￿￿￿￿ ￿￿,￿￿-￿￿%￿￿$ / ￿*￿￿￿￿ ￿ "￿￿￿￿,￿ ￿￿￿￿*￿ ￿￿ %’ ￿0 ￿ 1 ￿ ￿$ ￿￿￿￿7￿￿￿￿￿￿￿￿￿￿
￿￿￿. ￿ ￿￿￿￿￿￿￿￿￿￿ ￿"￿"￿ ￿￿￿￿ ￿￿ ￿&￿￿￿￿￿￿ ￿￿￿ ￿￿￿. ￿ ,￿ ￿￿￿ 5 ￿￿￿ ￿￿￿￿ ￿￿￿ ￿￿￿￿ ￿￿￿￿
4￿￿￿￿ ￿! ￿￿￿ 2￿￿￿￿￿ ￿(￿￿ ￿￿ ￿￿ %’ ￿ 0 8 1 ￿ &￿￿￿￿&￿￿￿￿￿￿￿ ￿￿￿￿￿ ￿￿￿. ,￿￿-￿"￿
96 (￿! ￿%,￿ ￿/ ￿*￿￿￿:￿ ￿&"￿￿,￿ ￿￿:￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿"￿￿*￿ ￿￿ ￿￿ %’ ￿￿￿￿￿￿;￿￿￿￿
￿￿ . ! ￿%￿ ￿￿￿￿￿￿&￿"￿￿￿￿￿ ￿￿￿. ￿ ￿￿￿￿￿￿ "￿￿ ￿￿￿￿￿ ￿￿￿￿ ￿￿￿￿￿￿￿ ￿"￿
&/ ￿￿￿*￿￿￿;￿￿￿￿￿ ￿ ￿￿￿￿￿￿￿￿￿￿ ￿"￿￿ / ￿*￿￿￿￿ ￿￿ ;￿￿￿# ￿￿￿￿ ￿# $ ￿￿ ￿￿ ￿￿ "￿:￿￿￿
￿￿￿￿￿*￿ ￿￿ %’ ￿￿￿￿￿￿￿￿ 2￿￿*￿,￿￿(￿￿￿￿<￿￿￿)￿￿ "￿￿￿￿￿￿￿￿￿￿￿￿=%￿￿￿￿￿￿￿=> ￿
￿￿￿￿ ￿￿￿￿￿￿￿ ￿￿ ￿ ￿￿￿ ￿ ￿￿￿￿ ￿￿￿￿￿ ￿ ￿￿ ￿￿ ￿￿￿ ￿ ! ￿￿￿￿ "￿￿￿￿ =$ ￿￿ ￿￿ . ￿ ￿￿￿ ￿ ￿&￿ ?-￿
￿￿￿ ￿￿￿￿￿ ￿ ￿￿")￿&￿ ￿￿ %’ ￿ ￿! ￿! ￿￿￿￿ "￿￿%￿ ￿￿￿￿￿ ￿￿ ￿￿(￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿
￿-￿￿ ￿￿￿￿￿ ! ￿￿￿￿ ￿"￿ ￿ / ￿￿￿ ￿￿￿ ￿￿￿ ￿&￿ ￿￿￿ ;￿￿￿ ￿￿￿￿￿￿￿ ￿ ￿-￿ ￿￿ ￿￿ %’ ￿
￿￿￿￿￿￿ ￿ 2￿￿*￿ ,￿￿(￿￿￿￿ <￿￿￿)￿￿ "￿￿ ￿￿￿￿￿￿￿￿￿￿ =%￿￿￿￿￿￿ ￿=> ￿ ￿￿￿￿ ￿￿￿￿￿￿￿
￿￿ ￿ ￿￿￿ ￿￿￿￿￿ ￿￿￿￿￿ ￿ ￿￿ ￿￿ ￿￿￿ ￿ ! ￿￿￿￿ "￿￿￿￿ =$ ￿￿ ￿￿ . ￿ ￿￿￿ ￿ ￿&￿ ?-￿ ￿￿￿ ￿￿￿￿￿ ￿
￿￿")￿&￿ ￿￿ %’ ￿￿! ￿! ￿￿￿￿ "￿￿%￿￿￿￿￿￿￿￿ ￿￿(￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿-￿￿ ￿ ￿￿￿￿
! ￿￿￿￿ ￿"￿￿ / ￿￿￿ ￿￿￿￿￿￿ ￿&￿￿￿￿ ;￿￿￿￿￿￿￿￿￿￿ ￿￿-￿ ￿￿ ￿￿ %’ ￿0 ￿ 1 ￿# ￿$ ￿ ￿￿ ￿￿￿￿￿￿
￿￿ ￿ ￿￿￿ ￿! ￿￿"￿"￿ ￿￿￿￿. ￿ ￿"￿ # $ ￿￿￿￿￿ ￿￿￿￿￿ ￿￿￿￿%￿￿ 0 ￿! ￿￿￿￿ ￿". ￿ ￿￿ ￿￿￿￿￿￿
￿￿￿￿￿ ￿￿￿ ￿)￿&1 ￿ 0 8 1 ￿ &￿￿￿￿ ￿ ￿￿￿! ￿￿￿￿￿￿ ￿￿￿￿￿￿￿ ￿"￿ &/ ￿ ￿￿*￿￿￿￿ ￿￿￿￿￿
4￿￿ ￿2 ￿ "￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿/ ￿=￿ ￿"￿￿(￿￿ ￿￿ ￿ ￿￿2￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿
￿￿ ￿￿￿￿￿￿’ ￿ ,￿￿&￿￿￿ 8 ￿￿￿ ￿￿￿￿￿ ￿￿￿￿￿ ￿ &￿￿￿￿￿￿ ￿-! ￿%￿ ￿￿￿￿￿￿ ￿￿*￿￿￿￿ ￿￿￿￿￿￿
￿ ￿￿￿￿￿￿￿,￿ ￿￿￿￿￿*￿ ￿"￿￿￿. ￿￿￿￿￿￿￿’ ￿
￿￿￿￿￿￿￿￿￿￿ ,￿ ￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿ # ￿￿￿@ ￿￿6 ￿￿￿￿ ￿￿￿￿￿ ￿￿￿. ￿ ￿￿￿￿￿￿ "￿￿ A B > ￿ ￿ ￿ ￿
￿￿"￿￿￿￿￿￿ ,￿ ￿￿￿ ￿"￿ ￿/ ￿*￿￿￿C ￿ ￿￿￿￿ ￿￿ ￿￿￿ ￿￿ ￿￿￿ ￿￿￿￿*"￿"%’ ￿ ￿￿￿￿￿￿￿￿
￿￿￿￿￿ ￿￿￿ ￿# . ￿ ￿￿￿￿￿￿ ￿"￿￿￿￿ ￿￿￿￿￿,￿￿￿. ! ￿%￿ ￿ ￿￿# . D ￿ ￿￿￿ ,￿ ￿ ￿￿￿￿$ ￿￿￿￿￿￿
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! ￿￿￿￿ ￿"￿￿￿￿ ,￿ ￿/ ￿*￿ ￿ ￿￿￿￿￿￿￿ &E￿￿￿￿￿￿￿-! ￿%￿ ￿￿￿￿￿ ￿￿￿
￿￿￿￿￿￿￿*￿ ￿￿￿ ￿￿￿’ ￿ ￿￿￿￿￿￿ # ￿ ￿￿ ￿￿￿￿￿￿ ￿￿￿￿,￿￿￿￿ ￿￿￿￿ ￿￿￿￿￿ ￿ &￿￿￿￿￿￿ ￿"￿"￿
￿￿￿￿ ￿ ￿/ ￿/ ￿￿ ￿￿￿ ￿ ￿"￿"￿ ￿￿￿￿￿ ￿￿ ￿￿￿￿￿￿￿ ,￿ ￿￿￿ "￿￿ ￿￿￿. ￿￿. ￿ ￿￿ ￿￿￿￿￿￿￿
￿￿￿￿&￿"￿￿￿￿￿! ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿ ￿&￿"￿￿￿￿￿￿￿￿ ￿ ￿￿￿￿￿￿￿￿
￿$ ￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿ ￿F &+￿￿ ￿ ￿"￿￿￿ ,￿￿￿-￿￿￿ # $ ￿￿￿￿ ￿￿ ￿￿ "￿￿ ￿ ￿￿￿*￿￿%￿ ￿￿ %’ ￿
￿ ￿-￿￿￿ "￿￿￿￿￿/ ￿/ ￿￿ ￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿ ￿￿/ ￿/ ￿￿ ￿￿￿ ￿"￿"￿￿￿￿6 ￿￿￿￿￿ ￿￿￿ ￿"￿
,￿￿ ￿ "￿"￿￿￿ ￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿ ￿￿￿ "￿￿,￿￿￿￿￿￿ ￿￿ ￿￿￿￿ ￿’ ￿
￿￿￿￿ ￿ ￿/ ￿/ ￿￿ ￿￿￿ ￿"￿"￿ ￿￿￿￿￿ ￿￿￿￿ ￿￿ ￿￿ ￿￿￿ "￿￿ &￿"￿￿￿)￿￿ ￿￿￿￿ ￿-! ￿￿￿:￿￿￿
￿￿￿￿￿ ￿ ￿￿￿ ￿￿￿￿ ￿￿￿￿ ￿￿￿￿￿￿￿￿ ￿￿￿6 ￿￿￿￿￿ ￿￿￿ &￿"￿￿￿)￿￿ "￿￿ ￿"￿"￿’ ￿
?￿￿*,￿￿￿￿￿￿￿￿ ￿ ￿￿￿￿=￿￿￿￿$ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ &￿￿￿￿￿￿￿￿￿,￿ ￿￿&￿"￿￿￿￿ ￿"￿
￿/ ￿*￿ ￿/ ￿/ ￿ ￿2￿￿￿ ￿￿￿￿￿ ￿￿ "￿￿ ￿￿￿￿ ￿ ￿/ ￿/ ￿￿ ￿￿￿ ￿￿￿￿￿ ￿"￿"￿’ ￿ # ￿￿￿￿￿
￿/ ;￿ ￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿ ￿￿"￿￿￿￿￿￿ ,￿ ￿￿￿ ￿"￿ ￿￿￿￿ ￿ ￿￿￿ ￿￿ ￿￿￿￿ ￿ ￿￿￿￿￿ . ￿￿. ￿
,￿ ￿￿￿ "￿￿￿￿￿/ ￿/ ￿￿ ￿￿￿ ￿&￿￿ ￿￿￿ ￿￿￿￿"￿"%’ ￿,￿￿￿. =￿￿￿￿￿￿G. ￿￿￿￿ ￿￿ )￿￿ "￿￿
￿￿ ￿ ￿￿￿ ￿￿￿. ￿￿￿￿￿￿ ￿￿. ;￿ "￿￿ ￿ ￿. ! ￿￿￿ ! ￿￿ ￿￿ ￿￿￿￿￿&￿￿￿ ￿￿G. ￿ ￿￿￿ ￿￿ )￿￿ "￿￿￿￿
+￿ ￿￿ ￿￿￿￿%￿￿￿￿￿￿ ￿￿￿￿￿ ,￿ ￿￿￿￿￿*￿ "￿￿ 4￿￿￿￿ ￿￿"￿ ￿￿ ￿￿￿*￿ ￿￿ %’ ￿
￿￿ ￿￿￿￿￿￿ ￿￿￿￿￿ "￿￿%￿ ￿/ ;￿ ￿￿￿￿￿￿￿￿￿￿ ￿ ￿/ ￿ ￿￿*￿￿￿ ￿￿￿. ￿￿￿￿￿￿ "￿￿￿￿
?￿ ￿ ￿￿￿￿￿￿ ￿ ￿￿￿￿￿ ￿ ￿￿￿￿ ￿! ￿￿￿￿ ￿"￿￿￿ ￿￿￿￿ ￿￿￿￿*￿ ￿￿ %’ ￿
￿￿￿￿￿ ￿￿￿￿ =￿ ￿ "￿! ￿￿￿￿ ,￿ ￿￿￿ "￿￿￿￿ ,￿￿%￿￿￿ ￿ ￿ ￿/ ￿￿￿*￿￿￿ ￿￿￿￿￿ ￿￿ ,￿ ￿￿￿ "￿￿
￿￿￿￿ ￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿ ,￿￿&￿￿￿ D ￿￿￿ 2￿ ￿￿￿￿￿ ￿￿ ￿￿￿￿￿￿￿ ￿/ ￿F ￿ ￿￿ %’ ￿ ￿￿￿￿
￿￿￿￿￿ ￿ ￿! ￿￿￿￿ 5 ￿ ￿￿ ￿￿￿ ￿ ￿￿ ￿￿ ￿￿￿ ￿ "￿￿￿￿ ￿￿￿￿￿ ￿￿￿. ￿ ￿￿￿￿￿￿ ￿"￿
H *￿*￿￿%￿ ￿￿￿￿ ￿’ ￿ ￿￿ ￿￿&￿￿￿￿￿￿￿ ! ￿￿+￿￿￿￿ ￿￿￿ ￿￿ ￿￿%￿ ￿￿￿￿￿ ￿ &￿￿￿￿￿￿
=￿ ￿ ￿! ￿￿￿￿ ￿"￿ ￿/ ￿*￿ ￿/ ￿F ￿￿￿ ,￿ ￿￿￿ ￿"￿ ￿￿ ￿￿ ￿￿￿￿&￿￿’ ￿ ￿￿￿￿￿￿ ￿￿￿￿
4￿￿ ￿2 ￿ "￿￿￿￿￿/ ￿/ ￿￿ ￿￿￿ ￿ ￿&￿4￿￿ ￿$ / ￿￿￿￿%￿,￿"￿￿￿￿"￿"￿￿￿￿￿￿￿￿￿￿&￿￿’ ￿
￿/ ;￿ ￿￿￿￿￿￿￿￿￿￿ ￿"￿"￿ ￿￿￿ ￿G￿￿￿￿￿ ￿￿ "￿￿￿￿ ,￿ :￿￿￿￿ ￿￿*￿￿￿ ￿￿￿￿￿
4￿￿ ￿2 ￿ "￿￿￿￿￿ ￿$ ￿￿￿￿￿￿￿￿(￿￿￿&￿￿’ ￿
￿￿ ￿￿￿￿￿￿￿￿ ! ￿￿+￿￿ ￿￿￿￿￿ ￿￿￿’ ￿￿￿ ￿￿￿￿￿ ￿￿￿￿￿*￿￿￿￿ ￿￿￿￿￿%’ ￿ +E￿￿￿￿￿￿
￿$ =￿ ￿,￿￿￿ ￿￿￿￿￿￿￿￿￿ ￿￿￿￿ *￿￿￿￿ ￿￿￿￿￿￿ 4￿￿ ￿2￿￿ ￿ ￿6 ￿￿ ￿￿￿￿￿￿￿￿ ￿￿ ,￿ ￿￿￿ "￿:￿￿￿
￿￿￿’ ￿￿￿ ￿￿￿￿:￿￿￿ =&￿￿￿￿￿￿*￿ ￿￿ %’ ￿ ￿￿ ￿￿ ￿￿￿￿￿￿￿￿ ￿￿ ￿ ￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿ ￿ &￿￿￿￿￿￿
=￿ ￿ ￿! ￿￿￿￿ %3 / ￿*￿ ￿￿ %￿ ￿￿￿￿,￿￿￿￿￿ ￿-￿ ￿￿ %’ ￿ ￿￿￿’ ￿￿￿ ￿￿￿￿￿ =$ ￿￿￿￿%￿ ?-￿
￿ ￿￿￿￿￿￿￿ 96 (￿￿￿￿￿￿￿ =$ ￿￿￿￿ ￿￿￿ ￿￿￿￿￿ ￿￿￿. ￿￿￿￿￿￿ "￿￿￿￿ ￿￿ ￿￿￿ ￿￿*￿ ￿￿ %’ ￿
￿￿￿ ￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿,￿ ￿￿￿￿*￿ "￿￿￿￿￿# $ ￿￿￿￿ ￿￿ ￿￿ "￿￿4￿￿￿￿￿ ￿￿￿*￿￿￿￿￿￿*￿ ￿￿ %’ ￿
￿￿￿￿￿￿8 ￿ =$ ￿￿￿￿￿￿￿￿ ￿￿￿￿￿ ￿￿ ￿ ￿￿￿ ￿￿￿￿￿ ￿￿￿￿ =￿ ￿ ￿ ￿￿ ,￿ ￿￿￿ "￿￿￿￿ ,￿ ￿￿￿￿￿￿￿￿
,￿ ￿￿￿￿ ￿"￿￿￿￿ ￿￿ ￿￿￿ +￿￿ ￿￿ %￿ ￿￿ ￿ ￿￿￿ ￿￿￿! ￿￿ ￿￿ ,￿ ￿￿￿+￿￿ ￿ "￿￿￿￿ ￿￿￿ ￿￿￿ ￿
! ￿￿￿￿￿￿￿￿ ￿￿￿￿ ￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿ ￿￿ ￿￿￿￿￿￿￿ ,￿ ￿￿￿￿￿&￿￿’ ￿ ￿$ ￿￿￿￿￿￿
￿! ￿￿￿￿ 5 ￿ ￿￿ ￿￿￿ ￿ ￿￿ ￿￿ ￿￿￿ ￿ ￿￿ ￿ ￿￿￿ %3 / ￿￿￿￿￿￿￿￿￿ 0 ￿*￿ ￿￿￿￿ ￿￿ ￿￿￿ ￿￿ &￿￿ ￿ ￿&￿￿￿
￿-! ￿%￿ "￿> ￿￿￿ ￿￿￿￿1 ￿￿￿￿￿￿&￿￿ ￿￿*￿# ￿ ￿￿￿￿ ￿￿ ￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿8 ￿
￿￿￿￿￿￿ ￿,￿￿. ￿ ￿￿ ￿￿,￿ ￿￿￿￿￿￿￿￿ ￿￿￿ "￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿&￿￿’ ￿￿￿ ￿￿￿￿?￿￿*￿￿￿￿￿￿
4￿￿ ￿2 ￿ ￿"￿ ￿-￿￿￿￿￿￿ ?-￿ # . ￿￿￿￿￿ ! ￿￿ (￿￿￿&￿￿’ ￿ ￿￿￿ ￿￿￿ ￿ +￿￿ ￿￿￿￿￿
+￿￿￿ ￿ &￿￿￿￿￿-! ￿%￿￿￿￿￿￿# ￿￿￿￿￿￿&￿￿￿ ￿"￿&￿"￿￿￿)￿￿+￿￿ ￿￿￿￿￿,￿￿ ￿￿￿￿’ ￿￿￿￿￿￿￿￿￿￿ 
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￿￿:￿￿￿￿ ￿# ￿￿￿￿￿ ￿￿￿ ￿ ￿￿￿￿ ￿# ￿￿￿￿8 ￿￿"￿"￿￿￿ ￿￿￿￿?￿￿*￿&￿"￿￿￿￿￿￿￿,￿￿ ￿￿￿￿’ ￿
￿￿￿+￿￿ ￿ "￿￿￿￿:￿￿￿# ￿￿;￿ ￿&￿￿￿￿￿*￿￿￿￿ ￿￿￿￿*"￿"%’ ￿
9￿￿*￿ ￿￿￿￿ ￿￿ ￿￿￿￿! ￿￿￿￿￿￿￿￿￿￿￿+￿ ￿￿ ￿￿￿￿)￿&￿￿￿ ￿￿ ￿￿ ￿￿ %’ ￿￿￿￿$ / ￿￿￿￿￿ ￿&￿￿￿￿￿￿
￿ ￿ ! ￿ $ ￿ ￿ ￿! ￿￿￿￿ ￿￿ ￿ ￿￿￿ ￿￿￿ ￿$ ￿￿￿￿￿ ￿ ￿￿￿￿￿￿$ ￿￿￿￿ ￿! ￿￿￿￿ "￿￿ ￿￿￿￿￿ 2￿￿*￿ "￿￿ ￿ ￿￿￿$ ￿
! ￿ ￿ ￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿-￿ ￿￿￿￿ ￿￿’ ￿
,￿￿&￿￿￿ I ￿￿￿ ￿! ￿￿￿ ￿￿ ￿ ￿￿9￿ ￿￿ "￿￿￿￿ ￿￿ ￿ ￿￿ ￿￿￿ ￿￿ ￿ ￿￿￿ ￿￿ ￿ ￿￿ ￿￿ ￿￿ ￿ ￿&￿￿￿ ￿"￿ ￿￿￿￿￿
￿￿￿￿￿￿￿# $ ￿￿￿￿￿￿￿%￿￿’ &￿$ ￿￿￿￿￿￿￿! ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿)￿￿ ￿￿￿￿￿￿ ￿￿￿￿￿￿’ ￿
￿￿:￿￿￿￿! ￿￿￿￿￿9￿ ￿￿ "￿￿￿￿￿￿￿￿￿￿,$ ,￿. ￿￿￿￿. ￿￿￿￿￿￿ / ￿￿￿￿￿￿ ￿￿ ￿￿￿￿’ ￿￿￿￿ ￿￿ / ￿￿￿
! ￿￿ (￿;￿ "￿￿￿-! ￿%￿ ￿￿ ￿ ￿￿ +￿￿￿￿ ￿&￿￿￿ "￿￿￿￿ ￿ ￿￿￿ ￿*￿￿￿￿￿ ￿￿ ￿￿￿￿￿ +￿ ￿￿ ￿￿￿ ￿)￿&￿
￿￿ ￿￿ ￿￿ ￿￿ %￿ ￿￿￿￿ ￿￿￿￿ ￿ +￿;￿ ￿&￿ ￿$ ￿￿￿￿’ ￿ ￿! ￿￿￿ +￿;￿ "￿￿￿-! ￿%￿ ￿ ￿￿￿
9￿￿*￿ ￿￿￿￿ ￿￿ ￿￿￿ ￿! ￿￿￿￿ ￿"￿ ￿￿￿￿ ￿￿￿ ￿ ,￿￿ ￿￿ ￿-￿ ￿￿ ￿￿ %￿ ￿￿￿ ￿￿ ￿￿￿￿￿￿’ ￿ ￿! ￿￿￿
￿! ￿￿￿￿￿￿￿￿ ￿￿￿￿￿ ￿￿￿ ￿! ￿￿￿"￿￿ 5 ￿ ￿&￿ J ￿￿￿￿*￿ ￿￿￿￿￿￿ ￿K ￿ ￿ ￿￿ ￿￿ ￿￿￿ ￿ +￿￿ ￿ ! ￿￿￿￿
￿￿￿"￿￿ ￿&￿￿’ ￿￿￿￿. ￿￿￿￿￿￿￿￿￿￿J ￿￿￿￿*￿ ￿￿￿￿￿￿￿K ￿￿￿￿,￿ ￿￿:￿ ￿&￿￿￿￿$ ￿￿ ￿,￿ ￿￿￿￿￿￿*￿
,￿￿ ￿￿ ￿￿ $ ￿￿￿ ￿ 9￿￿*￿￿￿￿￿ ￿￿ ￿￿￿ ￿￿ ￿ ￿￿￿ ￿￿￿￿￿ ￿￿￿￿ =￿ ￿ ￿ ￿! ￿￿￿￿ "￿:￿￿￿
￿￿￿￿￿*￿ ￿￿ %’ ￿￿ B ￿￿￿￿ ￿￿￿￿+￿￿￿￿￿￿￿￿￿ ￿$ ￿￿￿￿￿￿ ￿￿￿￿￿￿$ ￿￿￿￿￿! ￿￿￿"￿￿ 5 ￿ ￿&￿
￿! ￿￿￿J ￿￿￿￿*￿ ￿￿￿￿￿￿ ￿K ￿￿ ￿￿ ￿￿ ￿￿￿ ￿￿"￿￿ ￿￿ ￿￿￿￿￿￿%’ ￿
￿ ￿￿ ￿￿ ￿￿￿ ￿ ￿&￿ ￿￿￿￿￿ ￿￿￿(￿! ￿ . ￿ 9$ ￿ ￿=￿ ￿￿9￿ ￿￿ "￿￿￿￿ ￿￿￿￿ ￿￿￿￿￿￿￿￿ ￿￿￿￿￿ ￿￿"￿￿￿￿￿￿
,￿ ￿￿￿ "￿￿ ￿￿￿￿￿ ￿￿￿￿ ,￿￿&￿￿￿L ￿ ￿￿"￿ ￿&￿ ￿￿ %’ ￿ ,￿￿￿. ￿ ￿￿ ￿￿￿￿￿ ￿ ￿￿ ￿￿ ￿￿￿ ￿ ￿&￿
+￿￿C ￿￿￿￿￿￿￿C ￿￿￿￿"￿"￿￿￿9￿￿￿ ￿￿￿￿￿ "￿￿&￿"￿￿￿￿￿,￿￿￿. =￿￿￿￿,￿ ￿￿￿ "￿￿
￿￿￿ ￿￿ ￿￿￿￿￿￿￿￿￿’ ￿ ￿￿￿￿￿ ! ￿ ￿￿￿ "￿￿￿￿ ￿￿￿￿ ￿￿￿￿￿￿￿￿ ￿￿￿6 ￿￿￿ ￿￿￿ "￿￿
￿! ￿￿ ￿￿ ￿￿￿*￿ ￿￿￿￿ ￿’ ￿￿￿￿￿￿-! ￿%￿￿ 9(￿ ￿￿ ￿￿￿￿￿￿￿￿￿:"￿"￿￿￿￿,￿ ￿￿￿ "￿￿￿-! ￿%￿
￿￿￿￿ ￿ ￿￿￿ ￿￿ ￿￿￿￿ ￿￿ ￿￿￿ ￿￿￿ ￿￿￿￿ =￿￿￿￿￿ ￿ ￿". ￿ ￿￿ ￿￿￿ ￿￿ ￿ ￿￿￿ ,￿ ￿￿￿ "￿￿￿-! ￿%￿
￿￿￿￿ ￿ ￿￿￿ ￿￿ ￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿ ￿￿ ￿￿￿￿￿￿’ ￿ +￿￿￿ ￿￿ ￿ ￿￿￿ ￿￿￿￿￿ ￿￿9￿ ￿￿ ￿￿￿￿￿
￿ ￿￿ ￿￿ ￿￿￿ ￿ "￿￿￿￿ ￿￿￿￿￿ ￿ ￿ ?￿￿￿￿ ￿￿/ ;￿ "￿￿￿￿ ! ￿ ￿￿￿ "￿￿
￿￿￿￿￿￿ ￿ ￿￿*￿￿￿￿￿￿*￿ ￿￿￿￿ ￿’ ￿ ￿ ￿￿ ￿￿ ￿￿￿ ￿ ￿&￿ ! ￿￿￿￿ ￿￿￿ ￿&￿￿￿ ,￿￿-￿￿￿ ￿"￿ ￿/ ￿*￿
￿/ ￿F ￿￿￿￿ ! ￿￿+￿￿￿￿ ￿￿￿ ￿￿ ￿&￿￿’ ￿ ￿￿￿$ / ￿￿￿ ￿ ￿￿￿￿￿￿￿￿8 ￿ =￿ ￿ ￿! ￿￿￿￿ ￿￿￿. ￿
￿￿￿￿￿￿￿&￿￿’ ￿
,￿￿&￿￿￿ A ￿￿￿ +￿￿￿ ￿ &￿￿￿￿ =￿ ￿ ￿! ￿￿￿￿ ,￿ ￿￿￿ "￿￿￿￿ ￿￿ ￿,￿ ￿￿￿￿ ￿￿￿￿%￿
￿￿￿￿￿￿￿￿ ￿￿￿￿ ￿/ ￿*￿/ ￿F ￿￿￿ ￿￿￿￿￿￿￿￿8 ￿ ￿￿￿ ,￿ ￿"￿￿￿ ￿ "￿￿￿￿ ! ￿-￿/ ￿￿￿
￿￿"￿ ￿￿ ￿￿￿*￿ ￿￿ %’ ￿ ￿￿￿4￿￿ ￿2￿ ￿￿%￿ H ￿￿￿ ￿￿￿￿ ￿ ￿￿ ￿G￿￿￿￿￿￿￿￿￿ ￿￿ ￿￿￿￿￿￿￿￿￿ ￿￿
￿￿￿￿￿￿￿￿￿ ,￿ ￿￿￿￿￿￿￿￿ ￿ ￿￿ ￿ ￿￿ %’ ￿ ￿! ￿￿￿ 4￿￿ ￿2￿ ￿￿%￿ ￿￿:￿￿￿ ￿￿￿￿ ￿￿￿￿￿￿￿
￿￿￿￿￿￿￿￿￿￿￿ &￿"￿￿￿￿ ,￿ ￿￿￿￿ ￿￿￿￿*￿ ￿￿￿￿￿ ￿￿￿￿￿￿ ,￿￿￿. ! ￿%￿ ￿￿￿’ ￿￿￿ ￿￿￿￿￿
￿ ￿￿￿￿￿￿￿￿￿￿￿ ,￿ ￿￿￿￿*￿￿￿￿ ￿￿*￿ ￿￿ %’ ￿ ￿￿ ￿ ￿￿￿￿￿￿￿￿￿ =$ ￿￿￿￿ ￿￿￿￿￿￿ ￿ ￿￿￿￿￿￿￿
,￿￿￿. 9$ ￿￿￿￿￿￿￿￿￿ ￿￿ ￿ ￿￿￿￿￿￿￿￿￿ =$ ￿￿￿￿￿￿￿￿ ￿￿￿ ￿&￿ ￿￿￿￿￿￿￿￿￿￿￿&￿￿’ ￿
￿￿￿￿￿&￿￿￿ ￿￿￿(￿! ￿ ￿￿￿￿-! ￿%￿ ￿￿￿￿￿￿6 ￿￿￿ ￿￿￿￿ "￿￿ ! ￿ ￿ ￿￿ ￿￿￿*￿%￿ ￿￿￿￿ ￿￿￿￿￿￿￿ ￿ ￿￿;￿
,￿"￿￿ ￿￿￿*￿ ￿￿￿ ￿￿￿￿￿ ￿￿ %’ ￿ ￿￿ ￿￿(￿ ￿￿￿￿ ￿￿￿￿￿ ￿￿￿￿￿￿ ￿￿9￿ ￿￿ "￿￿￿￿
￿￿￿￿ ￿ ￿￿￿ ￿￿ ￿￿￿*￿￿￿ ￿/ ￿￿￿￿,￿￿￿￿￿￿￿￿￿￿￿ ,￿ ￿￿￿￿￿*￿ "￿￿￿￿￿￿ ￿￿ ￿ ￿￿￿￿￿￿￿￿￿
=￿$ ￿￿￿￿￿￿￿ "￿￿ ￿/ ￿￿￿￿ ￿￿ ￿￿￿*￿ ￿￿ %’ ￿ %￿/ ￿ ￿￿￿￿￿ ￿￿￿. ￿￿￿￿￿￿ "￿￿￿￿ ￿￿￿￿￿ ￿￿￿￿
￿￿￿￿￿ ￿￿ ￿￿￿￿￿￿￿￿￿%￿&￿￿￿￿￿￿￿￿￿￿￿&￿￿￿￿￿￿￿￿"￿"￿￿￿￿￿￿ ￿￿￿￿,￿ ￿￿￿ "￿￿￿￿￿"￿"￿
￿￿￿￿￿￿ M ￿ %￿/ ￿ &E￿)￿￿ ￿"￿ ￿￿￿￿ ￿&￿￿￿ ￿! ￿￿￿ ￿/ ￿￿￿￿,￿￿ ￿￿￿￿￿￿￿ "￿￿
￿￿;￿ ￿￿￿￿ ￿’ ￿ 
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+￿￿￿￿ ￿￿￿ ￿￿ ￿￿%￿ ￿￿ ￿￿￿￿￿￿￿*￿ ￿￿￿￿ ,￿￿ ￿￿ ￿￿ $ ￿￿￿ ￿ ￿￿￿’ ￿￿￿ ￿￿￿￿￿ 4￿￿￿￿ ￿
￿￿￿￿ ￿￿￿￿￿￿￿ ￿￿￿￿￿ 4￿￿ ￿2 ￿ "￿￿￿￿ ,￿ :￿￿￿￿￿￿*￿ ￿￿ %’ ￿ ￿￿ ￿￿￿￿￿ =￿ ￿ ,￿ ￿￿￿ "￿￿￿￿
￿￿￿￿ ￿￿￿ ￿ ￿ ￿/ ￿￿￿*￿￿￿ ￿￿￿￿￿ ￿￿￿. ￿￿￿. ￿ ￿"￿ ￿￿￿￿ ￿￿￿’ ￿￿￿ ￿￿￿￿￿ ￿￿￿￿￿
￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿’ ￿￿￿ ￿￿￿￿￿ ￿￿ ￿ ￿￿￿￿￿￿￿￿￿￿￿ =$ ￿￿ ￿￿￿ ￿￿￿ ￿ ￿￿ ￿￿￿￿ ￿￿ ￿￿￿￿’ ￿
￿￿ ￿￿￿￿￿ ￿￿￿￿￿ ￿￿￿￿￿￿￿ ,￿ ￿￿￿ "￿￿￿￿ ￿! ￿￿￿ J ￿￿ ￿ ￿￿￿￿￿￿￿￿￿￿K ￿ =$ ￿￿￿￿ ￿￿￿￿￿￿￿￿￿
,￿ ￿￿￿￿*￿ =$ ￿￿￿%￿￿￿￿ ￿￿ . ! ￿%￿ ￿￿￿￿￿ ￿￿￿￿￿￿￿ ,￿ ￿￿￿ "￿￿￿￿ ￿￿￿￿￿8 ￿ ￿￿￿￿￿￿ +￿￿￿
￿￿￿￿￿￿￿ ￿￿￿(￿! ￿ . ￿ 9$ ￿ ￿=￿ "￿￿￿￿ ￿￿. ! ￿,￿*￿ ￿￿ ￿￿￿￿￿￿￿ ,￿"￿￿". ￿ ￿￿ ￿￿ ! ￿￿￿￿￿￿
&￿ ￿￿￿￿￿*￿ ￿￿￿￿ ￿’ ￿ ￿￿ ￿￿￿￿￿ ￿ ￿￿ # ￿￿￿￿￿ ￿￿ ￿￿￿ "￿￿ ￿￿￿￿ ￿￿￿￿￿ ?￿$ ￿￿￿￿￿￿￿￿￿￿
￿￿ ￿￿￿ "￿￿￿￿￿￿￿8 ￿&￿"￿￿￿￿ "￿￿￿￿￿(￿! ￿ . ￿9$ ￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿"￿"%￿￿￿￿￿%￿
! ￿N￿￿￿￿￿ ￿￿ %’ ￿ ￿￿￿ ￿￿￿ ￿ J ￿ ￿ ￿ ￿&￿￿￿ ￿￿￿￿￿ ￿￿￿￿￿￿￿ ￿￿￿K ￿ ￿￿￿ ￿ 2 ￿ ￿￿￿ ￿￿￿’ ￿ 8 ￿
￿￿￿￿￿ ￿&￿ ￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿&￿￿￿ ￿￿￿￿￿ ￿￿￿￿￿￿￿ ￿￿￿￿ ￿ ￿/ ￿￿￿*￿￿￿ 4￿￿ ￿2 ￿
,￿ ￿￿￿￿￿*￿ "￿￿￿￿￿￿￿￿! ￿￿￿￿# . ￿￿￿￿￿ ￿￿￿*￿ ￿￿￿ ￿￿￿’ ￿
￿*￿￿￿%￿ ￿￿￿￿￿ ￿ ￿￿ ￿ ￿￿￿ ￿￿￿￿8 ￿ # ￿ ￿￿￿￿ ￿￿ ￿￿ ￿￿ ￿￿￿￿￿￿ ￿ ￿/ ￿ ￿￿*￿￿￿ ￿￿￿￿￿
,￿ ￿￿￿￿￿*￿ ￿"￿￿￿ ￿￿ ￿￿￿￿ ￿￿￿￿&￿￿’ ￿￿￿￿$ / ￿￿￿ ￿￿￿ ￿￿￿?￿￿*￿￿￿￿￿￿￿ O 8 ￿￿￿￿ ￿￿ ￿￿￿
￿(￿￿￿%P ￿
,￿￿&￿￿￿I ￿￿￿￿￿￿￿ ￿ ￿￿ +"￿"> ￿￿￿ ￿ ￿￿ ￿￿ ￿￿ ￿￿￿ ￿￿(￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿
,￿ . ￿. ￿ ￿"￿ ￿￿￿*￿￿’ ￿ 0 # ￿$ ￿￿ ￿￿ ￿￿￿￿￿￿ ￿￿ ￿ ￿￿￿ =/ ￿￿ "￿￿ ! ￿￿￿ ! ￿￿￿ ￿*￿￿￿*￿￿￿￿
￿&￿￿￿ "￿1 ￿ ￿￿￿ ￿&￿ ￿￿￿ ￿￿ ￿￿ ￿ ￿￿ ￿￿￿￿￿ ￿￿￿￿￿ ￿￿ ￿ ￿￿￿ ,￿￿&￿￿￿ ￿"￿ ￿￿￿￿￿
J ￿￿￿ ￿￿$ ￿￿￿￿"￿$ ￿K ￿ ￿! ￿￿￿￿ ￿"￿ %3 / ￿*￿ ￿￿￿￿ ￿’ ￿ ￿￿￿￿ "￿￿￿￿ ￿/ ￿￿￿&￿￿￿
J ￿￿￿￿￿￿￿￿￿￿￿￿,￿"￿￿￿ ￿! ￿￿￿K ￿ ￿/ ;￿ ￿￿￿￿￿￿￿￿￿￿ ￿￿￿ ￿￿$ ￿￿￿￿"￿$ ￿￿ ￿"$ ￿
￿ ￿$ / ￿￿￿ ￿￿ %￿ ￿￿￿￿￿￿￿ ,￿￿&￿￿￿ B ￿￿￿ ￿￿. ￿￿￿￿￿￿￿’ ￿ ￿! ￿￿! ￿￿￿￿ ￿/ ￿*￿/ ￿F ￿￿￿
￿/ ;￿ ￿￿￿￿￿￿￿￿￿￿ ￿ ￿/ ￿￿￿*￿￿￿ ￿￿￿ ￿G￿￿￿￿￿ ￿￿ "￿￿ ￿￿￿. ￿￿ ￿ ￿￿ ￿￿￿￿￿ ￿&￿ ￿ ￿$ / ￿￿￿ ￿
￿! ￿￿￿￿￿ ￿￿# ￿ ￿￿￿*￿￿ ￿￿￿￿￿￿￿￿%3 / ￿*￿ ￿￿￿￿ ￿’ ￿
￿! ￿￿￿ # $ ￿￿￿￿ ￿￿ ￿￿￿￿￿￿ ￿￿ ￿+"￿"￿ ￿￿￿￿￿￿￿￿￿ ￿-! ￿%￿ "￿￿ 4￿￿￿￿ ￿￿￿ ￿G￿￿￿￿￿ ￿￿ "￿￿￿￿
￿ *￿￿￿￿￿ ￿￿￿￿ ￿&￿￿￿ ￿ ￿￿ ￿￿ ￿￿￿ ￿ +￿￿ ￿￿￿ ￿￿"￿ ￿&￿ ￿￿ %’ ￿ ￿￿￿￿-￿￿￿ ￿￿ ￿￿￿￿￿
# ￿￿;￿ "￿￿￿￿ ￿/ ;￿ ￿￿￿￿￿￿￿￿￿￿ ￿ ￿/ ￿ ￿￿*￿￿￿ ￿￿￿ ￿G￿￿￿￿￿￿￿ ￿ ￿￿￿$ / ￿
￿￿￿ ￿G￿￿￿￿;￿￿￿￿ ￿￿/ ! ￿%￿ ￿￿￿￿ ￿￿ =￿$ ￿￿￿￿￿￿￿￿￿￿ ￿￿ ￿ ￿"￿￿￿￿￿￿ ￿￿ ￿￿￿￿￿￿￿￿
%3 / ￿*￿ ￿￿￿￿ ￿’ ￿+￿￿￿+￿￿￿￿￿￿,￿￿ ￿￿ ￿￿ $ ￿￿￿ ￿￿￿￿’ ￿￿￿ ￿￿￿￿￿9￿￿￿￿￿￿ ￿￿￿￿￿￿￿ ￿￿￿￿￿￿
￿￿9￿ ￿￿ "￿￿￿￿ ￿￿￿ ￿￿ ￿￿%￿ ￿￿￿￿￿ ￿￿￿ # &￿￿’ ￿ ￿￿￿￿ ￿￿￿￿￿ ￿￿￿￿￿￿
￿/ ￿￿￿￿,￿￿ ￿￿￿￿￿￿￿￿￿ ,￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿/ ￿￿￿&￿￿￿ ￿￿￿￿￿￿￿￿8 ￿ ￿￿￿
￿/ ￿*￿/ ￿F ￿￿’ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿’ ￿￿￿ ￿￿￿￿￿￿￿￿ ￿￿￿ ￿! ￿￿￿￿￿:"￿"￿
￿￿￿￿￿ ￿￿￿. ￿ ￿￿￿￿￿￿ ￿"￿ ￿/ ￿*￿/ ￿/ ￿ ￿￿￿￿￿*￿￿￿￿ ￿￿*￿ ￿￿ %’ ￿ ￿! ￿￿￿ ￿￿￿. ￿
￿￿￿￿￿￿ "￿￿￿/ ;￿￿￿￿￿￿￿￿￿￿￿￿ ￿/ ￿￿￿*￿￿￿￿￿￿ ￿G￿￿￿￿￿ ￿￿ ￿"￿￿ ￿! ￿￿￿￿*￿￿%￿ ￿￿ %’ ￿
￿! ￿￿￿￿ ￿*￿￿￿￿￿ ￿￿ ￿￿￿%￿ ￿￿ ￿￿￿ ￿￿ ￿￿￿￿￿ "￿￿ 4￿￿￿￿ ￿ ￿/ ;￿ ￿￿￿￿￿￿￿￿￿￿ ￿"￿"￿
￿￿￿ ￿G￿￿￿￿￿ ￿￿ "￿￿￿￿ ! ￿￿￿￿ ￿ ￿! ￿￿￿￿￿￿ ￿/ ￿￿￿￿ ￿&￿ ￿￿ %’ ￿ 9￿￿*￿ ￿=￿ ￿! ￿￿￿￿ "￿￿￿
￿￿￿￿￿￿# . ￿￿￿￿￿￿%￿￿￿￿ ￿￿ ￿￿ . ￿ ￿￿ ￿$ ￿￿￿￿￿￿￿￿ "￿￿￿￿ ￿ ￿￿￿￿￿ ￿￿ ￿￿￿￿ ￿￿*￿￿￿￿￿ ￿￿ ￿￿￿
&￿￿ ￿￿*￿ ￿￿￿￿￿ ￿! ￿￿￿"￿￿ "￿￿ ￿! ￿￿￿ ,￿ ￿￿￿￿￿*￿ &￿￿ ! ￿￿￿ ￿*￿ ￿￿￿￿ ￿￿ ￿￿￿
+￿￿ ￿ "￿￿￿￿￿￿￿￿￿￿,￿ ￿. ’ ￿￿￿￿￿￿￿￿￿￿ 
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! ￿￿+￿￿￿￿￿￿ ￿￿(￿￿￿)￿￿ "￿￿￿￿! ￿￿￿￿ ￿￿ ￿￿ ￿￿￿￿￿￿,￿-￿￿￿)￿&￿￿￿ ￿￿ ￿￿ ￿￿￿￿ ￿￿￿￿￿
￿! ￿￿￿ # $ ￿￿￿￿ ￿￿ ￿￿ "￿￿￿￿ +￿;￿ 2 ￿ ￿￿ %￿ ￿￿￿ ! ￿￿￿￿ ￿/ . ￿ ￿￿￿ ￿￿’ ￿ ￿! ￿￿￿ ￿ ￿￿ ￿￿=￿
￿￿￿￿￿￿￿￿￿￿￿ ￿￿(￿￿￿￿￿ &￿￿￿ "￿￿￿! ￿￿￿￿ ￿"￿*￿￿￿￿￿￿￿￿￿￿;￿ ￿￿ %’ ￿
 
Fig. 1  
 
9-￿ ￿￿ ￿￿Q 9-￿ ￿￿ ￿￿Q 9-￿ ￿￿ ￿￿Q 9-￿ ￿￿ ￿￿Q ￿￿/ ;￿￿￿￿￿￿￿￿￿￿￿￿"￿"￿+￿￿￿ ￿ &￿￿￿￿￿￿ ￿ ￿￿￿￿￿￿￿￿￿ ￿ &￿￿￿￿￿￿
=￿ ￿ ￿ ￿! ￿￿￿￿￿￿ ￿/ ￿*￿/ ￿F ￿￿￿ =￿ ￿ ￿ ￿￿ ,￿ ￿￿￿ "￿￿ ￿￿ ￿ ￿￿￿ ￿￿￿ ￿￿￿￿￿
￿ ￿￿ ￿ ￿￿￿￿￿￿￿￿/ ￿￿￿￿ ￿￿ ￿￿￿*￿￿￿￿￿ ￿ ￿￿￿￿￿￿￿￿￿=$ ￿)￿￿ "￿￿￿￿￿ ￿ ￿￿￿￿￿ ￿,￿ ￿"￿￿￿ ￿
￿￿￿￿￿￿￿ "￿’ ￿ ￿￿￿’ ￿￿￿ ￿￿￿￿￿ ￿￿￿ ￿G￿￿￿￿￿￿￿￿￿ ￿&￿￿￿ "￿￿￿￿ ￿ ￿/ ￿￿￿*￿￿￿ ￿￿￿￿￿
R￿￿￿￿ ￿￿￿￿￿￿￿￿ =￿ ￿ ￿ ￿,￿ ￿￿￿ "￿￿￿￿ ￿￿￿￿￿7￿￿￿ ￿￿ . ￿ ￿&￿￿￿ ￿￿￿￿￿
￿￿￿. ￿￿￿￿￿￿ ￿"￿ ￿￿￿￿￿ ￿￿ ￿￿￿￿=￿ ￿ ￿ ￿,￿ ￿￿￿"￿￿ 0 ￿￿￿$ / ￿￿￿ 1 ￿ ￿￿￿￿￿
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Chapter-2 S1 
Name  Acession No  IGVH   DH  JH  Germline No  No. 
mutation 
Mutation 
frequency 
Observed 
R/S H-FR 
Expected 
R/S H-FR 
p 
H-FR 
Observed R/S 
H-CDR 
Expected 
R/S H-
CDR 
p 
H-CDR 
P1C1  AM279466  VH1-02  DH2  JH3  X07448  14  6.39%  3.5(7/2)  3.51  0.1  ¥(5/0)  3.15  0.04 
P1C2  AM279467  VH1-02  DH6  JH4  X07448  19  8.68%  3.3(10/3)  3.51  0.1  5(5/1)  3.15  0.1 
P1C3  AM279468  VH1-02  DH2  JH5  X07448  7  3.20%  ¥(5/0)  3.51  0.2  ¥(2/0)  3.15  0.2 
P1C4  AM279469  VH1-02  DH3  JH4  X07448  7  3.20%  3(3/1)  3.51  0.1  2(2/1)  3.15  0.2 
P1C5  AM279470  VH1-02  DH3  JH5  X07448  13  5.94%  1.3(4/3)  3.51  0.02  ¥ (6/0)  3.15  0.01 
P1C6  AM279471  VH1-02  DH3  JH5  X07448  6  2.74%  1(2/2)  3.51  0.1  1(1/1)  3.15  0.4 
P1C7  AM279472  VH1-03  DH2  JH5  X62109  47  20.35%  2.7(19/7)  3.58  0.001  20(20/1)  3.34  0.00001 
P1C8  AM279473  VH1-03  DH6  JH4  X62109  21  9.59%  2(10/5)  3.60  0.07  ¥(6/0)  3.34  0.07 
P1C9  AM279474  VH1-08  DH1  JH4  M99637  4  1.83%  3(3/1)  3.37  0.3  ¥(0/0)  4.15  0.4 
P1C10  AM279475  VH1-08  DH6  JH5  M99637  21  9.59%  3.5(7/2)  3.37  0.008  11(11/1)  4.15  0.0002 
P1C11  AM279476  VH1-08  DH1  JH4  M99637  30  13.70%  2.5(15/6)  3.37  0.07  8(8/1)  4.15  0.07 
P1C12  AM279477  VH1-08  DH1  JH4  M99637  31  14.16%  2.6(16/6)  3.37  0.08  8(8/1)  4.15  0.08 
P1C13  AM279478  VH1-08  DH2  JH4  M99637  11  5.02%  0.8(4/5)  3.37  0.06  1(1/1)  4.15  0.2 
P1C14  AM279479  VH1-18  DH6  JH4  M99641  4  1.83%  0.5(1/2)  3.26  0.1  ¥(1/0)  3.45  0.3 
P1C15  AM279480  VH1-18  DH1  JH5  M99641  48  21.92%  3.3(23/7)  3.26  0.02  3.5(14/4)  3.45  0.01 
P1C16  AM279481  VH1-18  DH1  JH5  M99641  50  22.83%  2.3(23/10)  3.26  0.01  3.25(13/4)  3.45  0.03 
P1C17  AM279482  VH1-18  DH2  JH4  M99641  37  16.89%  1.6(13/8)  3.26  0.003  4.3(13/3)  3.45  0.004 
P1C18  AM279483  VH1-18  DH3  JH4  M99641  22  10.05%  3.6(11/3)  3.26  0.1  7(7/1)  3.45  0.04 
P1C19  AM279484  VH1-18  DH2  JH2  M99641  16  7.31%  2(6/3)  3.26  0.04  ¥(7/0)  3.45  0.008 
P1C20  AM279628  VH1-18  DH2  JH2  M99641  16  7.31%  2(6/3)  3.26  0.04  ¥(7/0)  3.45  0.008 
P1C21  AM279485  VH1-18  DH2  JH2  M99641  16  7.31%  2(6/3)  3.26  0.04  ¥(7/0)  3.45  0.008 
P1C22  AM279486  VH1-18  DH2  JH2  M99641  7  3.20%  ¥(1/0)  3.26  0.01  ¥(6/0)  3.45  0.0001 
P1C23  AM279487  VH1-24  DH4  JH6  M99642  12  5.48%  1(4/4)  3.38  0.04  1(2/2)  3.12  0.2 
P1C24  AM279488  VH1-69  DH3  JH6  L22582  20  9.13%  2.25(9/4)  3.26  0.07  6(6/1)  3.03  0.06 
P1C25  AM279489  VH1-69  DH2  JH6  L22582  26  11.87%  2.4(12/5)  3.26  0.05  ¥(9/0)  3.03  0.01 
P1C26  AM279490  VH1-69  DH2  JH6  L22582  47  21.46%  5.8(29/5)  3.26  0.1  (12/1)  3.03  0.03  
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P1C27  AM279491  VH3-07  DH1  JH3  M99649  19  8.44%  1.3(4/3)  3.23  0.0005  11(11/1)  5.09  0.00009 
P1C28  AM279492  VH3-15  DH4  JH5  X92216  16  6.93%  1(5/5)  3.19  0.01  2(4/2)  3.62  0.1 
P1C29  AM279629  VH3-15  DH4  JH5  X92216  16  6.93%  1(5/5)  3.19  0.01  2(4/2)  3.62  0.1 
P1C30  AM279493  VH3-23  DH1  JH3  M99660  25  11.11%  1.8(9/5)  3.17  0.009  1.75(7/4)  3.55  0.06 
P1C31  AM279494  VH3-74  DH3  JH4  L33851  11  4.89%  0.5(2/4)  3.11  0.005  ¥(5/0)  4.79  0.02 
P1C32  AM279495  VH4-39  DH6  JH4  L10094  16  7.02%  2.6(8/3)  2.99  0.1  4(4/1)  4.00  0.1 
P1C33  AM279496  VH4-34  DH3  JH6  X92255  33  15.07%  1.6(15/9)  3.07  0.03  2(6/3)  3.64  0.1 
P1C34  AM279497  VH4-59  DH2  JH3  L10088  19  8.80%  4(12/3)  2.99  0.1  0.3(1/3)  3.70  0.1 
P1C35  AM279498  VH4-59  DH3  JH4  L10088  25  11.57%  2.75(11/4)  2.99  0.04  2.3(7/3)  3.70  0.06 
P1C36  AM279499  VH4-59  DH3  JH6  L10088  37  17.13%  1.8(15/8)  2.99  0.009  13(13/1)  3.70  0.003 
P1C37  AM279500  VH4-61  DH1  JH6  M29811  35  15.77%  1.75(14/8)  2.99  0.01  1.6(8/5)  3.26  0.1 
P1C38  AM279501  VH4-61  DH2  JH5  M29811  33  14.86%  3.2(16/5)  2.99  0.07  ¥(12/0)  3.26  0.005 
P1C39  AM279502  VH5-51  DH5  JH5  M99686  20  9.13%  2.25(9/4)  3.38  0.06  1.3(4/3)  3.82  0.2 
P1C40  AM279503  VH5-51  DH1  JH4  M99686  31  14.16%  3.5(14/4)  3.38  0.03  3.3(10/3)  3.82  0.02 
P1C41  AM279630  VH5-51  DH1  JH4  M99686  31  14.16%  3.5(14/4)  3.38  0.03  3.3(10/3)  3.82  0.02 
P1C42  AM279504  VH5-51  DH6  JH6  M99686  17  7.76%  2(8/4)  3.38  0.1  ¥(5/0)  3.82  0.09 
P1C43  AM279505  VH5-51  DH5  JH5  M99686  18  8.22%  5(10/2)  3.38  0.1  ¥(6/0)  3.82  0.05 
P1C44  AM279506  VH5-51  DH3  JH3  M99686  30  13.70%  2.8(17/6)  3.38  0.1  2.5(5/2)  3.82  0.1 
P1C45  AM279507  VH5-a  DH3  JH3  X92227  40  18.26%  3.2(23/7)  3.52  0.1  4(8/2)  4.19  0.1 
P2C1  AM279508  VH1-03  DH1  JH4  X62109  27  12.33%  2.4(12/5)  3.60  0.03  4(8/2)  3.34  0.04 
P2C2  AM279631  VH1-03  DH1  JH4  X62109  27  12.33%  2.4(12/5)  3.60  0.03  4(8/2)  3.34  0.04 
P2C3  AM279509  VH1-03  DH3  JH5  X62109  54  24.66%  2.8(31/11)  3.60  0.09  5(10/2)  3.34  0.1 
P2C4  AM279632  VH1-03  DH3  JH5  X62109  54  24.66%  2.8(31/11)  3.60  0.09  5(10/2)  3.34  0.1 
P2C5  AM279633  VH1-03  DH3  JH5  X62109  54  24.66%  2.8(31/11)  3.60  0.09  5(10/2)  3.34  0.1 
P2C6  AM279510  VH1-03  DH5  JH3  X62109  23  10.50%  1.4(10/7)  3.60  0.03  5(5/1)  3.34  0.1 
P2C7  AM279511  VH1-18  DH5  JH4  M99641  17  7.76%  1.3(4/3)  3.26  0.002  4(8/2)  3.45  0.003 
P2C8  AM279512  VH1-18  DH3  JH4  M99641  39  17.81%  1.8(18/10)  3.26  0.02  0.8(5/6)  3.45  0.1 
P2C9  AM279634  VH1-18  DH3  JH4  M99641  39  17.81%  1.8(18/10)  3.26  0.02  0.8(5/6)  3.45  0.1 
P2C10  AM279513  VH1-18  DH5  JH2  M99641  36  16.44%  3.1(19/6)  3.26  0.09  4.5(9/2)  3.45  0.07 
P2C11  AM279514  VH1-18  DH3  JH6  M99641  21  9.59%  1.6(8/5)  3.26  0.02  1.6(5/3)  3.45  0.1 
P2C12  AM279515  VH1-18  DH3  JH6  M99641  22  10.05%  1.6(8/5)  3.26  0.01  1.25(5/4)  3.45  0.1 
P2C13  AM279516  VH1-46  DH3  JH4  X92343  35  15.98%  3.4(17/5)  3.43  0.04  5.5(11/2)  3.42  0.01 
P2C14  AM279635  VH1-46  DH3  JH4  X92343  35  15.98%  3.4(17/5)  3.43  0.04  5.5(11/2)  3.42  0.01 
P2C15  AM279517  VH1-46  DH3  JH4  X92343  20  9.13%  11(11/1)  3.43  0.1  7(7/1)  3.42  0.02 
P2C16  AM279518  VH1-46  DH3  JH4  X92343  27  12.33%  4.6(14/3)  3.43  0.1  ¥(10/0)  3.42  0.007 
P2C17  AM279519  VH1-46  DH2  JH4  X92343  21  9.59%  5.5(11/2)  3.43  0.1  3(6/2)  3.42  0.07  
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P2C18  AM279636  VH1-46  DH2  JH4  X92343  21  9.59%  5.5(11/2)  3.43  0.1  3(6/2)  3.42  0.07 
P2C19  AM279520  VH1-58  DH2  JH4  M29809  24  10,96%  2.6(13/5)  3,51  0.1  5(5/1)  2,86  0.1 
P2C20  AM279521  VH1-69  DH4  JH4  L22582  21  9.59%  1.6(7/6)  3.26  0.009  ¥(8/0)  3.03  0.01 
P2C21  AM279522  VH1-69  DH4  JH4  L22582  21  9.59%  1.3(8/6)  3.26  0.02  ¥(7/0)  3.03  0.03 
P2C22  AM279523  VH1-69  DH4  JH2  L22582  27  12.33%  1.3(9/7)  3.26  0.003  4.5(9/2)  3.03  0.002 
P2C23  AM279524  VH1-69  DH2  JH5  L22582  35  15.98%  2.1(13/6)  3.26  0.003  3(12/4)  3.03  0.005 
P2C24  AM279637  VH1-69  DH2  JH5  L22582  35  15.98%  2.1(13/6)  3.26  0.003  3(12/4)  3.03  0.005 
P2C25  AM279525  VH2-05  DH2  JH3  X62111  12  5.41%  1.6(5/3)  3.12  0.1  3(3/1)  3.68  0.2 
P2C26  AM279526  VH2-70  DH5  JH4  L21969  12  5.41%  0.75(3/4)  3.18  0.01  4(4/1)  4.62  0.1 
P2C27  AM279527  VH3-21  DH1  JH4  AB019439  35  15.98%  1.4(16/11)  3.12  0.03  7(7/1)  5.32  0.1 
P2C28  AM279638  VH3-21  DH1  JH4  AB019439  35  15.98%  1.4(16/11)  3.12  0.03  7(7/1)  5.32  0.1 
P2C29  AM279639  VH3-21  DH1  JH4  AB019439  35  15.98%  1.4(16/11)  3.12  0.03  7(7/1)  5.32  0.1 
P2C30  AM279528  VH3-30  DH2  JH4  X92214  16  7.31%  1.6(8/5)  3.17  0.1  2(2/1)  4.00  0.1 
P2C31  AM279529  VH3-30  DH2  JH6  L26401  17  7.76%  0.8(4/5)  3.17  0.002  7(7/1)  4.00  0.01 
P2C32  AM279530  VH3-48  DH3  JH4  M99675  24  10.96%  2.6(8/3)  3.27  0.005  ¥(13/0)  4.88  0.00006 
P2C33  AM279531  VH3-74  DH3  JH4  L33851  16  7.31%  2.3(7/3)  3.11  0.09  2(4/2)  4.79  0.1 
P2C34  AM279532  VH4-04  DH6  JH4  X05713  9  4.11%  ¥(3/0)  3.08  0.08  2(4/2)  4.19  0.04 
P2C35  AM279533  VH4-04  DH6  JH4  X05713  11  5.02%  1.3(4/3)  3.08  0.07  ¥(4/0)  4.19  0.08 
P2C36  AM279534  VH4-04  DH2  JH3  X05713  29  13.24%  1.2(9/7)  3.08  0.001  2.3(9/4)  4.19  0.03 
P2C37  AM279535  VH4-34  DH5  JH3  X92278  26  12.04%  1.2(9/7)  3.09  0.003  4(8/2)  3.64  0.03 
P2C38  AM279536  VH4-39  DH3  JH4  L10094  21  9.46%  3.3(10/3)  2.98  0.1  ¥(8/0)  4.00  0.01 
P2C39  AM279537  VH4-39  DH3  JH5  L10094  24  10.81%  1.4(10/7)  2.98  0.04  ¥(7/0)  4.00  0.07 
P2C40  AM279538  VH4-39  DH2  JH4  L10094  9  3.61%  2(2/1)  2,86  0.02  5(5/1)  4,00  0.007 
P2C41  AM279539  VH4-59  DH6  JH3  M95117  48  22.22%  2.2(22/10)  2.99  0.01  7(14/2)  3.70  0.01 
P2C42  AM279540  VH4-59  DH1  JH3  M95117  18  8.33%  1.5(9/6)  2.99  0.1  2(2/1)  3.70  0.2 
P2C43  AM279541  VH4-59  DH2  JH6  L10088  6  2.78%  0.6(2/3)  2.99  0.1  ¥(1/0)  3.70  0.4 
P2C44  AM279542  VH5-a  DH3  JH3  X92227  17  7.76%  4(12/3)  3.52  0.1  ¥(2/0)  4.19  0.2 
P2C45  AM279543  VH5-51  DH1  JH4  M99686  10  4.57%  2.5(5/2)  3.38  0.1  ¥ (3/0)  3.82  0.1 
P2C46  AM279544  VH5-51  DH6  JH4  M99686  23  10.50%  6.5(13/2)  3.38  0.1  1.6(5/3)  3.82  0.1 
P2C47  AM279640  VH5-51  DH6  JH4  M99686  23  10.50%  6.5(13/2)  3.38  0.1  1.6(5/3)  3.82  0.1 
P2C48  AM279545  VH5-51  DH3  JH3  M99686  44  20.09%  3.5(21/6)  3.38  0.02  3.2(13/4)  3.82  0.01 
P3C1  AM279546  VH1-02  DH2  JH4  X62106  24  10.96%  2.2(11/5)  3.51  0.05  2.5(5/2)  3.15  0.1 
P3C2  AM279547  VH1-02  DH3  JH4  X62106  13  5.94%  2(6/3)  3.51  0.1  1(2/2)  3.15  0.2 
P3C3  AM279548  VH1-02  DH3  JH3  X62106  17  7.76%  2.3(7/3)  3.51  0.05  1.3(4/3)  3.15  0.1 
P3C4  AM279549  VH1-02  DH6  JH5  X62106  23  10.50%  3.6(11/3)  3.51  0.07  2(6/3)  3.15  0.09 
P3C5  AM279550  VH1-02  DH6  JH5  X62106  45  20.55%  5.2(26/5)  3.51  0.1  1.8(9/5)  3.15  0.1  
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P3C6  AM279551  VH1-02  DH3  JH4  X62106  24  10.96%  1.8(11/6)  3.51  0.05  2.5(5/2)  3.15  0.1 
P3C7  AM279552  VH1-02  DH6  JH5  X62106  16  7.31%  10(10/1)  3.51  0.2  4(4/1)  3.15  0.1 
P3C8  AM279641  VH1-02  DH6  JH5  X62106  16  7.31%  10(10/1)  3.51  0.2  4(4/1)  3.15  0.1 
P3C9  AM279553  VH1-02  DH1  JH5  X62106  25  13.24%  4.8(19/4)  3.51  0.1  2(4/2)  3.15  0.1 
P3C10  AM279642  VH1-02  DH1  JH5  X62106  25  13.24%  4.8(19/4)  3.51  0.1  2(4/2)  3.15  0.1 
P3C11  AM279643  VH1-02  DH1  JH5  X62106  25  13.24%  4.8(19/4)  3.51  0.1  2(4/2)  3.15  0.1 
P3C12  AM279554  VH1-02  DH2  JH4  X62106  43  19.63%  1.5(19/13)  3.51  0.01  2.6(8/3)  3.15  0.1 
P3C13  AM279555  VH1-02  DH6  JH5  X62106  11  5.02%  3(6/2)  3.51  0.2  0.5(1/2)  3.15  0.2 
P3C14  AM279556  VH1-02  DH5  JH4  X62106  39  17.81%  4.1(25/6)  3.51  0.1  7(7/1)  3.15  0.1 
P3C15  AM279557  VH1-02  DH2  JH6  X62106  36  16.44%  2(20/10)  3.51  0.1  2(4/2)  3.15  0.1 
P3C16  AM279558  VH1-3  DH3  JH4  X62109  32  14.61%  4(16/4)  3.60  0.06  11(11/1)  3.34  0.008 
P3C17  AM279559  VH1-03  DH4  JH6  X62109  11  5.02%  1.2(5/4)  3.60  0.1  ¥(2/0)  3.34  0.2 
P3C18  AM279560  VH1-08  DH2  JH5  M99637  9  4.11%  5(5/1)  3.37  0.2  ¥(3/0)  4.15  0.1 
P3C19  AM279561  VH1-18  DH2  JH5  M99641  28  12.79%  2(12/6)  3.26  0.02  9(9/1)  3.45  0.02 
P3C20  AM279644  VH1-18  DH2  JH5  M99641  28  12.79%  2(12/6)  3.26  0.02  9(9/1)  3.45  0.02 
P3C21  AM279562  VH1-18  DH4  JH4  M99641  29  13.24%  4(12/3)  3.26  0.02  3.6(11/3)  3.45  0.003 
P3C22  AM279563  VH1-18  DH2  JH4  M99641  35  15.98%  1.8(17/9)  3.26  0.05  3.5(7/2)  3.45  0.1 
P3C23  AM279564  VH1-18  DH2  JH4  M99641  27  12.33%  2.1(15/7)  3.26  0.1  4(4/1)  3.45  0.2 
P3C24  AM279565  VH1-46  DH4  JH4  X92343  20  9.13%  2.6(9/4)  3.43  0.06  2.5(5/2)  3.42  0.1 
P3C25  AM279566  VH1-46  DH4  JH4  X92343  18  8.22%  1.8(7/4)  3.43  0.03  ¥(7/0)  3.42  0.01 
P3C26  AM279567  VH1-58  DH1  JH6  M29809  38  17.35%  2.7(18/7)  3.51  0.03  ¥(13/0)  2.86  0.003 
P3C27  AM279568  VH1-69  DH2  JH4  L22582  26  11.87%  4.6(14/3)  3.26  0.1  8(8/1)  3.03  0.03 
P3C28  AM279569  VH1-69  DH6  JH6  L22582  30  13.70%  4.5(18/4)  3.26  0.1  3(6/2)  3.03  0.1 
P3C29  AM279570  VH2-5  DH6  JH4  X69690  23  10.36%  1.4(7/5)  3.12  0.004  10(10/1)  3.68  0.003 
P3C30  AM279571  VH2-5  DH6  JH5  X69690  9  4.05%  0.6(2/3)  3.12  0.02  ¥(4/0)  3.68  0.04 
P3C31  AM279572  VH2-5  DH3  JH4  X69690  18  8.11%  1.6(8/5)  3.12  0.09  4(4/1)  3.68  0.2 
P3C32  AM279573  VH2-5  DH3  JH4  X69690  19  8.56%  1.6(8/5)  3.12  0.06  5(5/1)  3.68  0.1 
P3C33  AM279574  VH3-23  DH2  JH4  M99660  16  7.31%  1.3(4/3)  3.16  0.004  8(8/1)  3.55  0.002 
P3C34  AM279575  VH3-23  DIR1  JH3  M99660  19  8.68%  2(4/2)  3.16  0.0006  5.5(11/2)  3.55  0.00005 
P3C35  AM279576  VH4-04  DH3  JH4  X62112  25  11.57%  2.8(14/5)  2.99  0.1  5(5/1)  3.70  0.1 
P3C36  AM279577  VH4-59  DH3  JH4  X05713  36  16.44%  8(24/3)  3.08  0.08  8(8/1)  4.19  0.1 
P3C37  AM279578  VH4-59  DH3  JH4  L10088  26  12.04%  2(14/7)  2.99  0.1  ¥(5/0)  3.70  0.1 
P3C38  AM279579  VH4-61  DH3  JH5  M2981112  19  8.56%  3(9/3)  2.99  0.1  ¥(7/0)  3.26  0.02 
P3C39  AM279580  VH4-b  DH6  JH2  Z12367  16  7.31%  5.5(11/2)  2.94  0.1  2(2/1)  3.86  0.2 
P3C40  AM279581  VH4-b  DH6  JH2  Z12367  15  6.85%  5(10/2)  2.94  0.1  2(2/1)  3.86  0.2 
P3C41  AM279582  VH4-b  DH3  JH3  Z12367  17  7.76%  1.8(7/4)  2.94  0.07  5(5/1)  3.86  0.09  
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P3C42  AM279583  VH5-51  DH3  JH4  M99686  20  9.13%  2.3(9/4)  3.38  0.06  2.5(5/2)  3.82  0.1 
P3C43  AM279584  VH5-51  DH1  JH3  M99686  38  17.35%  3.1(19/6)  3.38  0.05  12/1  3.82  0.01 
P3C44  AM279585  VH5-51  DH3  JH4  M99686  16  7.31%  2.3(7/3)  3.38  0.08  5(5/1)  3.82  0.08 
P3C45  AM279586  VH5-51  DH2  JH6  M99686  16  7.31%  8(8/1)  3.38  0.1  6(6/1)  3.82  0.03 
P3C46  AM279587  VH7  DH6  JH1  X62110  29  13.24%  5.3(16/3)  3.19  0.1  2.3(7/3)  3.21  0.1 
P3C47  AM279588  VH7  DH6  JH6  X62110  16  7.31%  ¥(10/0)  3.19  0.1  ¥(6/0)  3.21  0.02 
P3C48  AM279589  VH7  DH5  JH4  L10057  14  6.39%  1.6(5/3)  3.19  0.04  5(5/1)  3.21  0.05 
P3C49  AM279590  VH7  DH1  JH4  X62110  21  9.59%  2.3(9/4)  3.19  0.05  ¥(8/0)  3.21  0.05 
 
Chapter-2-S2 
Name  Acession No  IGVH   DH  JH  Germline No  No. 
mutation 
Mutation 
frequency 
Observed 
R/S H-FR 
Expected 
R/S H-FR 
p 
H-FR 
Observed R/S 
H-CDR 
Expected 
R/S H-
CDR 
p 
H-CDR 
P4C1  AM279591  VH1-18  DH3  JH5  M99641  27  9,38%  1.7(12/7)  3.10  0.022  7(7/1)  3.45  0.033 
P4C2  AM279592  VH1-2  DH2  JH6  X62106  43  14,93%  4(24/6)  3.27  0.068  (13/0)  3.15  0.0013 
P4C3  AM279645  VH1-2  DH2  JH6  X62106  43  14,93%  4(24/6)  3.27  0.068  (13/0)  3.15  0.0013 
P4C4  AM279593  VH1-46  DH3  JH4  X92343  21  7,29%  1.8(9/5)  3.22  0.027  6(6/1)  3.42  0.314 
P4C5  AM279646  VH1-46  DH3  JH4  X92343  21  7,29%  1.8(9/5)  3.22  0.027  6(6/1)  3.42  0.314 
P4C6  AM279594  VH2-5  DH3  JH3  X69690  39  13.40%  1.5(17/11)  2.92  0.01  0.83(5/6)  3.68  0.18 
P4C7  AM279595  VH2-5  DH2  JH4  X69690  16  5.50%  1.1(7/6)  2.92  0.071  0.5(1/2)  3.68  0.23 
P4C8  AM279596  VH2-5  DH3  JH4  X69690  12  4.12%  2(4/2)  2.92  0.034  6/0  3.68  0.002 
P4C9  AM279597  VH2-5  DH3  JH3  X69690  29  9.97%  2(10/5)  2.92  0.002  3.6(11/3)  3.68  0.0008 
P4C10  AM279598  VH2-5  DH3  JH4  X69690  25  8.59%  1.8(9/5)  2.92  0.006  10(10/1)  3.68  0.0008 
P4C11  AM279647  VH2-5  DH3  JH4  X69690  25  8.59%  1.8(9/5)  2.92  0.006  10(10/1)  3.68  0.0008 
P4C12  AM279599  VH2-5  DH5  JH5  X69690  14  4.81%  1.5(6/4)  2.92  0.07  (4/0)  3.68  0.08 
P4C13  AM279600  VH2-5  DH3  JH4  X69690  11  3.78%  0.5(2/4)  2.92  0.003  4(4/1)  3.68  0.04 
P4C14  AM279601  VH2-26  DH3  JH6  M99648  16  5.50%  (12/0)  2.95  0.11  3(3/1)  3.90  0.2 
P4C15  AM279602  VH3-09  DH6  JH4  M99651  11  3.82%  4(4/1)  2.88  0.05  (6/0)  4.56  0.001 
P4C16  AM279603  VH3-23  DH6  JH4  M99660  17  5.90%  4(8/2)  2.91  0.08  (7/0)  3.55  0.003 
P4C17  AM279604  VH3-23  DH3  JH4  M99660  20  6.94%  4(4/1)  2.91  0.0001  14(14/1)  3.55  0.00000000
6 
P4C18  AM279605  VH3-23  DH3  JH4  M99660  10  3.47%  6(6/1)  2.91  0.2  (3/0)  3.55  0.09  
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P4C19  AM279606  VH3-23  DH6  JH6  M99660  23  7.99%  4.3(13/3)  2.91  0.1  1.3(4/3)  3.55  0.19 
P4C20  AM279607  VH3-23  DH2  JH6  M99660  21  7.29%  2.3(7/3)  2.91  0.003  2.6(8/3)  3.55  0.002 
P4C21  AM279608  VH3-30  DH2  JH4  L26401    51  17.7%  31/6  2,91  0.06  12/7  4.00  0.03 
P4C22  AM279609  VH3-49  DH6  JH4  M99676  11  3.74%  2.5(5/2)  2.99  0.1  1(2/2)  3.08  0.2 
P4C23  AM279610  VH3-74  DH6  JH4  L33851  18  6.25%  3.5(7/2)  2.86  0.028  2(6/3)  4.79  0.02 
P4C24  AM279611  VH4-59  DH3  JH4  L10088  36  12.63%  1.33(12/9)  2.80  0.0003  6.5(13/2)  3.70  0.0001 
P4C25  AM279612  VH4-59  DH6  JH4  L10088  11  3,86%  6/1  2,80  0.2  2/2  3,70  0.2 
P4C26  AM279613  VH4-59  DH2  JH6  L10088  31  10.88%  8.5(17/2)  2.80  0.12  5(10/2)  3.70  0.002 
P4C27  AM279614  VH4-61  DH6  JH4  L10088  31  11,68%  12/12  2,80  0.001  7/3  3,26  0.08 
P4C28  AM279615  VH4-61  DH3  JH4  L10097  55  18.90%  1.4(23/16)  2.80  0.0019  15(15/1)  3.26  0.003 
P4C29  AM279616  VH4-61  DH3  JH6  L10097  32  11.00%  1.6(13/8)  2.80  0.01  2.6(8/3)  3.26  0.03 
P4C30  AM279617  VH4-61  DH2  JH4  L10097  44  15.12%  1.8(20/11)  2.80  0.01  12(12/1)  3.26  0.007 
P4C31  AM279618  VH4-b  DH2  JH4  Z12367  33  11.46%  5.6(17/3)  2.76  0.07  2.25(9/4)  3.86  0.02 
P4C32  AM279619  VH5-51  DH6  JH4  M99686  14  4.86%  4(4/1)  3.24  0.006  8(8/1)  3.82  0.0001 
P4C33  AM279620  VH5-51  DH6  JH4  M99686  15  5.21%  4(4/1)  3.24  0.003  9(9/1)  3.82  0.00001 
P4C34  AM279621  VH5-51  DH6  JH4  M99686  16  5.56%  3(9/3)  3.24  0.1  1(2/2)  3.82  0.2 
P4C35  AM279622  VH5-51  DH1  JH3  M99686  8  2.78%  5(5/1)  3.24  0.2  (2/0)  3.82  0.268 
P4C36  AM279623  VH6-01  DH2  JH5  X92224/J  35  11.78%  1.4(14/10)  2.88  0.008  4.5(9/2)  3.91  0.04 
P4C37  AM279648  VH6-01  DH2  JH5  X92224/J  35  11.78%  1.4(14/10)  2.88  0.008  4.5(9/2)  3.91  0.04 
P4C38  AM279624  VH6-01  DH2  JH5  X92224/J  22  7.41%  3.2(13/4)  2.88  0.1  4(4/1)  3.91  0.2 
P4C39  AM279625  VH6-01  DH4  JH3  X92224/J  10  3.37%  2.5(5/2)  2.88  0.2  2(2/1)  3.91  0.2 
P4C40  AM279626  VH6-01  DH2  JH3  X92224/J  7  2.36%  1.5(3/2)  2.88  0.07  (4/0)  3.91  0.01 
P4C41  AM279627  VH6-01  DH2  JH4  X92224/J  10  3.37%  0.75(3/4)  2.88  0.04  (3/0)  3.91  0.1 
 
Chapter-2 S3 
NAME  VH   VH   N  DH  N   JH  CDR3 
 
P1C1  TGT  GCGCGA    GAACTCGGCGT  CA  ATGCTTTTGATATCTGG  11 
P1C2  TGT  GCGAGAGA  TATTGG  GCAGTGGCGGCTA  GAGT  ACTACTTTGACTACTGG  15  
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P1C3  TGC  GCGAG  GGG  TGAGGCGGTGACTGCGA  CCCGACAGG  ATTGGTCCGACCCCTGG  16 
P1C4  TGT  GCGAGAG  GACGGGG  GGTTCGGGGAGT  CGACCCCT  ACTACTCTGACTACTGG  16 
P1C5  TGT  GCGAGAGA  TAGCGATCCGTGGCTCCCCCGGAC  TTCCAGGAGT    TGGCTCGACCCCTGG  18 
P1C6  TGT  GCGACCG  GCACCAAGGGTC  ATTTCTATGATAGTTCTGGTT  TA  AACTGGTTCGACCCCTG
G 
19 
P1C7  TGT  GGGAGAGA  T  TGGCGGTTGATGCT  GGTGCG  CCAGTGG  11 
P1C8  TGT  GCGAGAG  GG  AGCAGTGGCTCAACC  CTTTGGCGG  TACTGG  12 
P1C9  TGC  GCGAGGGG    GTCCCCA    TATGACTACTGG  8 
P1C10  TGC  GCAAGAGG  ACCACC  CAAGGGCTGGT  C  CGACTTCTGG  11 
P1C11  TGT  GCGAGA  AT  GTATCGGACGAG  AGG  CTTTGACTACTGG  11 
P1C12  TGT  GCGAGA  AT  GTATCGGACGAG  AGG  CTTCGACTACTGG  11 
P1C13  TGT  GCGAGA    TTCTCGTCGAGT  GGCCCTGCGTG
GGATC 
TTGGCTACTGG  14 
P1C14  TGC  GCGAGA  TTGGGC  AGCAACAGTTGGTAC  TCTGGC  GACTACTGG  13 
P1C15  TGT  GCGAGAG  CGCTGAC  TATACAAGGGACG  TTAC  GGTTCGACCCCTGG  14 
P1C16  TGT  GCGAGAG  CGCTGAC  TATACAAGGGACG  TTAC  GATTCGATCCCTGG  14 
P1C17  TGT  GCGAGAGA  TCAGTCGTTCGA  TGATCGTGTCTGGTA  CTGGTC  CCTCTGG  15 
P1C18  TGT  GCGAGAGA  TTTTCGCCCTCCGAAGTTTGAGC  ACGCTAGTGGAGGTTAT  GC  CTTTGACTACTGG  20  
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P1C19 
P1C20 
TGT  GCGAGAGA  GGCCTCGATTTC  ATATTGTGTTGGTGGTACCTGCTACTC
C 
G  ACTGGTACTTCGATCTC
TGG 
22 
P1C21  TGT  GCGAGAGA  GGCCTCGATTTC  ATATTGTGTTGGTGGTACCTGCTACTC
C 
G  ACTGGCACTTCGATCTC
TGG 
22 
P1C22  TGT  GCGAGAGA  GGCCTTAACTTC  ATATTGTATTGGTGGTACCTGCTACTC
C 
G  ACTGGTACTTCGATCTC
TGG 
22 
P1C23  TGT  GCAGC    TACGGTTACTAC  GCCCCAAAATT
ACTTCA 
ACTACGCTTTGGACGTC
TGG 
17 
P1C24  TGT  GCGAGAG  CCC  GGAGCCCCTATTAT  TACTAT  TATAGTATGGACGTCTG
G 
15 
P1C25  TGT  GCGAGGG  GGCT  ACCATATTGTAGTAGTACCAGGTGCTC
TAC 
GGAATACGACT
TTTATTACAA 
TATGGACGCCTGG  24 
P1C26  TGT  GCGGG  GATGCTGCCC  TATTGTAGTAGAAGTGT  CTGTTCCAGTC
TTAAAGATTAC
TACTT 
TGGCTCGACCCCTGG  25 
P1C27  TGT  GCGAGAGA  G  GGTATAACTGGAGAGAC  GAAGGA  TGATGCTTTTGATATGT
GG 
16 
P1C28 
P1C29 
TGT  TCGA  TGG  GCCCACGGTGGGGA  GGG  TGG  8 
P1C30  TGT  GCGAAGG  GA  GGCCATCTG  AG  TCCTTTTGATATCTGG  11 
P1C31  TGT  GCAAG  G  GATACGTTGCCCGG  CGGTCT  CTTTGGCTACTGG  12 
P1C32  TGT  GCGAGACA  AGGG  GCAGTGGCCTCAA    ACTACTTTGACTACTGG  13 
P1C33  TGT  GCGAGAG  ATAATTG  GCATTACTATGGTTCGGGGGG    CCACTACTACTACGCTA
TGGACGTCTGG 
20 
P1C34  TGT  GCGACGG  G  GGTGG  C  GGATACTTTTGATGTCT
GG 
10 
P1C35  TGT  GCGAGAG  GAG  ATGATAGTAATGGTTAT  GGGGACATT  TGG  12  
 
    A-9 
 
 
 
 
 
 
Appendix 
P1C36  TGT  GCGAGAGA  TTGGCAC  TCTTACGATCTCTCG    TACTACGCTATGGACGT
CTGG 
16 
P1C37  TGT  GCGAAAGA    TAGCGGCAGCAATT  CGTTT  TACGTCATGGACGTCTG
G 
14 
P1C38  TGT  GCGCGA  TCG  ACCGAGGTGGTGACTGCTAT  GGGGGG  CTGGTTCGACTCCTGG  16 
P1C39  TGT  GCGCGAC  GAC  GTGACCACGCGTA  TGA  CGACTCCTGG  11 
P1C40  TGT  GCGCGA  GTAAATTTG  GGCCTAAGTCGA  C  ATTTTGACTACTGG  13 
P1C41 
P1C42 
TGT  GC  CCTAAA  AGGCGCAGGTGGAAC  TTAT  TATTACGATATGGACGT
CTGG 
15 
P1C43  TGT  GCGAGAC  GGCGCAATGAG  GGGTACAGCTATG  AAA  ACAATTGGTTCGACCGC
TGG 
17 
P1C44  TGT  GCGAGACA  CACCAGACAGGAC  TATTATGATAATGGAGGTTAT  CCTGTGTT  TCCTTTTGATATCTGG  21 
P1C45  TGT  GCGAGA  CGGCCGAAGG  GGCCCGTGGGGTT    TGCTTTTGATCTCTGG  14 
P2C1 
P2C2 
TGT  GCTAGA  C  GAAACT    ACTACTTTGACTTCTGG  9 
P2C3 
P2C4 
P2C5 
TGT  GTGA  CCGGGCCCGT  CGCTCTCTGGA  A  CGATCACTGG  11 
P2C6  TGT  GC  ATTC  GGCTACTTCTATGGTAA  TGCTCAC  GATATCTGG  12 
P2C7 
 
TGT  GCGAGGG  GGAAC  TACATCTATGGT    TATGACTACTGG  11 
P2C8 
P2C9 
TGT  GCGAG  GTCTAATTTG  GCGATTCTGACGGG  GGGGAC  TGCCTACTGG  14 
P2C10  TGT  GGGCG  CGTCC  TTGTCCCCACGAT  CTCCGTCTAT  TACCTCGATGTCTGG  15  
 
A-10 
 
 
 
 
 
     
Human Mucosal IgA in Health and Disease 
 
P2C11  TGC  GCGAGAG  GGGGA  TACTATGATAGTGGTGGTTATTACGAC  GTTTC  CTCCTTCTACATGGACG
TCTGG 
21 
P2C12  TGT  GCGAGAG  GGGGA  TACTATGATAGTGGTGGATATTACGAC  GTGTC  CTCCTTCTACATGGACG
TCTGG 
21 
P2C13 
P2C14 
TGT  GCGACAGA  ACATCC  TGGGTGGGGAG    ACTTTGACCACTGG  12 
P2C15  TGT  GCGACAGA  ACATCC  TGGGTGGGGAG    ACTTTGACCACTGG  12 
P2C16  TGT  GCGACAGA  ACATCC  TGGGTGGGGAG    ACTTTGACCACTGG  12 
P2C17 
P2C18 
TGT  GCGAGAG  GCG  ATTGTGGTGGTGCTTCCTGCTC  ATCACGGTACG
CCGCTATGTCG
ACCGTC 
GGATACTGG  22 
P2C19  TGT  GCGGCACA    TGTGAAGGATACTGC  CTC  CTATGACCACTGG  12 
P2C20  TGT  GCGGG  GACCCGGGGAACGCC  GACTGCGGTGACTAC  CC  TTGACCAGTGG  15 
P2C21  TGT  GCGGG  GACCCGGGGAACGCC  GACTGCGGTGACTAC  CC  TTGACCAGTGG  15 
P2C22  TGT  GCGAAGGA  TCCAGC  GACGACGGTGCC  CCA  CTACTGGTACTTCGATC
TCTGG 
16 
P2C23 
P2C24 
TGT  ACGAGA  GATCTGGTGAGCGGTGTTAAC  TGTGCTGTTGACACCT  GTTAT  GACGACTGG  18 
P2C25  TGT  GCAC  A  TGGAGAGTGGTATTC    TGCTTTTGACATGTGG  11 
P2C26  TGT  GCACGGA  C  GGATACAACTAAAGT  GGCA  TTTGACTACTGG  12 
P2C27 
P2C28 
P2C29 
TGT  GCAAGA    CGACGGGATGG  T  TACCTTGACTACTGG  10 
P2C30  TGT  GCTAAAGA  TCCCCG  AGGATATTGTGGTGGTGGTAGTTGCCA
CCC 
A  TCTTGG  16  
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P2C31  TGT  ACGAAAGA  TCGGAT  AGGCGATTGTACTGGTGGTGTTTGTTA
TA 
ACTC  CGGCTTGGACGTCTGG  20 
P2C32  TGT  GCGAGAGA  CCCCGGGCGGTCG  TGGGATTCTTGGAGTGG  CATATTG  GACCAATGG  17 
P2C33  TGT  GCGA  AGATTCATCCGACG  TCGGGTAGTAATTATTA  TGACCC  CTATGACAACTGG  17 
P2C34  TGT  GCGAGAG  TACGC  AGCAGTGCCTGGTAC  GTT  TCCGACTACTGG  13 
P2C35  TGT  GCGAGGAA  AAAGACGCAA  GAGTATAGCAGACC    CCACCTTGACTACTGG  15 
P2C36  TGT  GTGCGA  C  ATTGTAGTGCTGGTATCTGC  AGTCGC  GCTTTTGATATGTGG  15 
P2C37  TGT  GCGAG  GACGCAG  TATAATGGAGACTATTA    CGATGCTTTTAATGTCT
GG 
15 
P2C38  TGT  GCGAGATA  C  AGTTATGCATACCGC  ACGCC  TGACTACTGG  12 
P2C39  TGT  GCGAGACA  GGGGCAGC  TGACTTGGAATGA  A  AACTGGTTCGATCCCTG
G 
15 
P2C40  TGT  GCGAGACA  TCAGCCCTCC  TATTGTAGTAATGCCATCTGCTA  CCCGT  ACTACTTTGACTACTGG  20 
P2C41  TGT  GCG  GGGT  GGTTAAAGAAGTGGCAG  CACGTC  TTTGAGGTTTGG  13 
P2C42  TGT  GTGAGAG    GTATAGTGGGAGCTTCTA  GATCGGG  TCTTCATATCTGG  14 
P2C43  TGT  GCGAGAGA  CTGTCGGA  CACATTGTGGTGGTGACTG  GC  TGGACGTCTGG  15 
P2C44  TGT  GCGAG  CTCCCTC  TTATATGGTCCGGGGAGTTATTA  C  GATGGTTTGGATGTCTG
G 
17 
P2C45  TGT  GCGAGAC  CATC  CTGGAGCGAC  GGG  GACTACTGG  10  
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P2C46 
P2C47 
TGT  GCGAGAC  GGTCG  ATCGCAGCACTTGGTTC    CTTTGACTTTTGG  13 
P2C48  TGC  GCGCGAC  TCGGCAACTTT  TATGGATCGTCCAGTTA    TGACGCTTTTGATATGT
GG 
17 
P3C1  TGT  GCGACAG  CC  ACTGGTAGAG    ACTGG  7 
P3C2  TGT  GTGAGAGA    TGGGCATGTGTGG    TACTTTGACTACTGG  11 
P3C3  TGC  GCGAGTGA    GGCCCAGGG  CC  ATGCTTTTGATATCTGG  11 
P3C4  TGT  GCGAGA  CCCCCTC  GAATAGCAGTGAGAG  ACACACAGCC  GTTCGACCCCTGG  16 
P3C5  TGT  GCGAGA  CCCCCTC  GCATAAAAGTGAC  AGACACACAGC
CA 
TTCGACCCCTGG  16 
P3C6  TGT  GCGAGAGA  T  TATGACTATACTTCGGGGAGTTATTAT
AA 
TCCA  TACTTTGACTACTGG  18 
P3C7 
P3C8 
TGT  GCGAG  AGTCGCGCACCGAGAGCTGA  GCCGCAAATGGAGC  TG  TGGTTTGACTCCTGG  18 
P3C9 
P3C10 
P3C11 
TGT  GCGAG  AGTCGCGCGCCGAGTACTGA  GCCGGGAATAGACC  TG  TGGTTTGACTCCTGG  18 
P3C12  TGT  GCGAGAGA  TGGACACACTGCC  CTAGGTTATATGCC  CAAGGGGGGCC
TGGACGTG 
TGG  18 
P3C13  TGT  GCGAGA  CTCTCGCATCTTACGTCAATAGAA
C 
ATACCAGCATACGGT  TGGACCG  CTCGTGG  19 
P3C14  TGT  GCGCGAG  CTAAGGACTCGGTGACCCTCCGTG  GCACAGGTGGCTCC  CT  CTTTGACTCCTGG  19 
P3C15  TGC  GCGAGAG  GAGGC  TGTAGTGGTGGAGACTG  TACCTGCGCGG
GCGGGGACTAT
TGT 
TACTGCGGTCTGGACGT
CTGG 
24 
P3C16  TGC  G  AAAGGGGTG  TGGAGTGGGCATTTAAC  GACT  ACTACCTTGACTATTGG  15  
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P3C17  TGT  GCGAGGG  GGCCC  GAGTACGGTGGATAC  GAGG  ACTCCTACTCCGGTATG
GACGTCTGG 
18 
P3C18  TGT  GCGAGAG  A  TAGGGGTGGTAACT  C  CGGCTGGTTCGACCCCT
GG 
13 
P3C19 
P3C20 
TGT  GCGAGAG  G  CCAGCTGCTGAG    CGACTTCTGG  9 
P3C21  TGT  GCGCGAGA  GAAT  CGGGGGTCCCCC  ACTT  ACTTCTTTGACTATTGG  14 
P3C22  TGT  GCGAGAG  GGGGAGGGGGGGGTGGAGATTAC  TGTACTTCTGCCAGCTG  TCCTCTGTCGA  ACTGG  20 
P3C23  TGT  GCGAGA  ACTGGGGGTATCAGGT  TTGCAATGGTGACTGCTATTCC  CAATTTTTATG
AA 
GATTATTGG  21 
P3C24  TGT  GCTCGA  AGATT  CAACGGTGACTAC  CTTC  CCTACTTTGACAACTGG  14 
P3C25  TGT  GCTCGA  AGATT  CAACGGTGACTAC  CTTC  CCTACTTTGACTACTGG  14 
P3C26  TGT  GCGACTG  GGGCA  GGAACAGCGGGAG  AATATTCCTAC
TATC 
ATGGTCTGGACGTCTGG  18 
P3C27  TGT  GCGAGAG  G  TCCTGATCTGG  ACACT  TACTTTGACTCCTGG  12 
P3C28  TGC  GCGAGA  GGGGGGCCCCT  TACATCAGTGGGTGGTA  ACGTCTT  CTACAAAATGGACGTCT
GG 
19 
P3C29  TGT  GCAC  ACAGGC  GGTCTGGCAGCAACT  ATTACG  ATTTTGACTTCTGG  14 
P3C30  TGT  GTAC  ACCGGTCCGTCGTCC  GCAGCAGCCG  A  AACTGGTTCGACCCCTG
G 
15 
P3C31  TGT  GCACG  ACACATGGCC  TTCTATGGTACAGGGAGTTATT  T  CTACTTTGACTTTTGG  17 
P3C32  TGT  GCAC  ACCTTGCCTCCGGTAAT  TATTTTGGTGGTGGTTATTAC  GAACG  CTTTGACTACTGG  19  
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P3C33  TGT  GCGAAAGA    TTGGGGTAGTGGT  CT  CCACTTTGACTCCTGG  12 
P3C34  TGT  GCGA  GAGATCCG  CCCGCGGGG  GCGGTGTCTGG
CGGTCG 
TGCTTTTGATATCTGG  17 
P3C35  TGT  GCGAGAG  GG  GGGGCAATGACTAC  G  TCCTTTGACTACTGG  12 
P3C36  TGT  GCGAGAG  TCC  GTGCAGGGGGTTAT  GC  CTTTGACTACTGG  12 
P3C37  TGT  GCGAGAGA  TGAGCTC  GGAGCAGGAAGTT  CCATACCCTT  CTTTGAATTCTGG  16 
P3C38  TGT  GCGAGA  TGGATCCCCGTC  ATGGTTCGGGAACT  AGGTATATCAA
CCGG 
CTGGTTCGACTTCTGG  20 
P3C39  TGT  GCGAGA  GAGGAGTCAGTGGGTT  TGTCAGGGCCTGGTA  TCAAGAGAAGG
AACTT 
CCTCGATCGCTGG  21 
P3C40  TGT  GCGAGA  GAGGAGTCAGTGGGTT  TGTCAGGGCCTGGTA  TCAAGAGAAGG
AACTT 
CCTCGATCGCTGG  21 
P3C41  TGT  GCGAGA  GCCTTACTG  AGGAGCGGTGACTAC  GGCCGAATTCG  GGATGCTCTTGATATCT
GG 
19 
P3C42  TGT  GCGAGGAA  A  GATAGTAGTGGTTATTCCCCC  CCGGG  TGACTACTGG  14 
P3C43  TGT  GCGACA  TCCATGATAAAGGC  GGGGGGGCTTCGA  A  CCTTTGATGTCTGG  15 
P3C44  TGT  GCGAGA  CTGGG  TACCATGGTTCGGGGAGGTTT  GCCCGTT  TTTGACATCTGG  16 
P3C45  TGT  GCGAGACA  CGGAAAAA  CTGATGCTGTCCC  CAGCATCAG  CGCTATGGACGTCTGG  17 
P3C46  TGT  GCGCGAG  GGGCATACGTC  GATGCGGATGGTAC  G  TTCTTCCAGCACTGG  15 
P3C47  TGT  GCGAGGG  C  GGTCAGAGCAGCAGC  GACTCTG  TACCACTACTTCGGTAT
GGACGTCTGG 
18  
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P3C48  TGT  GCGAGAG  TGG  GCGAATACAGCTTT  TTGG  ACTGG  10 
P3C49  TGT  GCGAGAG  GAACGG  GATATAACACCAACTA  TTA  TGCCTTCTGG  13 
P4C1  TGT  GCGAGAG  TTTCCCCT  TCCTTACGAATG  CCTCTTGGGTC
AAGGGC 
CTGGTTCGACCCCTGG  19 
P4C2 
P4C3 
TGT  GCGAGAG  TGTCCGTCG  TTGTTATGGGGACT  CTTCGGGGACT
CAG 
CGGAATGGACGTCTGG  19 
P4C4 
P4C5 
TGT  GC  GGC  TACCTACGGGTC  TC  TTGACTACTGG  9 
P4C6  TGT  GC  TTCCC  GTGCTCAGTAT  CA  TGATGCTTTTGATACTT
GG 
12 
P4C7  TGT  GCAC  ACAGAG  GTGGCGGTGACTACGTT    TTTGACTACTGG  12 
P4C8  TGT  GCAC  ACAGACGCTCT  TATGGTGTAGGAAGTTATT  TCTTTGC  CCATTGG  15 
P4C9  TGT  GCAC  ATATGCCGGAA  AAATATGGTTATCCC  GCCCCGAGG  GCTTTTGATATCTGG  17 
P4C10 
P4C11 
TGT  GCAC  ACAGGCGGAGTGGGTC  GGTTCGGGGAATTATCGTA  GGCGCG  TTTGACTACTGG  18 
P4C12  TGT  GCAC  ACAATAAATATCCCATC  TGGACCCAGTGGCT  GATCACGT  ACAACTGGTTCGACCCC
TGG 
20 
P4C13  TGT  GCACG  CAGACGTC  AATATTATGATAGTAGTGCTTCTTACT
AC 
GTGT   
ACTACTTTGACTACTGG 
20 
P4C14  TGT  GCACGGGTAC  GAACCGCCGCCCCA  TTTCACGGTTTTTGGAGTAGTT  GGCGGA  ACTACTTCATGGACGTC
TGG 
23 
P4C15  TGT  GCAAAAGGCA  C  GTCAAAGGAGTGGCTGG  ACCTGGGGA  TTGACTACTGG  15 
P4C16  TGT  GCGAAAGA  TCGTGTGG  AGGGCGATGGCTGGT  C  CATTGACTTCTGG  14  
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P4C17  TGT  GCGAAAGA  ACATGAG  ATGACTATCGTCC  TTTGGGGGGGA  TTTGACTACTGG  16 
P4C18  TGT  GCGAAAG  GGCG  TTACTATGGTTCAGGGGCTTATT  TAAAT  TCTTTTGACTACTGG  17 
P4C19  TGT  GCGAAAG  TCTTAGGAGG  TAGCAGT  TGGTCCCACCG
TTACTACGC 
TATGGACGTCTGG  18 
P4C20  TGT  GCGAAAG  TCCGCCGTTCGAG  TTGTTCTAATGGTATATGTTATGC  AAACCTCCCGT
CCTACTT 
CTACTACCTTATGGACG
TCTGG 
27 
P4C21  TGT  GCGAGAG  GGGCCTATCATTATG  ATTATCGAGGTGAC  C  ACCACTTTGACTATTGG  17 
P4C22  TGT  TCTAGAGA  TCGT  GAGACATCAGCAGCTG  CCCGCCCT  TTTGACTACTGG  15 
P4C23  TGT  GCAAAA  CTC  ATAGCAACTGGGC  ACGCCGACAC  CTTTGACTCCTGG  14 
P4C24  TGT  GTGAAAG  TCGGGAGG  GATGTTATGACTGGT  GGGA  TTGAATTCTGG  14 
P4C25  TGT  GCGAGA  ATTTC  GTATAGGAGCAGCTGGTAC  GGGGACT  ACTACTTTGACTCCTGG  17 
P4C26  TGT  GCGAGAG  TGGGGGCAATG  TGTTCTAATGGTATCTGCAAT  TTAGACGCCCT
CTT 
CTACGGAGTGGACGTCT
GG 
23 
P4C27  TGT  GCGAGA  TT  TGTCGATGGCTGGTA  T  TACTTTGACTCCTGG  12 
P4C28  TGT  GTGAGA    ATTTCAAGGGCTC  CCATAGTCGG  CCTTGACTATTGG  13 
P4C29  TGT  GCGAGA  AG  TGTTCGGGGGGATTTT  TGGAGTCC  CTACTACTTCTACATGG
ACGTCTGG 
18 
P4C30  TGT  GCGAGAG  TGGGGCAGTGTGGTGGTGGCAC  CTGCTATTCC  ATGTCAGTAAT
TGGTACGATAA
AATAT 
TGG  22 
P4C31  TGT  GCGAGA  GTGGGTCAGTGTGA  TGGTGGCCTCTGTTACTC  TTTAGGAGTGC
CCGGTACGGTT
T 
ATAACTGG  22  
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P4C32  TGT  GCGAGAC  TCCC  GAGTATAGCAGCTCGTCC  G  TGGTTTGACTACTGG  14 
P4C33  TGT  GCGAGAC  TCCC  GAGTGTAGCAGCTCGTCG  G  TGGTTTGACTACTGG  14 
P4C34  TGT  GCGAGAC  TCCC  GAGTATAGCAGCTCGTCC  G  TGGTTTGACTACTGG  14 
P4C35  TGT  GCGAG  TCT  TCAACGTAATCA  GGGAGA  TGATGCTTTTGATATCT
GG 
14 
P4C36 
P4C37 
TGT  GCAAGA  TCAAGA  TGCAGTGGTGGCACTTG  TT  ACAACTGGTTCGTCACC
TGG 
16 
P4C38  TGC  GCCAGA  TCAAGG  TGTGGTGGTGGTACTTG  TT  ACAACTGGTTCATCTCG
TGG 
16 
P4C39  TGT  GCAAGA  CTCC  ACTACGGTGACTA  TAC  TGATGCTTTTGATATCT
GG 
14 
P4C40  TGT  GTAAGA    ATGAGTACCAACTGCTACG  GTTG  TGATGCGTTTGATATCT
GG 
15 
P4C41  TGT  GCAAGAGA  TCCTCCTTCAG  ACCAAGGG    TATGACTACTGG  12 
 
Chapter-4-S3 
Name  Acession No  IGVH   DH  JH  Germline No  No. 
mutation 
Mutation 
frequency 
Observed 
R/S H-FR 
Expected 
R/S H-FR 
p 
H-FR 
Observed R/S 
H-CDR 
Expected 
R/S H-
CDR 
p 
H-CDR 
11.477-1 
IgA1    VH1-3  DH2  JH6  16  15  6.85%  7/3  3.47  0.1  5/0  3.21  0.06 
4.477-1 
IgA1    VH1-18  DH3   JH4  13  11  5.02%  6/1  3.26  0.2  4/0  3.45  0.07 
19.477-1 
IgA1    VH1-18  DH5   JH4  13  12  5.48%  4/1  3.26  0.04  4/3  3.45  0.09 
3.477-1    VH1-18  DH5  JH3  14  20  9.13%  4/7  3.26  0.0002  6/3  3.45  0.06  
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IgA1 
6.477-1 
IgA1    VH1-18  DH3  JH6  25  10  4.57%  2/2  3.26  0.01  3/3  3.45  0.1 
16.477-1 
IgA1    VH1-46  DH6  JH4  11  15  6.85%  9/1  3.43  0.2  4/1  3.42  0.1 
14.477-1 
IgA1    VH1-69  DH2  JH5  20  53  24.20%  24/13  3.26  0.01  15/1  3.03  0.01 
23.477-1 
IgA1    VH3-21  DH3  JH4  21  26  11.87%  5/7  3.12  0.0000
3 
13/1  5.32  0.0002 
18.477_1 
IgA1 stop 
codon 
  VH3-33  DH2  JH5  21 
7  3.20%  4/1  3.17  0.2  2/0  4.63  0.1 
24.477-1 
IgA1    VH4-b  DH4    JH4  15  20  9.13%  11/5  2.94  0.1  4/0  3.86  0.2 
10.477-1 
IgA2    VH4-4  DH3  JH5  10  13  5.94%  3/2  3.08  0.008  7/1  4.19  0.002 
12.477-1 
IgA1    VH4-4-07  DH6  JH6  16  26  12.04%  7/10  3.01  0.0006  8/1  3.45  0.03 
20.477-1 
IgA1    VH4-4  DH2  JH3  19  24  10.96%  12/4  3.08  0.1  8/0  4.19  0.03 
17.477-1 
IgA1    VH4-39  DH6  JH4  16  30  13.51%  13/7  2.98  0.04  10/0  4.00  0.02 
21.477-1 
IgA1    VH4-39  DH3  JH6  22  14  6.31%  6/2  2.98  0.1  5/1  4.00  0.06 
22.477-1 
IgA1    VH4-39  DH3  JH6  22  13  5.86%  6/3  2.98  0.1  3/1  4.00  0.2 
9.477-1 
IgA1    VH4-59  DH3  JH4  14  11  5.09%  6/3  2.99  0.2  2/0  3.70  0.2 
5.477-
1,1.477-1, 
8.477-
1,2.477-1, 
7.477-
1,13.477-1, 
25.477-1 
IgA2 
 
VH4-61  DH6  JH3  12 
32  14.41%  11/5  2.99  0.004  16/0  3.53  0.00002  
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1.477-2 
IgA1   
VH3-72 
DH2  JH6  21  15  6.67%  6/1  3.16  0.07  7/1  4.00  0.01 
5.477-2 
IgA1   
VH3-72 
DH2  JH6  21  16  7,11%  6/2  3.16  0.05  7/1  4.00  0.01 
12.477-3 
IgA2    VH1-2  DH4  JH1  17  16  7.31%  13/1  3.33  0.04  2/0  3.15  0.2 
19.477-3 
IgA2    VH1-2  DH2  JH4  18  30  13.70%  17/5  3.33  0.1  7/1  3.15  0.1 
3.477-3 
IgA2    VH1-3  DH2  JH4  9  13  5.94%  4/1  3.47  0.02  7/1  3.21  0.002 
14.477-3 
IgA2    VH1-3  DH6  JH4  15  4  1.83%  2/0  3.47  0.3  1/1  3.21  0.3 
16.477-3 
IgA2    VH1-3  DH4  JH6  18  18  8.22%  8/3  3.47  0.07  4/3  3.21  0.1 
5.477-3 
IgA2    VH1-18  DH2  JH4  11  34  8.68%  10/4  3.26  0.1  5/0  3.45  0.1 
8.477-3 
IgA2    VH1-18  DH2  JH4  11  34  8.68%  10/4  3.26  0.1  5/0  3.45  0.1 
15.477-3 
IgA2    VH1-18  DH2  JH4  11  34  8.68%  10/4  3.26  0.1  5/0  3.45  0.1 
21.477_3 
IgA2    VH1-18  DH2  JH4  11  34  8.68%  10/4  3.26  0.1  5/0  3.45  0.1 
25.477_3 
IgA2    VH1-18  DH2  JH4  11  34  8.68%  10/4  3.26  0.1  5/0  3.45  0.1 
23.477-3 
IgA1 
germline 
  VH1-46  DH3  JH5  16  0  0  0  0  3.43  0  3.42  0 
4.477-3 
IgA2    VH1-46  DH2  JH6  21  15  6.85%  9/2  3.43  0.2  4/0  3.42  0.1 
7.477-3 
IgA2    VH3-23  DH3  JH4  12  24  10.96%  10/5  3.16  0.02  7/2  3.55  0.06 
13.477-3 
IgA2    VH3-23  DH6  JH4  14  6  2.74%  2/0  3.16  0.1  2/2  3.55  0.2 
18.477-3 
IgA2    VH4-4  DH3  JH5  10  13  5.94%  3/2  3.08  0.008  7/1  4.19  0.002 
9.477-3    VH4  DH6  JH4  11  8  3.70%  3/2  2.99  0.1  3/0  3.70  0.1  
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IgA2 
20.477-3 
IgA1    VH5-a  DH4  JH4  12  11  5.02%  5/1  3.52  0.1  5/0  4.19  0.02 
2.477-3 
IgA2    VH5-a  DH3  JH5  13  10  4.57%  4/3  3.52  0.1  2/1  4.19  0.2 
1.477-3 
IgA2    VH5-51  DH1  JH5  15  20  9.13%  8/1  3.38  0.03  9/2  3.82  0.002 
20.477-4 
IgA1    VH1-46  DH2  JH4  12  40  18.26%  19/10  3.43  0.03  7/4  3.42  0.1 
1.477-4 
IgA1    VH1-69  DH2  JH4  14  28  12.79%  9/3  3.26  0.002  14/2  3.03  0.00003 
7.513-1 
IgA2    VH1-2  DH6  JH4  16  22  10.05%  13/3  3.33  0.1  5/1  3.15  0.1 
23.513-1 
IgA1    VH1-3  DH3  JH4  14  12  5.48%  1/5  3.47  0.0002  4/2  3.21  0.08 
17.513-1 
IgA1    VH1-18  DH1  JH6  16  7  3.20%  3/1  3.26  0.1  3/0  3.45  0.08 
13.513-1 
IgA1    VH1-18  DH3  JH3  19  25  11.42%  15/1  3.26  0.1  7/2  3.45  0.06 
4.513-1 
IgA2    VH1-18  DH3  JH6  22  14  6.39%  6/3  3.26  0.02  2/3  3.45  0.2 
20.513-1 
IgA2    VH1-24  DH6  JH4  13  13  5.94%  6/3  3.38  0.1  4/0  3.12  0.1 
3.513-1 
IgA1    VH1-46  DH5  JH4  9  15  6.85%  4/5  3.43  0.006  5/1  3.42  0.06 
15.513-1 
IgA2    VH1-69  DH3  JH6  16  15  6.85%  8/2  3.26  0.1  4/1  3.03  0.1 
5.513-1 
IgA1    VH1-69  DH3  JH6  20  26  11.87%  7/7  3.26  0.004  10/2  3.03  0.004 
16.513-1 
IgA2    VH3-7  DH3  JH4  9  22  10.05%  10/2  3.23  0.06  5/5  5.09  0.1 
25.513-1 
IgA1    VH3-7  DH2  JH1  12  23  10,50%  11/0  3,23  0.08  9/3  5,09  0.01 
8.513-1 
IgA1 
15 
nucleotide 
 
VH3-21  DH3  JH6  20  34  15,53%  18/4  3,12  0.1  6/6  5,32  0.1  
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21.513-1 
IgA2    VH3-23  DH5    JH6  17  34  15,53%  15/4  3,16  0.02  10/5  3,55  0.03 
24.513-1 
IgA2    VH3-23  DH3  JH3  19  18  8,22%  8/4  3,16  0.08  6/0  3,55  0.04 
19.513-1 
IgA2    VH3-33  DH2  JH3  11  23  10,50%  15/1  3,17  0.1  7/0  4,63  0.06 
12.513-1 
IgA2    VH3-48  DH6    JH3  14  8  3,65%  2/2  3,19  0.04  4/0  4,88  0.03 
18.513-1 
IgA1    VH3-49  DH6  JH6  16  29  12,89%  15/4  3,43  0.1  8/2  3,08  0.07 
2.513-1 
IgA2    VH3-64  DH3  JH4  17  31  14,16%  15/5  3,25  0.06  10/1  3,86  0.02 
14.513-1 
IgA2    VH3-64  DH3  JH4  17  21  9,59%  7/6  3,25  0.009  8/0  3,86  0.01 
1.513-1 
IgA1    VH4-39  DH5  JH5  13  41  18,47%  20/9  2,98  0.06  9/3  4,00  0.1 
6.513-1 
IgA1    VH4-4  DH3  JH4  17  25  11,57%  14/3  3,01  0.1  7/1  3,45  0.05 
16.513-1 
IgA1    VH6-1  DH1  JH6  16  14  6,14%  7/4  3,11  0.1  3/0  3,91  0.2 
4.513-2 
IgA1    VH1-18  DH3  JH4  20  14  6,39%  6/1  3,26  0.09  6/1  3,45  0.02 
18.513-2 
IgA1    VH3-7  DH3  JH4  13  11  5,02%  3/4  3,23  0.02  4/0  5,09  0.09 
24.513-2 
IgA2    VH3-15  DH3  JH4  12  12  5,33%  4/1  3,19  0.05  6/1  3,62  0.01 
12.513-2 
IgA2    VH3-15  DH3  JH4  13  6  2,67%  2/0  3,19  0.1  4/0  3,62  0.01 
14.513-2 
IgA2    VH3-15  DH3  JH4  13  6  2,67%  2/0  3,19  0.1  4/0  3,62  0.01 
21.513-2 
IgA1    VH3-15  DH5  JH4  13  9  4,00%  4/1  3,19  0.1  4/0  3,62  0.05 
7.513-2 
IgA1    VH3-15  DH2    JH3  28  16  7,11%  7/5  3,19  0.1  3/1  3,62  0.1 
13.513-2 
IgA1    VH3-23  DH1  JH4  14  10  4,57%  2/4  3,16  0.02  4/0  3,55  0.05  
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19.513-2 
IgA1    VH3-23  DH3  JH4  16  18  8,22%  9/1  3,16  0.1  8/0  3,55  0.004 
15.513-2 
IgA2    VH3-23  DH3    JH4  21  23  10,50%  5/6  3,16  0.0002  12/0  3,55  0.0001 
25.513-2 
IgA2    VH3-73  DH1  JH6  9  11  4,89%  4/2  3,17  0.08  4/1  3,39  0.09 
6.513-2 
IgA1    VH3-74  DH2  JH4  6  26  11,87%  10/5  3,11  0.01  10/1  4,79  0.008 
17.513-2 
IgA2    VH3-74  DH3  JH6  9  13  5,94%  3/2  3,11  0.003  7/1  4,79  0.003 
23.513-2 
IgA2    VH3-74  DH3  JH5  19  8  3,65%  3/0  3,11  0.1  4/1  4,79  0.03 
22.513-2 
IgA1    VH4-28  DH6  JH6  12  5  2,28%  1/0  2,98  0.08  3/1  4,44  0.03 
9.513-2 
IgA1    VH4-39  DH4  JH4  12  20  9,01%  6/4  2,98  0.008  9/1  4,00  0.004 
3.513-2 
IgA2    VH4-39  DH6  JH5  14  22  9,91%  11/5  2,98  0.1  4/2  4,00  0.2 
8.513-2 
IgA1    VH4-59  DH2  JH3  25  12  5,56%  9/0  2,99  0.1  2/1  3,70  0.2 
2.513-2 
IgA2    VH4-61  DH6    JH2  14  17  7,66%  10/0  2,99  0.1  6/1  3,53  0.04 
19.513-2 
IgA1    VH5-a  DH1  JH4  13  11  5,02%  7/3  3,52  0.1  1/0  4,19  0.1 
5.513-2 
IgA2    VH6-1  DH1  JH3  16  22  9,65%  10/4  3,11  0.09  4/4  3,91  0.1 
3.516-1 
IgA1    VH1-2  DH3  JH4  12  42  19,18%  26/7  3,33  0.1  8/1  3,15  0.1 
7.516-1 
IgA2    VH1-2  DH4  JH4  13  31  14,16%  21/3  3,33  0.1  7/0  3,15  0.1 
1.516-1 
IgA1    VH1-2  DH5  JH4  14  42  19,18%  22/7  3,33  0.07  8/5  3,15  0.1 
12.516-1 
IgA2    VH1-2  DH6  JH4  16  34  15,53%  15/8  3,33  0.02  8/3  3,15  0.09 
18.516-1 
IgA1    VH1-18  DH6  JH4  14  15  6,85%  4/3  3,26  0.007  7/1  3,45  0.005 
19.516-1    VH1-18  DH5  JH4  18  35  15,98%  17/6  3,26  0.05  10/2  3,45  0.03  
 
    A-23 
 
 
 
 
 
 
Appendix 
IgA1 
25.516-1 
IgA2    VH1-18  DH4  JH2  20  6  2,74%  3/0  3,26  0.2  1/2  3,45  0.1 
5.516-1 
IgA2    VH3-15  DH3  JH4  19  5  2,22%  2/1  3,19  0.2  0/2  3,62  0.3 
16.516-1 
IgA1    VH3-30  DH3  JH5  11  28  12,79%  8/8  3,17  0.0007  10/2  4,04  0.01 
6.516-1 
IgA2    VH3-48  DH3  JH6  20  16  7,31%  7/2  3,19  0.08  6/1  4,88  0.03 
23.516-1 
IgA2    VH3-66  DH4  JH4  15  5  2,31%  0/0  3,26  0.009  4/1  3,64  0.002 
11.516-1 
IgA1    VH3-74  DH3  JH4  19  33  15,07%  8/7  3,11  0.0000
4 
17/1  4,79  0.00001 
2.516-1 
IgA2    VH4-4  DH3  JH5  13  8  3,70%  4/2  3,01  0.2  2/0  3,45  0.2 
10.516-1 
IgA1    VH4-39  DH3  JH4  21  33  14,86%  15/7  2,98  0.05  9/2  4,00  0.07 
8.516-1 
IgA2    VH4-59  DH2  JH4  10  21  9,72%  8/1  2,99  0.02  11/1  3,70  0.4 
20.516-1 
IgA2    VH4-59  DH5  JH4  13  17  7,87%  8/2  2,99  0.1  7/0  3,70  0.02 
14.516-1 
IgA1    VH4-59  DH3  JH4  15  25  11,57%  10/6  2,99  0.02  7/2  3,70  0.06 
9.516-1 
IgA1    VH4-59  DH2  JH4  16  21  9,72%  8/9  2,99  0.02  3/1  3,70  0.1 
17.516-1 
IgA1    VH4-59  DH3  JH4  17  47  21,76%  18/11  2,99  0.001  18/0  3,70  0.0001 
15.516-1 
IgA1    VH4-59  DH3  JH4  21  14  6,48%  5/4  2,99  0.04  5/0  3,70  0.04 
21.516-1 
IgA2    VH4-61  DH6  JH5  13  12  5,41%  9/0  2,99  0.1  2/1  3,53  0.2 
16.509-1 
IgA1    VH1-3  DH6   JH4  14  18  8,22%  8/5  3,47  0.07  4/1  3,21  0.1 
5.509-1 
IgA1    VH1-18  DH6  JH4  10  15  6.85%  6/2  3.26  0.06  5/2  3.45  0.06 
25.509-1 
IgA1    VH1-18  DH1  JH6  12  18  8.22%  6/5  3.26  0.01  3/4  3.45  0.2  
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18.509-1 
IgA1    VH1-18  DH5  JH6  19  30  13.70%  11/7  3.26  0.005  10/2  3.45  0.01 
8.509-1 
IgA2    VH1-46  DH2  JH3  23  27  12.33% 
 
9/3  3.43  0.002  15/0  3.42  0.000005 
21.509-1 
IgA1    VH1-69  DH1  JH5  13  25  11.42%  16/3  3.26  0.1  5/1  3.03  0.1 
13.509-1 
IgA1    VH1-69  DH2  JH6  14  20  9.13%  4/5  3.26  0.0002  10/1  3.03  0.0004 
22.509-1 
IgA1    VH1-69  DH2  JH6  20  12  5.48%  4/3  3.26  0.04  2/3  3.03  0.1 
19.509-1 
IgA1    VH1-69  DH3  JH6  29  25  11.42%  15/3  3.26  0.1  6/1  3.03  0.1 
20.509-1 
IgA2    VH4-4  DH2  JH6  14  24  10.96%  10/4  3.08  0.03  10/0  4.19  0.003 
17.509-1 
IgA1    VH4-39  DH6  JH4  12  15  6.76%  3/2  2.98  0.002  8/2  4.00  0.002 
6.509-1 
IgA2    VH4-61  DH2  JH4  14  29  13.06%  15/6  2.99  0.1  8/0  3.53  0.07 
14.509-1 
IgA1    VH4-59  DH3   JH6  22  18  8.33%  9/3  2.99  0.1  5/1  3.70  0.09 
7.509-1 
IgA2    VH5-51  DH3  JH4  13  11  5.02%  5/3  3.38  0.1  2/1  3.82  0.2 
1.509-2 
IgA1    VH1-3  DH2  JH6  20  3  1.37%  1/0  3.47  0.2  1/1  3.21  0.3 
5.509-2 
IgA1    VH1-3  DH2  JH6  20  3  1.37%  1/0  3.47  0.2  1/1  3.21  0.3 
14.509-2 
IgA1    VH1-3  DH2  JH6  20  3  1.37%  1/0  3.47  0.2  1/1  3.21  0.3 
19.509-2 
IgA1    VH1-3  DH2  JH6  20  3  1.37%  1/0  3.47  0.2  1/1  3.21  0.3 
17.509-2 
IgA2    VH1-18  DH6  JH2  18  20  9.13%  8/4  3.26  0.03  7/1  3.45  0.02 
7.509-2 
IgA2    VH1-46  DH2  JH5  21  17  7.76%  7/6  3.43  0.05  4/0  3.42  0.1 
8.509-2 
IgA2    VH1-46  DH2   JH5  21  18  8,22%  7/7  3.43  0.05  4/0  3.42  0.1 
20.509-2    VH1-46  DH2   JH5  21  17  7.76%  7/6  3.43  0.05  4/0  3.42  0.1  
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IgA2 
16.509-2 
IgA2    VH1-69  DH3  JH4  12  22  10.05%  8/6  3.26  0.01  8/0  3.03  0.01 
2.509-2 
IgA2    VH3-7  DH4  JH4  5  15  6.85%  5/3  3.23  0.02  7/0  5.09  0.008 
12.509-2 
IgA2    VH3-15  DH1  JH4  12  13  5,78%  6/2  3,19  0.1  4/1  3,62  0.1 
21.509-2 
IgA1    VH3-23  DH1  JH4  16  20  9,13%  8/2  3,16  0.03  8/2  3,55  0.009 
9.509-2 
IgA2 (15 
nucleotides 
Extra) 
 
VH3-33  DH3  JH4  10  31  7,31%  4/4  3,17  0.004  6/2  4,63  0.03 
18.509-2 
IgA1    VH3-33  DH5  JH4  15  10  4,27%  5/3  3,12  0.1  1/1  4,63  0.3 
25.509-2 
IgA1    VH3-49  DH6  JH4  16  6  2,67%  5/0  3,35  0.1  1/0  3,08  0.4 
15.509-2 
IgA1    VH3-72  DH3  JH3  11  12  5,33%  6/1  3,16  0.1  5/0  4,00  0.04 
3.509-2 
IgA2    VH4-4  DH5  JH5  13  16  7,31%  11/3  3,08  0.1  2/0  4,19  0.2 
24.509-2 
IgA1    VH4-39  DH3  JH2  18  14  6,31%  2/3  2,98  0.0009  7/2  4,00  0.005 
625-b1-20 
IgA2  2041031  VH1-2  DH3  JH5  16  25  11,42%  10/1  3,51  0,018  14/0  3,15  0,000007 
625-b1-18 
IgA2  2041023  VH1-18  DH5  JH4  11   12  5,48%  2/2  3,26  0,0023  8/0  3,45  0,00016 
625-b1-11 
IgA2  2040983  VH1-18  DH3  JH4  15  7  3,20%  4/3  3,26  0,29  0/0  3,45  0,27 
625-b1-16 
IgA2  2041007  VH1-46    JH3  9  25  11,42%  13/3  3,43  0,10  8/1  3,42  0,031 
625-b1-5 
IgA2  2041030  VH1-46  DH2  JH2  17  31  14,16%  12/1  3,43  0,0073  16/2  3,42  0,000009 
625-b1-6 
IgA1  2041038  VH1-69  DH5   JH5  15  24  10,96%  10/5  3,26  0,033  8/1  3,03  0,022 
625-b1-24 
IgA2  2040968  VH2-5  DH6   JH5  14  61  27,48%  40/3  3,12  0,054  18/0  3,68  0,010 
625-b1-2  2041006  VH3-7  DH3    JH6  14  15  6,85%  7/2  3,23  0,12  5/1  5,09  0,082  
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IgA2 
625-b1-15 
IGA2  2040999  VH3-21   DH4   JH6  14  5  2,28%  1/0  3,12  0,082  3/1  5,32  0,041 
625-b1-14 
IGA1  2040993  VH3-23  DH3    JH6  6  15  6,85%  7/2  3,16  0,12  4/2  3,55  0,14 
625-b1-25 
IgA2  2040976  VH3-23  DH5    JH4  9  14  6,39%  3/3  3,16  0,0038  6/2  3,55  0,016 
625-b1-21 
IgA2  2041039  VH3-23  DH4  JH4  16  16  7,31%  4/3  3,16  0,0046  8/1  3,55  0,0021 
625-b1-13 
IGA2  2040991  VH3-48  DH2    JH4  17  16  7,31%  6/2  3,19  0,042  7/1  4,38  0,011 
625-b1-3 
IgA2  2041014  VH4-59  DH2  JH1  12  22  10,19%  15/2  2,99  0,12  4/1  3,70  0,21 
625-b1-9 
IgA2  2040967  VH4-59  DH6  JH4  12  23  10,65%  6/7  2,99  0,0010  8/2  3,70  0,017 
625-b1-22 
IgA2  2041047  VH4-59  DH2  JH5  12  26  12,04%  14/3  2,99  0,13  8/1  3,70  0,032 
625-b1-8 
IgA1  2040959  VH4-59  DH1  JH6  14  21  9,72%  10/8  2,99  0,095  3/0  3,70    0,23 
625-b1-7 
IgA1  2041046  VH4-59  DH2  JH4  16  24  11,11%  11/4  2,99  0,066  8/1  3,70  0,021 
625-b1-17 
IgA2  2041015  VH4-61  DH5  JH4  10  45  20,83%  14/11  2,99  0,0000
9  19/1  3,54  0,00002 
625-b1-10 
IgA1  2040975  VH4-61  DH4  JH6  15  2  0,93%  1/0  2,99  0,48  1/0  3,70  0,27 
625-b1-4 
IgA2  2041022  VH5-51  DH2  JH6  22  5  2,28%  2/1  3,38  0,22  2/0  3,82  0,17 
625-b2-20 
IgA1  
  VH1-18  DH6  JH4  13  5  2,28%  4/0  3,26  0,25  1/0  3,45  0,40 
625-b2-25 
IgA1 
  VH1-46  DH3  JH1  12  12  5,48%  4/3  3,43  0,039  4/1  3,42  0,092 
625-b2-12 
IgA2 
  VH1-69  DH5  JH6  21  39  17,81%  13/3  3,26  0,0005  22/0  3,03  0,00000001 
625-b2-4 
IgA1 
  VH2-5  DH5  JH2  12  15  6,76%  7/3  3,12  0,13  2/3  3,68  0,25 
625-b2-18 
IgA2 
  VH3-7  DH2  JH6  14  19  8,68%  16/2  3,23  0,016  1/0  5,09  0,091  
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625-b2-23 
IgA1 
  VH3-7  DH5  JH4  17  12  5,48%  6/1  3,23  0,18  2/3  5,09  0,29 
625-b2-13 
IgA1 
  VH3-9  DH5  JH6  17  6  2,74%  3/0  3,09  0,28  2/1  4,56  0,21 
625-b2-9 
IgA2 
  VH3-15  DH6  JH4  8  10  4,44%  5/3  3,19  0,21  2/0  3,62  0,30 
625-b2-14 
IgA1 
  VH3-23  DH  JH6  11  15  6,85%  7/2  3,16  0,12  4/2  3,55  0,14 
625-b2-15 
IgA2 
  VH3-23  DH2  JH4  13  10  4,57%  4/1  3,16  0,11  4/1  3,55  0,058 
625-b2-16 
IgA2 
  VH3-23  DH3  JH3  13  15  6,85%  4/0  3,16  0,0085  11/0  3,55  0,000002 
625-b2-22 
IgA1 
  VH3-23  DH1  JH4  17  10  4,57%  5/0  3,16  0,20  5/0  3,55  0,014 
625-b2-3 
IgA2 
  VH3-23  DH6  JH4  19  21  9,59%  9/2  3,16  0,054  10/0  3,55  0,00095 
625-b2-6 
IgA2 
  VH3-23  DH2  JH6  21  3  1,37%  3/0  3,16  0,20  0/0  3,55  0,56 
625-b2-17 
IgA2 
  VH3-74  DH3  JH3  11  48  21,92%  24/3  3,11  0,051  20/1  4,79  0,000091 
625-b2-2 
IgA1 
  VH3-74  DH3  JH6  13  25  11,42%  15/2  3,04  0,15  8/0  4,79  0,042 
625-b2-19 
IgA1 
  VH4-39  DH2  JH6  19  6  2,70%  2/0  2,98  0,16  3/1  4,00  0,067 
625-b2-11 
IgA2 
  VH4-59  DH6  JH4  17  9  4,17%  5/1  2,99  0,25  3/0  3,70  0,12 
625-b2-5 
IgA2 
  VH4-59  DH3  JH5  18  14  6,48%  6/2  2,99  0,098  5/1  3,54  0,045 
625-b2-1 
IgA2 
  VH4-61  DH5  JH4  10  44  20,37%  14/10  2,99  0,0001
4 
17/1  3,54  0,00021 
625-b2-7 
IgA2 
  VH5-51  DH3  JH6  12  14  6,39%  10/0  3,38  0,15  3/1  3,82  0,23 
625-b2-21 
IgA2 
  VH5-51  DH2  JH4  13  10  4,57%  4/1  3,38  0,10  3/2  3,82  0,16 
625-b2-8 
IgA1 
  VH6-1  DH3  JH4  13  5  2,19%  4/0  3,11  0,22  1/0  3,91  0,40 
625-c1-12 
IgA2 
2040987  VH1-2  DH4  JH4  12  23  10,50%  13/2  3,51  0,15  7/1  3,15  0,047  
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625-c1-19 
IgA2 
2041035  VH1-2  DH6  JH4  17  29  13,24%  20/2  3,51  0,10  5/2  3,15  0,19 
625-c1-7 
IgA1 
2041042  VH1-2  DH2  JH6  17  10  4,57%  5/2  3,51  0,19  3/0  3,15  0,15 
625-c1-10 
IgA2 
2040971  VH1-2  DH1  JH6  17  18  8,22%  9/4  3,51  0,12  4/1  3,15  0,18 
625-c1-18 
IgA2 
2041027  VH1-2  DH2  JH4  17  10  4,57%  6/1  3,51  0,25  3/0  3,15  0,15 
625-c1-3 
IgA2 
2041010  VH1-18  DH5  JH4  11  12  5,48%  2/2  3,26  0,0026  8/0  3,45  0,00016 
625-c1-6 
IgA2 
2041034  VH1-18  DH4  JH4  12  30  13,70%  18/5  3,26  0,14  5/2  3,45  0,19 
625-c1-16 
IgA2 
2041011  VH1-46  DH6  JH4  12  13  5,94%  4/4  3,43  0,022  5/0  3,42  0,040 
625-c1-1 
IgA1  2040994  VH1-46  DH6  JH5  17  15  6,85%  5/2  3,43  0,022  7/1  3,42  0,0058 
625-c1-4 
IgA1 
2041018  VH1-46  DH1  JH2  18  24  10,96%  10/8  3,43  0,029  6/0  3,42  0,11 
625-c1-8 
IgA2 
2041050  VH1-46  DH3  JH4  24  32  14,61%  16/6  3,43  0,068  8/2  3,42  0,083 
625-c1-15 
IgA2 
2041003  VH1-69  DH1  JH4  11  23  10,50%  10/3    3,26  0,048  5/5  3,03    0,15 
625-c1-9 
IgA2 
2040963  VH1-69  DH3  JH5  17  22  10,05%  10/3  3,26  0,067  5/4  3,03  0,14 
625-c1-11 
IgA1 
2040979  VH1-69  DH2  JH3  18  3  1,37%  1/0  3,26  0,29  2/0  3,03  0,068 
625-c1-14 
IgA2 
2040995  VH1-69  DH3  JH3  22  4  1,83%  1/0  3,26  0,15  3/0  3,03  0,014 
625-c2-1 
IgA2  2041083  VH1-2  DH4  JH5  10  2  0,91%  1/0  3,51  0,47  1/0  3,15  0,27 
625-c2-14 
IgA1 
2041092  VH1-2  DH6  JH6  12  29  13,24%  13/6  3,51    0,032  9/1  3,15  0,025 
625-c2-12 
IgA1 
2041076  VH1-2  DH2  JH4  13  14  6,39%  8/2  3,51  0,20  4/0  3,15  0,12 
625-c2-16 
IgA1 
2041108  VH1-2  DH3  JH5  15  36  16,44%  9/3  3,51  0,0000
1  22/2  3,15  0,00000000
2 
625-c2-6  2041123  VH1-2  DH2  JH5  19  14  6,39%  7/3  3,51  0,15  4/0  3,15  0,12  
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IgA1 
625-c2-2 
IgA1  2041091  VH1-18  DH2  JH4  14  32  14,61%  20/2  3,26  0,13  10/0  3,45  0,021 
625-c2-20 
IgA1 
2041116  VH1-18  DH2  JH4  14  32  14,61%  20/2  3,26  0,13  10/0  3,45  0,021 
625-c2-4 
IgA1 
2041107  VH1-18  DH3  JH6  20  27  12,33%  17/2  3,26  0,14  3/5  3,45  0,16 
625-c2-9 
IgA2 
2041052  VH1-46  DH3  JH4  9  16  7,31%  5/4  3,43  0,013  5/2  3,42  0,079 
625-c2-10 
IgA2 
2041060  VH1-46  DH3  JH4  9  16  7,31%  5/4    3,43  0,013  5/2  3,42  0,079 
625-c2-11 
IgA2 
2041068  VH1-46  DH6  JH3  9  17  7,76%  7/3  3,43  0,053  5/2  3,42  0,093 
625-c2-7 
IgA1 
2041131  VH1-46  DH6  JH1  12  12  5,48%  4/3  3,43  0,039  4/1  3,42  0,092 
625-c2-21 
IgA1 
2041124  VH1-46  DH5  JH4  14  17  7,76%  7/5  3,43  0,053  5/0  3,42  0,093 
625-c2-8 
IgA1 
2041139  VH1-46  DH4  JH5  15  17  7,76%  6/2  3,43  0,022  7/2  3,42  0,012 
625-c2-5 
IgA1 
2041115  VH1-46  DH2  JH5  20  17  7,76%  6/3  3,43  0,022  7/1  3,72  0,013 
625-c2-3 
IgA2 
2041099  VH1-46  DH2  JH4  21  12  5,48%  4/2  3,43  0,039  5/1  3,42  0,030 
625-c2-23 
IgA2  2041140  VH1-46  DH2  JH4  21  13  5,94%  4/2  3,43  0,022  6/1  3,42  0,011 
625-c2-15 
IgA1 
2041100  VH1-46  DH4  JH4  22  19  8,68%  11/3  3,43  0,17  3/2  3,42  0,24 
625-c2-13 
IgA2  2041084  VH1-46  DH3  JH4  24  32  14,61%  16/6  3,43  0,068  8/2  3,42  0,083 
625-c2-22 
IgA2 
2041132  VH1-69  DH4  JH4  16  47  21,46%  21/5  3,26  0,013  19/2  3,03  0,000059 
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IgG sequences 
 
Name  Acession No  IGVH   DH  JH  Germline No  No. 
mutation 
Mutation 
frequency 
Observed 
R/S H-FR 
Expected 
R/S H-FR 
p 
H-FR 
Observed R/S 
H-CDR 
Expected 
R/S H-
CDR 
p 
H-CDR 
625-B1-11 
IgG3  2049034  VH1-2  DH1   JH4  12  22  10,05%  12/5  3,51  0.14  5/0  3,15  0,15 
625-B1-2 
IgG2  2049025  VH1-2  DH2  JH4  13  17  7,76%  7/2  3,51  0.051 
  7/1  3,15  0.011 
625-B1-5 
IgG1  2049028  VH1-2  DH3  JH4  14  17  5,02%  8/1  3,51  0.1  1/1  3,15  0.004 
625-B1-17 
IgG1  2049040  VH1-2  DH3  JH4  14  17  19,18%  37/3    3,51  0,0000
8  1/1  3,15  0,004 
625-B1-18 
IgG2  2049041  VH1-18  DH4  JH4  16  6  2,74%  3/1  3,26  0,27  2/0  3,45  0,20 
625-B1-7 
IgG1  2049030  VH1-69  DH5  JH4  15  15  6,85%  8/2  3,26  0,1  4/1  3,03  0.1 
625-B1-23 
IgG2 
2049046 
  VH3-7  DH5  JH3  12  17  7,76%  6/3  3,23  0,025  8/0  5,09  0,0049 
625-B1-9 
IgG2  2049032  VH3-13  DH1  JH4  15  15  6,94%  11/0  3,10  0,12  4/0  3,40  0,13 
625-B1-14 
IgG2  2049037  VH3-13  DH1  JH4  15  15  6,94%  11/0  3,10  0.12  4/0  3,40  0,13 
625-B1-20 
IgG2  2049043  VH3-15  DH3  JH5  7  6  2,67%  3/2  3,19  0,28  1/0  3,62  0,39 
625-B1-6 
IgG2  2049029  VH3-21  DH4  JH4  10  13  5,94%  1/5  3,12  0.0001  7/0  5,32  0.003 
625-B1-24 
IgG2  2049047  VH3-21  DH4  JH4  13  13  5,94%  6/3  3,12  0,13  2/2  5,32  0,28 
625-B1-21 
IgG2  2049044  VH3-21  DH4  JH3  14  26  11,87%  5/3  3,12  0,0000
3  16/2  5,32    0,000001  
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625-B1-12 
IgG2  2049035  VH3-21  DH2  JH4  16  13  5,94%  5/2  3,12  0.07  6/0  5,32  0.016 
625-B1-16 
IgG2  2049039  VH3-21  DH2  JH4  16  14  6,39%  5/3  3,12  0,046  6/0  5,32  0,023 
625-B1-1 
IgG2  2048114  VH3-23  DH3  JH4  12  33  15,07%  15/1  3,16  0.038  16/1  3,55  0.00003 
625-B1-19 
IgG2  2049042  VH3-23  DH3  JH4  12  17  7,76%  10/1  3,16  0,19  5/1  3,55  0,095 
625-B1-10 
IgG2  2049033  VH3-23  DH2  JH4  13  12  5,48%  5/1  3,16  0,10  6/0  3,55  0,007 
625-B1-4 
IgG2  2049027  VH3-23  DH3  JH4  15  23  10,50%  9/6  3,16  0.025  5/3  3,55  0.168 
625-B1-15 
IgG2  2049038  VH3-48  DH6  JH6  19  8  3,65%  1/2  3,19  0,0086  4/1  4,38  0,032 
625-B1-3 
IgG2  2049026  VH4-31  DH2  JH6  22  6  2,70%  3/0  3,08  0.288  3/0  3,39  0.062 
625-B1-8 
IgG2 
2049031  VH4-59  DH2  JH4  12  20  9,26%  13/3  2,99  0.14  4/0  3,70  0.1 
625-B1-25 
IgG1 
2049048  VH4-59  DH2  JH6  15  13  6,02%  4/2  2,99  0,026  4/3  3,70  0,10 
625-B1-13 
IgG3  2049036  VH4-59  DH1  JH6  18  59  27,31%  37/4  3,04  0,09  16/2  3,70  0,014 
625-B2-4 
IgG2 
2049052  VH1-2  DH3  JH4  9  21  9,59%  10/1  3,51  0.082  10/0  3,15  0,0007 
625-B2-12 
IgG2  2049060  VH1-2  DH2  JH5  12  17  7,76%  7/6  3,51  0,05  4/0  3,15  0,17 
625-B2-1 
IgG2 
2049049  VH1-2  DH2  JH2  12  9  4,11%  4/2  3,51  0,15  2/1  3,15  0,27 
625-B2-3 
IgG2  2049051  VH1-2  DH2  JH2  12  9  4,11%  4/2  3,51  0,15  2/1  3,15  0,27 
625-B2-11 
IgG2  2049059  VH1-2  DH2  JH2  12  9  4,11%  4/2  3,51  0,15  2/1  3,15  0,27 
625-B2-14 
IgG2  2049062  VH1-2  DH2  JH2  12  9  4,11%  4/2  3,51  0,16  2/1  3,15  0,27 
625-B2-19 
IgG2  2049067  VH1-46  DH3  JH5  15  21  9,59%  10/4  3,43  0,085  6/1  3,42  0,079 
625-B2-2 
IgG1  2049050  VH1-69  DH4  JH6  17  26  11,87%  14/4  3,26  0,12  6/2  3,03  0,12  
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625-B2-10 
IgG1  2049058  VH2-5  DH2  JH4  13  7  3,15%  4/3  3,12  0,29  0/0  3,68  0,24 
625-B2-9 
IgG2  2049057  VH2-26  DH6  JH3  14  10  4,50%  4/3  3,19  0,12  3/0  3,90  0,17 
625-B2-13 
IgG2 
2049061  VH3-7  DH6  JH4  10  12  5,48%  6/2  3,23  0,18  2/2  5,09  0,29 
625-B2-16 
IgG2  2049064  VH3-7  DH1  JH4  11  9  4,11%  4/0  3,23  0,17  5/0  5,09  0,011 
625-B2-23 
IgG1  2049071  VH3-7  DH1  JH4  11  9  4,11%  4/0  3,23  0,17  5/0  5,09  0,011 
625-B2-6 
IgG2  2049054  VH3-21  DH2  JH6  17  17  7,76%  3/1  3,12  0,0005  12/1  5,32  0,000003 
625-B2-18 
IgG3  2049066  VH3-23  DH6  JH3  15  21  9,59%  8/4  3,16  0,026  8/1  3,55  0,013 
625-B2-22 
IgG2 
2049070  VH3-23  DH3  JH4  15  17  7,76%  6/4  3,16  0,027  6/1  3,55  0,039 
625-B2-21 
IgG1  2049069  VH3-53  DH3  JH6  16  0  0,00%  0/0  3,19  0  0/0  3,68  0 
625-B2-17 
IgG1  2049065  VH3-73  DH6  JH4  14  11  4,89%  5/0  3,17  0,16  5/1  3,39  0,029 
625-B2-7 
IgG2  2049055  VH4-b  DH6  JH4  11  15  6,85%  7/3  2,94  0,13  4/1  3,86  0,15 
625-B2-15 
IgG2  2049063  VH4-4  DH1  JH4  15  20  9,26%  8/4  3,01  0,04  8/0  3,45  0,007 
625-B2-25 
IgG1  2049073  VH4-4  DH6  JH5  15  1  0,46%  1/0  3,01  0,59  0/0  3,45  0,83 
625-B2-24 
IgG1  2049072  VH4-30-2  DH4  JH4  14  5  2,25%  4/0  3,02  0,23  1/0  3,26  0,40 
625-B2-20 
IgG2  2049068  VH4-30-4  DH2  JH3  15  17  7,76%  5/2  2,98  0,013  9/1  3,68  0,0011 
625-B2-5 
IgG2  2049053  VH4-39  DH3  JH5   19  7  3,15%  2/0  2,98  0,094  5/0  4,00  0,003 
625-c1-23 
IgG2  2049095  VH1-2  DH6  JH4  11  41  18,72%  21/5  3,51  0,057  14/1  3,15  0,0032 
625-c1-22 
IgG1  2049094  VH1-2  DH3  JH5  14  23  10,50%  12/5  3,51  0,11  5/1  3,15  0,16 
625-c1-9  2049081  VH1-18  DH2  JH3  13  36  16,44%  16/5  3,26  0,023  12/3  3,45  0,0083  
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IgG1 
625-c1-1 
IgG1  2049074  VH1-18  DH3  JH6  20  0  0,00%  0/0  3,26  1  0/0  3,45  1 
625-c1-18 
IgG2  2049090  VH1-46  DH1  JH5  18  20  9,13%  8/2  3,43  0,032  10/0    3,42  0,00056 
625-c1-25 
IgG2  2049097  VH1-46  DH1  JH5  18  21  9,59%  8/2  3,43  0,021  10/1  3,42  0,0009 
625-c1-2 
IgG1  2049075  VH1-69  DH6  JH4  16  20  9,13%  9/3  3,26  0,073  7/1  3,03  0,024 
625-c1-7 
IgG1  2049079  VH1-69  DH6  JH3  17  15  6,85%  7/2  3,26  0,12  3/3  3,03  0,23 
625-c1-5 
IgG1  2049077  VH1-69  DH3  JH6  18  21  9,59%  8/4  3,26  0,023  9/0  3,03  0,003 
625-c1-15 
IgG1 
2049087 
  VH3-11  DH2  JH4  12  5  2,28%  2/0  3,24  0,23  3/0  4,35  0,038 
625-c1-8 
IgG2 
2049080 
  VH3-23  DH4  JH4  13  19  8,68%  3/3  3,16  0,0001  13/0  3,55  0,0000009 
625-c1-6 
IgG2  2049078  VH3-30-3  DH3  JH4  13  14  6,39%  6/3  3,17  0,097  4/1  4,00  0,13 
625-c1-20 
IgG3  2049092  VH3-33  DH3  JH4  13  18  8,22%  7/2  3,17  0,041  7/2  4,63  0,022 
625-c1-17 
IgG2  2049089  VH3-48  DH2  JH4  12  21  9,59%  6/2  3,19  0,0031  11/2  4,88  0,00034 
625-c1-10 
IgG1  2049082  VH3-73  DH6  JH6  13  5  2,22%  4/1  3,17  0,23  0/0  3,39  0,35 
625-c1-16 
IgG1  2049088  VH4-b  DH6  JH4  14  4  1,83%  3/0  2,94  0,33  1/0  3,86  0,39 
625-c1-12 
IgG2  2049084  VH4-30-4  DH5  JH3  15  15  6,76%  3/3  3,02  0,0027  7/2  3,68  0,0081 
625-c1-21 
IgG2  2049093  VH4-30-4  DH1  JH3  15  12  5,41%  6/1  3,02  0,19  4/1  3,68  0,10 
625-c1-19 
IgG1  2049091  VH4-59  DH2  JH6  15  8  3,70%  4/0  2,99  0,23  2/2  3,70  0,25 
625-c1-4 
IgG1  2049076  VH4-59  DH6  JH4  17  4  1,85%  1/1  2,99  0,15  0/2  3,54  0,49 
625-c1-11 
IgG1  2049083  VH5-51  DH3  JH4  14  2  0,91%  1/0  3,38  0,47  1/0  3,82  0,28  
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625-c2-1 
IgG2 
2049098  VH1-2  DH2  JH4  13  7  3,20%  3/1  3,51  0,18  2/1  3,15  0,23 
625-c2-13 
IgG2 
2049110  VH1-2  DH6  JH4  15  2  0,91%  1/0  3,51  0,47  1/0  3,15  0,27 
625-c2-15 
IgG2  2049112  VH1-2  DH2  JH6  17  14  6,39%  7/1  3,51  0,15  5/1  3,15  0,049 
625-c2-22 
IgG2  2049120  VH1-2  DH2  JH6  17  14  6,39%  7/1  3,51  0,15  5/1  3,15  0,049 
625-c2-10 
IgG1  2049107  VH1-2  DH3  JH1  18  21  9,59%  9/5  3,51  0,044  2/5  3,15  0,18 
625-c2-5 
IgG2 
2049102  VH1-46  DH3  JH5  15  20  9,13%  12/2  3,43  0,17  5/1  3,42  0,13 
625-c2-11 
IgG2 
2049108  VH1-46  DH3  JH5  20  22  10,05%  10/3  3,43  0,061  9/0  3,42  0,0051 
625-c2-8 
IgG1 
2049105  VH1-69  DH3  JH3  20  19  8,68%  9/4  3,26  0,099  3/3  3,03  0,24 
625-c2-25 
IgG1  2049123  VH3-23  DH4  JH6  18  0  0,00%  0/0  3,16  1.0  0/0  3,55  1.0 
625-c2-3 
IgG2  2049100  VH3-33  DH4  JH4  12  14  6,39%  7/2  3,24  0,16  5/0  3,89    0,057 
625-c2-23 
IgG2 
2049121  VH3-72  DH6  JH4  12  7  3,11%  2/1  3,16  0,094  4/0  4,00  0,025 
625-c2-2 
IgG1 
2049099  VH4-4  DH4  JH4  11  4  1,85%  1/0  3,01  0,15  3/0  3,45  0,014 
625-c2-6 
IgG2  2049103  VH4-4  DH2  JH4  15  22  10,19%  11/2  3,01  0,11  9/0  3,45  0,0037 
625-c2-4 
IgG2  2049101  VH4-30-4  DH2  JH3  
  15  22  9,91%  9/6  3,02  0,047  6/1  3,68  0,10 
625-c2-7 
IgG2  2049104  VH4-30-4  DH2  JH3  15  22  9,91%  9/6  3,02  0,047  6/1  3,68  0,10 
625-c2-9 
IgG4  2049106  VH4-31  DH3  JH5  15  16  7,21%  7/2  3,08  0,10  7/0  3,39  0,010 
625-c2-17 
IgG2  2049114  VH4-39  DH3  JH4  6  8  3,60%  3/1  2,98  0,14  4/0  4,00  0,035 
625-c2-24 
IgG2  2049122  VH4-39  DH3  JH4  6  8  3,60%  3/1  2,98  0,14  4/0  4,00  0,035 
625-c2-14  2049111  VH4-59  DH3  JH5  11  9  4,17%  5/2  2,99  0,25  2/0  3,70  0,27  
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IgG4 
625-c2-16 
IgG4  2049113  VH4-59  DH3  JH5  11  9  4,17%  5/2  2,99  0,25  2/0  3,70  0,27 
625-c2-20 
IgG4  2049117  VH4-59  DH3  JH5  11  9  4,17%  5/2  2,99  0,25  2/0  3,70  0,27 
625-c2-21 
IgG4 
2049118  VH4-59  DH3  JH5  11  9  4,17%  5/2  2,99  0,25  2/0  3,70  0,27 
625-c2-19 
IgG2  2049116  VH4-59  DH2  JH4  12  26  12,04%  15/2  2,99  0,15  7/2  3,70  0,069 
625-c2-18 
IgG1 
2049115  VH5-51  DH3  JH4  18  23  10,50%  10/3  3,38  0,044  8/2  3,82  0,023 
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Clonally related cells  Sample  Seque
nced 
Productively 
rearranged 
sequences 
100% identical  Sequences 
excluding 
100% 
identical 
sequences 
Without 
identical 
sequences 
With 
identical 
sequences 
Unique 
sequences 
Minimal 
coverage 
Unique 
sequences 
Maximal 
coverage 
Minimal 
coverage 
Maximum 
coverage 
477-1 (NI)  25  24  1 set x 5 clones  20  1set(1x2)  1set (1x
5id + 
2) 
15  15  25  37 
477-2 (I)  25  22  1 sets (1 set x 22 clones)  1  0  0  1  0  ??  ?? 
477-3 (I)  25  19  1set (1set x 5 clones)  15  0  0  15  14  0  26 
477-4 (I)  25  18  1 set x 17 clones  2  0  0  2  1  100  95 
509-1 (NI)  25  14  0  14  0  0  14  14  0  0 
509-2 (I)  25  18  0  18  2sets(1x3, 
1x4) 
0  11  11  38  38 
513-1 (NI)  25  22  0  22  1set(1x2)  0  20  20  10  10 
513-2 (I)  25  21  0  21  0  0  21  21  0  0 
516-1 (NI)  25  21  0  21  0  0  21  21  0  0 
625 B1 IgA (I)  25  22  0  22  0  0  22  22  0  0 
625 B2 IgA (I)  25  23  0  23  0  0  23  23  0  0 
625 C1 IgA (I)  25  17  0  17  0  0  17  17  0  0 
625 C2 IgA (I)  25  22  1set (1x2)  21  0  2set(2x2)  17  16  20  27 
625 B1 IgG (I)  25  24  2sets(2x2)  22  0  2set(2x2)  18  16  18  33 
625 B2 IgG (I)  25  24  2sets(1x2, 1x4)  20  0  0  20  18  0  25 
625 C1 IgG (I)  25  21  0  21  0  0  21  21  0  0 
625 C2 IgG (I)  25  24  4 sets(3x2, 1x4)  18  0  0  18  14  0  41 
 
Table-2: Coverage Table, (I).3 –inflamed , (NI) –non inflamed  
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Chapter-6 Table-1 
 
Name  Acession No  IGVH   DH  JH  Germline No  No. 
mutation 
Mutation 
frequency 
Observed 
R/S H-FR 
Expected 
R/S H-FR 
p 
H-FR 
Observed R/S 
H-CDR 
Expected 
R/S H-
CDR 
p 
H-CDR 
22-1SS 
IgA1    VH1-18  DH2  JH4  13  28  11.87%  13/5  3.26  0.09  6/2  3.45  0.1 
3-1SS 
IgA1    VH1-18  DH6  JH1  16  15  6.85  9/2  3.26  0.2  0/4  3.45  0.06 
4-1SS 
IgA1    VH1-18  DH6  JH6  16  34  15.53  18/3  3.26  0.09  9/4  3.45  0.05 
17-1SS 
IgA1    VH1-18  DH2  JH1  17  27  12,33%  13/6  3.26  0.07  7/1  3.45  0.08 
12-1SS 
IgA1    VH1-18  DH3  JH5  18  16  7.41  8/4  3.30  0.1  4/0  3.45  0.1 
6-1SS 
IgA1    VH1-69  DH3  JH1  17  23  10.5  11/7  3.26  0.02  5/0  3.03  0.1 
11-1SS 
IgA1    VH1-69  DH3  JH1  17  29  13.24  13/6  3.26  0.03  6/4  3.03  0.1 
10-1SS 
IgA1    VH1-69  DH3  JH3  19  13  5.48  4/3  3.26   0.04  2/3  3.03  0.2 
8-1SS 
IgA1    VH3-11  DH6  JH5  15  25  11.42  8/5  3.24  0.003  10/2  4.35  0.005 
2-1SS 
IgA1    VH3-21  DH1  JH4  11  16  7.31  4/2  3.12  0.004  9/1  5.32  0.0006 
14-1SS 
IgA1    VH3-23  DH6  JH4  13  16  7.31  4/2   3.16  0.004  3/7  3.55  0.2 
1-1SS 
IgA1    VH3-23  DH3  JH3  18  33  15.07  11/5  3.16  0.001  13/4  3.55  0.001 
7-1SS 
IgA1    VH3-73  DH6  JH6  14  25  11.11  10/3  3.17  0.03  10/2  3.39  0.007  
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23-1SS 
IgA1    VH4-4  DH2  JH6  16  12  5.48  5/3  3.08  0.1  3/1  4.19  0.2 
25-1SS 
IgA1    VH4-4  DH3  JH2  20  31  14.16  13/7  3.08  0.02  11/0  4.19  0.009 
15-1SS 
IgA1    VH4-31  DH4  JH2  11  30  13,51%  13,51%  3,08  0.09  4/3  3,39  0.1 
19-1SS 
IgA1    VH4-39  DH3  JH4  17  28  12,61%  10/7  2,98  0.02  7/4  4,00  0.1 
9-1SS 
IgA1    VH4-39  DH3  JH4  17  27  12.16  9/6  2.98  0.006  8/4  4.00  0.06 
16-1SS 
IgA1    VH4-39  DH3  JH4  17  31  13,96%  12/7  2.98  0.01  8/4  4,00  0.09 
20-1SS 
IgA1    VH4-39  DH3  JH4  17  32  14,41%  10/8  2,98  0.001  10/4  4,00  0.03 
13_1SS 
IgA1    VH4-59  DH3  JH2  12  24  11,11%  9/5  2,99  0.01  10/0  3,70  0.002 
21-1SS 
IgA1    VH4-61  DH1  JH2  12  18  8.11  7/3  2.99  0.02  8/0  3.53  0.003 
24-1SS 
IgA1    VH5-a  DH1  JH4  11  29  13.24  18/2  3.52  0.1  7/2  4.19  0.1 
18-2SS 
IgA1    VH1-2  DH3  JH5  14  22  10.5  7/8  3.33  0.003  6/1  3.15  0.08 
12-2SS 
IgA1    VH1-8  DH3  JH6  13  34  15.53  12/10  3.37  0.001  10/2  4.15  0.02 
14-2SS 
IgA1    VH1-8  DH3  JH6  30  29  13.24  13/3  3.37  0.03  10/3  4.15  0.01 
19-2SS 
IgA1    VH1-18  DH1  JH3  14  37  16.89  19/5  3.26  0.07  8/5  3.45  0.1 
22-2SS 
IgA1    VH1-18  DH3  JH3  21  18  8.22  9/2  3.26  0.1  7/0  3.45  0.01 
2-2SS 
IgA1    VH3-7  DH4  JH4  12  34  15.53  18/4  3.23  0.09  7/5  5.09  0.1 
7-2SS 
IgA1    VH3-9  DH3  JH4  16  23  10.50  8/5  3.09  0.01  10/0  4.56  0.003 
11-2SS 
IgA1    VH3-30  DH3  JH4  12  25  11.42  6/6  3.17  0.0002  11/2  4.04  0.001 
10-2SS    VH3-30  DH6  JH5  14  24  10.96  10/3  3.17  0.03  10/1  4.04  0.003  
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IgA1 
13-2SS 
IgA1    VH4-4  DH3  JH6  17  23  10.65  5/7  3.01  0.0002  10/1  3.45  0.001 
16-2SS 
IgA1    VH4-4  DH3  JH2  20  35  15.98  15/8  3.08  0.02  12/0  4.19  0.008 
9-2SS 
IgA1    VH4-31  DH3  JH6  14  34  15.23  15/8  3.08  0.03  8/3  3.39  0.1 
4-2SS 
IgA1    VH4-31  DH3  JH6  14  29  13.06  11/7  3.08  0.01  10/1  3.39  0.01 
6-2SS 
IgA1    VH4-31  DH3  JH3  19  17  7.66  4/4  3.08  0.003  9/0  3.39  0.0008 
3-2SS 
IgA1    VH4-39  DH3  JH4  17  30  13.51  12/4  2.98  0.02  9/5  4.00  0.04 
24-2SS 
IgA1    VH4-39  DH3  JH4  17  26  11.71  9/6  2.98  0.009  7/4  4.00  0.09 
23-2SS 
IgA1    VH4-34  DH5  JH6  19  28  12.96  13/7  3.09  0.05  8/0  3.64  0.02 
5-2SS 
IgA1    VH4-55  DH5  JH4  16  20  9.13  14/3  3.00  0.1  3/0  4.26  0.2 
17-2SS 
IgA1    VH4-59  DH3  JH4  12  14  6.48  7/3  2.99  0.1  3/1  3.70  0.1 
15-2SS 
IgA1    VH4-59  DH4  JH2  17  26  2.99  15/3  2.99  0.1  7/1  3.70  0.06 
1-2SS 
IgA1    VH4-61  DH3  JH4  14  14  6.31  5/3  2.99  0.05  4/2  3.53  0.1 
20-2SS 
IgA1    VH4-61  DH3  JH4  15  25  11.26  7/10  2.99  0.0001  7/1  3.53  0.08 
25-2SS 
IgA1    VH4-61  DH3  JH4  15  25  11,26%  7/10  2,99  0.0001  7/1  3.53  0.08 
21-2SS 
IgA1    VH4-61  DH3  JH4  15  29  13,06%  11/5  2,99  0.01  12/1  3,53  0.001 
8-2SS 
IgA    VH5-51  DH5  JH2  17  13  5.94  5/2  3.38  0.06  6/0  3.82  0.01 
10-3SS 
IgA1    VH1-2  DH2  JH1  8  30  13,70%  18/8  3,33  0.1  3/1  3,15  0.1 
3-3SS 
IgA1    VH1-2  DH5  JH4  13  28  12,79%  15/3  3,33  0.1  10/0  3,15  0.008  
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24-3SS 
IgA2    VH1-2  DH4  JH4  14  15  6,85%  10/3  3,33  0.1  2/0  3,15  0.2 
6-3SS  
IgA2     VH1-18  DH2  JH4  14  24  10,96%  12/6  3,26  0.1  6/0  3,45  0.1 
4-3SS 
IgA1    VH1-18  DH6  JH4  18  39  17,81%  25/9  3,26  0.1  5/0  3,45  0.1 
22-3SS 
IgA1     VH1-18  DH6  JH4  18  39  17,81%  25/9  3,26  0.1  5/0  3,45  0.1 
5-3SS 
IgA1    VH1-58  DH4  JH4  12  23  10,50%  11/5  3,39  0.07  7/0  2,86  0.04 
25-3SS 
IgA1    VH1-58  DH2  JH4  16  6  2,74%  4/1  3,39  0.3  1/0  2,86  0.4 
11-3SS 
IgA1    VH2-5  DH3  JH6  12  34  15,32%  18/5  3,12  0.1  9/2  3,68  0.07 
15-3SS 
IgA2     VH3-7  DH3  JH4  12  27  12,33%  14/4  3,23  0.1  6/3  5,09  0.1 
16-3SS 
IgA2     VH3-7  DH3  JH4  12  27  12,33%  14/4  3,23  0.1  6/3  5,09  0.1 
21-3SS 
IgA2    VH3-7  DH2  JH5  14  28  12,79%  18/2  3,23  0.1  7/1  5,09  0.1 
13-3SS 
IgA1    VH3-9  DH2  JH3  17  0  0,00%  0/0  3,09  0  0/0  4,56  0/0 
14-3SS 
IgA1    VH3-9  DH6  JH4  18  21  9,59%  4/6  3,09  0.0001  10/1  4,56  0.001 
20-3SS 
IgA1    VH3-9  DH6  JH4  18  21  9,59%  4/6  3,09  0.0001  10/1  4,56  0.001 
18-3SS 
IgA2    VH3-30-3  DH3  JH4  13  19  8,68%  4/2  3,17  0.0006  11/2  4,00  0.00007 
1-3SS 
IgA1    VH3-33  DH6  JH5  12  24  10,96%  7/5  3,17  0.002  9/3  4,63  0.01 
7-3SS 
IgA1    VH4-34  DH5  JH3  28  25  11,57%  13/6  3,09  0.01  6/0  3,64  0.1 
17-3SS 
IgA2    VH4-39  DH3  JH4  21  23  10,36%  8/5  2,98  0.01  10/0  4,00  0.003 
2-3SS 
IgA1    VH4-59  DH5  JH3  13  50  23,15%  21/12  2,99  0.005  13/4  3,70  0.02 
23-3SS    VH5-51  DH3  JH5  11  28  12,79%  14/6  3,38  0.08  8/0  3,82  0.05  
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IgA2 
8-3SS 
IgA1    VH5-51  DH6  JH4  13  15  6,85%  5/6  3,38  0.02  4/0  3,82  0.1 
22-4SS 
IgA2    VH1-3  DH3  JH4  15  15  7,31%  5/4  3,47  0.01  7/0  3,21  0.008 
21-4SS 
IgA2    VH1-18  DH1  JH3  13  16  7,31%  6/2  3,26  0.04  7/1  3,45  0.008 
5-4SS 
IgA2    VH1-18  DH4  JH6  23  20  9,13%  11/3  3,26  0.1  5/1  3,45  0.1 
12-4SS 
IgA1    VH1-46  DH3  JH4  10  15  6,85%  10/1  3,43  0.1  4/0  3,42  0.1 
1-4SS 
IgA2     VH1-46  DH3  JH4  11  23  10,50%  13/2  3,43  0.1  7/1  3,42  0.05 
9-4SS 
IgA1     VH1-46  DH3  JH4  11  27  12,33%  13/4  3,43  0.06  9/1  3,42  0.01 
17-4SS 
IgA1    VH1-46  DH3  JH6  20  29  13,24%  5/10  3,43  0.0000
02  13/1  3,42  0.0003 
2-4SS 
IgA1    VH1-69  DH4  JH4  14  34  15,53%  17/4  3,26  0.07  10/3  3,03  0.02 
18-4SS 
IgA1    VH1-69  DH5  JH3  14  26  11,87%  12/4  3,26  0.05  10/0  3,03  0.004 
15-4SS 
IgA2    VH3-11  DH6  JH1  15  12  5,48%  4/2  3,24  0.04  5/1  4,35  0.03 
25-4SS 
IgA2    VH3-21  DH2  JH1  16  4  1,83%  2/1  3,12  0.3  1/0  5,32  0.4 
11-4SS 
IgA2    VH3-23  DH3  JH4  14  25  11,42%  9/3  3,16  0.01  12/1  3,55  0.0002 
7-4SS 
IgA1    VH3-72  DH3  JH6  23  13  5,78%  5/1  3,16  0.08  6/1  4,00  0.01 
6-4SS 
IgA1    VH3-74  DH1  JH4  9  19  8,68%  4/5  3,11  0.0007  8/2  4,79  0.009 
13-4SS 
IgA2    VH4-39  DH5  JH4  12  11  4,95%  5/2  2,98  0.1  4/0  4,00  0.09 
4-4SS 
IgA1    VH4-39  DH6  JH4  13  28  12,61%  8/5  2,98  0.001  11/4  4,00  0.005 
20-4SS 
IgA1    VH4-59  DH2  JH3  10  16  7,41%  6/8  2,99  0.04  2/0  3,70  0.2  
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23-4SS 
IgA2    VH4-59  DH3  JH4  14  18  8,33%  4/5  2,99  0.001  9/0  3,70  0.0008 
19-4SS 
IgA1    VH4-59  DH4  JH4  14  38  17,59%  16/9  2,99  0.01  11/2  3,70  0.02 
14-4SS 
IgA2    VH4-59  DH1  JH6  16  32   14,81%  18/3  2,99  0.1  11/0  3,70  0.006 
3-4SS 
IgA1    VH4-59  DH3  JH6  22  24  11,11%  9/7  2,99  0.01  6/2  3,70  0.1 
10-4SS 
IgA1    VH4-61  DH2  JH6  23  26  11,71%  8/7  2,99  0.003  11/0  3,53  0.002 
24-4SS 
IgA2    VH7-4-1  DH2  JH4  10  16  7,31%  2/2  3,18  0.0001  10/2  3,21  0.00004 
22-5SS  
IgA1    VH1-3  DH3  JH6  12  19  8.68%  9/2  3.47  0.09  5/3  3.21  0.1 
2-5SS  
IgA2    VH1-8  DH1   JH5  14  31  14.16%  13/6  3.37  0.01  9/3  4.15  0.04 
20-5SS  
IgA1    VH1-8  DH2   JH6  18  17  7.76%  5/8  3.37  0.003  3/1  4.15  0.2 
21-5SS 
IgA1    VH1-8  DH2  JH6  18  17  7.76%  5/8  3.37  0.003  3/1  4.15  0.2 
23-5SS 
IgA2    VH1-18  DH6   JH2  17  21  9.59%  9/4  3.26  0.05  6/2  3.45  0.07 
9-5SS  
IgA1    VH1-24  DH6   JH4  9  20  9.13%  11/2  3.38  0.1  7/0  3.12  0.02 
10-5SS 
IgA2    VH1-46  DH3  JH4  9  14  6.39%  5/4  3.43  0.03  5/0  3.42  0.05 
19-5SS 
IgA1    VH1-69  DH6  JH2  17  27  12.33%  8/5  3.26  0.001  10/4  3.03  0.005 
14-5SS 
IgA1    VH3-11  DH4   JH3  12  31  14.16%  13/5  3.24  0.02  13/0  4.35  0.001 
8-5SS 
IgA2    VH3-23  DH3   JH4  9  18  8.22%  5/3  3.16  0.005  8/2  3.55  0.004 
1-5SS 
IgA1    VH3-23  DH2   JH4  13  28  10.05%  8/4  3.16  0.02  7/1  3.55  0.04 
13-5SS 
IgA1    VH3-23  DH6   JH4  13  24  10.96%  10/5  3.16  0.03  9/0  3.55  0.009 
3-5SS    VH3-23  DH3   JH6  16  20  9.13%  9/3  3.16  0.07  7/1  3.55  0.02  
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IgA2 
18-5SS 
IgA1    VH3-33  DH6  JH6  22  26  11.87%  12/6  3.17  0.06  5/3  4.63  0.1 
24-5SS 
IgA1    VH3-72  DH2   JH6  21  15  6.67%  6/1  3.16  0.07  7/1  4.00  0.01 
16-5SS 
IgA1    VH3-74  DH2   JH5  18  21  9,59%  9/4  3,11  0.05  5/3  4,79  0.1 
17-5SS 
IgA1    VH3-74  DH2   JH5  18  21  9,59%  9/4  3,11  0.05  5/3  4,79  0.1 
4-5SS 
IgA1    VH4-4  DH1   JH4  15  25  11,57%  15/7  3,01  0.1  3/0  3,45  0.2 
6-5SS 
IgA1    VH4-59  DH5   JH6  17  20  9,26%  6/9  2,99  0.005  5/0  3,70  0.1 
12-5SS 
IgA1    VH5-51  DH3   JH4  16  2  0,91%  2/0  3,38  0.3  0/0  3,82  0.6 
20-6SS 
IgA1    VH1-18  DH6  JH6  18  30  13.70%  15/4  3.26  0.08  9/2  3.45  0.03 
10-6SS 
IgA2 
  VH1-18  DH2  JH3  21  36  16.44%  19/9  3.26  0.09  7/1  3.45  0.1 
15-6SS 
IgA2    VH1-24  DH6  JH3  9  7  3.20%  1/3  3.38  0.01  3/0  3.12  0.07 
24-6SS 
IgA2    VH1-46  DH6  JH4  19  27  12.33%  7/4  3.43  0.0002  14/2  3.42  0.00002 
4-6SS 
IgA1    VH1-58  DH3  JH4  14  24  10.96%  13/5  3.39  0.1  4/2  2.86  0.2 
2-6SS 
IgA1    VH1-69  DH6  JH4  16  28  12.79%  13/3  3.26  0.05  9/3  3.03  0.02 
13-6SS 
IgA2    VH3-7  DH2  JH6  14  13  5.94%  1/3  3.23  0.0001  7/2  5.09  0.003 
25-6SS 
IgA1    VH3-11  DH5  JH4  14  19  8.68%  10/4  3.24  0.1  4/1  4.35  0.2 
5-6SS 
IgA2    VH3-15  DH1  JH4  12  35  15.56%  10/12  3.19  0.0003  11/2  3.62  0.02 
6-6SS 
IgA2    VH3-15  DH2  JH4  16  19  8.44%  8/5  3.19  0.07  3/3  3.62  0.2 
19-6SS 
IgA1    VH3-15  DH2  JH4  16  17  7.56%  4/4  3.19  0.003  6/3  3.62  0.05  
 
A-44 
 
 
 
 
 
     
Human Mucosal IgA in Health and Disease 
 
23-6SS 
IgA1    VH3-15  DH2  JH4  16  21  9.33%  8/5  3.19  0.03  4/4  3.62  0.1 
9-6SS 
IgA1    VH3-21  DH2  JH3  14  21  9.59%  3/5  3.12  0.0000
2  12/1  5.32  0.00007 
21-6SS 
IgA2    VH3-48  DH3  JH4  13  23  6,39%  5/5  3,19  0.04  4/0  4,88  0.1 
16-6SS 
IgA2    VH3-74  DH6  JH1  14  22  10,05%  12/3  3,11  0.1  7/0  4,79  0.05 
7-6SS 
IgA2    VH4-4  DH4  JH4  12  15  6,94%  6/3  3,01  0.06  6/0  3,45  0.01 
18-6SS 
IgA2    VH4-4  DH6  JH1  13  16  7,41%  7/3  3,01  0.08  4/2  3,45  0.01 
8-6SS 
IgA1    VH4-34  DH6  JH6  15  24  11,11%  13/5  3,09  0.1  6/0  3,64  0.1 
22-6SS 
IgA1    VH4-39  DH2  JH5  10  26  11,71%  12/4  2,98  0.07  10/0  4,00  0.009 
11-6SS 
IgA2    VH4-39  DH2  JH1  21  8  3,60%  4/1  2,98  0.1  3/0  4,00  0.1 
3-6SS  
IgA2    VH4-59  DH3  JH3  13  17  7,87%  4/9  2,99  0.002  2/2  3,70  0.1 
1-6SS 
IgA1    VH4-59  DH4  JH6  19  14  6,48%  8/2  2,99  0.2  2/2  3,70  0.1 
17-6SS 
IgA2    VH4-59  DH2  JH5  19  16  7,41%  6/5  2,99  0.04  5/0  3,70  0.07 
2-7SS 
IgA2    VH1-8  DH6  JH4  10  16  7,31%  6/3  3,37  0.03  4/3  4,15  0.1 
4-7SS 
IgA1    VH1-8  DH7  JH3  11  0  0  0  0  0  0  0  0 
20-7SS    VH1-08  DH4  JH3  15  7  3,20%  4/0  3,37  0.2  2/1  4,15  0.2 
15-7SS    VH1-18  DH3  JH3  12  3  1,37%  2/0  3,26  0.4  1/0  3,45  0.3 
16-7SS    VH1-18  DH3  JH3  12  3  1,37%  2/0  3,26  0.4  1/0  3,45  0.3 
5-7SS 
IgA2    VH1-18  DH1  JH6  23  22  10,05%  13/2  3,26  0.1  6/1  3,45  0.09 
10-7SS 
IgA2    VH1-18  DH1  JH6  13  44  20,09%  19/4  3,26  0.01  20/1  3,45  0.000008 
1-7SS 
IgA2    VH1-18  DH3  JH6  15  43  19,63%  18/4  3,26  0.007  20/1  3,45  0.000005  
 
    A-45 
 
 
 
 
 
 
Appendix 
6-7SS 
IgA2    VH1-18  DH3  JH6  15  43  19,63%  18/4  3,26  0.007  20/1  3,45  0.000005 
17-7SS     VH1-18  DH3  JH6  15  43  19,63%  18/4  3,26  0.007  20/1  3,45  0.000005 
18-7SS     VH1-18  DH3  JH6  15  43  19,63%  18/4  3,26  0.007  20/1  3,45  0.000005 
19-7SS     VH1-18  DH3  JH6  15  43  19,63%  18/4  3,26  0.007  20/1  3,45  0.000005 
21-7SS     VH1-46  --  JH6  9  19  8,68%  4/8  3,43  0.0004  4/3  3,42  0.1 
22-7SS     VH1-46  DH5  JH3  19  21  9,59%  8/5  3,43  0.02  7/1  3,42  0.03 
23-7SS     VH1-69  DH1  JH4  12  18  8,22%  6/5  3,26  0.01  6/1  3,03  0.04 
24-7SS    VH1-69  DH3  JH6  17  10  4,57%  5/2  3,26  0.2  3/0  3,03  0.1 
8-7SS 
IgA2    VH2-5  DH2  JH5  17  7  3,15%  2/0  3,12  0.08  4/1  3,68  0.02 
25-7SS    VH3-07  DH2  JH3  14  14  6,39%  10/0  3,23  0.1  3/1  5,09  0.2 
13-7SS 
IgA1    VH4-34  DH6  JH2  14  14  6,48%  6/4  3,09  0.09  4/0  3,64  0.1 
9-7SS 
IgA1    VH5-51  DH6  JH4  12  25  11,42%  11/5  3,38  0.04  9/0  3,82  0.01 
13-8SS 
IgA1    VH1-2  DH3  JH5  13  32  14.61%  12/6  3.33  0.005  12/2  3.15  0.002 
19-8SS 
IgA1    VH1-3  DH3  JH5  10  17  7.76%  4/5  3.47  0.001  7/1  3.21  0.01 
6-8SS 
IgA1    VH1-3  DH3  JH5  10  17  7.76%  4/5  3.47  0.001  7/1  3.21  0.01 
10-8SS 
IgA1    VH1-3  DH3  JH5  10  17  7.76%  4/5  3.47  0.001  7/1  3.21  0.01 
7-8SS 
IgA1    VH1-8  DH2  JH4  13  27  12.33%  13/9  3.37  0.06  4/1  4.15  0.1 
17-8SS 
IgA1    VH1-8  DH2  JH4  13  27  12.33%  13/9  3.37  0.06  4/1  4.15  0.1 
9-8SS 
IgA1    VH1-8  DH3  JH4  13  28  12.79%  14/7  3.37  0.08  5/2  4.15  0.1 
22-8SS 
IgA1    VH1-8  DH3  JH4  13  28  12.79%  14/7  3.37  0.08  5/2  4.15  0.1 
23-8SS 
IgA1    VH1-8  DH3  JH4  13  28  12.79%  14/7  3.37  0.08  5/2  4.15  0.1 
4-8SS 
IgA1    VH1-18  DH2  JH4  15  36  16.44%  16/12  3.26  0.02  3/5  3.45  0.07 
3-8SS    VH1-46  DH6  JH4  15  4  1.83%  1/0  3.43  0.1  3/0  3.42  0.02  
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IgA1 
18-8SS 
IgA1    VH1-46  DH3  JH6  19  36  16.44%  15/6  3.43  0.01  10/5  3.42  0.03 
11-8SS 
IgA1    VH1-69  DH2  JH4  13  35  15.98%  22/5  3.26  0.1  6/2  3.03  0.1 
16-8SS 
IgA1    VH1-69  DH2  JH4  13  34  15.53%  22/4  3.26  0.1  6/2  3.03  0.1 
2-8SS 
IgA1    VH1-69  DH2  JH4  14  28  12.79%  9/3  3.26  0.002  14/2  3.03  0.00003 
15-8SS 
IgA1    VH1-69  DH3  JH4  15  20  9.13%  7/6  3.26  0.01  6/1  3.03  0.06 
12-8SS 
IgA1    VH1-69  DH3  JH5  19  36  16.44%  19/8  3.26  0.09  8/1  3.03  0.1 
20-8SS 
IgA1    VH3-33  DH6  JH1  15  54  24,66%  31/7  3,17  0.1  13/3  4,63  0.06 
14-8SS 
IgA1    VH4-61  DH3  JH3  18  28  12,61%  15/3  2,99  0.1  9/1  3,53  0.03 
8-8SS 
IgA1    VH5-a  DH1  JH4  13  27  12,33%  13/8  3,52  0.06  2/4  4,19  0.08 
25-8SS 
IgA1    VH5-a  DH3  JH3  14  14  6,39%  8/2  3,52  0.1  3/1  4,19  0.1 
1-8SS 
IgA1    VH5-51  DH3  JH5  24  21  9,59%  11/4  3,52  0.1  5/1  4,19  0.1 
5-8SS 
IgA1    VH7-4-1  DH6  JH5  14  3  1,37%  1/1  3,18  0.1  1/0  3,21  0.1 
12_9SS 
IgA2 
  VH1-2  DH5  JH3  11  29  13.24%  21/5  3.33  0.06  3/0  3.15  0.1 
6_9SS 
IgA1 
  VH1-2  DH3  JH4  16  28  12.79%  15/7  3.33  0.1  6/0  3.15  0.1 
15_9SS 
IgA1 
  VH1-8  DH6  JH6  14  14  6.39%  5/3  3.37  0.03  5/1  4.15  0.05 
4_9SS 
IgA1 
  VH1-18  DH6  JH4  13  32  14.61%  18/4  3.26  0.1  8/2  3.45  0.08 
19_9SS 
IgA1 
  VH1-18  DH3  JH4  16  21  9.59%  11/4  3.26  0.1  5/1  3.45  0.1 
23_9SS 
IgA1 
  VH1-18  DH3  JH4  16  25  11.42%  13/7  3.26  0.1  4/1  3.45  0.2  
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20_9SS 
IgA1 
  VH1-18  DH3  JH4  16  20  9.13%  13/4  3.26  0.1  3/0  3.45  0.2 
21_9SS 
IgA1 
  VH1-18  DH3  JH4  16  18  8.22%  10/5  3.26  0.1  3/0  3.45  0.2 
22_9SS 
IgA1 
  VH1-18  DH3  JH4  16  12  5.48%  6/2  3.26  0.1  3/1  3.45  0.2 
1_9SS 
IgA1 
  VH3-7  DH6  JH4  13  9  4.11%  2/1  3.23  0.02  6/0  5.09  0.001 
3_9SS 
IgA1 
  VH3-23  DH1  JH4  14  35  15.98%  13/8  3.16  0.004  12/2  3.55  0.006 
11_9SS 
IgA1 
  VH3-30  DH2  JH4  15  19  8.68%  7/3  3.17  0.02  7/2  4.04  0.02 
17_9SS 
IgA1 
  VH3-30  DH2  JH4  15  6  2.74%  2/1  3.17  0.1  3/0  4.04  0.06 
5_9SS 
IgA1 
  VH3-30  DH3  JH4  17  33  15.07%  12/5  3.17  0.004  14/2  4.04  0.0005 
8_9SS 
IgA1 
  VH3-30  DH3  JH5  19  17  7.76%  6/2  3.17  0.02  8/1  4.04  0.003 
14_9SS  
IgA1 
  VH3-30  DH3  JH4  21  17  7.76%  3/6  3.17  0.0004  8/0  4.04  0.003 
7_9SS 
IgA2 
  VH3-48  DH1  JH5  10  20  9.13%  5/4  3.19  0.001  10/1  4.88  0.0009 
16_9SS 
IgA1 
  VH3-48  DH4  JH4  10  27  12.33%  10/3  3.19  0.02  13/1  4.88  0.0002 
10_9SS 
IgA1 
  VH3-48  DH3  JH4  14  32  14.61%  5/10  3.19  0.0000
003 
14/3  4.88  0.0005 
24_9SS 
IgA1 
  VH3-48  DH3  JH4  14  34  13.24%  9/5  3.19  0.001  13/2  4.88  0.0006 
18_9SS 
IgA1 
  VH3-74  DH3  JH4  11  17  7.76%  7/5  3.11  0.06  5/0  4.79  0.1 
13_9SS 
IgA1 
  VH4-4  DH3  JH3  14  38  17.35%  19/6  3.08  0.06  12/1  4.19  0.02 
25_9SS 
IgA1 
  VH4-59  DH4  JH3  15  15  6.94%  5/6  2.99  0.02  4/0  3.70  0.1 
9_9SS 
IgA1 
  VH7-4-1  DH1  JH4  9  8  3.65%  2/3  3.18  0.04  3/0  3.21  0.1 
24-10SS 
IgA1    VH1-2  No D 
region  JH4  9  28  12.79%  13/7  3.33  0.05  7/1  3.15  0.09  
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18-10SS 
IgA1    VH1-2  DH5  JH5  12  27  12.33%  13/7  3.33  0.06  6/1  3.15  0.1 
6-10SS 
IgA2    VH1-2  DH3  JH5  15  30  13.70%  17/6  3.33  0.1  6/1  3.15  0.1 
17-10SS 
IgA1    VH1-3  DH2  JH6  15  22  10.05%  8/6  3.47  0.02  7/1  3.21  0.04 
20-10SS 
IgA1    VH1-18  DH3  JH4  16  22  10.05%  11/5  3.26  0.1  5/1  3.45  0.1 
25-10SS 
IgA1    VH1-18  DH3  JH4  16  31  14.16%  14/11  3.26  0.03  2/4  3.45  0.06 
10-10SS 
IgA1    VH1-69  DH4  JH6  13  13  5.94%  5/5  3.26  0.06  3/0  3.03  0.1 
3-10SS 
IgA1    VH1-69  DH6  JH5  16  12  5.48%  2/2  3.26  0.002  8/0  3.03  0.0001 
8-10SS 
IgA1    VH1-69  DH6  JH5  16  12  5.48%  2/2  3.26  0.002  8/0  3.03  0.0001 
23-10SS 
IgA1    VH1-69  DH3  JH3  17  33  15.07%  11/9  3.26  0.001  12/1  3.03  0.003 
21-10SS 
IgA1    VH1-69  DH6  JH3  18  20  9.13%  7/4  3.26  0.01  7/2  3.03  0.02 
19-10SS 
IgA2    VH2-5  DH6  JH3  15  13  5.86%  4/3  3.12  0.03  5/1  3.68  0.05 
12-10SS 
IgA1    VH2-26  DH3  JH4  14  10  4.50%  2/4  3.19  0.01  4/0  3.90  0.06 
5-10SS 
IgA1    VH3-30  No D 
region  JH6  4  16  7.31%  7/4  3.17  0.08  5/0  4.04  0.08 
7-10SS 
IgA1    VH3-7  DH5  JH4  11  39  17.81%  17/9  3.23  0.01  10/3  5.09  0.07 
15-10SS 
IgA1    VH3-30  DH6   JH4  14  21  9.59%  11/5  3.17  0.1  4/1  4.04  0.2 
2-10SS 
IgA2    VH3-48  DH1  JH4  13  21  8.22%  3/4  3.19  0.0002  11/0  4.88  0.00005 
22-10SS 
IgA1    VH3-74  DH3  JH4  11  32  14.61%  14/5  3.11  0.03  12/1  4.79  0.005 
11-10SS 
IgA2    VH4-34  DH1  JH6  11  4  1.85%  2/2  3.09  0.3  0/0  3.64  0.4 
16-10SS    VH4-39  DH6  JH4  14  38  17.12%  21/7  2.98  0.1  9/1  4.00  0.1  
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IgA2 
1-10SS 
IgA2    VH4-59  DH2  JH3  14  37  17.13%  17/8  2.99  0.03  10/2  3.70  0.03 
9-10SS 
IgA1    VH5-51  DH5  JH4  13  7  3.20%  1/2  3.38  0.02  4/0  3.82  0.01 
4-10SS 
IgA1    VH7-4-1  DH1  JH4  9  8  3.65%  3/3  3.18  0.1  2/0  3.21  0.2 
13-10SS 
IgA1    VH7-4-1  DH1  JH4  9  11  5.02%  5/3  3.18  0.1  2/1  3.21  0.2 
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IgA1 
4-10SS 
IgA1    VH7-4-1  DH1  JH4  9  8  3.65%  3/3  3.18  0.1  2/0  3.21  0.2 
13-10SS 
IgA1    VH7-4-1  DH1  JH4  9  11  5.02%  5/3  3.18  0.1  2/1  3.21  0.2 
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Abbreviation 
NEF      Negative Factor 
S        Switch 
NIK       NF-kB-inducing kinase 
ASC      Antibody secreting cells 
HEV       high endothelial venules  
MALT     Mucosal Associated Lymphoid tissue 
SC        secretory component 
IgAN      IgA nephropathy  
APC      antigen-presenting cells 
AID       Activation-induced cytidine deaminase  
SHM      Somatic hypermutation 
CSR      class switching recombination  
FDC       Follicular dendritic cells  
TLR      Toll Like Receptors  
IgA       Immunoglobulin A  
LP        lamina propria  
GC       Germinal center 
NIK       NF-kB-inducing kinase  
PEC       peritoneal cavity  
BLC      B lymphocyte chemoattractant  
NF-kB      Nuclear factor-kB  
RANK      receptor activator of NF-kB  
UNG      uracil-DNA glycosylase  
MMR       Mismatch repair  
GALT      Gut-Associated Lymphoid Tissue   
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i-LP       intestinal lamina propria  
BALT      Bronchus Associated Lymphoid Tissues  
HEV      high endothelial venules  
pIgR       poly immunoglobulin receptor  
ASGP-R     asialoglycoprotein 
ALC       alcoholic liver cirrhosis  
CD       Crohn’s disease  
UC       ulcerative colitis  
IBD      Inflammmatory bowel disease  
BsAb       bispecific antibodies  
TRAIL     Tumor necrosis factor (TNF)-related apoptosis-inducing ligand 
BAFF      B-cell activating factor 
GM       Genetically Modified  
GRAS      Generally Regarded As Safe 
ScFv       single chain antibodies  
TTFs       Trefolin factors  
EGP-2      Epithelial glycoprotein-2  
 